<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">76004</article-id><article-id pub-id-type="doi">10.7554/eLife.76004</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Evolutionary Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Physics of Living Systems</subject></subj-group></article-categories><title-group><article-title>Design of an optimal combination therapy with broadly neutralizing antibodies to suppress HIV-1</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-264355"><name><surname>LaMont</surname><given-names>Colin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-182456"><name><surname>Otwinowski</surname><given-names>Jakub</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="pa1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-264351"><name><surname>Vanshylla</surname><given-names>Kanika</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-264352"><name><surname>Gruell</surname><given-names>Henning</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0725-7138</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-100896"><name><surname>Klein</surname><given-names>Florian</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-162124"><name><surname>Nourmohammad</surname><given-names>Armita</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6245-3553</contrib-id><email>armita@uw.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf3"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0087djs12</institution-id><institution>Max Planck Institute for Dynamics and Self-Organization</institution></institution-wrap><addr-line><named-content content-type="city">Göttingen</named-content></addr-line><country>Germany</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00rcxh774</institution-id><institution>Laboratory of Experimental Immunology, Institute of Virology Faculty of Medicine and University Hospital Cologne, University of Cologne</institution></institution-wrap><addr-line><named-content content-type="city">Cologne</named-content></addr-line><country>Germany</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00cvxb145</institution-id><institution>Department of Physics, University of Washington</institution></institution-wrap><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/007ps6h72</institution-id><institution>Fred Hutchinson Cancer Research Center</institution></institution-wrap><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Sprenger</surname><given-names>Kayla</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/042nb2s44</institution-id><institution>Massachusetts Institute of Technology</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Davenport</surname><given-names>Miles P</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03r8z3t63</institution-id><institution>University of New South Wales</institution></institution-wrap><country>Australia</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>†</label><p>Dyno Therapeutics, Cambridge, United States</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>19</day><month>07</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e76004</elocation-id><history><date date-type="received" iso-8601-date="2021-12-01"><day>01</day><month>12</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2022-07-04"><day>04</day><month>07</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2021-12-05"><day>05</day><month>12</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.12.03.21267269"/></event></pub-history><permissions><copyright-statement>© 2022, LaMont et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>LaMont et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-76004-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-76004-figures-v2.pdf"/><abstract><p>Infusion of broadly neutralizing antibodies (bNAbs) has shown promise as an alternative to anti-retroviral therapy against HIV. A key challenge is to suppress viral escape, which is more effectively achieved with a combination of bNAbs. Here, we propose a computational approach to predict the efficacy of a bNAb therapy based on the population genetics of HIV escape, which we parametrize using high-throughput HIV sequence data from bNAb-naive patients. By quantifying the mutational target size and the fitness cost of HIV-1 escape from bNAbs, we predict the distribution of rebound times in three clinical trials. We show that a cocktail of three bNAbs is necessary to effectively suppress viral escape, and predict the optimal composition of such bNAb cocktail. Our results offer a rational therapy design for HIV, and show how genetic data can be used to predict treatment outcomes and design new approaches to pathogenic control.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>broadly neutralizing antibody</kwd><kwd>HIV combination therapy</kwd><kwd>population genetics</kwd><kwd>evolutionary control</kwd><kwd>optimization</kwd><kwd>stochastic processes</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Viruses</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>1310</award-id><principal-award-recipient><name><surname>Nourmohammad</surname><given-names>Armita</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000001</institution-id><institution>National Science Foundation</institution></institution-wrap></funding-source><award-id>2045054</award-id><principal-award-recipient><name><surname>Nourmohammad</surname><given-names>Armita</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution>Max Planck Institute for Dynamics and Self-organization</institution></institution-wrap></funding-source><award-id>Open access funding</award-id><principal-award-recipient><name><surname>LaMont</surname><given-names>Colin</given-names></name><name><surname>Nourmohammad</surname><given-names>Armita</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Computational evolutionary model to predict the efficacy of broadly neutralizing antibodies (bNAbs) in suppressing HIV and to design optimal combination therapy with bNAbs.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Recent discoveries of highly potent broadly neutralizing antibodies (bNAbs) provide new opportunities to successfully prevent, treat, and potentially cure infections from evolving viruses such as HIV-1 (<xref ref-type="bibr" rid="bib100">Walker et al., 2011</xref>; <xref ref-type="bibr" rid="bib99">Walker et al., 2009</xref>; <xref ref-type="bibr" rid="bib53">Liao et al., 2013</xref>; <xref ref-type="bibr" rid="bib66">Mouquet and Nussenzweig, 2013</xref>; <xref ref-type="bibr" rid="bib47">Klein et al., 2013</xref>; <xref ref-type="bibr" rid="bib50">Kwong et al., 2013</xref>; <xref ref-type="bibr" rid="bib10">Caskey et al., 2015</xref>; <xref ref-type="bibr" rid="bib12">Caskey et al., 2017</xref>; <xref ref-type="bibr" rid="bib4">Baron et al., 2018</xref>; <xref ref-type="bibr" rid="bib89">Sok and Burton, 2018</xref>; <xref ref-type="bibr" rid="bib110">Zwick et al., 2001</xref>; <xref ref-type="bibr" rid="bib7">Burton et al., 2012</xref>, influenza <xref ref-type="bibr" rid="bib90">Sparrow et al., 2016</xref>, and the Dengue virus <xref ref-type="bibr" rid="bib23">Ekiert and Wilson, 2012</xref>; <xref ref-type="bibr" rid="bib22">Durham et al., 2019</xref>). bNAbs target vulnerable regions of a virus, such as the CD4 binding site of HIV <italic>env</italic> protein, where escape mutations can be costly for the virus (<xref ref-type="bibr" rid="bib99">Walker et al., 2009</xref>; <xref ref-type="bibr" rid="bib16">Chen et al., 2009</xref>; <xref ref-type="bibr" rid="bib108">Zhou et al., 2010</xref>; <xref ref-type="bibr" rid="bib100">Walker et al., 2011</xref>; <xref ref-type="bibr" rid="bib53">Liao et al., 2013</xref>; <xref ref-type="bibr" rid="bib101">West et al., 2014</xref>; <xref ref-type="bibr" rid="bib8">Burton and Hangartner, 2016</xref>). As a result, eliciting bNAbs is the goal of a universal vaccine against the otherwise rapidly evolving HIV-1. Apart from vaccination, bNAbs can also offer significant advances in therapy against both HIV-1 and influenza (<xref ref-type="bibr" rid="bib101">West et al., 2014</xref>; <xref ref-type="bibr" rid="bib11">Caskey et al., 2016</xref>; <xref ref-type="bibr" rid="bib37">Gruell and Klein, 2018</xref>; <xref ref-type="bibr" rid="bib22">Durham et al., 2019</xref>). Specifically, augmenting current anti-retroviral therapy (ART) drugs with bNAbs may provide the next generation of HIV therapies (<xref ref-type="bibr" rid="bib41">Horwitz et al., 2013</xref>; <xref ref-type="bibr" rid="bib37">Gruell and Klein, 2018</xref>).</p><p>Recent studies have used bNAb therapies to curb infections by the Simian immunodeficiency virus (SHIV) in non-human primates (<xref ref-type="bibr" rid="bib87">Shingai et al., 2013</xref>; <xref ref-type="bibr" rid="bib5">Barouch et al., 2013</xref>; <xref ref-type="bibr" rid="bib44">Julg et al., 2017</xref>), and HIV-1 infections in human clinical trials (<xref ref-type="bibr" rid="bib10">Caskey et al., 2015</xref>; <xref ref-type="bibr" rid="bib3">Bar et al., 2016</xref>; <xref ref-type="bibr" rid="bib12">Caskey et al., 2017</xref>; <xref ref-type="bibr" rid="bib4">Baron et al., 2018</xref>). Monotherapy trials with potent bNAbs, including 3BNC117 (<xref ref-type="bibr" rid="bib10">Caskey et al., 2015</xref>, VRC01 <xref ref-type="bibr" rid="bib3">Bar et al., 2016</xref>, and 10–1074 <xref ref-type="bibr" rid="bib12">Caskey et al., 2017</xref>) indicate that administering bNAbs is safe and can suppress viral load in patients. Nonetheless, in each trial, escape mutants emerge resulting in a viral rebound after about 20 days past infusion of the bNAb. However, in trials that administered a combination of 10–1074 and 3BNC117, viral rebound was substantially suppressed (<xref ref-type="bibr" rid="bib87">Shingai et al., 2013</xref>; <xref ref-type="bibr" rid="bib4">Baron et al., 2018</xref>). The success of combination therapy is not surprising. For example, combinations of drugs has been repeatedly used against infectious agents, including current HIV ART cocktails and combination antibiotic treatments against Tuberculosis (<xref ref-type="bibr" rid="bib54">Lienhardt et al., 2012</xref>).</p><p>The principle behind combination therapy with either drugs or antibodies is clear: It is harder for a pathogen population to acquire resistance against multiple treatment targets simultaneously than to acquiring resistance against each target separately. But deciding on combination therapy means navigating an enormous number of possible treatment options.</p><p>Experimental data from neutralization assays against pseudo-viruses together with modeling and machine learning techniques have been used to statistically characterize the efficacy of bNAbs and their combinations against different variants of HIV (<xref ref-type="bibr" rid="bib98">Wagh et al., 2016</xref>; <xref ref-type="bibr" rid="bib104">Yu et al., 2019</xref>). Using these neutralization models, an optimal combination therapy was proposed based on their breadth, potency of neutralization, and other relevant measures (<xref ref-type="bibr" rid="bib98">Wagh et al., 2016</xref>; <xref ref-type="bibr" rid="bib104">Yu et al., 2019</xref>). In another study, pharmacokinetic dynamics was coupled with drug-interaction models to determine an optimal dosing strategies (<xref ref-type="bibr" rid="bib61">Mayer et al., 2022</xref>). These modeling approaches shed light on how combinations of bNAbs that can neutralize a panel of viruses. However, the key obstacle in bNAb therapy is the possibility of viral escape.</p><p>To characterize viral escape, mechanistic models, partly inspired by previous work on HIV escape from the anti-retro viral therapy (ART), have been developed to explain the dynamics of viremia in patients, following passive infusion of bNAbs. By making a fit to the trial data, these models are used to infer parameters related to the efficacy of a bNAb in clearing virions, reducing viral load and infectivity, and also to infer the characteristics of the HIV and the T-cell populations, such as the initial viral population size, the death rates of uninfected and infected T-cells, and the number of virions released by an infected T-cell (<xref ref-type="bibr" rid="bib74">Perelson et al., 1996</xref>; <xref ref-type="bibr" rid="bib77">Ribeiro and Bonhoeffer, 2000</xref>; <xref ref-type="bibr" rid="bib80">Rong et al., 2010</xref>; <xref ref-type="bibr" rid="bib79">Rong et al., 2007</xref>; <xref ref-type="bibr" rid="bib97">Tomaras et al., 2008</xref>; <xref ref-type="bibr" rid="bib58">Lu et al., 2016</xref>; <xref ref-type="bibr" rid="bib76">Reeves et al., 2020</xref>; <xref ref-type="bibr" rid="bib81">Saha and Dixit, 2020</xref>; <xref ref-type="bibr" rid="bib9">Cardozo-Ojeda and Perelson, 2021</xref>; <xref ref-type="bibr" rid="bib92">Stephenson et al., 2021</xref>). These detailed mechanistic models cannot easily generalize from one trial to another in order to predict the efficacy of a new bNAb mono- or combination therapy.</p><p>Evolution of the HIV-1 population is another key factor to consider in modeling the dynamics and escape of viruses in response to therapy. Studies on population genetics of HIV-1 have found rapid intra-patient evolution and turnover of the virus (<xref ref-type="bibr" rid="bib52">Lemey et al., 2006</xref>; <xref ref-type="bibr" rid="bib105">Zanini et al., 2015</xref>) and have indicated that the efficacy of drugs in ART can severely impact the mode of viral evolution and escape (<xref ref-type="bibr" rid="bib25">Feder et al., 2016</xref>). Despite the complex evolutionary dynamics of HIV-1 within patients due to individualized immune pressure (<xref ref-type="bibr" rid="bib70">Nourmohammad et al., 2019</xref>), genetic linkage (<xref ref-type="bibr" rid="bib105">Zanini et al., 2015</xref>), recombination (<xref ref-type="bibr" rid="bib67">Neher and Leitner, 2010</xref>; <xref ref-type="bibr" rid="bib105">Zanini et al., 2015</xref>), and epistasis between loci (<xref ref-type="bibr" rid="bib6">Bonhoeffer et al., 2004</xref>; <xref ref-type="bibr" rid="bib107">Zhang et al., 2020</xref>), the genetic composition of a population can still provide valuable information about the evolutionary significance of specific mutations, especially in highly vulnerable regions of the virus. For example, analysis of genomic covariation in the Gag protein of HIV-1 has been successful in predicting fitness effect of mutations in relatively conserved regions of the virus, which could inform the design of rational T-cell therapies that target these vulnerable regions (<xref ref-type="bibr" rid="bib28">Ferguson et al., 2013</xref>). In the context of bNAb therapy trials, an evolutionary model accounting for the intrinsic fitness cost associated with escape variants against a specific bNAb has been used to characterize HIV-1 dynamics and escape following bNAb infusion (<xref ref-type="bibr" rid="bib63">Meijers et al., 2021</xref>).</p><p>In this study, we present a coarse-grained evolutionary model of viral response to bNAb infusion that uses genetic data of HIV-1 in untreated patient to predict bNAb therapy outcome by characterizing the chances of viral escape from a given bNAb in patients. Specifically, we develop a statistical inference framework that uses the high throughput longitudinal survey of viral sequences collected from 11 ART-naive patients over about 10 years of infection (<xref ref-type="bibr" rid="bib105">Zanini et al., 2015</xref>) to characterize the evolutionary fate of escape mutations and to predict patient outcomes in recent mono- and combination therapy trials with 10–1074 and 3BNC117 bNAbs (<xref ref-type="bibr" rid="bib10">Caskey et al., 2015</xref>; <xref ref-type="bibr" rid="bib12">Caskey et al., 2017</xref>; <xref ref-type="bibr" rid="bib4">Baron et al., 2018</xref>), and a trial with PGT121 bNAb (<xref ref-type="bibr" rid="bib92">Stephenson et al., 2021</xref>). Using the accumulated intra-patient genetic variation from deep sequencing of HIV-1 populations in ART–naive patients (<xref ref-type="bibr" rid="bib105">Zanini et al., 2015</xref>), we can estimate the diversity and the fitness effects of mutations at sites mediating escape. These variables parametrize our individual-based model for viral dynamics and characterize the expected path for a potential escape of HIV-1 populations in response to bNAb therapies in patients enrolled in the clinical trials. Although our coarse-grained model does not accurately reproduce the detailed dynamics of viremia in each patient and lacks the mechanistic insight of richer models proposed by <xref ref-type="bibr" rid="bib74">Perelson et al., 1996</xref>; <xref ref-type="bibr" rid="bib80">Rong et al., 2010</xref>; <xref ref-type="bibr" rid="bib79">Rong et al., 2007</xref>; <xref ref-type="bibr" rid="bib97">Tomaras et al., 2008</xref>; <xref ref-type="bibr" rid="bib9">Cardozo-Ojeda and Perelson, 2021</xref>; <xref ref-type="bibr" rid="bib92">Stephenson et al., 2021</xref>, it still accurately predicts the distribution of viral rebound times in response to passive bNAb infusions — a key measure the efficacy for a bNAb clinical trial.</p><p>Our prediction for the viral rebound time in response to a bNAb relies on only a few patient-specific parameters (i.e. the genetic diversity of patients prior to treatment), and is primarily done based on the inferred genetic parameters from the deep sequencing of HIV-1 populations in a separate cohort of ART-naive patient. Therefore, our model could be used to guide therapy trial design with bNAbs against which viral escape variants are previously characterized. To this end, we use our approach to assess a broader panel of nine bNAbs, for which escape sites can be identified from prior deep mutational scanning experiments (<xref ref-type="bibr" rid="bib21">Dingens et al., 2019</xref>), to characterize the therapeutic efficacy of each of these bNAbs and to propose optimal combination therapies that can efficiently curb an HIV-1 infection. Our results showcase how the wealth of genetic data can be leveraged to guide rational therapy approaches against HIV. Importantly, this approach is potentially applicable to therapy designs against other evolving pathogens, such as chronic viruses like HCV, resistant bacteria, or cancer tumor cells.</p><sec id="s1-1"><title>Model</title><sec id="s1-1-1"><title>HIV-1 response to therapy</title><p>After infusion of bNAbs in a patient, the antibodies bind and neutralize the susceptible strains of HIV. The neutralized subpopulation of HIV-1 no longer infects T-cells, and the plasma RNA copy-number associated with this neutralized population decays. The dynamics of viremia in HIV-1 patients off ART following a bNAb therapy with 3BNC117 (<xref ref-type="bibr" rid="bib10">Caskey et al., 2015</xref>), 10–1074 (<xref ref-type="bibr" rid="bib12">Caskey et al., 2017</xref>), and their combination (<xref ref-type="bibr" rid="bib4">Baron et al., 2018</xref> ) are shown in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplements 1</xref>–<xref ref-type="fig" rid="fig3s3">3</xref>. With competition of the neutralized strains removed, the resistant subpopulation grows until the viral load typically recovers to a level close to the pretreatment state (i.e. the carrying capacity); see <xref ref-type="fig" rid="fig1">Figure 1A</xref>. The time it takes for the viral load to recover is the <italic>rebound time</italic>—a key quantity that characterizes treatment efficacy within a patient. Although the details of the viremia dynamics, especially at beginning and at the end of the therapy, may be complex (<xref ref-type="bibr" rid="bib58">Lu et al., 2016</xref>; <xref ref-type="bibr" rid="bib76">Reeves et al., 2020</xref>; <xref ref-type="bibr" rid="bib81">Saha and Dixit, 2020</xref>; <xref ref-type="bibr" rid="bib63">Meijers et al., 2021</xref>), the rebound time can be approximately modeled using a logistic growth after bNAb infusion (t &gt; 0),<disp-formula id="equ1"><label>(1)</label><mml:math id="m1"><mml:mrow><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mtable columnalign="left left" rowspacing=".2em" columnspacing="1em" displaystyle="false"><mml:mtr><mml:mtd><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mtd><mml:mtd><mml:mi>t</mml:mi><mml:mo>≤</mml:mo><mml:mn>0</mml:mn></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mi>r</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mfrac><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>x</mml:mi></mml:mrow><mml:mi>x</mml:mi></mml:mfrac><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mi>γ</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:mtd><mml:mtd><mml:mi>t</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn></mml:mtd></mml:mtr></mml:mtable><mml:mo fence="true" stretchy="true" symmetric="true"/></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>with the initial condition set for pre-treatment fraction of resistant subpopulation <inline-formula><mml:math id="inf1"><mml:mrow><mml:mi>x</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>r</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>r</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></inline-formula>, where <inline-formula><mml:math id="inf2"><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>r</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="inf3"><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> denote the size of resistant and susceptible subpopulations at time <inline-formula><mml:math id="inf4"><mml:mrow><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula>, respectively. Here, <inline-formula><mml:math id="inf5"><mml:mi>γ</mml:mi></mml:math></inline-formula> is the growth rate of the resistant population, <inline-formula><mml:math id="inf6"><mml:mi>r</mml:mi></mml:math></inline-formula> is the neutralization rate impacting the susceptible subpopulation, and <inline-formula><mml:math id="inf7"><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula> is the carrying capacity (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, Methods). In our analysis, we set <inline-formula><mml:math id="inf8"><mml:mrow><mml:mi>γ</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>3</mml:mn></mml:mrow><mml:mo>⁢</mml:mo><mml:msup><mml:mtext> days</mml:mtext><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math></inline-formula> or a doubling time of <inline-formula><mml:math id="inf9"><mml:mrow><mml:mi/><mml:mo>∼</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula> days, the known HIV-1 growth rate in patients (<xref ref-type="bibr" rid="bib74">Perelson et al., 1996</xref>). We infer the neutralization rate <inline-formula><mml:math id="inf10"><mml:mi>r</mml:mi></mml:math></inline-formula> as a global parameter for each trial, since it depends on the neutralization efficacy of a bNAb at the concentration used in the trial. We will infer the patient-specific pre-treatment fraction of resistant subpopulation <inline-formula><mml:math id="inf11"><mml:mi>x</mml:mi></mml:math></inline-formula>, using a population genetics based approach based on which we characterize the mutational target size and selection cost of escape in the absence of a bNAb (see below). The maximum-likelihood fits of <inline-formula><mml:math id="inf12"><mml:mrow><mml:mi>N</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> to the viremia measurements in <xref ref-type="fig" rid="fig2">Figures 2</xref> and <xref ref-type="fig" rid="fig3">3</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplements 1</xref>–<xref ref-type="fig" rid="fig3s3">3</xref> specifies the initial resistant fraction <italic>x</italic><sub><italic>p</italic></sub> and the rebound time <inline-formula><mml:math id="inf13"><mml:msub><mml:mi>T</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:math></inline-formula> in each patient <inline-formula><mml:math id="inf14"><mml:mi>p</mml:mi></mml:math></inline-formula>, which in this simple model, is given by <inline-formula><mml:math id="inf15"><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo>-</mml:mo><mml:mrow><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo>⁢</mml:mo><mml:mrow><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:math></inline-formula> (Methods).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Schematics for the evolutionary dynamics of viral rebound.</title><p>(<bold>A</bold>) The viral dynamics after the initiation of a treatment with bNAb infusion (<inline-formula><mml:math id="inf16"><mml:mrow><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula>) is determined by two competing processes. Susceptible strains (sus) undergo exponential decay (red line) with decay rate given by <inline-formula><mml:math id="inf17"><mml:mi>r</mml:mi></mml:math></inline-formula>, while the resistant mutants (mut) undergo logistic growth back up to the carrying capacity (<inline-formula><mml:math id="inf18"><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula>) of the patient. In the deterministic limit (<xref ref-type="disp-formula" rid="equ1">Equation 1</xref>), the rebound time is linearly related to the log-frequency of the mutant fraction. (<bold>B</bold>) The schematic shows the four stochastic processes of birth, death, mutation, and neutralization with their respective rates for susceptible (purple) and resistant (blue) variants. These processes define the evolution of a viral population. Note that both the susceptible and the resistant variants are subject to birth and death with their respective rates. (<bold>C</bold>) The birth and death rates can be visualized as a region of size <inline-formula><mml:math id="inf19"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mi>β</mml:mi><mml:mo>+</mml:mo><mml:mi>δ</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> which is partitioned into birth and death events. In the absence of antibodies, the susceptible population has balanced birth and death rates, <inline-formula><mml:math id="inf20"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>, while the resistant population has a negative net birth rate equal to the fitness difference <inline-formula><mml:math id="inf21"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:msub><mml:mi>δ</mml:mi><mml:mi>m</mml:mi></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mi>m</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>. After introduction of the antibody, the susceptible population decays at rate <inline-formula><mml:math id="inf22"><mml:mi>r</mml:mi></mml:math></inline-formula>, and without competition from the susceptible population, the resistant population grows at the free growth-rate <inline-formula><mml:math id="inf23"><mml:mi>γ</mml:mi></mml:math></inline-formula>. (<bold>D</bold>) Mutational target size is inferred a priori from the genotype-phenotype mapping, which can be visualized as a bipartite graph. The nodes correspond to codons, while the edges are the mutations which link one codon to another, weighted according to the respective mutation rates. The average edge weight from codons of susceptible variants to the escape mutants determines the rate of escape mutations <inline-formula><mml:math id="inf24"><mml:mi>μ</mml:mi></mml:math></inline-formula>. Mutations can be divided into two types: transitions (black) are within-class, and transversions (red) are out of class nucleotide changes. Transitions occur at about 8 times higher rate than transversions (<xref ref-type="fig" rid="fig2">Figure 2</xref>). (<bold>E</bold>) A coarse grained fitness and mutation model for two of the escape sites (281 and 282) against antibody 3BNC117 are shown. Left: At each escape mediating site, amino acids fall into one of three groups: (<bold>i</bold>) susceptible (wild-type), (ii) escape mutant, and (iii) fatal. For an escape-class amino acid at site <inline-formula><mml:math id="inf25"><mml:mi>i</mml:mi></mml:math></inline-formula> the virus incurs a fitness cost <inline-formula><mml:math id="inf26"><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math></inline-formula>, and these costs are additive across sites. Right: Mutations at a given site <inline-formula><mml:math id="inf27"><mml:mi>i</mml:mi></mml:math></inline-formula> occur with (independent) forward <inline-formula><mml:math id="inf28"><mml:msub><mml:mi>μ</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math></inline-formula> and backward <inline-formula><mml:math id="inf29"><mml:msubsup><mml:mi>μ</mml:mi><mml:mi>i</mml:mi><mml:mo>†</mml:mo></mml:msubsup></mml:math></inline-formula> rates which govern the substitution events between amino acid classes.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76004-fig1-v2.tif"/></fig><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Statistics of viral genome sequences from bNAb-naive HIV-1 patients.</title><p>(<bold>A</bold>) Statistics of the high-throughput longitudinal data collected from HIV-1 populations in 11 ART-naive patients from <xref ref-type="bibr" rid="bib105">Zanini et al., 2015</xref>, is shown. Some of the have low diversity (vertical red lines) and were not usable for our study. Usable samples (vertical black lines) amount to 4–10 samples per patient, collected over 5–10 years of infection. (<bold>B</bold>) Lower panels show the relative frequencies (cube-root transformed for legibility) of different amino acids in four patients at the 3 escape sites against the 10–1074 bNAb, estimated from the polymorphism data at the nucleotide level in each patient over time. Despite 10–1074 being a broadly neutralizing antibody, mutations associated with escape (indicated by a *) are commonly observed in untreated patients. The upper right panel shows the number of individuals (out of the cohort of 11 bNAb-naive HIV-1 patients) that carry mutations associated with escape against the indicated bNAbs. (<bold>C</bold>) The nucleotide diversity associated with transversion <inline-formula><mml:math id="inf30"><mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mtext>tv</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mo>⁢</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>e</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mtext>tv</mml:mtext></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> is shown against the transition diversity <inline-formula><mml:math id="inf31"><mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mo>⁢</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>e</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> for all patients (colors) and all time points. The covariance of these two diversity measurements yields an estimate for the transition/transversion ratio <inline-formula><mml:math id="inf32"><mml:mrow><mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mtext>tv</mml:mtext></mml:msub></mml:mrow><mml:mo>=</mml:mo><mml:mn>7.6</mml:mn></mml:mrow></mml:math></inline-formula>. (<bold>D</bold>) Left: The transition diversity is shown to grow as a function of time since infection in all the 11 patients (colors according to (<bold>A</bold>)). Right: The neutral diversity of viral populations in patients (points) from the three different clinical trials (<xref ref-type="bibr" rid="bib10">Caskey et al., 2015</xref>; <xref ref-type="bibr" rid="bib12">Caskey et al., 2017</xref>; <xref ref-type="bibr" rid="bib4">Baron et al., 2018</xref>) analyzed in this study resemble the larger diversities of long-established viral populations in untreated patients. (<bold>E</bold>) The inferred forward and backward mutation rates (<inline-formula><mml:math id="inf33"><mml:mrow><mml:mi>μ</mml:mi><mml:mo rspace="4.2pt">,</mml:mo><mml:msup><mml:mi>μ</mml:mi><mml:mo>†</mml:mo></mml:msup></mml:mrow></mml:math></inline-formula>), relative to the transition rate, and the median selection strength <inline-formula><mml:math id="inf34"><mml:mrow><mml:mi>σ</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mo>⁢</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>e</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mtext>sus</mml:mtext></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mtext>res</mml:mtext></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></inline-formula> at each escape site against the two bNAbs (10–1074, and 3BNC117) from the trial data used in this study are shown. Compared to the 10–1074 bNAb, escape from the 3BNC117 bNAb appears to be less costly, and is associated with a smaller mutational target.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76004-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Inference of neutral diversity from genetic data.</title><p>(<bold>A</bold>) The inter-decile ranges of neutral diversity estimates for 10<sup>3</sup> simulations of genomes of 10<sup>2</sup> independent neutral sites are shown. The true values of the diversity used for simulations are shown in black. Inter-decile maximum likelihood estimate (MLE) for the diversity <inline-formula><mml:math id="inf35"><mml:mi>θ</mml:mi></mml:math></inline-formula> from <xref ref-type="disp-formula" rid="equ23">Equation 22</xref> are shown in red, and the observed variance of allele frequency <inline-formula><mml:math id="inf36"><mml:mi>x</mml:mi></mml:math></inline-formula> as a measure of diversity <inline-formula><mml:math id="inf37"><mml:mrow><mml:mi>θ</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mo>⁢</mml:mo><mml:mi>x</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>x</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></inline-formula> is shown in blue. The inferred diversity associated with transversions <inline-formula><mml:math id="inf38"><mml:msub><mml:mi>θ</mml:mi><mml:mtext>tv</mml:mtext></mml:msub></mml:math></inline-formula> is shown against that of the transition <inline-formula><mml:math id="inf39"><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:math></inline-formula> for patients (colors) enrolled in (<bold>B</bold>) the longitudinal study with high throughput HIV-1 sequence data (<xref ref-type="bibr" rid="bib105">Zanini et al., 2015</xref>), and in the bNAB trials with (<bold>C</bold>) 10–1074 (<xref ref-type="bibr" rid="bib12">Caskey et al., 2017</xref>), (<bold>D</bold>) 3BNC117 (<xref ref-type="bibr" rid="bib10">Caskey et al., 2015</xref>), and (<bold>E</bold>) combination of 10–1074 and 3BNC117 (<xref ref-type="bibr" rid="bib4">Baron et al., 2018</xref>). We find that all four diversity distributions share similar ratios <inline-formula><mml:math id="inf40"><mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mtext>tv</mml:mtext></mml:msub></mml:mrow></mml:math></inline-formula>, indicated in each panel.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76004-fig2-figsupp1-v2.tif"/></fig></fig-group><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Statistics of viral rebound in clinical trials with bNAbs.</title><p>(<bold>A</bold>) Panels show viremia of three patients from the 3BNC117 trial over time (black circles) and the fitted model of the viral decay and rebound processes from <xref ref-type="disp-formula" rid="equ1">Equation 1</xref> (orange line). The viral rebound time <inline-formula><mml:math id="inf41"><mml:mi>T</mml:mi></mml:math></inline-formula> and the fitted carrying capacity <inline-formula><mml:math id="inf42"><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula> is shown in each panel. Shown are examples of a non-responder (NR; left), a rebound occurring during the trial window (<inline-formula><mml:math id="inf43"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>0</mml:mn><mml:mo>&lt;</mml:mo><mml:mi>T</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>56</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> days; center), and a late rebound (<inline-formula><mml:math id="inf44"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>T</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>56</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> days; right). (<bold>B</bold>) We compare the distribution of rebound times in patients from the three clinical trials with 10–1074 <xref ref-type="bibr" rid="bib12">Caskey et al., 2017</xref>, 3BNC117 <xref ref-type="bibr" rid="bib82">Scheid et al., 2016</xref>, and the combination of the two bNAbs <xref ref-type="bibr" rid="bib4">Baron et al., 2018</xref> to the predictions from the simulations based on our evolutionary model (<xref ref-type="fig" rid="fig1">Figure 1</xref>, and Methods). The error bars show the inter decile range (0.1–0.9 quantiles) generated by the simulations for the corresponding trial. (<bold>C</bold>) The summary table shows the number of patients for whom the infecting HIV-1 population shows no response (NR), rebound during the trial window <inline-formula><mml:math id="inf45"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>0</mml:mn><mml:mo>&lt;</mml:mo><mml:mi>T</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>56</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>, and a late rebound (<inline-formula><mml:math id="inf46"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>T</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>56</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> days) in each trial. Note that three patients were excluded from the 3BNC117 trial (*) because of insufficient dosage leading to weak viral response: <inline-formula><mml:math id="inf47"><mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>⁢</mml:mo><mml:mtext>mg</mml:mtext></mml:mrow><mml:mo>/</mml:mo><mml:mtext>kg</mml:mtext></mml:mrow></mml:math></inline-formula> compared to the <inline-formula><mml:math id="inf48"><mml:mrow><mml:mn>3</mml:mn><mml:mo>-</mml:mo><mml:mrow><mml:mrow><mml:mn>30</mml:mn><mml:mo>⁢</mml:mo><mml:mtext>mg</mml:mtext></mml:mrow><mml:mo>/</mml:mo><mml:mtext>kg</mml:mtext></mml:mrow></mml:mrow></mml:math></inline-formula> in the other treatment groups. (<bold>D</bold>) Plotted are 1,200 trajectories of the mutant viral population simulated using our individual based model. Due to the individual birth-death events, fluctuations are larger when the population size is smaller. At a critical threshold, <inline-formula><mml:math id="inf49"><mml:msub><mml:mi>x</mml:mi><mml:mtext>ext</mml:mtext></mml:msub></mml:math></inline-formula>, fluctuations are large enough to lead to almost certain extinction in the existing viral population. The critical threshold (yellow line) is an order of magnitude larger than the post-treatment spontaneously-generated mutant fraction (red line). (<bold>E</bold>) The predicted fraction of escape events associated with post-treatment spontaneous mutations (red) and the pre-treatment standing variation (yellow) are shown for the three trials. Late rebound events are indicated in blue. Because the spontaneously-generated mutant fraction is smaller than the extinction threshold, these mutations contribute to less than 4% of escape events (red), and escape is likely primarily driven driven by standing variation (yellow), that is, pre-existing escape variants.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76004-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Dynamics of viremia in patients from the 10–1074 trial.</title><p>Panels shows the measured viremia over time (black dots) and the fitted deterministic dynamics from <xref ref-type="disp-formula" rid="equ5">Equation 5</xref> (red line) for all patients off ART in the 10–1074 trial <xref ref-type="bibr" rid="bib12">Caskey et al., 2017</xref>. Patient-specific fitted carrying capacity <inline-formula><mml:math id="inf50"><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula> and the estimated rebound times are reported in each panel. A common decay rate <inline-formula><mml:math id="inf51"><mml:mrow><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mn>0.36</mml:mn><mml:mo>⁢</mml:mo><mml:msup><mml:mtext> day</mml:mtext><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math></inline-formula> is fitted to all patient data in this trial, and growth rate is set to <inline-formula><mml:math id="inf52"><mml:mrow><mml:mn>0.33</mml:mn><mml:mo>⁢</mml:mo><mml:msup><mml:mtext> day</mml:mtext><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76004-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Dynamics of viremia in patients from the 3BNC117 trial.</title><p>Similar to <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref> but for the 3BNC117 trial <xref ref-type="bibr" rid="bib10">Caskey et al., 2015</xref>. The cohort treated with a low dosage of bNAb (<inline-formula><mml:math id="inf53"><mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>⁢</mml:mo><mml:mtext> mg</mml:mtext></mml:mrow><mml:mo>/</mml:mo><mml:mtext>kg</mml:mtext></mml:mrow></mml:math></inline-formula> as opposed to <inline-formula><mml:math id="inf54"><mml:mrow><mml:mn>3</mml:mn><mml:mo>-</mml:mo><mml:mrow><mml:mrow><mml:mn>30</mml:mn><mml:mo>⁢</mml:mo><mml:mtext> mg</mml:mtext></mml:mrow><mml:mo>/</mml:mo><mml:mtext>kg</mml:mtext></mml:mrow></mml:mrow></mml:math></inline-formula>) is shown in yellow; these patients exhibited a very weak response to there treatment and were excluded from our analysis. A common decay rate <inline-formula><mml:math id="inf55"><mml:mrow><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mn>0.23</mml:mn><mml:mo>⁢</mml:mo><mml:msup><mml:mtext> day</mml:mtext><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math></inline-formula> is fitted to all patient data in this trial, and growth rate is set to <inline-formula><mml:math id="inf56"><mml:mrow><mml:mn>0.33</mml:mn><mml:mo>⁢</mml:mo><mml:msup><mml:mtext> day</mml:mtext><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76004-fig3-figsupp2-v2.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>Dynamics of viremia in patients from the combination therapy trial.</title><p>Similar to <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref> but for the combination therapy with 10–1074 and 3BNC117 <xref ref-type="bibr" rid="bib4">Baron et al., 2018</xref>. A common decay rate <inline-formula><mml:math id="inf57"><mml:mrow><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mn>0.33</mml:mn><mml:mo>⁢</mml:mo><mml:msup><mml:mtext> day</mml:mtext><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math></inline-formula> is fitted to all patients off ART in this trial, and growth rate is set to <inline-formula><mml:math id="inf58"><mml:mrow><mml:mn>0.33</mml:mn><mml:mo>⁢</mml:mo><mml:msup><mml:mtext> day</mml:mtext><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76004-fig3-figsupp3-v2.tif"/></fig></fig-group><p>The rebound times following passive infusion of 3BNC117 (<xref ref-type="bibr" rid="bib10">Caskey et al., 2015</xref> and 10–1077 <xref ref-type="bibr" rid="bib12">Caskey et al., 2017</xref>) bNAbs range from 1 to 4 weeks, with a small fraction of patients exceeding the monitoring time window in the studies (late rebounds past 56 days). The distribution of rebound times summarizes the escape response of the virus to a therapy and directly relates to the distribution for the pre-treatment fraction of resistant variants <inline-formula><mml:math id="inf59"><mml:mrow><mml:mi>P</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> across patients <inline-formula><mml:math id="inf60"><mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>T</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>∼</mml:mo><mml:mrow><mml:msup><mml:mi>x</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo>⁢</mml:mo><mml:mi>P</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></inline-formula>.</p></sec><sec id="s1-1-2"><title>Stochastic evolutionary dynamics of HIV-1 subject to bNAb therapy</title><p>The fate of an HIV-1 population subject to bNAb therapy depends on the composition of the pre-treatment population with resistant and susceptible variants, and the establishment of resistant variants following the treatment. To capture these effects, we construct an individual-based stochastic model for viral rebound (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). We specify a coarse-grained phenotypic model, where a viral strain of type <inline-formula><mml:math id="inf61"><mml:mi>a</mml:mi></mml:math></inline-formula> is defined by a binary state vector <inline-formula><mml:math id="inf62"><mml:mrow><mml:msup><mml:mover accent="true"><mml:mi>ρ</mml:mi><mml:mo stretchy="false">→</mml:mo></mml:mover><mml:mi>a</mml:mi></mml:msup><mml:mo>=</mml:mo><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:msubsup><mml:mi>ρ</mml:mi><mml:mn>1</mml:mn><mml:mi>a</mml:mi></mml:msubsup><mml:mo>,</mml:mo><mml:mi mathvariant="normal">…</mml:mi><mml:mo>,</mml:mo><mml:msubsup><mml:mi>ρ</mml:mi><mml:mi mathvariant="normal">ℓ</mml:mi><mml:mi>a</mml:mi></mml:msubsup><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>, with <inline-formula><mml:math id="inf63"><mml:mi mathvariant="normal">ℓ</mml:mi></mml:math></inline-formula> entries for potentially escape-mediating epitope sites; the binary entry of the state vector at the epitope site <inline-formula><mml:math id="inf64"><mml:mi>i</mml:mi></mml:math></inline-formula> represents the presence (<inline-formula><mml:math id="inf65"><mml:mrow><mml:msubsup><mml:mi>ρ</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>) or absence (<inline-formula><mml:math id="inf66"><mml:mrow><mml:msubsup><mml:mi>ρ</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula>) of an escape mediating mutation against a specified bNAb at this site of variant <inline-formula><mml:math id="inf67"><mml:mi>a</mml:mi></mml:math></inline-formula>. We assume that a variant is resistant to a given antibody if at least one of the entries of its corresponding state vector is non-zero. For multivalent treatment, a virus must be resistant to all antibodies comprising the treatment to have a positive growth after infusion.</p><p>At each generation, a virus with phenotype <inline-formula><mml:math id="inf68"><mml:mi>a</mml:mi></mml:math></inline-formula> can undergo one of three processes: birth, death and mutation to another type <inline-formula><mml:math id="inf69"><mml:mi>b</mml:mi></mml:math></inline-formula>, with rates <inline-formula><mml:math id="inf70"><mml:msub><mml:mi>β</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:math></inline-formula>, <inline-formula><mml:math id="inf71"><mml:msub><mml:mi>δ</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:math></inline-formula>, and <inline-formula><mml:math id="inf72"><mml:msub><mml:mi>μ</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mo>→</mml:mo><mml:mi>b</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>, respectively (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). The net growth rate of the viral subpopulation with phenotype <inline-formula><mml:math id="inf73"><mml:mi>a</mml:mi></mml:math></inline-formula> is the birth rate minus the death rate, <inline-formula><mml:math id="inf74"><mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). The total rate of events (birth and death) per virion <inline-formula><mml:math id="inf75"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> modulates the amount of stochasticity in this birth-death process (Methods), which we assume to be constant across phenotypic variants. The continuous limit for this birth-death process results in a stochastic evolutionary dynamics for the sub-population size <inline-formula><mml:math id="inf76"><mml:msub><mml:mi>N</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:math></inline-formula>,<disp-formula id="equ2"><label>(2)</label><mml:math id="m2"><mml:mrow><mml:mtable columnalign="right left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mrow><mml:mstyle mathsize="0.85em"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mtable columnalign="left left" rowspacing=".2em" columnspacing="1em" displaystyle="false"><mml:mtr><mml:mtd><mml:mrow><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">N</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">b</mml:mi><mml:mspace width="thinmathspace"/></mml:mrow><mml:mrow><mml:mi mathvariant="bold">o</mml:mi><mml:mi mathvariant="bold">r</mml:mi></mml:mrow><mml:mrow><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mspace width="thinmathspace"/></mml:mrow><mml:mi>a</mml:mi><mml:mrow><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mo>:</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mi>ϕ</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mi>b</mml:mi></mml:mrow></mml:munder><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>b</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>μ</mml:mi><mml:mrow><mml:msub><mml:mrow/><mml:mrow><mml:mi>b</mml:mi><mml:mo stretchy="false">→</mml:mo><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>μ</mml:mi><mml:mrow><mml:msub><mml:mrow/><mml:mrow><mml:mi>a</mml:mi><mml:mo stretchy="false">→</mml:mo><mml:mi>b</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mspace width="1em"/><mml:mo>+</mml:mo><mml:msqrt><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mi>λ</mml:mi></mml:msqrt><mml:mspace width="thinmathspace"/><mml:mi>η</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd/></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">N</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">b</mml:mi><mml:mspace width="thinmathspace"/></mml:mrow><mml:mrow><mml:mi mathvariant="bold">a</mml:mi><mml:mi mathvariant="bold">n</mml:mi><mml:mi mathvariant="bold">d</mml:mi></mml:mrow><mml:mrow><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mspace width="thinmathspace"/></mml:mrow><mml:mi>a</mml:mi><mml:mrow><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mo>:</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>−</mml:mo><mml:mi>r</mml:mi><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mi>b</mml:mi></mml:mrow></mml:munder><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>b</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>μ</mml:mi><mml:mrow><mml:msub><mml:mrow/><mml:mrow><mml:mi>b</mml:mi><mml:mo stretchy="false">→</mml:mo><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>μ</mml:mi><mml:mrow><mml:msub><mml:mrow/><mml:mrow><mml:mi>a</mml:mi><mml:mo stretchy="false">→</mml:mo><mml:mi>b</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msqrt><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mi>λ</mml:mi></mml:msqrt><mml:mspace width="thinmathspace"/><mml:mi>η</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr></mml:mtable><mml:mo fence="true" stretchy="true" symmetric="true"/></mml:mrow></mml:mstyle></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf77"><mml:mrow><mml:mi>η</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> is a Gaussian random variable with mean <inline-formula><mml:math id="inf78"><mml:mrow><mml:mrow><mml:mo stretchy="false">⟨</mml:mo><mml:mrow><mml:mi>η</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo stretchy="false">⟩</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula> and correlation <inline-formula><mml:math id="inf79"><mml:mrow><mml:mrow><mml:mo stretchy="false">⟨</mml:mo><mml:mrow><mml:mi>η</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>⁢</mml:mo><mml:mi>η</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi>t</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo stretchy="false">⟩</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mi>δ</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>t</mml:mi><mml:mo>-</mml:mo><mml:msup><mml:mi>t</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></inline-formula> (Methods). Here, <italic>f</italic><sub><italic>a</italic></sub> denotes the intrinsic fitness of variant <inline-formula><mml:math id="inf80"><mml:mi>a</mml:mi></mml:math></inline-formula> and its net growth rate <inline-formula><mml:math id="inf81"><mml:mi>γ</mml:mi></mml:math></inline-formula> is mediated by a competitive pressure <inline-formula><mml:math id="inf82"><mml:mrow><mml:mi mathsize="90%">ϕ</mml:mi><mml:mo mathsize="90%" stretchy="false">=</mml:mo><mml:mrow><mml:mfrac><mml:mn mathsize="90%">1</mml:mn><mml:msub><mml:mi mathsize="90%">N</mml:mi><mml:mi mathsize="90%">k</mml:mi></mml:msub></mml:mfrac><mml:mo>⁢</mml:mo><mml:mrow><mml:msub><mml:mo largeop="true" mathsize="90%" stretchy="false" symmetric="true">∑</mml:mo><mml:mi mathsize="90%">b</mml:mi></mml:msub><mml:mrow><mml:msub><mml:mi mathsize="90%">N</mml:mi><mml:mi mathsize="90%">b</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:msub><mml:mi mathsize="90%">f</mml:mi><mml:mi mathsize="90%">b</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:math></inline-formula> with the rest of the population constrained by the carrying capacity <inline-formula><mml:math id="inf83"><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula>, such that <inline-formula><mml:math id="inf84"><mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo>-</mml:mo><mml:mi>ϕ</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula>. In the presence of a bNAb, birth is effectively halted for susceptible variants and their death rate is set by the neutralization rate of the antibody, resulting in a net growth rate, <inline-formula><mml:math id="inf85"><mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mtext>sus.</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo>-</mml:mo><mml:mi>r</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula>. At the carrying capacity, the competitive pressure is the mean population fitness <inline-formula><mml:math id="inf86"><mml:mrow><mml:mi>ϕ</mml:mi><mml:mo>=</mml:mo><mml:mover accent="true"><mml:mi>f</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>, making the net growth rate of the whole population zero (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). When susceptible variants are neutralized by a bNAb, the competitive pressure <inline-formula><mml:math id="inf87"><mml:mi>ϕ</mml:mi></mml:math></inline-formula> drops, and as a result, the resistant variants can rebound to carrying capacity, at growth rates near their intrinsic fitness.</p><p>To connect the birth-death model (<xref ref-type="disp-formula" rid="equ2">Equation 2</xref>) with data, we should relate the simulation parameters of a birth-death process to molecular observables. We have already made a connection between the birth and death rates of a variant and its intrinsic fitness in <xref ref-type="disp-formula" rid="equ2">Equation 2</xref>. In addition, the neutral diversity <inline-formula><mml:math id="inf88"><mml:mi>θ</mml:mi></mml:math></inline-formula> of a population at steady-state can be expressed as <inline-formula><mml:math id="inf89"><mml:mrow><mml:mi>θ</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mo>⁢</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mi>μ</mml:mi></mml:mrow><mml:mo>/</mml:mo><mml:mi>λ</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula>, where <inline-formula><mml:math id="inf90"><mml:mrow><mml:mi>μ</mml:mi><mml:mo>≈</mml:mo><mml:mrow><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>-</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:msup><mml:mo>/</mml:mo><mml:mtext> day</mml:mtext></mml:mrow></mml:mrow></mml:math></inline-formula> is the per-nucleotide mutation rate, which we infer from intra-patient longitudinal HIV-1 sequence data (<xref ref-type="bibr" rid="bib105">Zanini et al., 2015</xref>) (Methods). For consistency, we set the total rate of events <inline-formula><mml:math id="inf91"><mml:mi>λ</mml:mi></mml:math></inline-formula> to be at least as large as the fastest process in the dynamics, which in this case is the growth rate of resistant viruses <inline-formula><mml:math id="inf92"><mml:mrow><mml:mi>γ</mml:mi><mml:mo>≈</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>3</mml:mn><mml:mo>⁢</mml:mo><mml:mtext> days</mml:mtext></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>, we choose <inline-formula><mml:math id="inf93"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>0.5</mml:mn><mml:mo>⁢</mml:mo><mml:mtext> days</mml:mtext></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> (Methods). Therefore, the key parameters of the birth-death model, that is, <inline-formula><mml:math id="inf94"><mml:mrow><mml:mi>β</mml:mi><mml:mo rspace="4.2pt">,</mml:mo><mml:mi>δ</mml:mi><mml:mo rspace="4.2pt">,</mml:mo><mml:mrow><mml:mtext> and </mml:mtext><mml:mo>⁢</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> can be expressed in terms of the intrinsic fitness of the variants <italic>f</italic><sub><italic>a</italic></sub> and the neutral diversity <inline-formula><mml:math id="inf95"><mml:mi>θ</mml:mi></mml:math></inline-formula>, which we will infer from data.</p></sec></sec></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Population genetics of HIV-1 escape from bNAbs</title><p>HIV-1 escape from different bNAbs has been a subject of interest for vaccine and therapy design, and a number of escape variants against different bNAbs have been identified in clinical trials or in infected individuals (<xref ref-type="bibr" rid="bib59">Lynch et al., 2015</xref>; <xref ref-type="bibr" rid="bib10">Caskey et al., 2015</xref>; <xref ref-type="bibr" rid="bib82">Scheid et al., 2016</xref>; <xref ref-type="bibr" rid="bib12">Caskey et al., 2017</xref>; <xref ref-type="bibr" rid="bib4">Baron et al., 2018</xref>). This in-vivo data is often complemented with information from co-crystallized structures of bNAbs with the HIV-1 envelope protein (<xref ref-type="bibr" rid="bib73">Pancera et al., 2017</xref>), and in-vitro deep mutational scanning (DMS) experiments, in which the relative change in the growth rate of tens of thousands of viral mutants are measured in the presence of different bNAbs (<xref ref-type="bibr" rid="bib21">Dingens et al., 2019</xref>; <xref ref-type="bibr" rid="bib20">Dingens et al., 2017</xref>; <xref ref-type="bibr" rid="bib83">Schommers et al., 2020</xref>). We identify escape mutations against each of the bNAbs in this study by using information from clinical trials, the characterized binding sites, and the DMS assays (Methods); the list of escape mutations against each bNAb is given in <xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>.</p><p>The rise and establishment of an escape variant against a specific bNAb depend on three key factors, (i) neutral genetic diversity of the viral population, (ii) the mutational target size for escape from the bNAb (i.e. the number of paths leading to escape, weighted by their respective probabilities), and (iii) the intrinsic fitness associated with such mutations. Although viremia traces in clinical trials and growth experiments can be used to model the escape dynamics (<xref ref-type="bibr" rid="bib38">Haddox et al., 2018</xref>; <xref ref-type="bibr" rid="bib59">Lynch et al., 2015</xref>; <xref ref-type="bibr" rid="bib58">Lu et al., 2016</xref>; <xref ref-type="bibr" rid="bib76">Reeves et al., 2020</xref>; <xref ref-type="bibr" rid="bib81">Saha and Dixit, 2020</xref>; <xref ref-type="bibr" rid="bib63">Meijers et al., 2021</xref>), they do not offer a comprehensive statistical description for HIV-1 escape as they are limited by the number of enrolled individuals. Alternatively, mutation and fitness characteristics of such escape-mediating variants can be inferred from a broader cohort of untreated and bNAb-naive patients (<xref ref-type="bibr" rid="bib42">Illingworth et al., 2020</xref>; <xref ref-type="bibr" rid="bib57">Louie et al., 2018</xref>). We will infer statistical parameters for our coarse-grained fitness model (<xref ref-type="fig" rid="fig1">Figure 1E</xref>) from the large amount of high-throughput HIV-1 sequence data from <xref ref-type="bibr" rid="bib105">Zanini et al., 2015</xref> (see <xref ref-type="fig" rid="fig2">Figure 2A and B</xref> for details) and use them to parameterize the birth-death model (<xref ref-type="fig" rid="fig1">Figure 1B</xref>).</p><sec id="s2-1-1"><title>Diversity of the viral population</title><p>The neutral genetic diversity <inline-formula><mml:math id="inf96"><mml:mrow><mml:mi>θ</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mo>⁢</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mi>μ</mml:mi></mml:mrow><mml:mo>/</mml:mo><mml:mi>λ</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> (i.e. the number of segregating alleles) is an observable that relates to key population genetics parameters, that is, the per-nucleotide mutation rate <inline-formula><mml:math id="inf97"><mml:mi>μ</mml:mi></mml:math></inline-formula>, the population carrying capacity <inline-formula><mml:math id="inf98"><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula>, and the total number of events per virus in the birth-death process <inline-formula><mml:math id="inf99"><mml:mi>λ</mml:mi></mml:math></inline-formula>, which determines the noise amplitude in the evolutionary dynamics (Methods). <inline-formula><mml:math id="inf100"><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="inf101"><mml:mi>λ</mml:mi></mml:math></inline-formula> together determine the effective population size <inline-formula><mml:math id="inf102"><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>e</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:mi>λ</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula>. We use synonymous changes as a proxy for diversity associated with the neutral variation in an HIV-1 population at a given time point within a patient. By developing a maximum-likelihood approach based on the multiplicities of different synonymous variants, we can accurately infer the neutral diversity of a population from the large survey of synonymous sites in the HIV-1 genome (Methods and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Importantly, we infer the neutral diversity of transition <inline-formula><mml:math id="inf103"><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:math></inline-formula> and transversion <inline-formula><mml:math id="inf104"><mml:msub><mml:mi>θ</mml:mi><mml:mtext>tv</mml:mtext></mml:msub></mml:math></inline-formula> mutations separately, and consistent with previous work (<xref ref-type="bibr" rid="bib25">Feder et al., 2016</xref>; <xref ref-type="bibr" rid="bib106">Zanini et al., 2017</xref>), find that transitions occur with a rate of about 8 times larger than transversions (<xref ref-type="fig" rid="fig2">Figure 2C</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B-E</xref>).</p><p>Our inference indicates that the neutral diversity grows over the course of an infection in untreated HIV-1 patients from <xref ref-type="bibr" rid="bib105">Zanini et al., 2015</xref> (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). The patients enrolled in the three bNAb trials (<xref ref-type="bibr" rid="bib10">Caskey et al., 2015</xref>; <xref ref-type="bibr" rid="bib12">Caskey et al., 2017</xref>; <xref ref-type="bibr" rid="bib4">Baron et al., 2018</xref>) show a broad range of neutral diversity prior to bNAb therapy (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). In addition to the circulating viruses in a patient’s sera, the viral reservoir, which consists of replication-competent HIV-1 in latently infected cells or un-sampled tissue, can also contribute to a bNAb escape in a patient. Evidence that the latent reservoir can contribute to HIV escape from bnAbs is directly visible in trials as the failure of pre-trial sequencing to exclude patients who do not harbor escape variants. We model the effect of the reservoir as augmenting the neutral diversity by a constant multiplicative factor <inline-formula><mml:math id="inf105"><mml:msub><mml:mi>r</mml:mi><mml:mtext>resv.</mml:mtext></mml:msub></mml:math></inline-formula>, so that patients with more diverse sera, representing usually longer infections, are also expected to have correspondingly more diverse reservoir populations. By fitting the observed rebound data, we infer the reservoir factor <inline-formula><mml:math id="inf106"><mml:mrow><mml:msub><mml:mi>r</mml:mi><mml:mtext>resv.</mml:mtext></mml:msub><mml:mo>≃</mml:mo><mml:mn>2.07</mml:mn></mml:mrow></mml:math></inline-formula> (Methods, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). We use the augmented genetic diversity of HIV-1 prior to the bNAb therapy in each trial to generate the rebound time and the probability of HIV-1 escape in patients.</p></sec><sec id="s2-1-2"><title>Mutational target size for escape</title><p>We define the mutational target size for escape from a bNAb as the number of trajectories that connect the susceptible codon to codons associated with escape variants, weighed by their probability of occurrences (Methods). The connecting paths with only single nucleotide transitions or transversions dominate the escape and can be represented as connected graphs shown in <xref ref-type="fig" rid="fig1">Figure 1D</xref>. To characterize the target size of escape for each bNAb, we determine the forward mutation rate <inline-formula><mml:math id="inf107"><mml:mrow><mml:mi>μ</mml:mi><mml:mo>≡</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mrow><mml:mtext>sus.</mml:mtext><mml:mo>→</mml:mo><mml:mtext>res.</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> from the susceptible codons to the resistant (escape) codons, and the reverse mutation rate <inline-formula><mml:math id="inf108"><mml:mrow><mml:msup><mml:mi>μ</mml:mi><mml:mo>†</mml:mo></mml:msup><mml:mo>≡</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mrow><mml:mtext>sus.</mml:mtext><mml:mo>←</mml:mo><mml:mtext>res.</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> back to the susceptible variant (<xref ref-type="fig" rid="fig1">Figure 1D</xref>, Methods). The mutational target sizes vary across bNAbs, with HIV-1 escape being most restricted from 10E8 (<inline-formula><mml:math id="inf109"><mml:mrow><mml:mrow><mml:mi>μ</mml:mi><mml:mo>/</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:mrow><mml:mo>=</mml:mo><mml:mn>1.8</mml:mn></mml:mrow></mml:math></inline-formula> where <inline-formula><mml:math id="inf110"><mml:msub><mml:mi>μ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:math></inline-formula> is the single-nucleotide transition substitution rate) and most accessible in the presence of 10–1074 (<inline-formula><mml:math id="inf111"><mml:mrow><mml:mrow><mml:mi>μ</mml:mi><mml:mo>/</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:mrow><mml:mo>=</mml:mo><mml:mn>4.9</mml:mn></mml:mrow></mml:math></inline-formula>); see <xref ref-type="fig" rid="fig4">Figure 4C</xref> and <xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref> for the list of mutational target size for escape against all bNAbs in this study.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Statistics of viral escape for optimal combination therapy with bNAbs.</title><p>(<bold>A</bold>) The posterior distribution for inferred selection strength on the escape-mediating sites associated with each of the 9 bNAbs in this study is shown (right); white line: median, box: 50% around the median, bar: 80% around median. Each escape site is color coded by its location on the <italic>env</italic> gene (left) and each antibody by its associated epitope location. (<bold>B</bold>) The harmonic mean of the selection strength <inline-formula><mml:math id="inf112"><mml:mi>σ</mml:mi></mml:math></inline-formula> associated with cost of escape (scaled by transition diversity <inline-formula><mml:math id="inf113"><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:math></inline-formula>) is shown against the mutational target size for each bNAb; error bars indicate 50% around the median. For antibodies to be broadly neutralizing, it is sufficient that viral escape from them to be associated with a small mutational target size or a large fitness cost. The mutational target size is found to be weakly correlated with the average cost of escape from a given bNAb. We identify two distinct strategies for antibody breadth—selection limited and mutational-target-size limited escape pathways each highlighted in gray. (<bold>C</bold>) bNAb therapies with 1, 2, and 3 antibodies are ranked based on the predicted probability of early viral rebound, and in each case, six therapies with highest efficacies are shown; best ranked therapy is associated with the lowest probability of early rebound (<italic>lt</italic><sub>56</sub> days); indicate 50% around the median. Also for reference, the probability of early viral rebound two therapies from the trials in this study (10–1074 and 10–1074+3BNC117) are shown.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76004-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Robustness of selection inference to intra-patient temporal correlations of HIV-1 alleles and clade-specific sampling.</title><p>Fitness cost for escape mediating sites of different bNAbs is shown based on the selection inference using (<bold>A</bold>) the time-averaged likelihood (<xref ref-type="disp-formula" rid="equ41">Equation 40</xref> <inline-formula><mml:math id="inf114"><mml:mi>t</mml:mi></mml:math></inline-formula>-averaged) with data from all patients, as a reference (similar to <xref ref-type="fig" rid="fig4">Figure 4A</xref>), (<bold>B</bold>) the time-averaged likelihood (<xref ref-type="disp-formula" rid="equ41">Equation 40</xref> <inline-formula><mml:math id="inf115"><mml:mi>t</mml:mi></mml:math></inline-formula>-averaged) with data from patients infected with HIV-1 clade B only, and (<bold>C</bold>) independent time likelihood (<xref ref-type="disp-formula" rid="equ41">Equation 40</xref> <inline-formula><mml:math id="inf116"><mml:mi>t</mml:mi></mml:math></inline-formula>-independent) with data from all patients. Limiting the inference to patients infected with clade B virus in (<bold>B</bold>) result in minor changes in the inferred selection strength and a slight increase in uncertainties due to a smaller data. However, the general structure of the posteriors remain similar to (<bold>A</bold>). Treating all time points as independent in (<bold>C</bold>) increases the effective sample-size of the data and reduces model uncertainty. Nonetheless, except for slight changes on the selection ordering of escape sites against 3BNC117, the median of the selection posteriors remain similar to (<bold>A</bold>). The color code is similar to <xref ref-type="fig" rid="fig4">Figure 4A</xref> and is determined by the <italic>env</italic> region associated with each site.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76004-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Robustness of selection inference to genetic linkage and hitchhiking.</title><p>Results of selection inference for simulated populations that carry escape mediating sites linked with other selected sites in the genome are shown. The blue shading shows the interdecile ranges (0.1–0.9 quantiles) for the inferred maximum likelihood estimates (MLE) of scaled selection <inline-formula><mml:math id="inf117"><mml:mrow><mml:mover accent="true"><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>/</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> on the escape mediating sites versus the true values used in the simulations, for different genetic linkage effects (columns) and different values of population diversity (rows). Each inferred value is based on 10 realizations of simulations (in-silico patients) for populations evolving over time, with samples taken at 10 time points spaced at 100 days. Simulations are done on whole genomes of length 512, in which 32 sites under strong selection <inline-formula><mml:math id="inf118"><mml:mrow><mml:mn>0.02</mml:mn><mml:mo>⁢</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> are equally spaced throughout the genome; <italic>f</italic><sub>0</sub> is the base growth rate of <inline-formula><mml:math id="inf119"><mml:mrow><mml:mn>1.0</mml:mn><mml:mo>⁢</mml:mo><mml:msup><mml:mtext> day</mml:mtext><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>. Each day, the preferred allele in one of the 32 sites is swapped (selection changes sign) with probability <inline-formula><mml:math id="inf120"><mml:msub><mml:mi>p</mml:mi><mml:mtext>flip</mml:mtext></mml:msub></mml:math></inline-formula>. The rate of selection fluctuation <inline-formula><mml:math id="inf121"><mml:msub><mml:mi>p</mml:mi><mml:mtext>flip</mml:mtext></mml:msub></mml:math></inline-formula> and the recombination rate <inline-formula><mml:math id="inf122"><mml:mi>χ</mml:mi></mml:math></inline-formula> are given in each panel. The carrying capacity is set to <inline-formula><mml:math id="inf123"><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mn>5</mml:mn><mml:mo>,</mml:mo><mml:mn>000</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>, and the event rate is <inline-formula><mml:math id="inf124"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mo>⁢</mml:mo><mml:msup><mml:mtext> day</mml:mtext><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math></inline-formula>; see Algorithm 3 (Appendix 5). To initialize, we let the populations equilibrate for <inline-formula><mml:math id="inf125"><mml:mrow><mml:mn>4</mml:mn><mml:mo>⁢</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>e</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> generations, and then gather data for maximum likelihood inference of selection at the escape mediating sites. In all panels, the median MLE for selection (black line) closely matches the true selection strength (redline). Quantile lines are smoothened by a Gaussian kernel. Variation is largest when diversity is low and when mutants are rare, which concords with the results from the Bayesian inference procedure.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76004-fig4-figsupp2-v2.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Minimum disparity estimation for adjustment of diversity.</title><p>(<bold>A</bold>) The predicted rebound times without including an increase in diversity due to reservoirs (i.e. <inline-formula><mml:math id="inf126"><mml:mrow><mml:msub><mml:mi>ξ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> in <xref ref-type="disp-formula" rid="equ43">Equation 42</xref>) qualitatively matches the data from the three trials (histograms in each panel), with an overestimation in the number of non-responders and patients with late rebound. For comparison, the predictions with reservoir-corrected diversity is shown in <xref ref-type="fig" rid="fig3">Figure 3A</xref>. (<bold>B</bold>) The disparity <inline-formula><mml:math id="inf127"><mml:mrow><mml:mi>R</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>ξ</mml:mi><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> (<xref ref-type="disp-formula" rid="equ36">Equation 35</xref>) is shown as a function of the reservoir factor <inline-formula><mml:math id="inf128"><mml:mi>ξ</mml:mi></mml:math></inline-formula> for the three trials (colors; left panel). The total disparity over all trials is shown in the right panel, where <inline-formula><mml:math id="inf129"><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>R</mml:mi></mml:msub></mml:math></inline-formula> indicates the reduction in disparity by using the optimal reservoir factor <inline-formula><mml:math id="inf130"><mml:mrow><mml:msup><mml:mi>ξ</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mo>=</mml:mo><mml:mn>2.1</mml:mn></mml:mrow></mml:math></inline-formula>. (<bold>C</bold>) The distribution for the reduction in disparity <inline-formula><mml:math id="inf131"><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>R</mml:mi></mml:msub></mml:math></inline-formula> (<xref ref-type="disp-formula" rid="equ42">Equation 41</xref>) is shown for 1000 realizations of simulated data under the null hypothesis with <inline-formula><mml:math id="inf132"><mml:mrow><mml:msub><mml:mi>ξ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>. The large reduction in disparity indicates that the null hypothesis can be rejected with <inline-formula><mml:math id="inf133"><mml:mrow><mml:mtext>p-value</mml:mtext><mml:mo>=</mml:mo><mml:mn>0.004</mml:mn></mml:mrow></mml:math></inline-formula> (<xref ref-type="disp-formula" rid="equ43">Equation 42</xref>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76004-fig4-figsupp3-v2.tif"/></fig><fig id="fig4s4" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 4.</label><caption><title>Disparity analysis for robustness of selection inference.</title><p>(<bold>A</bold>) The disparity <inline-formula><mml:math id="inf134"><mml:mrow><mml:mi>R</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msub><mml:mi>ξ</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> (<xref ref-type="disp-formula" rid="equ36">Equation 35</xref>) is shown as a function of rescaling of the selection strength <inline-formula><mml:math id="inf135"><mml:mrow><mml:mi>σ</mml:mi><mml:mo>/</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:mrow></mml:math></inline-formula> by a multiplicative factor <inline-formula><mml:math id="inf136"><mml:msub><mml:mi>ξ</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></inline-formula>. The total disparity over all trials is shown in the right panel, where <inline-formula><mml:math id="inf137"><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>R</mml:mi></mml:msub></mml:math></inline-formula> indicates the reduction in disparity by using the optimal selection factor <inline-formula><mml:math id="inf138"><mml:mrow><mml:msub><mml:mi>ξ</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>.8</mml:mn></mml:mrow></mml:math></inline-formula>. In this case the null hypothesis is that the inferred selection by the Bayesian procedure in <xref ref-type="disp-formula" rid="equ32">Equation 31</xref> requires no further rescaling for the model to fit the distribution of the rebound times (i.e. <inline-formula><mml:math id="inf139"><mml:mrow><mml:msub><mml:mi>ξ</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>). The large <inline-formula><mml:math id="inf140"><mml:mrow><mml:mtext>p-value</mml:mtext><mml:mo>=</mml:mo><mml:mn>0.49</mml:mn></mml:mrow></mml:math></inline-formula> shown in (<bold>B</bold>) indicates that the null hypothesis cannot be rejected and we have no statistical justification for adding an adjustment factor for selection inferred from untreated patients.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76004-fig4-figsupp4-v2.tif"/></fig></fig-group></sec><sec id="s2-1-3"><title>Fitness effect of escape mutations</title><p>Since bNAbs target highly conserved regions of the virus, we expect HIV-1 escape mutations to be intrinsically deleterious for the virus (<xref ref-type="bibr" rid="bib28">Ferguson et al., 2013</xref>; <xref ref-type="bibr" rid="bib63">Meijers et al., 2021</xref>), and incur a fitness cost relative to pre-treatment baseline <italic>f</italic><sub>0</sub>. We assume that fitness cost associated with escape mutations are additive and background-independent so the fitness of a variant <inline-formula><mml:math id="inf141"><mml:mi>a</mml:mi></mml:math></inline-formula> in the absence of bNAb follows, <inline-formula><mml:math id="inf142"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>-</mml:mo><mml:mrow><mml:msub><mml:mo largeop="true" symmetric="true">∑</mml:mo><mml:mi>i</mml:mi></mml:msub><mml:mrow><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi></mml:msubsup></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:math></inline-formula>, where <inline-formula><mml:math id="inf143"><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math></inline-formula> is the cost associated with the presence of a escape mutation at site <inline-formula><mml:math id="inf144"><mml:mi>i</mml:mi></mml:math></inline-formula> (i.e., for <inline-formula><mml:math id="inf145"><mml:mrow><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>); see <xref ref-type="fig" rid="fig1">Figure 1D</xref>.</p><p>Interestingly, we observe the escape variants against different bNAbs to be circulating in the HIV-1 populations from the cohort of ART- and bNAb-naive patients (<xref ref-type="bibr" rid="bib105">Zanini et al., 2015</xref>, <xref ref-type="fig" rid="fig2">Figure 2B</xref>). We use this data (<xref ref-type="bibr" rid="bib105">Zanini et al., 2015</xref>) and extract the multiplicity of susceptible and escape variants in HIV-1 populations at each sampled time point from a given patient. We use a single locus approximation under strong selection to represent the stationary distribution of the underlying frequency of escape alleles <inline-formula><mml:math id="inf146"><mml:mi>x</mml:mi></mml:math></inline-formula> in each patient from (<xref ref-type="bibr" rid="bib105">Zanini et al., 2015</xref>), <inline-formula><mml:math id="inf147"><mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo>;</mml:mo><mml:mi>σ</mml:mi><mml:mo>,</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>∼</mml:mo><mml:mrow><mml:msup><mml:mi>x</mml:mi><mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>+</mml:mo><mml:mi>θ</mml:mi></mml:mrow></mml:msup><mml:mo>⁢</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>x</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>+</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup></mml:mrow></mml:msup><mml:mo>⁢</mml:mo><mml:mrow><mml:mi>exp</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mrow><mml:mo>-</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>⁢</mml:mo><mml:mi>x</mml:mi></mml:mrow></mml:mrow><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:math></inline-formula>, given the (scaled) fitness difference between the susceptible and the escape variants <inline-formula><mml:math id="inf148"><mml:mrow><mml:mi>σ</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mo>⁢</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>e</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mtext>sus</mml:mtext></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mtext>mut</mml:mtext></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></inline-formula>; see Methods.</p><p>Based on the statistics of escape and susceptible variants in all patients, we define a likelihood function that determines a Bayesian posterior for selection <inline-formula><mml:math id="inf149"><mml:mi>σ</mml:mi></mml:math></inline-formula> associated with escape at each site (Methods). We found that it is statistically more robust to infer the strength of selection relative to a reference diversity measure <inline-formula><mml:math id="inf150"><mml:mrow><mml:mrow><mml:mi>σ</mml:mi><mml:mo>/</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mtext>sus.</mml:mtext></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mtext>res.</mml:mtext></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>/</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>, for which we choose the transition rate (Methods). This approach generates unbiased selection estimates in simulations and is robust to effects of linkage and recombination (Methods and Model robustness <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). The inferred values of the scaled fitness costs <inline-formula><mml:math id="inf151"><mml:mrow><mml:mi>σ</mml:mi><mml:mo>/</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:mrow></mml:math></inline-formula> are shown for the escape-mediating sites of the trial bNAbs in <xref ref-type="fig" rid="fig2">Figure 2E</xref>, and are reported in <xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>.</p></sec></sec><sec id="s2-2"><title>Predicting the efficacy of bNAb therapy in clinical trials</title><p>Monotherapy trials with 10–1074 (<xref ref-type="bibr" rid="bib12">Caskey et al., 2017</xref>, 3BNC117 <xref ref-type="bibr" rid="bib10">Caskey et al., 2015</xref>,PGT121 <xref ref-type="bibr" rid="bib92">Stephenson et al., 2021</xref>), and the combination therapy with 10–1074+3BNC117 in <xref ref-type="bibr" rid="bib4">Baron et al., 2018</xref> have shown variable outcomes. In some patients, bNAb therapy did not suppress the viral load, whereas in others suppression was efficient and no rebound was observed up to 56 days after infusion (end of surveillance in these trials); see <xref ref-type="fig" rid="fig3">Figure 3A</xref> for examples of patients with different rebound times, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplements 1</xref>–<xref ref-type="fig" rid="fig3s3">3</xref> for the viremia traces in all patients, and <xref ref-type="fig" rid="fig3">Figure 3B and C</xref> for the distributions and the summary statistics of the rebound times in patients in different trials.</p><p>Although we infer a large intrinsic fitness cost for a virus to harbor an escape allele (<xref ref-type="fig" rid="fig2">Figure 2E</xref>), these variants can emerge or already be present due to the large intra-patient diversity of HIV-1 populations (<xref ref-type="fig" rid="fig2">Figure 2C</xref>), or a larger mutational target size for these escape variants. Deep sequencing data in untreated (likely bNAb-naive) patients shows circulation of resistant variants against a panel of bNAbs in the majority of patients (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Our goal is to predict the efficacy of a bNAb trial, using the fitness effect and the mutational target size for escape from a given bNAb, both of which we infer from the high-throughput HIV-1 sequence data collected from bNAb-naive patients in <xref ref-type="bibr" rid="bib105">Zanini et al., 2015</xref> (<xref ref-type="fig" rid="fig2">Figure 2E</xref>, <xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>). In addition, we modulate these measures with the patient-specific neutral diversity <inline-formula><mml:math id="inf152"><mml:mi>θ</mml:mi></mml:math></inline-formula> inferred from whole genome sequencing of HIV-1 populations in each patient prior to bNAb therapy (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). These quantities parametrize the birth-death process for viral escape in a bNAb therapy (<xref ref-type="fig" rid="fig1">Figure 1A</xref>), which we use to characterize the distribution of rebound times in a given trial (Methods).</p><p>For both the 3BNC117 and the 10–1074 trials (<xref ref-type="bibr" rid="bib10">Caskey et al., 2015</xref>; <xref ref-type="bibr" rid="bib12">Caskey et al., 2017</xref>), we see an excellent agreement between our predictions of the rebound time distribution and data; see <xref ref-type="fig" rid="fig3">Figure 3B</xref>, and Methods and <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref> for statistical accuracy of this comparison. For the PGT121 trial, the genomic data from patients’ HIV-1 populations are insufficient and therefore, we used the neutral diversity <inline-formula><mml:math id="inf153"><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:math></inline-formula> estimated from the other three trials to predict the associated rebound time distribution (Appendix 4). Still, we see a good agreement between our predictions of the rebound time distribution and data; see <xref ref-type="fig" rid="app4fig1">Appendix 4—figure 1</xref>.</p><p>By assuming an additive fitness effect for escape from 10 to 1074 and 3BNC117, we also accurately predict the distribution of rebound times in the combination therapy (<xref ref-type="bibr" rid="bib4">Baron et al., 2018</xref>, <xref ref-type="fig" rid="fig3">Figure 3B</xref>). The agreement of our results with data for combination therapy is consistent with the fact that the escape mediating sites from 10 to 1074 and 3BNC117 are spaced farther apart on the genome than 100 bp, beyond which linkage disequilibrium diminishes due to frequent recombination in HIV (<xref ref-type="bibr" rid="bib105">Zanini et al., 2015</xref>). Importantly, in all the trials, our evolutionary model accurately predicts the fraction of participants for whom we should expect a late viral rebound (more than 56 days past bNAb infusion)—the quantity that determines the efficacy of a treatment.</p><p>Apart from the overall statistics of the rebound times, our stochastic model also enables us to characterize the relative contributions of the pre-treatment standing variation of the HIV-1 population versus the spontaneous mutations emerging during a trial to viral escape from a given bNAb. Given the large population size of HIV-1 and a high mutation rate (<inline-formula><mml:math id="inf154"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>μ</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>−</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math></inline-formula> per generation), spontaneous mutations generate a fraction <inline-formula><mml:math id="inf155"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mi>x</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>μ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math></inline-formula> of resistant variants during a trial, which we can express as,<disp-formula id="equ3"><label>(3)</label><mml:math id="m3"><mml:mrow><mml:msup><mml:mi>x</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>μ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mrow><mml:msubsup><mml:mo largeop="true" symmetric="true">∫</mml:mo><mml:mn>0</mml:mn><mml:mrow><mml:mn>56</mml:mn><mml:mo>⁢</mml:mo><mml:mtext> wks</mml:mtext></mml:mrow></mml:msubsup><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mrow><mml:mi>x</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>⁢</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:mrow><mml:mi>r</mml:mi><mml:mo>⁢</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:mrow></mml:msup><mml:mo>⁢</mml:mo><mml:mi>μ</mml:mi><mml:mo>⁢</mml:mo><mml:mi>γ</mml:mi><mml:mo>⁢</mml:mo><mml:mtext>d</mml:mtext><mml:mo>⁢</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>In the best case scenario, there are no resistant virions prior to treatment i.e., <inline-formula><mml:math id="inf156"><mml:mrow><mml:mrow><mml:mi>x</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula>. Since the neutralization rate <inline-formula><mml:math id="inf157"><mml:mi>r</mml:mi></mml:math></inline-formula> and the growth rate <inline-formula><mml:math id="inf158"><mml:mi>γ</mml:mi></mml:math></inline-formula> are comparable, this deterministic approach predicts that mutations can generate a resistant fraction of <inline-formula><mml:math id="inf159"><mml:mrow><mml:msup><mml:mi>x</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>μ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mo>≈</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>-</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> during a trial. However, stochastic effects from random birth and death events play an important role in the fate and establishment of these resistant variants. The probability of extinction for a variant at frequency <inline-formula><mml:math id="inf160"><mml:mi>x</mml:mi></mml:math></inline-formula> can be approximated as <inline-formula><mml:math id="inf161"><mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mtext>extinct</mml:mtext><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>≈</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:mrow><mml:mi>x</mml:mi><mml:mo>/</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mtext>ext</mml:mtext></mml:msub></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math></inline-formula> (see Extinction Probability); here <inline-formula><mml:math id="inf162"><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mtext>ext</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:msub><mml:mi>μ</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mo>⁢</mml:mo><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mi>γ</mml:mi><mml:mo>⁢</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mo>⁢</mml:mo><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>≈</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>-</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> and a variant with fraction <inline-formula><mml:math id="inf163"><mml:mi>x</mml:mi></mml:math></inline-formula> that falls below this critical value is likely to go extinct (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Since the total integrated mutational flux fraction during a trial is <inline-formula><mml:math id="inf164"><mml:mrow><mml:msup><mml:mi>x</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>μ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mo>∼</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>-</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>, mutational flux rarely decides the outcome of patient treatment. Indeed, we infer that spontaneous mutations contribute to less than 4% of escape events in all the three trials and escape is primarily attributed to the standing variation from the serum or the reservoirs prior to therapy (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). A similar conclusion was previously drawn based on a mechanistic model of escape in VRC01 therapy trials (<xref ref-type="bibr" rid="bib81">Saha and Dixit, 2020</xref>).</p></sec><sec id="s2-3"><title>Devising optimal bNAb therapy cocktails</title><p>Clinical trials with bNAbs have been instrumental in demonstrating the potential role of bNAbs as therapy agents and in measuring the efficacy of each bNAb to suppress HIV. Still, these clinical trials can only test a small fraction of the potential therapies that can be devised. It is therefore important that trials test therapies that have been optimized based on surrogate estimates of treatment efficacy. The accuracy of our predictions for the rebound time of a HIV-1 population subject to bNAb therapy suggests a promising approach to the rational design of therapies based on genetic data of HIV populations collected from bNAb-naive patients.</p><p>Here, we use viral genome sequences to infer the efficacy of therapies with bNAbs, for which clinal trials are not yet performed. To do so, we first need to identify the routes of HIV escape from these bNAbs. We use deep mutational scanning data (DMS) on HIV-1 subject to 9 different bNAbs from <xref ref-type="bibr" rid="bib21">Dingens et al., 2019</xref> together with information from literature to identify the escape mediating variants from each of these bNAbs (Methods and Table S1). We then determine the mutational target size and the fitness effect of these escape variants using high-throughput sequences of HIV-1 in bNAb-naive patients from <xref ref-type="bibr" rid="bib105">Zanini et al., 2015</xref>; these inferred values are reported in <xref ref-type="fig" rid="fig4">Figure 4A and B</xref> and Table S1. Using the inferred fitness and mutational parameters and by setting the pre-treatment neutral diversity <inline-formula><mml:math id="inf165"><mml:mi>θ</mml:mi></mml:math></inline-formula> to be comparable to that of the patients in the previous three trials with 10–1074 and 3BNC117 (<xref ref-type="fig" rid="fig2">Figure 2C</xref>), we simulate treatment outcomes for these 9 bNAbs and their twofold and threefold combinations.</p><p>Interestingly, we infer that escape from mono-therapies is almost certain and a combination of at least three antibodies is necessary to limit the probability of early rebound (&lt;56 days) to below 1% (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). When considering each of the nine antibodies, interesting patterns emerge. We find that the mutational target size and the fitness cost of escape, estimated as the harmonic-mean selection cost of individual sites, obey a roughly linear relationship (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). As all these bNAbs have similar overall breadth (i.e. they neutralize over 70% of panel strains), this result suggests that for an antibody to be broad, its escape mediating variants should either be rare (i.e. small mutational target size) or intrinsically costly (i.e. incurring a high fitness cost), but it is not necessary to satisfy both of these requirements. For instance, we find that resistant variants against 10E8 weaker negative selection but escape target size is small, while PGT151 has a larger escape target size but makes up for it by having resistant variants with unavoidably high fitness cost.</p><p>The fitness-limited versus the mutation-limited strategies have different implications for the design of combination cocktails. The small mutational target size of 10E8 makes it the best candidate antibody for mono-therapy among the antibodies we consider because the escape variants against this antibody are less likely to circulate in a patient’s serum prior to treatment. However, in combination, 10E8 appears less often in top ranked therapies than PGT151. PGT151 is unremarkable on its own because of a relatively large target size, but the high cost of escape makes it especially promising in combination therapies. Overall, fitness-limited bNAbs like PGT151 are more effective against high diversity viral populations, while mutation-limited bNAbs such as 10E8 are more effective against low diversity viral populations. Indeed, the best ranked therapy, namely the combination of PG9, PGT151, and VRC01, combines antibodies that target different regions of the virus and also have both types of fitness- and mutation-limited strategies for coverage against the full variability of viral diversities found in pre-treatment individuals (<xref ref-type="fig" rid="fig4">Figure 4C</xref>) participating in the clinical trials.</p><p>Escape from bNAbs in multivalent therapy is also influenced by the non-independence of escape pathways. Several of the bNAbs (e.g. 10–1074 and PG121) in this study target the same (or structurally adjacent) epitopes and escape from them is mediated by the same mutations. The sharing of mutational pathways invalidates the assumption of independence and may make our predictions too optimistic. However, the best performing antibody combinations in <xref ref-type="fig" rid="fig4">Figure 4C</xref> target multiple epitopes to reduce the chances of collective escape. Therefore, the assumptions of independent fitness effects and independent mutational pathways in this case are not consequential for the main predictions of our model (i.e., the choice of bNAb combinations). In vitro data shown in <xref ref-type="bibr" rid="bib48">Kong et al., 2015</xref> suggest that additive and independent effects are the norm, but that small but consistent synergistic effects may imply that our assumption of site-wise independence is conservative. More data on HIV escape from combinations of bNAbs would be informative for further modeling efforts and relevant for long-term therapy design.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>HIV therapy with passive bNAb infusion has become a promising alternative to anti-retroviral drugs for suppressing and preventing the disease in patients without a need for daily administration. The current obstacle is the frequent escape of the virus seen in mono- and even combination bNAb therapy trials (<xref ref-type="bibr" rid="bib10">Caskey et al., 2015</xref>; <xref ref-type="bibr" rid="bib3">Bar et al., 2016</xref>; <xref ref-type="bibr" rid="bib12">Caskey et al., 2017</xref>; <xref ref-type="bibr" rid="bib4">Baron et al., 2018</xref>). The key is to identify bNAb cocktails that can target multiple vulnerable regions on the virus in order to reduce the likelihood for the rise of resistant variants with escape-mediating mutations in all these regions. Identifying an optimal bNAb cocktail can be a combinatorially difficult problem, and designing patient trials for all the potential combinations is a costly pursuit.</p><p>Here, we have proposed a computational approach to predict the efficacy of a bNAb therapy trial based on population genetics of HIV escape, which we parametrize using high-throughput HIV-1 sequence data collected from a separate cohort of bNAb-naive patients (<xref ref-type="bibr" rid="bib105">Zanini et al., 2015</xref>). Specifically, we infer the mutational target size for escape and the fitness cost associated with escape-mediating mutations in the absence of a given bNAb. These quantities together with the neutral diversity of HIV-1 within a patient parametrize our stochastic model for HIV dynamics subject to bNAb infusion, based on which we can accurately predict the distribution of rebound times for HIV in therapy trials with 10–1074, 3BNC117 and their combination, as well as a trial with PGT121 bNAb. Consistent with previous work on VRC01 (<xref ref-type="bibr" rid="bib81">Saha and Dixit, 2020</xref>), we found that viral rebounds in bNAb trials are primarily mediated by the escape variants present either in the patients’ sera or their latent reservoirs prior to treatment, and that the escape is not likely to be driven by the emergence of spontaneous mutations that establish during the therapy.</p><p>One key measure of success for a bNAb trial is the suppression of early viral rebound. Our model can accurately predict the rebound times of HIV-1 subject to three distinct therapies (<xref ref-type="bibr" rid="bib10">Caskey et al., 2015</xref>; <xref ref-type="bibr" rid="bib12">Caskey et al., 2017</xref>; <xref ref-type="bibr" rid="bib4">Baron et al., 2018</xref>), based on the fitness and the mutational characteristics of escape variants inferred from high-throughput HIV-1 sequence data. This approach enables us to characterize routes of HIV-1 escape from other bNAbs, for which therapy trials are not available, and to design optimal therapies. We used deep mutational scanning data <xref ref-type="bibr" rid="bib21">Dingens et al., 2019</xref> to identify escape-mediating variants against 9 different bNAbs for HIV. Our genetic analysis shows that bNAbs gain breadth and limit viral escape either due to their small mutational target size for escape or because of the large intrinsic fitness cost incurred by escape mutations. bNAbs with mutation-limited strategy are more effective at preventing escape in patients with low viral genetic diversity, while bNAbs with selection-limited strategy are more effective at high viral diversity.</p><p>Combination therapy with more than two bnAbs (or drugs in ART) has long been shown to be more effective in suppressing early viral rebound, both in theory and practice (<xref ref-type="bibr" rid="bib74">Perelson et al., 1996</xref>; <xref ref-type="bibr" rid="bib25">Feder et al., 2016</xref>; <xref ref-type="bibr" rid="bib98">Wagh et al., 2016</xref>; <xref ref-type="bibr" rid="bib46">Klein et al., 2012</xref>; <xref ref-type="bibr" rid="bib65">Mendoza et al., 2018</xref>; <xref ref-type="bibr" rid="bib104">Yu et al., 2019</xref>). In addition to corroborating this conclusion quantitatively, we provide a method for assessing new bnAbs for which escape mutations are known. Our method can be understood as a tool to navigate the combinatorial explosion of higher order cocktails for which we cannot possibly test all combinations. By assessing the evolvability of resistance against different combinations we can identify the best therapies to target for clinical trial. Specifically, we show that to suppress the chance of viral rebound to below 1%, we show that a combo-therapy with 3 bNAbs with a mixture of mutation- and selection-limited strategies that target different regions of the viral envelope is necessary. Such combination can counter the full variation of viral diversity observed in patients. We found that PG9, PG151, and VRC01, which respectively target V2 loop, Interface, and CD4 binding site of HIV envelope, form an optimal combination for a 3-bNAb therapy to limit HIV escape in patients infected with clade B of the virus.</p><p>The statistical agreement between our coarse-grained model and the observed distribution of the viral rebound times in trials (<xref ref-type="fig" rid="fig3">Figure 3B</xref>) implies that many of the mechanistic details are of secondary importance in predicting viral escape. Nonetheless, our approach falls short of reproducing the detailed characteristics of viremia traces in patients, especially at very short or very long times, during which the dynamics of T-cell response or the decay of bNAbs could play a role (<xref ref-type="bibr" rid="bib58">Lu et al., 2016</xref>; <xref ref-type="bibr" rid="bib76">Reeves et al., 2020</xref>; <xref ref-type="bibr" rid="bib81">Saha and Dixit, 2020</xref>). The relationship between the short-term suppression of the virus, which is the focus of this analysis, and the long-term treatment success is complicated by reestablishment of HIV from the latent reservoirs and different modes of intra-host HIV evolution (<xref ref-type="bibr" rid="bib56">Liu et al., 2019</xref>; <xref ref-type="bibr" rid="bib60">Margolis et al., 2017</xref>).</p><p>One strategy to achieve a longer term treatment success is by combining bNAb therapy with ART. One main advantage of bNAb therapy is the fact that it can be administered once every few months, in contrast to ART, which should be taken daily and missing a dose could lead to viral rebound. Although multivalent bNAb therapy reduces the chances of short-term viral escape, viral escape remains a real obstacle for longer term success of a treatment with bNAbs. Alternatively, (fewer) bNAbs can be administered in combination with ART (<xref ref-type="bibr" rid="bib41">Horwitz et al., 2013</xref>; <xref ref-type="bibr" rid="bib37">Gruell and Klein, 2018</xref>), whereby ART could lower the replication rate of the HIV population, reducing the viral diversity and the chances of viral escape. Specifically, we can expect that emergence and establishment of rare (i.e., strongly deleterious) escape variants against bNAbs to be less likely in ART+ patients, which suggests that fitness-limited bNAbs should be more effective in conjunction with ART. More data would be necessary to understand the long-term efficacy of such augmented therapy, and specifically the role of viral reservoirs in this context. A modeling approach could then shed light on how ART administration and bNAb therapy could be combined to efficiently achieve viral suppression.</p><sec id="s3-1"><title>Limitations</title><p>We rest our analysis primarily on the predictive power of the observed variant frequencies in the untreated patients. Our model weighs these frequencies with respect to the viral diversity in a mathematically and biologically consistent way. However, we ignore the dynamics of antibody concentration and IC<sub>50</sub> neutralization during treatments, the details of T-cell dynamics during infection (<xref ref-type="bibr" rid="bib75">Perelson, 2002</xref>), and also the evolutionary features of the genetic data, such as epistasis between loci (<xref ref-type="bibr" rid="bib6">Bonhoeffer et al., 2004</xref>; <xref ref-type="bibr" rid="bib107">Zhang et al., 2020</xref>, genetic linkage <xref ref-type="bibr" rid="bib105">Zanini et al., 2015</xref>, and codon usage bias <xref ref-type="bibr" rid="bib64">Meintjes and Rodrigo, 2005</xref>).</p><p>In our model of viral escape, we neglect the possibility of incomplete escape of the virus due to the reduced neutralization efficacy of bNAbs as their concentrations decay during trials. In Appendix 3, we show that this simplifying assumption is valid as long as the IC<sub>50</sub> is not the same order of magnitude as the initial dosage concentration of the infused bNAb. Notably, the data from therapy trials used in this study fall into the regime for which we can neglect the impact of incomplete neutralization (<xref ref-type="fig" rid="app3fig2">Appendix 3—figure 2</xref>). However, taking into account the dependence of viral fitness on bNAb concentration and its neutralization efficacy, as in the model proposed by <xref ref-type="bibr" rid="bib63">Meijers et al., 2021</xref>, could improve the long-term predictive power of our approach.</p><p>Our predictions are limited by our ability to identify the escape variants for each bNAb, either based on the in vivo trial data and patient surveillance, or in-vitro assays such as DMS experiments. In Appendix 4, we compare the accuracy of our predictions for the rebound time distributions of HIV using DMS-inferred versus trial-inferred escape variants against the 10–1074 and the PGT121 bNAbs, and we find good agreements between the two approaches in both cases. However, it should be noted that identifying escape variants from DMS experiments lead to a more optimistic prediction for treatment success during the first 8 weeks of trials (i.e. they suggest a later rebound). One reason for this discrepancy may be related to the distinct genetic composition of viruses in the two approaches. DMS experiments characterize HIV escape by introducing mutations on a single genetic background (<xref ref-type="bibr" rid="bib21">Dingens et al., 2019</xref>; <xref ref-type="bibr" rid="bib20">Dingens et al., 2017</xref>; <xref ref-type="bibr" rid="bib83">Schommers et al., 2020</xref>) (e.g. the HIV-1 strain BF520.W14M.C2 in <xref ref-type="bibr" rid="bib20">Dingens et al., 2017</xref>), whereas clinical data contain diverse populations of viruses between and within individuals. It is more likely for diverse viral populations to contain variants in which positive epistasis between escape mutations and the background genome is present. Therefore, it is reasonable to expect that genetic data originating in clinical trials show more pathways of escape, resulting in a faster viral rebound following bNAb infusion. Nevertheless, DMS experiments are less costly for identifying escape variants compared to trials, and they provide a baseline to assess the efficacy of different bNAbs for therapy and further in-vivo investigations. More experiments would be necessary for a more systematic understanding of the limitations of each approach.</p><p>It should be noted that our analysis in <xref ref-type="fig" rid="fig4">Figure 4C</xref> only focuses on one aspect of therapy optimization, that is, the suppression of escape. Other factors, including potency (neutralization efficacy) and half-life of the bNAb, or the patient’s toleration to bNAbs at different dosages should also be taken into account for therapy design. For example, the bNAb 10E8, which we identified as of the most promising mono-therapy candidates in <xref ref-type="fig" rid="fig4">Figure 4C</xref>, is shown to be poorly tolerated by patients with short half-life (<xref ref-type="bibr" rid="bib49">Kwon et al., 2016</xref>), making it undesirable for therapy purposes. Thus, the bNAb candidates shown in <xref ref-type="fig" rid="fig4">Figure 4C</xref> should be taken as a guideline to be complemented with further assessment of efficacy and safety for therapy design.</p></sec><sec id="s3-2"><title>Outlook</title><p>Our approach showcases that, when feasible, combining high-throughput genetic data with ecological and population genetics models can have surprisingly broad applicability, and their interpretability can shed light into the complex dynamics of pathogens subject to therapy. Application of similar methods to therapy design to curb the escape of cancer tumors against immune- or chemo-therapy, the resistance in bacteria against antibiotics, or the escape of seasonal influenza against vaccination is a promising avenue for future work. However, we expect that more sophisticated methods for inferring fitness from evolutionary trajectories may be necessary to capture the dynamical response of these populations.</p></sec></sec><sec id="s4" sec-type="methods"><title>Methods</title><sec id="s4-1"><title>Data and code accessibility</title><p>The code for the algorithms used in this work and the data are available on GitHub at <ext-link ext-link-type="uri" xlink:href="https://github.com/StatPhysBio/HIVTreatmentOptimization">https://github.com/StatPhysBio/HIVTreatmentOptimization</ext-link> (copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:776b6f1495f749cd2e687e53359fdde9593b5a47;origin=https://github.com/StatPhysBio/HIVTreatmentOptimization;visit=swh:1:snp:ac91d9b0c04aa7418b4e7a98db0addd24199f914;anchor=swh:1:rev:0194cf6e554996a066633e99dd53cd5901da552e">swh:1:rev:0194cf6e554996a066633e99dd53cd5901da552e</ext-link>, <xref ref-type="bibr" rid="bib14">Chelate, 2022a</xref>) and in the Julia package <ext-link ext-link-type="uri" xlink:href="https://github.com/StatPhysBio/EscapeSimulator">https://github.com/StatPhysBio/EscapeSimulator</ext-link> (copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:c6cfa184d349a3272b0211efac8fc1f0f3d398e3;origin=https://github.com/StatPhysBio/EscapeSimulator;visit=swh:1:snp:1727701be1d35fdeb61fdd39bc0a9bbc0c1cb90a;anchor=swh:1:rev:9a343f598820bafddfc7ea4547cefa90bf96fd6e">swh:1:rev:9a343f598820bafddfc7ea4547cefa90bf96fd6e</ext-link>, <xref ref-type="bibr" rid="bib15">Chelate, 2022b</xref>).</p></sec><sec id="s4-2"><title>Description of molecular data</title><sec id="s4-2-1"><title>Data from bNAb trials</title><p>In this study, we considered four clinical trials for passive therapy with bNAbs:</p><list list-type="bullet"><list-item><p>Monoclonal therapy with 3BNC117 bNAb <xref ref-type="bibr" rid="bib10">Caskey et al., 2015</xref> and sequences reported in <xref ref-type="bibr" rid="bib84">Schoofs et al., 2016</xref>. There were 16 patients enrolled, 13 of whom were off anti-retroviral therapy (ART).</p></list-item><list-item><p>Monoclonal therapy with 10–1074 bNAb <xref ref-type="bibr" rid="bib12">Caskey et al., 2017</xref>, with 19 patients enrolled, 16 of whom were off ART.</p></list-item><list-item><p>Combination therapy with 10–1074+3BNC117 bNAb <xref ref-type="bibr" rid="bib4">Baron et al., 2018</xref>, with 7 patients off ART.</p></list-item><list-item><p>Monoclonal therapy with PGT121 with 17 patients off ART. <xref ref-type="bibr" rid="bib92">Stephenson et al., 2021</xref>. Far fewer viral sequences were available for this trial, and therefore, we could not reliably infer the neural diversity of viruses within patients, as we did for other trials. We only used this trial to compare our predictions based on the DMS-inferred with the trial-inferred escape pathways in Appendix 4.</p></list-item></list><p>All sequenced patients across all trials were infected with distinct HIV-1 clade B viral strains. We limited our analyses to those patients not on ART at the time of treatment initiation. In these studies, the injected bNAb level falls off over time within patients and therefore, we only considered dynamics within an 8-week window since infusion. This assures that rebound is not confounded by a drop in bNAb below sensitive-strain neutralizing levels of <inline-formula><mml:math id="inf166"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mtext>IC</mml:mtext><mml:mrow><mml:msub><mml:mn>50</mml:mn><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:mn>2</mml:mn><mml:mi>μ</mml:mi><mml:mtext>g/m</mml:mtext></mml:mrow></mml:mstyle></mml:math></inline-formula>.</p><p>We used single-genome sequence data of <italic>env</italic> collected from all patients in each trial to characterize the diversity of HIV-1 population within each patient shown in <xref ref-type="fig" rid="fig2">Figure 2</xref> available from <xref ref-type="bibr" rid="bib105">Zanini et al., 2015</xref> and accessible through European Nucleotide Archive (Accession no: PRJEB9618). The patient sequence data for each trial is available through <xref ref-type="bibr" rid="bib10">Caskey et al., 2015</xref> GeneBank accession number: KX016803, <xref ref-type="bibr" rid="bib12">Caskey et al., 2017</xref> GenBank accession numbers KY323724.1 - KY324834.1, and <xref ref-type="bibr" rid="bib4">Baron et al., 2018</xref>, GenBank accession numbers MH632763 - MH633255.</p></sec><sec id="s4-2-2"><title>Longitudinal HIV-1 sequence data from untreated patients</title><p>Single nucleotide polymorphism (SNP) data was obtained from <xref ref-type="bibr" rid="bib105">Zanini et al., 2015</xref> and aligned to the HXB2 reference using HIV-align tool (<xref ref-type="bibr" rid="bib33">Gaschen et al., 2001</xref>). The dataset includes 11 patients observed for 5–8 years of infection, with HIV-1 sequence data sampled over 6–12 time points per patient (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p><p>Patient 4 and patient 7 were excluded from the original analysis done in <xref ref-type="bibr" rid="bib105">Zanini et al., 2015</xref> because of suspected superinfection and failure to amplify early samples, respectively. These patients were included in our analysis, since (i) super-infection poses no additional difficulties for our tree-free procedure, and (ii) only time points with measurable viral diversity entered into our selection likelihood, which automatically limits our analysis to samples with high-quality sequences.</p><p>All patients were infected with clade B of HIV, except for patient 6 (clade C), and patient 1 (clade 01_AE). We assessed the robustness of our inference to exclusion of these patients from our analysis in Effect of genomic linkage on the inference of selection. Overall, our inference was not strongly affected by this choice (Model robustness <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>), and therefore, we included these patients in our main analyses to enhance the statistics with larger data.</p><p>For our analysis we considered only data reported in single nucleotide polymorphism (SNP) counts. The number of raw SNP counts are the result of amplification and must be converted into estimates for the number of pre-amplification template fragments. Zanini et. al. reported that on average about 10<sup>2</sup> templates of amplicon were associated with the fragments of the envelope (<italic>env</italic>) protein <xref ref-type="bibr" rid="bib105">Zanini et al., 2015</xref>. We converted raw SNP counts into templates by normalizing to 120 counts and rounding the resulting number to the nearest integer.</p></sec></sec><sec id="s4-3"><title>Identifying escape-mediating variants against bNAbs</title><p>The starting point for our analysis of HIV response to a given a bNAb is the description of the escape-mediating amino acids in the HIV <italic>env</italic> protein. We use a combination of methods to identify the escape variants for a given bNAb. First, we use deep mutational scanning (DMS) data of HIV-1 in the presence of a bNAb from <xref ref-type="bibr" rid="bib21">Dingens et al., 2019</xref> to identify these mutations. These DMS experiments have created libraries of all single mutations from a given genomic background of HIV-1 and tested the fitness of these variants (i.e. growth on T-cell culture) in the absence and presence of nine different bNAbs, including the 10–1074 and 3BNC117 <xref ref-type="bibr" rid="bib21">Dingens et al., 2019</xref>.</p><p>Escape variants in DMS data are identified as those which are strongly selected for only in the presence of a bNAb. Specifically, we identify escape variants as those which show 3-logs-change in their frequency in the presence versus absence of a bNAb. DMS data reflects in vitro escape in cell culture. However, some of these variants may not be viable in vivo. To identify the reasonable candidates of escape in vivo, we limit our set to the variants that are also observed in the circulating viral strains of untreated HIV-1 patients from <xref ref-type="bibr" rid="bib105">Zanini et al., 2015</xref>. It should be noted that since we use HIV-1 sequence data from <xref ref-type="bibr" rid="bib105">Zanini et al., 2015</xref> to infer selection on escape mediating variants in the absence of a bNAb, the candidates of escape that are not observed in the dataset <xref ref-type="bibr" rid="bib105">Zanini et al., 2015</xref> would be inferred to be strongly deleterious, and hence, unlikely to contribute to our predictions of viral rebound.</p><p>Our analysis of DMS data results in a set of escape mediating amino acids for 10–1074 that is consistent with the escape variants that emerge in response to the bNAb trial (<xref ref-type="bibr" rid="bib12">Caskey et al., 2017</xref>; <xref ref-type="bibr" rid="bib92">Stephenson et al., 2021</xref> Appendix 4). However, the DMS data is very noisy for bNAbs that target CD4 binding site of HIV, that is, 3BNC117 and VRC01 (<xref ref-type="bibr" rid="bib21">Dingens et al., 2019</xref>). One reason for this observation may be that the CD4 binding site is crucial for the entry of HIV to the host’s T-cells and mutations in this region are highly deleterious. As a results, only a small number of variants with mutations in this region can survive in the absence of a bNAb in a DMS experiment. Growth in the absence of a bNAb is the first step in the DMS experiments, which is then followed by exposure of the replicated variants to a bNAb. Therefore, a low multiplicity of variants in the absence of a bNAb could result in a noisy pattern of growth of the small subpopulation in the next stage of the experiment, in which growth is subject to a CD4-targeting bNAb.</p><p>For the CD4 binding site antibodies 3BNC117 and VRC01, we used additional data to call the escape variants. For 3BNC117, we used a combination of trial-patient sequences (<xref ref-type="bibr" rid="bib10">Caskey et al., 2015</xref>; <xref ref-type="bibr" rid="bib82">Scheid et al., 2016</xref>), that is post-treatment enrichment, along with contact site information compiled in the crystallographic studies to narrow down candidate sites (<xref ref-type="bibr" rid="bib109">Zhou et al., 2015</xref>; <xref ref-type="bibr" rid="bib51">LaBranche et al., 2018</xref>). For VRC01, we assumed a similar escape pattern to 3BNC117 but included sites known from other studies (<xref ref-type="bibr" rid="bib59">Lynch et al., 2015</xref>) and the clear DMS signal at HXB2 site 197. The sites we called were similar to those identified using humanized-mouse models of HIV infection (<xref ref-type="bibr" rid="bib41">Horwitz et al., 2013</xref>), although more complex mutational patterns were seen in the soft-randomization scanning of <xref ref-type="bibr" rid="bib71">Otsuka et al., 2018</xref>. Although the complete list of escape substitutions are unknown and background-dependent (<xref ref-type="bibr" rid="bib71">Otsuka et al., 2018</xref>), the escape profiles which are most important are those that are most likely to be seen consistently in data and to be correctly identified. The list of substitutions are shown in <xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>.</p></sec><sec id="s4-4"><title>Statistics and dynamics of viral rebound</title><sec id="s4-4-1"><title>Inference of growth parameters from dynamics of viremia</title><p>The concentration of viral RNA copies in blood serum is a delayed reflection of the total viral population size <inline-formula><mml:math id="inf167"><mml:mrow><mml:mi>N</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>, containing a resistant and susceptible subpopulations, with respective sizes <inline-formula><mml:math id="inf168"><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>r</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="inf169"><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>. After infusion of bNAbs in a patient, the susceptible sub-population decays due to neutralization by bNAbs and the resistant sub-population grows and approaches the carrying capacity <inline-formula><mml:math id="inf170"><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula>, with the dynamics,<disp-formula id="equ4"><label>(4)</label><mml:math id="m4"><mml:mrow><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>N</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mi>γ</mml:mi><mml:msub><mml:mi>N</mml:mi><mml:mi>r</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>r</mml:mi></mml:msub><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>N</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mi>r</mml:mi><mml:msub><mml:mi>N</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula></p><p>Here, <inline-formula><mml:math id="inf171"><mml:mi>γ</mml:mi></mml:math></inline-formula> is the growth rate of the resistant population, and <inline-formula><mml:math id="inf172"><mml:mi>r</mml:mi></mml:math></inline-formula> is the neutralization rate impacting the susceptible subpopulation. By setting the initial condition for fraction of resistant subpopulation prior to treatment (at time <inline-formula><mml:math id="inf173"><mml:mrow><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula>) <inline-formula><mml:math id="inf174"><mml:mrow><mml:mi>x</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>r</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>r</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></inline-formula>, we can characterize the evolution of the total viremia in a patient. This dynamics is governed by the combined processes of neutralization by the infused bNAb and the viral rebound (<xref ref-type="fig" rid="fig1">Figure 1A</xref>), which entails,<disp-formula id="equ5"><label>(5)</label><mml:math id="m5"><mml:mrow><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mtable columnalign="left left" rowspacing=".2em" columnspacing="1em" displaystyle="false"><mml:mtr><mml:mtd><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mtd><mml:mtd><mml:mi>t</mml:mi><mml:mo>≤</mml:mo><mml:mn>0</mml:mn></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mi>r</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mfrac><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>x</mml:mi></mml:mrow><mml:mi>x</mml:mi></mml:mfrac><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mi>γ</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:mtd><mml:mtd><mml:mi>t</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn></mml:mtd></mml:mtr></mml:mtable><mml:mo fence="true" stretchy="true" symmetric="true"/></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>We use <xref ref-type="disp-formula" rid="equ5">Equation 5</xref> to define the evolution of blood concentration of viral RNA sequences which is observed indirectly via noisy viremia measurement data from <xref ref-type="bibr" rid="bib10">Caskey et al., 2015</xref>; <xref ref-type="bibr" rid="bib12">Caskey et al., 2017</xref>; <xref ref-type="bibr" rid="bib4">Baron et al., 2018</xref>. To connect the data with the simple model of viral dynamics in <xref ref-type="disp-formula" rid="equ5">Equation 5</xref>, we fit the initial frequency of resistant mutants <inline-formula><mml:math id="inf175"><mml:mi>x</mml:mi></mml:math></inline-formula> for each patient separately, and fit a global estimate for the decay rate of susceptible variants <inline-formula><mml:math id="inf176"><mml:mi>r</mml:mi></mml:math></inline-formula> shared across all patients in a trial, using a joint maximum-likelihood procedure. In addition, we fix the growth rate <inline-formula><mml:math id="inf177"><mml:mi>γ</mml:mi></mml:math></inline-formula> to 1/3 days, corresponding to a doubling time of approximately 2 days <xref ref-type="bibr" rid="bib31">García et al., 1999</xref>. Our analyses indicate that the initial viremia decline lagged treatment by about 1 day (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplements 1</xref>–<xref ref-type="fig" rid="fig3s3">3</xref>), consistent with previous findings (<xref ref-type="bibr" rid="bib43">Ioannidis et al., 2000</xref>), and therefore, we included a 1 day lag between the fitted viremia response model and the treatment.</p><p><inline-formula><mml:math id="inf178"><mml:mi>t</mml:mi></mml:math></inline-formula> The number of viral RNA copies in a blood sample is subject to count fluctuations with respect to the true number of circulating virions in a given volume of the blood. We use a Poisson sampling model to define a likelihood for our model of viral population. The likelihood of observing viral counts in a sample collected from patient at time is given by a Poisson distribution,<disp-formula id="equ6"><label>(6)</label><mml:math id="m6"><mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:mi>η</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:mi>η</mml:mi></mml:mrow></mml:msup><mml:mo>⁢</mml:mo><mml:mfrac><mml:msup><mml:mi>η</mml:mi><mml:mi>k</mml:mi></mml:msup><mml:mrow><mml:mi>k</mml:mi><mml:mo>!</mml:mo></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>with rate parameter set by the model value of the viral multiplicity <inline-formula><mml:math id="inf179"><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> (<xref ref-type="disp-formula" rid="equ5">Equation 5</xref>). We use the Poisson likelihood in <xref ref-type="disp-formula" rid="equ6">Equation 6</xref> to characterize an error model to fit the parameters of the viral dynamics in <xref ref-type="disp-formula" rid="equ5">Equation 5</xref>. However, since the mean and variance of the Poisson distribution are related, combining data with different mean values <inline-formula><mml:math id="inf180"><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> at different times and from different patients can cause inconsistencies in evaluations of errors in our fits. To overcome this problem, we use a variance stabilizing transformation (<xref ref-type="bibr" rid="bib62">McCullagh and Nelder, 2019</xref>) and define a change in variable <inline-formula><mml:math id="inf181"><mml:mrow><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>n</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mi>p</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:msqrt><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:msqrt></mml:mrow></mml:math></inline-formula>. This transformed variable has a constant variance, and in the limit of large-sample size, it is Gaussian distributed with a mean and variance given by, <inline-formula><mml:math id="inf182"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>n</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>∼</mml:mo><mml:mrow><mml:mi mathvariant="script">N</mml:mi></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msqrt><mml:mi>λ</mml:mi></mml:msqrt><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>4</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula>. The constant variance of the transformed variable enables us to combine data from all patients and time points, irrespective of the sample’s viral loads, and fit the model parameters <inline-formula><mml:math id="inf183"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>r</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula> using (non-linear) least-squares fitting of the function<disp-formula id="equ7"><label>(7)</label><mml:math id="m7"><mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>r</mml:mi><mml:mo>,</mml:mo><mml:mrow><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo stretchy="false">}</mml:mo></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:munder><mml:mo largeop="true" movablelimits="false" symmetric="true">∑</mml:mo><mml:mrow><mml:mi>p</mml:mi><mml:mo>:</mml:mo><mml:mrow><mml:mtext> patients</mml:mtext><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:mrow></mml:munder><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msqrt><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>t</mml:mi><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:mrow><mml:mi>r</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:msqrt><mml:mo>-</mml:mo><mml:msqrt><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:msqrt></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>Here, <inline-formula><mml:math id="inf184"><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>t</mml:mi><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:mrow><mml:mi>r</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> is the model estimate of viremia in patient <inline-formula><mml:math id="inf185"><mml:mi>p</mml:mi></mml:math></inline-formula> at time <inline-formula><mml:math id="inf186"><mml:mi>t</mml:mi></mml:math></inline-formula> (<xref ref-type="disp-formula" rid="equ5">Equation 5</xref>), given the pre-treatment fraction of resistant variants <italic>x</italic><sub><italic>p</italic></sub>, and the decay rate <inline-formula><mml:math id="inf187"><mml:mi>r</mml:mi></mml:math></inline-formula>.</p><p>Note that the viremia measurements have a minimum sensitivity threshold of 20 RNA copies per ml. We treat the data points below the threshold of detection as missing data and if <inline-formula><mml:math id="inf188"><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> is below the threshold of detection we impute <inline-formula><mml:math id="inf189"><mml:mrow><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mtext>min</mml:mtext><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>20</mml:mn><mml:mo>,</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></inline-formula>.</p><p>The fitted viremia curves for patients enrolled in the three bNAb trials under consideration are shown in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplements 1</xref>–<xref ref-type="fig" rid="fig3s3">3</xref>, and the respective decay rates <inline-formula><mml:math id="inf190"><mml:mi>r</mml:mi></mml:math></inline-formula> for each experiment are,<disp-formula id="equ8"><label>(8)</label><mml:math id="m8"><mml:mrow><mml:mtable rowspacing="4pt" columnspacing="1em" rowlines="solid"><mml:mtr><mml:mtd><mml:mtext>trial</mml:mtext></mml:mtd><mml:mtd><mml:mtext>10-1074</mml:mtext></mml:mtd><mml:mtd><mml:mtext>3BNC117</mml:mtext></mml:mtd><mml:mtd><mml:mtext>Combination</mml:mtext></mml:mtd><mml:mtd><mml:mtext>Avg</mml:mtext></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mtext>fitted</mml:mtext><mml:mspace width="thinmathspace"/><mml:mi>r</mml:mi><mml:mspace width="thinmathspace"/><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mtext>days</mml:mtext><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mtd><mml:mtd><mml:mn>0.36</mml:mn></mml:mtd><mml:mtd><mml:mn>0.23</mml:mn></mml:mtd><mml:mtd><mml:mn>0.33</mml:mn></mml:mtd><mml:mtd><mml:mn>0.31</mml:mn></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula></p></sec><sec id="s4-4-2"><title>Individual-based model for viral population dynamics</title><p>To encode for different viral variants, we specify a coarse-grained phenotypic model, where a viral strain of type <inline-formula><mml:math id="inf191"><mml:mi>a</mml:mi></mml:math></inline-formula> is defined by a binary state vector <inline-formula><mml:math id="inf192"><mml:mrow><mml:msup><mml:mover accent="true"><mml:mi>ρ</mml:mi><mml:mo stretchy="false">→</mml:mo></mml:mover><mml:mi>a</mml:mi></mml:msup><mml:mo>=</mml:mo><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:msubsup><mml:mi>ρ</mml:mi><mml:mn>1</mml:mn><mml:mi>a</mml:mi></mml:msubsup><mml:mo>,</mml:mo><mml:mi mathvariant="normal">…</mml:mi><mml:mo>,</mml:mo><mml:msubsup><mml:mi>ρ</mml:mi><mml:mi mathvariant="normal">ℓ</mml:mi><mml:mi>a</mml:mi></mml:msubsup><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>, with <inline-formula><mml:math id="inf193"><mml:mi mathvariant="normal">ℓ</mml:mi></mml:math></inline-formula> entries for potentially escape-mediating epitope sites; the binary entry of the state vector at the epitope site <inline-formula><mml:math id="inf194"><mml:mi>i</mml:mi></mml:math></inline-formula> represents the presence (<inline-formula><mml:math id="inf195"><mml:mrow><mml:msubsup><mml:mi>ρ</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>) or absence (<inline-formula><mml:math id="inf196"><mml:mrow><mml:msubsup><mml:mi>ρ</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula>) of a escape mediating mutation against a specified bNAb at site <inline-formula><mml:math id="inf197"><mml:mi>i</mml:mi></mml:math></inline-formula> of variant <inline-formula><mml:math id="inf198"><mml:mi>a</mml:mi></mml:math></inline-formula>. We assume that a variant is resistant to a given antibody if at least one of the entries of its corresponding state vector is non-zero.</p><p>We define an individual-based stochastic birth-death model (<xref ref-type="bibr" rid="bib102">Wilkinson, 2019</xref>) to capture the competitive dynamics of different HIV variants within a population. This dynamic model will allow us to predict the distribution of rebound times under any combination of antibodies.</p><p>We assume that a viral strain of type <inline-formula><mml:math id="inf199"><mml:mi>a</mml:mi></mml:math></inline-formula> can undergo one of three processes: birth, death and mutation to another type <inline-formula><mml:math id="inf200"><mml:mi>b</mml:mi></mml:math></inline-formula> with rates <inline-formula><mml:math id="inf201"><mml:msub><mml:mi>β</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:math></inline-formula>, <inline-formula><mml:math id="inf202"><mml:msub><mml:mi>δ</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:math></inline-formula>, and <inline-formula><mml:math id="inf203"><mml:msub><mml:mi>μ</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mo>→</mml:mo><mml:mi>b</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>, respectively:<disp-formula id="equ9"><mml:math id="m9"><mml:mrow><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mtext>birth</mml:mtext><mml:mo>:</mml:mo><mml:mspace width="1em"/><mml:mo stretchy="false">[</mml:mo><mml:mi>a</mml:mi><mml:mo stretchy="false">]</mml:mo><mml:mover><mml:mo stretchy="false">⟶</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mover><mml:mn>2</mml:mn><mml:mo stretchy="false">[</mml:mo><mml:mi>a</mml:mi><mml:mo stretchy="false">]</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mtext>death</mml:mtext><mml:mo>:</mml:mo><mml:mspace width="1em"/><mml:mo stretchy="false">[</mml:mo><mml:mi>a</mml:mi><mml:mo stretchy="false">]</mml:mo><mml:mover><mml:mo stretchy="false">⟶</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mover><mml:mo>∗</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mtext>mutation</mml:mtext><mml:mo>:</mml:mo><mml:mspace width="1em"/><mml:mo stretchy="false">[</mml:mo><mml:mi>a</mml:mi><mml:mo stretchy="false">]</mml:mo><mml:mover><mml:mo stretchy="false">⟶</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mo stretchy="false">→</mml:mo><mml:mi>b</mml:mi></mml:mrow></mml:msub></mml:mover><mml:mo stretchy="false">[</mml:mo><mml:mi>b</mml:mi><mml:mo stretchy="false">]</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula></p><p>We specify an intrinsic fitness f<sub>a</sub> for a given variant a, defined as the growth rate of the virus in the absence of neutralizing antibody or competition. Since bNAbs target highly vulnerable regions of the virus, we expect that HIV-1 escape mutations to be in trinsically deleterious for the virus and to confer a fitness cost relative to the susceptible viral variants prior to the infusion of bNAbs. Assuming that fitness cost of escape is additive across sites and background-independent, we can express the fitness of a variant as , where Δ is the cost associated with the presence of an escape mutation at site of variant (i.e., for = 1).</p><p>We assume that growth is self-limiting via a competition for host T-cells. This competition enforces a carrying capacity, which sets the steady-state population size <inline-formula><mml:math id="inf204"><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula>. Competition is mediated through a competitive pressure term <inline-formula><mml:math id="inf205"><mml:mrow><mml:mi>ϕ</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mstyle displaystyle="false"><mml:msub><mml:mo largeop="true" symmetric="true">∑</mml:mo><mml:mi>a</mml:mi></mml:msub></mml:mstyle><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:mrow></mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>K</mml:mi></mml:msub></mml:mfrac></mml:mrow></mml:math></inline-formula> which attenuates the net growth rate <inline-formula><mml:math id="inf206"><mml:msub><mml:mi>γ</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:math></inline-formula> so that <inline-formula><mml:math id="inf207"><mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo>-</mml:mo><mml:mi>ϕ</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula>. At the carrying capacity, the competitive pressure equals the mean population fitness <inline-formula><mml:math id="inf208"><mml:mrow><mml:mi>ϕ</mml:mi><mml:mo>=</mml:mo><mml:mover accent="true"><mml:mi>f</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>, making the net growth rate of the population zero.</p><p>The net growth rate of a variant <inline-formula><mml:math id="inf209"><mml:mi>a</mml:mi></mml:math></inline-formula> is given by its birth rate minus the death rate: <inline-formula><mml:math id="inf210"><mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>. We assume that the total rate of events (i.e. the sum of birth and death events) is equal for all types, that is, <inline-formula><mml:math id="inf211"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:mrow><mml:mo rspace="4.2pt">,</mml:mo><mml:mrow><mml:mo>∀</mml:mo><mml:mi>a</mml:mi></mml:mrow></mml:mrow></mml:mrow></mml:math></inline-formula>. Assuming that <inline-formula><mml:math id="inf212"><mml:mi>λ</mml:mi></mml:math></inline-formula> is constant is to be agnostic about the mechanism of a fitness decrease, attributing fitness loss equally to (i) an increase in the death rate and (ii) a decrease in the birth rate.</p><p>Because the absolute magnitude of <inline-formula><mml:math id="inf213"><mml:mi>β</mml:mi></mml:math></inline-formula> and <inline-formula><mml:math id="inf214"><mml:mi>δ</mml:mi></mml:math></inline-formula> asymptotically converge in the continuum limit for a surviving population, that is, <inline-formula><mml:math id="inf215"><mml:mrow><mml:mrow><mml:msub><mml:mo>lim</mml:mo><mml:mrow><mml:mi>N</mml:mi><mml:mo>→</mml:mo><mml:mi mathvariant="normal">∞</mml:mi></mml:mrow></mml:msub><mml:mo>⁡</mml:mo><mml:mrow><mml:mi>β</mml:mi><mml:mo>/</mml:mo><mml:mi>δ</mml:mi></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>, it is impossible to distinguish between (i) and (ii) in the continuous limit. Choosing constant <inline-formula><mml:math id="inf216"><mml:mi>λ</mml:mi></mml:math></inline-formula> simplifies both theoretical calculations and the simulation algorithm.</p><p>This leads to the following equations for the birth and the death rates:<disp-formula id="equ10"><label>(9)</label><mml:math id="m10"><mml:mrow><mml:mtable columnalign="right left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>λ</mml:mi><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:mfrac><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:msub><mml:mi>δ</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>λ</mml:mi><mml:mo>−</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:mfrac></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula></p><p>In the presence of an antibody, birth is effectively halted for susceptible variants, resulting in birth and death rate for a susceptible variant <inline-formula><mml:math id="inf217"><mml:mi>s</mml:mi></mml:math></inline-formula>,<disp-formula id="equ11"><label>(10)</label><mml:math id="m11"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:msub><mml:mi>δ</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>r</mml:mi></mml:mrow></mml:math></disp-formula></p><p>so that the susceptible phenotype decays at rate <inline-formula><mml:math id="inf218"><mml:mi>r</mml:mi></mml:math></inline-formula>.</p><p>We assume that mutations occur independently at each site,<disp-formula id="equ12"><label>(11)</label><mml:math id="m12"><mml:mtable columnspacing="5pt" displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi>μ</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mo>→</mml:mo><mml:mi>b</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mtable columnspacing="5pt" displaystyle="true" rowspacing="0pt"><mml:mtr><mml:mtd columnalign="left"><mml:msub><mml:mi>μ</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mrow><mml:mrow><mml:mtext>if </mml:mtext><mml:mo>⁢</mml:mo><mml:msup><mml:mi>ρ</mml:mi><mml:mi>a</mml:mi></mml:msup></mml:mrow><mml:mo>-</mml:mo><mml:msup><mml:mi>ρ</mml:mi><mml:mi>b</mml:mi></mml:msup></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mn>1</mml:mn><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"><mml:msubsup><mml:mi>μ</mml:mi><mml:mi>i</mml:mi><mml:mo>†</mml:mo></mml:msubsup></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mrow><mml:mrow><mml:mtext>if </mml:mtext><mml:mo>⁢</mml:mo><mml:msup><mml:mi>ρ</mml:mi><mml:mi>a</mml:mi></mml:msup></mml:mrow><mml:mo>-</mml:mo><mml:msup><mml:mi>ρ</mml:mi><mml:mi>a</mml:mi></mml:msup></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mn>1</mml:mn><mml:mi>s</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"><mml:mn>0</mml:mn></mml:mtd><mml:mtd columnalign="left"><mml:mtext>otherwise</mml:mtext></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:mtd><mml:mtd/></mml:mtr></mml:mtable></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf219"><mml:msub><mml:mn>1</mml:mn><mml:mi>s</mml:mi></mml:msub></mml:math></inline-formula> is the vector which has only one non-zero entry at site <inline-formula><mml:math id="inf220"><mml:mi>i</mml:mi></mml:math></inline-formula>, and <inline-formula><mml:math id="inf221"><mml:msub><mml:mi>μ</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="inf222"><mml:msubsup><mml:mi>μ</mml:mi><mml:mi>i</mml:mi><mml:mo>†</mml:mo></mml:msubsup></mml:math></inline-formula> are the forward the backward mutation rates at site <inline-formula><mml:math id="inf223"><mml:mi>i</mml:mi></mml:math></inline-formula>, respectively. We characterize the state of a population by vector <inline-formula><mml:math id="inf224"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="bold-italic">n</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mi>M</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula>, where <italic>n</italic><sub><italic>a</italic></sub> is the number of type <inline-formula><mml:math id="inf225"><mml:mi>a</mml:mi></mml:math></inline-formula> variants within the population. We approximate the evolution of the population state distribution using a Fokker-Planck equation (see Appendix 2).</p><p>Of special interest for our analysis is the steady-state density of frequencies, which we use to describe the initial state of the population (before treatment) and to infer selection intensity. In the steady state, the population is fluctuating around carrying capacity <inline-formula><mml:math id="inf226"><mml:mrow><mml:mrow><mml:msub><mml:mo largeop="true" symmetric="true">∑</mml:mo><mml:mi>a</mml:mi></mml:msub><mml:msub><mml:mi>n</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:mrow><mml:mo>≈</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> and we can represent the population state via allele frequencies <inline-formula><mml:math id="inf227"><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>. In the simple case of a bi-allelic problem, the equilibrium allele frequency distribution <inline-formula><mml:math id="inf228"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mtext>eq</mml:mtext></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> follows the Wright-equilibrium distribution (<xref ref-type="bibr" rid="bib19">Crow and Kimura, 2010</xref>) with modified rates,<disp-formula id="equ13"><label>(12)</label><mml:math id="m13"><mml:mrow><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mtext>eq</mml:mtext></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mi>Z</mml:mi></mml:mfrac><mml:mo>⁢</mml:mo><mml:mfrac><mml:mrow><mml:mpadded width="+3.3pt"><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:mo>⁢</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mrow><mml:mi>λ</mml:mi></mml:mfrac><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>⁢</mml:mo><mml:mi>x</mml:mi></mml:mrow></mml:msup></mml:mpadded><mml:mo>⁢</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>x</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:mo>⁢</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mrow><mml:mi>λ</mml:mi></mml:mfrac><mml:mo>⁢</mml:mo><mml:msup><mml:mi>μ</mml:mi><mml:mo>†</mml:mo></mml:msup></mml:mrow></mml:msup><mml:mo>⁢</mml:mo><mml:msup><mml:mi>x</mml:mi><mml:mrow><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:mo>⁢</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mrow><mml:mi>λ</mml:mi></mml:mfrac><mml:mo>⁢</mml:mo><mml:mi>μ</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>x</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>⁢</mml:mo><mml:mi>x</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mo>≡</mml:mo><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mi>Z</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>σ</mml:mi><mml:mo>,</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>⁢</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>⁢</mml:mo><mml:mi>x</mml:mi></mml:mrow></mml:mrow></mml:msup><mml:mo>⁢</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>x</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup></mml:msup><mml:mo>⁢</mml:mo><mml:msup><mml:mi>x</mml:mi><mml:mi>θ</mml:mi></mml:msup></mml:mrow><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>x</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>⁢</mml:mo><mml:mi>x</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf229"><mml:mi>Z</mml:mi></mml:math></inline-formula> is the normalization factor, <italic>f</italic><sub>1</sub> is the intrinsic fitness of the variant of interest, <italic>f</italic><sub>0</sub> is the fitness of the competing variant, <inline-formula><mml:math id="inf230"><mml:mi>μ</mml:mi></mml:math></inline-formula> and <inline-formula><mml:math id="inf231"><mml:msup><mml:mi>μ</mml:mi><mml:mo>†</mml:mo></mml:msup></mml:math></inline-formula> are the forward and backward mutation rates, <inline-formula><mml:math id="inf232"><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula> is the carrying capacity, and <inline-formula><mml:math id="inf233"><mml:mi>λ</mml:mi></mml:math></inline-formula> is the total rate of events in the birth-death process, which sets a characteristic time scale over which the impact of selection and mutations can be measured. In this case, we can define an ‘effective population size’ that sets the effective size of a bottleneck and the natural time scale of evolution as <inline-formula><mml:math id="inf234"><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>e</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:mi>λ</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula>, and specify a scaled selection factor <inline-formula><mml:math id="inf235"><mml:mrow><mml:mi>σ</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>e</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mi>s</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>e</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></inline-formula>, and scaled forward mutation and backward mutation rates (diversity) <inline-formula><mml:math id="inf236"><mml:mrow><mml:mi>θ</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mo>⁢</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>e</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mi>μ</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula>, and <inline-formula><mml:math id="inf237"><mml:mrow><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup><mml:mo>=</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mo>⁢</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>e</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:msup><mml:mi>μ</mml:mi><mml:mo>†</mml:mo></mml:msup></mml:mrow></mml:mrow></mml:math></inline-formula>. The normalization factor is given by,<disp-formula id="equ14"><label>(13)</label><mml:math id="m14"><mml:mrow><mml:mi>Z</mml:mi><mml:mo>≡</mml:mo><mml:mrow><mml:mi>Z</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>σ</mml:mi><mml:mo>,</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mi class="ltx_font_mathcaligraphic">ℬ</mml:mi><mml:mo>⁢</mml:mo><mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup><mml:mo rspace="4.2pt" stretchy="false">)</mml:mo></mml:mrow><mml:mn>1</mml:mn></mml:msub><mml:mo>⁢</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:mrow><mml:mi>θ</mml:mi><mml:mo>+</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup></mml:mrow><mml:mo>,</mml:mo><mml:mrow><mml:mo>-</mml:mo><mml:mi>σ</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf238"><mml:mrow><mml:mmultiscripts><mml:mi>F</mml:mi><mml:mn>1</mml:mn><mml:none/><mml:mprescripts/><mml:mn>1</mml:mn><mml:none/></mml:mmultiscripts><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mo>⋅</mml:mo><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> denotes a Kummer confluent hypergeometric function and <inline-formula><mml:math id="inf239"><mml:mrow><mml:mrow><mml:mi class="ltx_font_mathcaligraphic">ℬ</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">Γ</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mi>θ</mml:mi><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mo>⁢</mml:mo><mml:mi mathvariant="normal">Γ</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Γ</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mrow><mml:mi>θ</mml:mi><mml:mo>+</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup></mml:mrow><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:math></inline-formula> is the Euler beta function.</p></sec><sec id="s4-4-3"><title>Extinction Probability</title><p>The logistic dynamics describing a patient’s viremia over time in <xref ref-type="disp-formula" rid="equ5">Equation 5</xref> is the deterministic approximation to the underlying birth-death process. However, the resistant population can also go extinct due stochastic effects, which in turn contribute to the probability of late rebound in a population. To capture this effect, we derive an approximate closed form expression for the probability of extinction.</p><p>Using the standard birth-death process generating function theory <xref ref-type="bibr" rid="bib1">Allen, 2010</xref> the probability <inline-formula><mml:math id="inf240"><mml:mrow><mml:mi>P</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mtext>extinct</mml:mtext><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> that a population consisting of <italic>n</italic><sub><italic>i</italic></sub> resistant variants of type <inline-formula><mml:math id="inf241"><mml:mi>i</mml:mi></mml:math></inline-formula> go extinct can be expressed as,<disp-formula id="equ15"><label>(14)</label><mml:math id="m15"><mml:mrow><mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mtext>extinct</mml:mtext><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:msub><mml:mi>δ</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mi>β</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfrac><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:msup></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>To characterize the probability of extinction for a population of size <inline-formula><mml:math id="inf242"><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula> with pre-treatment fraction of <inline-formula><mml:math id="inf243"><mml:msup><mml:mi>i</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mo>⁢</mml:mo><mml:mi>h</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> resistant variants <italic>x</italic><sub><italic>i</italic></sub>, we can convolve the extinction probability in <xref ref-type="disp-formula" rid="equ15">Equation 14</xref> with a Binomial probability density for sampling <italic>n</italic><sub><italic>i</italic></sub> resistant variants from <inline-formula><mml:math id="inf244"><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula> trials. Given that the pre-treatment fraction of resistant variants is small <inline-formula><mml:math id="inf245"><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>≪</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="inf246"><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula> is large, this Binomial distribution can be well approximated by a Poisson distribution, <inline-formula><mml:math id="inf247"><mml:mrow><mml:mtext>Poiss</mml:mtext><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>;</mml:mo><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> with rate <inline-formula><mml:math id="inf248"><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>, resulting in an extinction probability,<disp-formula id="equ16"><label>(15)</label><mml:math id="m16"><mml:mtable columnspacing="5pt" displaystyle="true" rowspacing="0pt"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>P</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mtext>extinct</mml:mtext><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mi/><mml:mo>=</mml:mo><mml:mrow><mml:mstyle displaystyle="false"><mml:msub><mml:mo largeop="true" symmetric="true">∑</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:msub></mml:mstyle><mml:mrow><mml:mtext>Poiss</mml:mtext><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>;</mml:mo><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>⁢</mml:mo><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mstyle displaystyle="false"><mml:mfrac><mml:msub><mml:mi>δ</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mi>β</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfrac></mml:mstyle><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:msup></mml:mrow></mml:mrow></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd columnalign="left"><mml:mrow><mml:mi/><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mi>exp</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mo>-</mml:mo><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>⁢</mml:mo><mml:mrow><mml:mstyle displaystyle="false"><mml:msub><mml:mo largeop="true" symmetric="true">∑</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:msub></mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:mfrac><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:msup><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>!</mml:mo></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>⁢</mml:mo><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mstyle displaystyle="false"><mml:mfrac><mml:msub><mml:mi>δ</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mi>β</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfrac></mml:mstyle><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:msup></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd columnalign="left"><mml:mrow><mml:mi/><mml:mo>=</mml:mo><mml:mrow><mml:mi>exp</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mo>-</mml:mo><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mstyle displaystyle="false"><mml:mfrac><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfrac></mml:mstyle><mml:mo>⁢</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula></p><p>Using the expressions for the growth in the absence of competition, <inline-formula><mml:math id="inf249"><mml:mrow><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> (since <inline-formula><mml:math id="inf250"><mml:mrow><mml:mi>ϕ</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula>), and assuming that fitness is small relative to the total rate of birth and death events <inline-formula><mml:math id="inf251"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>≪</mml:mo><mml:mi>λ</mml:mi></mml:mrow></mml:math></inline-formula>, we can use the approximation <inline-formula><mml:math id="inf252"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>λ</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow><mml:mo>≈</mml:mo><mml:mrow><mml:mi>λ</mml:mi><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>, to arrive at,<disp-formula id="equ17"><label>(16)</label><mml:math id="m17"><mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mtext>extinct</mml:mtext><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>≈</mml:mo><mml:mrow><mml:mi>exp</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mo>-</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mo>⁢</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mrow><mml:mi>λ</mml:mi></mml:mfrac><mml:mo>⁢</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mi>exp</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mo>-</mml:mo><mml:mfrac><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mtext>ext</mml:mtext></mml:msub></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula></p><p><inline-formula><mml:math id="inf253"><mml:msub><mml:mi>x</mml:mi><mml:mtext>ext</mml:mtext></mml:msub></mml:math></inline-formula> where the characteristic escape threshold can be written in terms of concrete genetic observables,<disp-formula id="equ18"><label>(17)</label><mml:math id="m18"><mml:mrow><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mtext>ext</mml:mtext></mml:msub><mml:mo>≡</mml:mo><mml:mfrac><mml:mi>λ</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mo>⁢</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mrow><mml:mfrac><mml:msub><mml:mi>μ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub><mml:msub><mml:mi>f</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfrac><mml:mo>⁢</mml:mo><mml:msubsup><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p><xref ref-type="fig" rid="fig3">Figure 3</xref> shows that this threshold can well separate the fate of stochastic evolutionary trajectories, simulated with relevant parameters for intra-patient HIV evolution.</p></sec><sec id="s4-4-4"><title>Numerical simulations of the birth-death process</title><p>To treat the full viral dynamics including mutations, and transient competition effects, we can exactly simulate the viral dynamics defined by our individual based model. Below are the key steps in this simulation.</p><sec id="s4-4-4-1"><title>Population initialization</title><p>At the starting point, we set the population size (i.e. the carrying capacity in the simulations) <inline-formula><mml:math id="inf254"><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula> as a free parameter chosen to be large enough to make discretization effects small. The population is then evolved through time using an exact stochastic sampling procedure (the Gillespie algorithm Gillespie (1977)). Simulating the outcome of this stochastic evolution generates the distribution of rebound times and the probability of late rebound—the key quantities related to treatment efficacy.</p><p>The input to our procedure is a list of antibodies for which we specify (i) the escape mediating sites for each antibody, and the (invariant) quantities describing (ii) the site-specific cost of escape <inline-formula><mml:math id="inf255"><mml:mfrac><mml:mi>σ</mml:mi><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:mfrac></mml:math></inline-formula>, and (iii) the forward and backward mutation rates <inline-formula><mml:math id="inf256"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mfrac><mml:mi>θ</mml:mi><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:mfrac><mml:mo>,</mml:mo><mml:mfrac><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:mfrac><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>. To simulate the trial outcome for each patient, we use the neutral population diversity <inline-formula><mml:math id="inf257"><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:math></inline-formula> directly inferred from the patients; see Inference of mutation rates and the neutral diversity within a population. From this, we construct the list of <inline-formula><mml:math id="inf258"><mml:mi>L</mml:mi></mml:math></inline-formula> site parameters (concatenated across all antibodies) for selection and diversity: <inline-formula><mml:math id="inf259"><mml:msub><mml:mi>σ</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>L</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>, <inline-formula><mml:math id="inf260"><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>L</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>, <inline-formula><mml:math id="inf261"><mml:msubsup><mml:mi>θ</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>L</mml:mi></mml:mrow><mml:mo>†</mml:mo></mml:msubsup></mml:math></inline-formula>.</p><p>We assume that at the start of the simulation, populations are in the steady state and that the potential escape sites are at linkage equilibrium. The approximate linkage equilibrium assumption is justified since the distance between these escape sites along the HIV-1 genome is greater than the characteristic recombination length scale <inline-formula><mml:math id="inf262"><mml:mrow><mml:mi/><mml:mo>≈</mml:mo><mml:mrow><mml:mn>100</mml:mn><mml:mo>⁢</mml:mo><mml:mtext>bp</mml:mtext></mml:mrow></mml:mrow></mml:math></inline-formula> of the virus (<xref ref-type="bibr" rid="bib105">Zanini et al., 2015</xref>). As a result, we draw an independent frequency <italic>x</italic><sub><italic>i</italic></sub> from the stationary distribution <inline-formula><mml:math id="inf263"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mtext>eq</mml:mtext></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>x</mml:mi><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:mrow><mml:msub><mml:mi>σ</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msubsup><mml:mi>θ</mml:mi><mml:mi>i</mml:mi><mml:mo>†</mml:mo></mml:msubsup></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> in <xref ref-type="disp-formula" rid="equ13">Equation 12</xref> to describe the state of a give site <inline-formula><mml:math id="inf264"><mml:mi>i</mml:mi></mml:math></inline-formula>, and use these frequencies to construct the initial viral genotypes <inline-formula><mml:math id="inf265"><mml:msup><mml:mi>ρ</mml:mi><mml:mi>v</mml:mi></mml:msup></mml:math></inline-formula> for each virus <inline-formula><mml:math id="inf266"><mml:mi>v</mml:mi></mml:math></inline-formula> in our initial population; see Algorithm 1 (Appendix 5). In simulations, we show that this assumption does not bias our results even when <inline-formula><mml:math id="inf267"><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:math></inline-formula> is fluctuating and recombination is absent (Section 6.1 and <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>).</p><p>To sample from the stationary distribution itself, we define a novel Gibbs-sampling procedure (<xref ref-type="bibr" rid="bib34">Geman and Geman, 1984</xref>) for generating the allele frequencies of the escape variants for the initial state of the population <inline-formula><mml:math id="inf268"><mml:mrow><mml:mi>x</mml:mi><mml:mo>∼</mml:mo><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mtext>eq</mml:mtext></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>x</mml:mi><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>,</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></inline-formula> (<xref ref-type="disp-formula" rid="equ13">Equation 12</xref>). To characterize this procedure, we expand the exponential selection factor <inline-formula><mml:math id="inf269"><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mi>σ</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>x</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:math></inline-formula> in the original distribution, which results in,<disp-formula id="equ19"><label>(18)</label><mml:math id="m19"><mml:mtable columnspacing="5pt" displaystyle="true" rowspacing="0pt"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mtext>eq</mml:mtext></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>x</mml:mi><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>,</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mi/><mml:mo>=</mml:mo><mml:mrow><mml:mstyle displaystyle="false"><mml:mfrac><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:mi>σ</mml:mi></mml:mrow></mml:msup><mml:mrow><mml:mi>Z</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>σ</mml:mi><mml:mo>,</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>⁢</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mi>σ</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>x</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:msup><mml:mo>⁢</mml:mo><mml:mstyle displaystyle="false"><mml:mfrac><mml:mrow><mml:msup><mml:mi>x</mml:mi><mml:mi>θ</mml:mi></mml:msup><mml:mo>⁢</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>x</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup></mml:msup></mml:mrow><mml:mrow><mml:mi>x</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>x</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd columnalign="left"><mml:mrow><mml:mi/><mml:mo>=</mml:mo><mml:mrow><mml:mstyle displaystyle="false"><mml:msubsup><mml:mo largeop="true" symmetric="true">∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mi mathvariant="normal">∞</mml:mi></mml:msubsup></mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:mfrac><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:mi>σ</mml:mi></mml:mrow></mml:msup><mml:mrow><mml:mi>Z</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>σ</mml:mi><mml:mo>,</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>⁢</mml:mo><mml:mstyle displaystyle="false"><mml:mfrac><mml:msup><mml:mi>σ</mml:mi><mml:mi>k</mml:mi></mml:msup><mml:mrow><mml:mi>k</mml:mi><mml:mo>!</mml:mo></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>⁢</mml:mo><mml:msup><mml:mi>x</mml:mi><mml:mi>θ</mml:mi></mml:msup><mml:mo>⁢</mml:mo><mml:mstyle displaystyle="false"><mml:mfrac><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>x</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup><mml:mo>+</mml:mo><mml:mi>k</mml:mi></mml:mrow></mml:msup><mml:mrow><mml:mi>x</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>x</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mrow></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd columnalign="left"><mml:mrow><mml:mi/><mml:mo>≡</mml:mo><mml:mrow><mml:mstyle displaystyle="false"><mml:msubsup><mml:mo largeop="true" symmetric="true">∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mi mathvariant="normal">∞</mml:mi></mml:msubsup></mml:mstyle><mml:mrow><mml:msub><mml:mi>Q</mml:mi><mml:mtext>eq</mml:mtext></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo>,</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>,</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula></p><p>Here, <inline-formula><mml:math id="inf270"><mml:mrow><mml:msub><mml:mi>Q</mml:mi><mml:mtext>eq</mml:mtext></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo>,</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>,</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> is a joint distribution over <inline-formula><mml:math id="inf271"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo>,</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, and the desired distribution over the allele frequency <inline-formula><mml:math id="inf272"><mml:mi>x</mml:mi></mml:math></inline-formula> can be achieved by marginalizing the joint distribution over the discrete variable <inline-formula><mml:math id="inf273"><mml:mi>k</mml:mi></mml:math></inline-formula>. We can also express the conditional distributions for <inline-formula><mml:math id="inf274"><mml:mi>x</mml:mi></mml:math></inline-formula> and <inline-formula><mml:math id="inf275"><mml:mi>k</mml:mi></mml:math></inline-formula> as,<disp-formula id="equ20"><label>(19)</label><mml:math id="m20"><mml:mtable columnspacing="5pt" displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi>Q</mml:mi><mml:mtext>eq</mml:mtext></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>x</mml:mi><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>,</mml:mo><mml:mi>σ</mml:mi><mml:mo>,</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mi/><mml:mo>=</mml:mo><mml:mstyle displaystyle="false"><mml:mfrac><mml:mrow><mml:msub><mml:mi>Q</mml:mi><mml:mtext>eq</mml:mtext></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo>,</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>,</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mstyle scriptlevel="-1"><mml:mrow><mml:mo largeop="true" symmetric="true">∫</mml:mo><mml:mrow><mml:mtext>d</mml:mtext><mml:mo>⁢</mml:mo><mml:mpadded width="+1.7pt"><mml:mi>x</mml:mi></mml:mpadded><mml:mo>⁢</mml:mo><mml:msub><mml:mi>Q</mml:mi><mml:mtext mathsize="71%">eq</mml:mtext></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo>,</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>,</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mo mathsize="71%" stretchy="false">†</mml:mo></mml:msup></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mstyle></mml:mfrac></mml:mstyle><mml:mo>=</mml:mo><mml:mrow><mml:mtext>Beta</mml:mtext><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo>;</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:mrow><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup><mml:mo>+</mml:mo><mml:mi>k</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula><disp-formula id="equ21"><label>(20)</label><mml:math id="m21"><mml:mtable columnspacing="5pt" displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi>Q</mml:mi><mml:mtext>eq</mml:mtext></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:mrow><mml:mi>x</mml:mi><mml:mo>,</mml:mo><mml:mi>σ</mml:mi><mml:mo>,</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mi/><mml:mo>=</mml:mo><mml:mstyle displaystyle="false"><mml:mfrac><mml:mrow><mml:msub><mml:mi>Q</mml:mi><mml:mtext>eq</mml:mtext></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo>,</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>,</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mstyle displaystyle="false"><mml:msub><mml:mo largeop="true" symmetric="true">∑</mml:mo><mml:mi>k</mml:mi></mml:msub></mml:mstyle><mml:mrow><mml:msub><mml:mi>Q</mml:mi><mml:mtext>eq</mml:mtext></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo>,</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>,</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>=</mml:mo><mml:mrow><mml:mtext>Poisson</mml:mtext><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo>;</mml:mo><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>x</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>⁢</mml:mo><mml:mi>σ</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula></p><p>We use these conditional distributions to define a joint Gibbs sampler for <inline-formula><mml:math id="inf276"><mml:msub><mml:mi>Q</mml:mi><mml:mtext>eq</mml:mtext></mml:msub></mml:math></inline-formula>. We summarize the resulting <inline-formula><mml:math id="inf277"><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo>,</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>∼</mml:mo><mml:mrow><mml:msub><mml:mi>Q</mml:mi><mml:mtext>eq</mml:mtext></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo>,</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>,</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></inline-formula> in the joint Gibbs sampler in Algorithm 2 (Appendix 5). This chain mixes extremely quickly and avoids calculation of the hypergeometric function for the normalization factor (<xref ref-type="disp-formula" rid="equ21">Equation 20</xref>), which is computationally costly; see Algorithm 2 (Appendix 5).</p></sec><sec id="s4-4-4-2"><title>Simulation of the evolutionary process</title><p>We use a Gillespie algorithm to simulate the evolutionary process, where we break up the reaction calculation into two parts: randomly choosing a viral strain <inline-formula><mml:math id="inf278"><mml:msub><mml:mi>ρ</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math></inline-formula> from the population and then determining whether it reproduces or dies based on its fitness <italic>f</italic><sub><italic>i</italic></sub> and escape status; see Algorithm 3 (Appendix 5).</p></sec></sec></sec><sec id="s4-5"><title>Determining the simulation parameters of the birth-death process from genetic data</title><p>We set the intrinsic growth rate (fitness) of the wild-type virus, in the absence of competition to be <inline-formula><mml:math id="inf279"><mml:mrow><mml:mi>γ</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>3</mml:mn><mml:mo>⁢</mml:mo><mml:mtext> days</mml:mtext></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>, consistent with intra-patient doubling time of the virus (<xref ref-type="bibr" rid="bib32">García et al., 2001</xref>; <xref ref-type="bibr" rid="bib43">Ioannidis et al., 2000</xref>; <xref ref-type="bibr" rid="bib31">García et al., 1999</xref>). We infer the neutralization rate <inline-formula><mml:math id="inf280"><mml:mi>r</mml:mi></mml:math></inline-formula> by fitting the viremia curves (<xref ref-type="fig" rid="fig3">Figure 3</xref>) in the trials under study, and use the averaged decay rate <inline-formula><mml:math id="inf281"><mml:mrow><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mn>0.31</mml:mn></mml:mrow></mml:math></inline-formula> for simulations, fitted using <xref ref-type="disp-formula" rid="equ8">Equation 8</xref>. For the absolute mutation rate <inline-formula><mml:math id="inf282"><mml:msub><mml:mi>μ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:math></inline-formula> (per nucleotide per day), we use <inline-formula><mml:math id="inf283"><mml:mrow><mml:mn>1.1</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>-</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> which is the average of the reported values for transitions per site per day from <xref ref-type="bibr" rid="bib106">Zanini et al., 2017</xref>. Using the covariance of neutral diversity in twofold and four-fold synonymous sites, we determine the transition/transversion diversity ratio to be <inline-formula><mml:math id="inf284"><mml:mrow><mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mtext>tv</mml:mtext></mml:msub></mml:mrow><mml:mo>=</mml:mo><mml:mn>7.8</mml:mn></mml:mrow></mml:math></inline-formula> (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). We use these values to determine the forward and backward mutation rates <inline-formula><mml:math id="inf285"><mml:msub><mml:mi>μ</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="inf286"><mml:msubsup><mml:mi>μ</mml:mi><mml:mi>s</mml:mi><mml:mo>†</mml:mo></mml:msubsup></mml:math></inline-formula> for each site (see Inference of mutational target size for each bNAb).</p><p>Generally, the trial patients show viral populations with larger neutral diversity at the start of the trial compared to the patients enrolled in the high-throughput study of <xref ref-type="bibr" rid="bib105">Zanini et al., 2015</xref> (<xref ref-type="fig" rid="fig2">Figure 2</xref>). We account for differences in the genetic makeup of the patients enrolled in the trial by directly estimating the neutral diversity <inline-formula><mml:math id="inf287"><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:math></inline-formula> from the synonomous site-frequency data of patients, before the start of the trial. The estimated viral diversity <inline-formula><mml:math id="inf288"><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:math></inline-formula>, coupled with the mutation rate <inline-formula><mml:math id="inf289"><mml:mrow><mml:mi>μ</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mn>1.1</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>-</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mo>⁢</mml:mo><mml:mtext> /day / nt</mml:mtext></mml:mrow></mml:mrow></mml:math></inline-formula>, and the total rate of birth and death events in the viral population <inline-formula><mml:math id="inf290"><mml:mi>λ</mml:mi></mml:math></inline-formula>, set the carrying capacity <inline-formula><mml:math id="inf291"><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula> for a given individual,<disp-formula id="equ22"><label>(21)</label><mml:math id="m22"><mml:mrow><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mfrac><mml:mi>λ</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mo>⁢</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:mrow></mml:mfrac><mml:mo>⁢</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:mrow></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>It should be noted that the value of <inline-formula><mml:math id="inf292"><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula>, as the number of viruses in our individual-based simulations, is not related to the maximal viral load in the viremia measurements (i.e. steady state copy number per ml) as this relationship depends on the microscopic details of the population dynamics.</p><p>The total rate of birth and death events <inline-formula><mml:math id="inf293"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mi>β</mml:mi><mml:mo>+</mml:mo><mml:mi>δ</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> tunes the amount of stochasticity, that is, more events cause noisier dynamics. Notably, stochasticity can be linked to the size of the population <inline-formula><mml:math id="inf294"><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula>, which is directly coupled to <inline-formula><mml:math id="inf295"><mml:mi>λ</mml:mi></mml:math></inline-formula> (<xref ref-type="disp-formula" rid="equ22">Equation 21</xref>). We set the value of <inline-formula><mml:math id="inf296"><mml:mi>λ</mml:mi></mml:math></inline-formula> self-consistently by requiring the minimum frequency of a variant in our simulations <inline-formula><mml:math id="inf297"><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mtext>min</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:mo>⁢</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:mrow><mml:mi>λ</mml:mi></mml:mfrac><mml:mo>⁢</mml:mo><mml:msubsup><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:mrow></mml:math></inline-formula> to be smaller than the escape threshold <inline-formula><mml:math id="inf298"><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mtext>ext</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mfrac><mml:msub><mml:mi>μ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub><mml:mi>γ</mml:mi></mml:mfrac><mml:mo>⁢</mml:mo><mml:msubsup><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:mrow></mml:math></inline-formula> due to stochasticity (<xref ref-type="disp-formula" rid="equ18">Equation 17</xref>). We set <inline-formula><mml:math id="inf299"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mo>⁢</mml:mo><mml:msup><mml:mtext>day</mml:mtext><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math></inline-formula> so that <inline-formula><mml:math id="inf300"><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mtext>min</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mn>3</mml:mn></mml:mfrac><mml:mo>⁢</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mtext>ext</mml:mtext></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>. Increasing <inline-formula><mml:math id="inf301"><mml:mi>λ</mml:mi></mml:math></inline-formula> results in an increase in the size of population <inline-formula><mml:math id="inf302"><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula> in our simulations, which is computationally costly, without qualitatively changing the statistics of the rebound trajectories.</p></sec><sec id="s4-6"><title>Inference of mutation rates and the neutral diversity within a population</title><p>Previous work has indicated an order of magnitude difference between the rate of transitions (mutations within a nucleotide class) and transversions (out-class mutations) in HIV (<xref ref-type="bibr" rid="bib68">Nielsen, 2006</xref>; <xref ref-type="bibr" rid="bib106">Zanini et al., 2017</xref>; <xref ref-type="bibr" rid="bib96">Theys et al., 2018</xref>; <xref ref-type="bibr" rid="bib26">Feder et al., 2017</xref>). Therefore, to infer the neutral diversity parameter <inline-formula><mml:math id="inf303"><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:math></inline-formula>, we also account for the differences between transition and transversion rates.</p><p>Consider the set of sequences sampled from a patient’s viral population at a particular time. Two neutral alleles that are linked by a symmetric mutational process <inline-formula><mml:math id="inf304"><mml:mrow><mml:msub><mml:mi>μ</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>→</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mo>→</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> have a simple count likelihood. The probability to see allele 1 with multiplicity <inline-formula><mml:math id="inf305"><mml:mi>n</mml:mi></mml:math></inline-formula> and allele 2 with multiplicity <inline-formula><mml:math id="inf306"><mml:mi>m</mml:mi></mml:math></inline-formula> is given by a binomial distribution <inline-formula><mml:math id="inf307"><mml:mrow><mml:mtext>Binom</mml:mtext><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:mi>x</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> with parameter <inline-formula><mml:math id="inf308"><mml:mi>x</mml:mi></mml:math></inline-formula> denoting the probability for occurrence of allele 1, convolved with the neutral biallelic frequency distribution <inline-formula><mml:math id="inf309"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mtext>eq</mml:mtext></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mrow><mml:mi>x</mml:mi><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:mi>σ</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>θ</mml:mi></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> from <xref ref-type="disp-formula" rid="equ13">Equation 12</xref>. Using this probability distribution, we can evaluate the log-likelihood <inline-formula><mml:math id="inf310"><mml:mrow><mml:mi class="ltx_font_mathcaligraphic">ℒ</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>θ</mml:mi><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:mrow><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mi>m</mml:mi></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> for the neutral diversity <inline-formula><mml:math id="inf311"><mml:mi>θ</mml:mi></mml:math></inline-formula> given the observations <inline-formula><mml:math id="inf312"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula> for the multiplicities of the two alleles in the population,<disp-formula id="equ23"><label>(22)</label><mml:math id="m23"><mml:mrow><mml:mi class="ltx_font_mathcaligraphic">ℒ</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>θ</mml:mi><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:mrow><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mi>m</mml:mi></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi/><mml:mo>=</mml:mo><mml:mrow><mml:mi>log</mml:mi><mml:mo>⁢</mml:mo><mml:mstyle displaystyle="true"><mml:mrow><mml:mo largeop="true" rspace="4.2pt" symmetric="true">∫</mml:mo><mml:mrow><mml:mrow><mml:mrow><mml:mtext>d</mml:mtext><mml:mo>⁢</mml:mo><mml:mpadded width="+1.7pt"><mml:mi>x</mml:mi></mml:mpadded><mml:mo>⁢</mml:mo><mml:mtext>Binom</mml:mtext><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:mi>x</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>×</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mtext>eq</mml:mtext></mml:msub></mml:mrow><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mrow><mml:mi>x</mml:mi><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:mi>σ</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>θ</mml:mi></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mstyle></mml:mrow></mml:mrow><mml:mrow><mml:mi/><mml:mo>=</mml:mo><mml:mrow><mml:mi>log</mml:mi><mml:mo>⁢</mml:mo><mml:mstyle displaystyle="true"><mml:mrow><mml:mo largeop="true" symmetric="true">∫</mml:mo><mml:mrow><mml:mrow><mml:mtext>d</mml:mtext><mml:mo>⁢</mml:mo><mml:mpadded width="+1.7pt"><mml:mi>x</mml:mi></mml:mpadded><mml:mo>⁢</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mfrac linethickness="0pt"><mml:mrow><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mi>m</mml:mi></mml:mrow><mml:mi>n</mml:mi></mml:mfrac><mml:mo>)</mml:mo></mml:mrow><mml:mo>⁢</mml:mo><mml:msup><mml:mi>x</mml:mi><mml:mi>n</mml:mi></mml:msup><mml:mo>⁢</mml:mo><mml:mpadded width="+1.7pt"><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>x</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mi>m</mml:mi></mml:msup></mml:mpadded></mml:mrow><mml:mo>×</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mi>x</mml:mi><mml:mrow><mml:mi>θ</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo>⁢</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>x</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mi>θ</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>Z</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>θ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:mstyle></mml:mrow></mml:mrow></mml:math></disp-formula></p></sec><sec id="s4-7"><title>Inference of netral diversity, mutational target size, and selection from genetic data</title><p>To estimate the transition diversity, we only use twofold synonymous sites, and treat each site independently but with a shared diversity parameter <inline-formula><mml:math id="inf313"><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:math></inline-formula>. For example, consider neutral variations for two amino acids glutamine and phenylalanine. The third position in a codon for both of these amino acids are twofold synonymous, as the two possible codons for glutamine are CAG and CAA, and for phenylalanine are TTT, and TTC. Now consider that in the data a conserved glutamine has <inline-formula><mml:math id="inf314"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:math></inline-formula> G’s and <inline-formula><mml:math id="inf315"><mml:mrow><mml:mi>m</mml:mi><mml:mo>=</mml:mo><mml:mn>97</mml:mn></mml:mrow></mml:math></inline-formula> A’s in the third codon position, and a conserved phenylalanine has <inline-formula><mml:math id="inf316"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>10</mml:mn></mml:mrow></mml:math></inline-formula> T’s and <inline-formula><mml:math id="inf317"><mml:mrow><mml:mi>m</mml:mi><mml:mo>=</mml:mo><mml:mn>90</mml:mn></mml:mrow></mml:math></inline-formula> C’s at its third codon position. In this case, the combined log-likelihood for the shared diversity parameter is <inline-formula><mml:math id="inf318"><mml:mrow><mml:mrow><mml:mi class="ltx_font_mathcaligraphic">ℒ</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>θ</mml:mi><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:mtext>data</mml:mtext></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mi class="ltx_font_mathcaligraphic">ℒ</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>θ</mml:mi><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:mrow><mml:mn>3</mml:mn><mml:mo>,</mml:mo><mml:mn>97</mml:mn></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mi class="ltx_font_mathcaligraphic">ℒ</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>θ</mml:mi><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:mrow><mml:mn>10</mml:mn><mml:mo>,</mml:mo><mml:mn>90</mml:mn></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:math></inline-formula>. Extending to all of sites in the <italic>env</italic> protein, the maximum-likelihood estimator for the transition diversity <inline-formula><mml:math id="inf319"><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:math></inline-formula> can be evaluated by maximizing the likelihood summed over all conserved twofold synonymous sites,<disp-formula id="equ24"><label>(23)</label><mml:math id="m24"><mml:mrow><mml:msubsup><mml:mi>θ</mml:mi><mml:mrow><mml:mrow><mml:mtext>ts</mml:mtext></mml:mrow></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>arg</mml:mi><mml:mo>⁡</mml:mo><mml:munder><mml:mo movablelimits="true" form="prefix">max</mml:mo><mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mrow><mml:mtext>ts</mml:mtext></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:munder><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mtext>two-fold sites</mml:mtext></mml:mrow></mml:munder><mml:mrow><mml:mrow><mml:mi mathvariant="script">L</mml:mi></mml:mrow></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mrow><mml:mtext>ts</mml:mtext></mml:mrow></mml:mrow></mml:msub><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msub><mml:mo>;</mml:mo><mml:mi>m</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mi>G</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>In <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref> (panel A), we show that the maximum likelihood estimation method described above has better properties than the more commonly used estimator of the variance <inline-formula><mml:math id="inf320"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mover><mml:mrow><mml:mi>x</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo accent="false">¯</mml:mo></mml:mover></mml:mrow></mml:mstyle></mml:math></inline-formula> <xref ref-type="bibr" rid="bib93">Stoddart and Taylor, 1988</xref>.</p><p>In a similar way, the likelihood for the transversion <inline-formula><mml:math id="inf321"><mml:msub><mml:mi>θ</mml:mi><mml:mtext>tv</mml:mtext></mml:msub></mml:math></inline-formula> is determined from polymorphic data at all conserved four-fold synonymous sites. One such example is the third position in a glycine codon, where (GGT, GGC, GGA, GGG) translate to the same amino acid. The maximum-likelihood estimator for the transversions is<disp-formula id="equ25"><label>(24)</label><mml:math id="m25"><mml:mrow><mml:msubsup><mml:mi>θ</mml:mi><mml:mrow><mml:mrow><mml:mtext>tv</mml:mtext></mml:mrow></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>arg</mml:mi><mml:mo>⁡</mml:mo><mml:munder><mml:mo movablelimits="true" form="prefix">max</mml:mo><mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mrow><mml:mtext>tv</mml:mtext></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:munder><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mtext>four-fold sites</mml:mtext></mml:mrow></mml:munder><mml:mrow><mml:mrow><mml:mi mathvariant="script">L</mml:mi></mml:mrow></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mrow><mml:mtext>tv</mml:mtext></mml:mrow></mml:mrow></mml:msub><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mi>G</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msub><mml:mo>;</mml:mo><mml:mi>m</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>The factor of 2 in the argument of the likelihood accounts for the multiplicity of mutational pathways, e.g. from a <inline-formula><mml:math id="inf322"><mml:mi>G</mml:mi></mml:math></inline-formula> nucleotide there are two transversion possibilities, <inline-formula><mml:math id="inf323"><mml:mrow><mml:mi>G</mml:mi><mml:mo>→</mml:mo><mml:mi>C</mml:mi></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="inf324"><mml:mrow><mml:mi>G</mml:mi><mml:mo>→</mml:mo><mml:mi>A</mml:mi></mml:mrow></mml:math></inline-formula> for moving from one allele to the other <xref ref-type="bibr" rid="bib45">Kimura, 1981</xref>.</p><p>Using this likelihood approach, we can infer the neutral diversities <inline-formula><mml:math id="inf325"><mml:msubsup><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext><mml:mo>*</mml:mo></mml:msubsup></mml:math></inline-formula> and <inline-formula><mml:math id="inf326"><mml:msubsup><mml:mi>θ</mml:mi><mml:mtext>tv</mml:mtext><mml:mo>*</mml:mo></mml:msubsup></mml:math></inline-formula> for each patient at each time point from the polymorphism in twofold and fourfold synonymous sites. To characterize the ratio of transition to transversion rates, we use linear regression on the entire patient population and sample history and infer a constant ratio <inline-formula><mml:math id="inf327"><mml:mrow><mml:mrow><mml:msub><mml:mi>μ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mtext>tv</mml:mtext></mml:msub></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mtext>tv</mml:mtext></mml:msub></mml:mrow><mml:mo>=</mml:mo><mml:mn>7.8</mml:mn></mml:mrow></mml:math></inline-formula> (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). In <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>, we also show that the estimate for this ratio is relatively consistent across different data sources, produced even by different sequencing technologies. The previously reported relative rate of transitions to transversions, based on the estimates of sequence divergence along phylogenetic trees of HIV-1 is <inline-formula><mml:math id="inf328"><mml:mrow><mml:mrow><mml:msub><mml:mi>μ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mtext>tv</mml:mtext></mml:msub></mml:mrow><mml:mo>=</mml:mo><mml:mn>5.6</mml:mn></mml:mrow></mml:math></inline-formula> (<xref ref-type="bibr" rid="bib106">Zanini et al., 2017</xref>), which is similar to our maximum likelihood estimate.</p><sec id="s4-7-1"><title>Inference of mutational target size for each bNAb</title><p>The nucleotide triplets which encode for amino acids at an escape site undergo substitutions which can change the amino acid type and create an escape variant. The changes in the state of an amino acid codon can be modeled as a Markov jump process and can be visualized as a weighted graph where the nodes represent codon states, and edges represent single nucleotide substitutions linking two codon states (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). In our mutational model, these edges have weights associated with either the mutation rates for transitions <inline-formula><mml:math id="inf329"><mml:msub><mml:mi>μ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:math></inline-formula> or transversions <inline-formula><mml:math id="inf330"><mml:msub><mml:mi>μ</mml:mi><mml:mtext>tv</mml:mtext></mml:msub></mml:math></inline-formula>. We call this the <italic>codon substitution graph</italic>.</p><p>The codon states can be clustered into three distinct classes: (i) codons which are fatal <inline-formula><mml:math id="inf331"><mml:mi>F</mml:mi></mml:math></inline-formula>, (ii) wild-type (i.e. susceptible to neutralization by the bNAb) <inline-formula><mml:math id="inf332"><mml:mi>W</mml:mi></mml:math></inline-formula>, and escape mutants (i.e. resistant to the bNAb) <inline-formula><mml:math id="inf333"><mml:mi>M</mml:mi></mml:math></inline-formula>. We expect the escape mutants to be at a selective disadvantage compared to the resistant wild-type, and that the most common escape codons to be those which are adjacent to wild-type states.</p><p>The mutational target size is determined by the density of paths from the wild-type <inline-formula><mml:math id="inf334"><mml:mi>W</mml:mi></mml:math></inline-formula> to the escape mutants <inline-formula><mml:math id="inf335"><mml:mi>M</mml:mi></mml:math></inline-formula>.<disp-formula id="equ26"><label>(25)</label><mml:math id="m26"><mml:mrow><mml:mi>μ</mml:mi><mml:mo>=</mml:mo><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mi>W</mml:mi><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mi>c</mml:mi><mml:mo>∈</mml:mo><mml:mi>W</mml:mi><mml:mo>;</mml:mo><mml:mi>d</mml:mi><mml:mo>∈</mml:mo><mml:mi>M</mml:mi></mml:mrow></mml:munder><mml:mo stretchy="false">[</mml:mo><mml:mi>c</mml:mi><mml:mo>−</mml:mo><mml:mi>d</mml:mi><mml:mo>=</mml:mo><mml:mtext>ts</mml:mtext><mml:mo stretchy="false">]</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mrow><mml:mrow><mml:mtext>ts</mml:mtext></mml:mrow></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>c</mml:mi><mml:mo>−</mml:mo><mml:mi>d</mml:mi><mml:mo>=</mml:mo><mml:mtext>tv</mml:mtext><mml:mo stretchy="false">]</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mrow><mml:mrow><mml:mtext>tv</mml:mtext></mml:mrow></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ27"><label>(26)</label><mml:math id="m27"><mml:mrow><mml:msup><mml:mi>μ</mml:mi><mml:mrow><mml:mo>†</mml:mo></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mi>M</mml:mi><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mi>c</mml:mi><mml:mo>∈</mml:mo><mml:mi>W</mml:mi><mml:mo>;</mml:mo><mml:mi>d</mml:mi><mml:mo>∈</mml:mo><mml:mi>M</mml:mi></mml:mrow></mml:munder><mml:mo stretchy="false">[</mml:mo><mml:mi>c</mml:mi><mml:mo>−</mml:mo><mml:mi>d</mml:mi><mml:mo>=</mml:mo><mml:mtext>ts</mml:mtext><mml:mo stretchy="false">]</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mrow><mml:mrow><mml:mtext>ts</mml:mtext></mml:mrow></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>c</mml:mi><mml:mo>−</mml:mo><mml:mi>d</mml:mi><mml:mo>=</mml:mo><mml:mtext>tv</mml:mtext><mml:mo stretchy="false">]</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mrow><mml:mrow><mml:mtext>tv</mml:mtext></mml:mrow></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>The functions <inline-formula><mml:math id="inf336"><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mo>-</mml:mo><mml:mi>d</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mtext>ts</mml:mtext></mml:mrow><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:math></inline-formula> or <inline-formula><mml:math id="inf337"><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mo>-</mml:mo><mml:mi>d</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mtext>tv</mml:mtext></mml:mrow><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:math></inline-formula> are 1 when the two codons are separated by a transition or transversion, and are zero otherwise. Note that since we only have an estimate for the ratio of the transition to transversion rates <inline-formula><mml:math id="inf338"><mml:mrow><mml:msub><mml:mi>μ</mml:mi><mml:mtext>tv</mml:mtext></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:mrow></mml:math></inline-formula>, we can only determine the scaled mutational target sizes, <inline-formula><mml:math id="inf339"><mml:mrow><mml:mover accent="true"><mml:mi>μ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:mrow><mml:mi>μ</mml:mi><mml:mo>/</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="inf340"><mml:mrow><mml:msup><mml:mover accent="true"><mml:mi>μ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mo>†</mml:mo></mml:msup><mml:mo>=</mml:mo><mml:mrow><mml:msup><mml:mi>μ</mml:mi><mml:mo>†</mml:mo></mml:msup><mml:mo>/</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>, which are sufficient for inference of selection in the next section. The full list of mutational target sizes inferred for the bNAbs in this study are shown in <xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>.</p><p>When discussing the mutational target size of escape from a given bNAb, we refer to the total mutation rate from the susceptible (wild type) to the escape variant as,<disp-formula id="equ28"><label>(27)</label><mml:math id="m28"><mml:mrow><mml:mi>μ</mml:mi><mml:mo>=</mml:mo><mml:mstyle displaystyle="true" scriptlevel="0"><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>∈</mml:mo><mml:mtext> esc. sites</mml:mtext></mml:mrow></mml:munder><mml:msub><mml:mi>μ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mo stretchy="false">→</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>where the sum runs over all the mediating escape sites <inline-formula><mml:math id="inf341"><mml:mi>i</mml:mi></mml:math></inline-formula>, and can be interpreted as the average number of accessible escape variants. In the strong selection regime, we can write the frequency of escape mutants as,<disp-formula id="equ29"><label>(28)</label><mml:math id="m29"><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mtext>mut</mml:mtext></mml:mrow></mml:msub><mml:mo>≈</mml:mo><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:munder><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mstyle displaystyle="true" scriptlevel="0"><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:munder><mml:mfrac><mml:msub><mml:mi>μ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mo stretchy="false">→</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>≈</mml:mo><mml:mfrac><mml:mi>μ</mml:mi><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:mtext>hm</mml:mtext></mml:mrow></mml:msub></mml:mfrac></mml:mstyle></mml:mrow></mml:math></disp-formula></p></sec><sec id="s4-7-2"><title>Inference of selection for escape mutations against each bNAb</title><p>Here, we develop an approximate likelihood approach to infer the selection ratio <inline-formula><mml:math id="inf342"><mml:mrow><mml:mover accent="true"><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:mfrac><mml:mi>σ</mml:mi><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:mfrac></mml:mrow></mml:math></inline-formula>, using the high-throughput sequence data from bNAb-naive HIV-1 patients from <xref ref-type="bibr" rid="bib106">Zanini et al., 2017</xref>. The quantity <inline-formula><mml:math id="inf343"><mml:mover accent="true"><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:math></inline-formula> is a dimensionless ratio which is independent of the coalescence timescale <inline-formula><mml:math id="inf344"><mml:msub><mml:mi>N</mml:mi><mml:mi>e</mml:mi></mml:msub></mml:math></inline-formula>, and therefore, represents a stable target for inference.</p><p>We assume that the probability to sample <inline-formula><mml:math id="inf345"><mml:mi>m</mml:mi></mml:math></inline-formula> escape mutants and <inline-formula><mml:math id="inf346"><mml:mi>s</mml:mi></mml:math></inline-formula> susceptible (wild-type) alleles at a given site in the genome of HIV in a population sampled from a patient at a given time point follows a binomial distribution <inline-formula><mml:math id="inf347"><mml:mrow><mml:mtext>Binom</mml:mtext><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mrow><mml:mi>s</mml:mi><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:mi>x</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>, governed by the underlying frequency <inline-formula><mml:math id="inf348"><mml:mi>x</mml:mi></mml:math></inline-formula> of the mutant allele. In addition, the frequency <inline-formula><mml:math id="inf349"><mml:mi>x</mml:mi></mml:math></inline-formula> of the allele of interest itself is drawn from the equilibrium distribution <inline-formula><mml:math id="inf350"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mtext>eq</mml:mtext></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>x</mml:mi><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>,</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> (<xref ref-type="disp-formula" rid="equ13">Equation 12</xref>), governed by the diversity <inline-formula><mml:math id="inf351"><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:math></inline-formula> inferred from the neutral sites, the estimated mutational target sizes <inline-formula><mml:math id="inf352"><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi>μ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:mrow><mml:mi>μ</mml:mi><mml:mo>/</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:mrow></mml:mrow><mml:mo>,</mml:mo><mml:mrow><mml:msup><mml:mover accent="true"><mml:mi>μ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mo>†</mml:mo></mml:msup><mml:mo>=</mml:mo><mml:mrow><mml:msup><mml:mi>μ</mml:mi><mml:mo>†</mml:mo></mml:msup><mml:mo>/</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:mrow></mml:mrow></mml:mrow></mml:math></inline-formula>, and the unknown selection ratio <inline-formula><mml:math id="inf353"><mml:mrow><mml:mover accent="true"><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>/</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>. As a result, we can characterize the probability <inline-formula><mml:math id="inf354"><mml:mrow><mml:mi>P</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mrow><mml:mi>s</mml:mi><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub><mml:mo>,</mml:mo><mml:mover accent="true"><mml:mi>μ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mo>,</mml:mo><mml:msup><mml:mover accent="true"><mml:mi>μ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mo>†</mml:mo></mml:msup><mml:mo>,</mml:mo><mml:mover accent="true"><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> to sample <inline-formula><mml:math id="inf355"><mml:mi>m</mml:mi></mml:math></inline-formula> escape mutants and <inline-formula><mml:math id="inf356"><mml:mi>s</mml:mi></mml:math></inline-formula> susceptible-type alleles, given the scaled selection and diversity parameters as,<disp-formula id="equ30"><label>(29)</label><mml:math id="m30"><mml:mrow><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>P</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mtext>ts</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mrow><mml:mover><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:mi>P</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mi>σ</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mover><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mrow><mml:mtext>ts</mml:mtext></mml:mrow></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>θ</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mover><mml:mi>μ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mrow><mml:mtext>ts</mml:mtext></mml:mrow></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mrow><mml:mo>†</mml:mo></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mover><mml:mi>μ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mo>†</mml:mo></mml:mrow></mml:msup><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mrow><mml:mtext>ts</mml:mtext></mml:mrow></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>=</mml:mo><mml:mo>∫</mml:mo><mml:mrow><mml:mtext>d</mml:mtext></mml:mrow><mml:mi>x</mml:mi><mml:mspace width="thinmathspace"/><mml:mtext>Binom</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mtext>eq</mml:mtext></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mi>σ</mml:mi><mml:mo>,</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mrow><mml:mo>†</mml:mo></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mi>Z</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>σ</mml:mi><mml:mo>,</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mrow><mml:mo>†</mml:mo></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac><mml:mrow><mml:mrow><mml:mo maxsize="1.2em" minsize="1.2em">(</mml:mo></mml:mrow><mml:mfrac linethickness="0pt"><mml:mrow><mml:mi>s</mml:mi><mml:mo>+</mml:mo><mml:mi>m</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:mfrac><mml:mrow><mml:mo maxsize="1.2em" minsize="1.2em">)</mml:mo></mml:mrow></mml:mrow><mml:mo>∫</mml:mo><mml:mspace width="thinmathspace"/><mml:mrow><mml:mtext>d</mml:mtext></mml:mrow><mml:mi>x</mml:mi><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mi>σ</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mi>x</mml:mi><mml:mrow><mml:mi>θ</mml:mi><mml:mo>+</mml:mo><mml:mi>m</mml:mi></mml:mrow></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>x</mml:mi><mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:msup><mml:mi>θ</mml:mi><mml:mrow><mml:mo>†</mml:mo></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>s</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>x</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula></p><p>Here, <inline-formula><mml:math id="inf357"><mml:mrow><mml:mi>Z</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>σ</mml:mi><mml:mo>,</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> is a confluent hypergeometric function of the model parameters that sets the normalization factor for the allele frequency distribution <inline-formula><mml:math id="inf358"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mtext>eq</mml:mtext></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> (<xref ref-type="disp-formula" rid="equ14">Equation 13</xref>). It should be noted that the viral population is in fact out of equilibrium, due to constant changes in immune pressure evolution from the B-cell and T-cell populations (<xref ref-type="bibr" rid="bib69">Nourmohammad et al., 2016</xref>). Although we are ignoring these significant complications, we later use the same equilibrium distribution in a consistent way to generate standing variation in simulations. For the model to make accurate predictions, it is not necessary that the equilibrium model be exactly correct, but only that it is rich enough to provide a consistent description for the distribution of mutant frequencies observed across viral populations.</p><p>We will use the probability density in <xref ref-type="disp-formula" rid="equ30">Equation 29</xref> to define a log-likelihood function in order to infer the scaled selection <inline-formula><mml:math id="inf359"><mml:mrow><mml:mover accent="true"><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>/</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> from data. To do so, we first express the logarithm of this probability density as,<disp-formula id="equ31"><label>(30)</label><mml:math id="m31"><mml:mrow><mml:mtable columnalign="right left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:mi>P</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mrow><mml:mtext>ts</mml:mtext></mml:mrow></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mrow><mml:mover><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:mi>P</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mi>σ</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mover><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mrow><mml:mtext>ts</mml:mtext></mml:mrow></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>θ</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mover><mml:mi>μ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mrow><mml:mtext>ts</mml:mtext></mml:mrow></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mrow><mml:mo>†</mml:mo></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mover><mml:mi>μ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mo>†</mml:mo></mml:mrow></mml:msup><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mrow><mml:mtext>ts</mml:mtext></mml:mrow></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>=</mml:mo><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:mi>Z</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>σ</mml:mi><mml:mo>,</mml:mo><mml:mi>θ</mml:mi><mml:mo>+</mml:mo><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mrow><mml:mo>†</mml:mo></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>s</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>−</mml:mo><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:mi>Z</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>σ</mml:mi><mml:mo>,</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mrow><mml:mo>†</mml:mo></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mtext>const.</mml:mtext></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>=</mml:mo><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="double-struck">E</mml:mi></mml:mrow></mml:mrow><mml:msub><mml:mrow><mml:mo>[</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mi>σ</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msup><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mtext>Beta</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mi>θ</mml:mi><mml:mo>+</mml:mo><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mrow><mml:mo>†</mml:mo></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>s</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="double-struck">E</mml:mi></mml:mrow></mml:mrow><mml:msub><mml:mrow><mml:mo>[</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mi>σ</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msup><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mtext>Beta</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mrow><mml:mo>†</mml:mo></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mtext>const.</mml:mtext></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula></p><p>where the constant factors (const.) are independent of selection, and <inline-formula><mml:math id="inf360"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="double-struck">E</mml:mi></mml:mrow></mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mo>⋅</mml:mo><mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mrow><mml:mtext>Beta</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mo>⋅</mml:mo><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> denotes the expectation of the argument over a Beta distribution with parameters specified in the subscript. The expression in <xref ref-type="disp-formula" rid="equ31">Equation 30</xref> implies that we can evaluate the likelihood of selection strength by computing the difference between the logarithms of the expectation for <inline-formula><mml:math id="inf361"><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>⁢</mml:mo><mml:mi>x</mml:mi></mml:mrow></mml:mrow></mml:msup></mml:math></inline-formula> over allele frequencies drawn from two neutral distributions (Beta distributions), with parameters <inline-formula><mml:math id="inf362"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="inf363"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>θ</mml:mi><mml:mo>+</mml:mo><mml:mi>m</mml:mi></mml:mrow><mml:mo>,</mml:mo><mml:mrow><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup><mml:mo>+</mml:mo><mml:mi>s</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, respectively. This approach is more attractive as it would not require direct evaluation of the confluent hypergeometric functions for the normalization factors in <xref ref-type="disp-formula" rid="equ30">Equation 29</xref>. Estimating these normalization factors is computationally intensive for large values of <inline-formula><mml:math id="inf364"><mml:mi>σ</mml:mi></mml:math></inline-formula>, since many terms in the underlying hypergeometric series should be taken into account to stably compute them. However, evaluating the expectations via sampling from these two neutral distributions has the disadvantage that it is subject to variations across simulations. We reduce the variance of our estimate of <inline-formula><mml:math id="inf365"><mml:mrow><mml:mrow><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:mi>P</mml:mi></mml:mrow><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mrow><mml:mi>s</mml:mi><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>,</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> in <xref ref-type="disp-formula" rid="equ31">Equation 30</xref> by using a mixture-importance sampling scheme (<xref ref-type="bibr" rid="bib72">Owen and Zhou, 2000</xref>) with the details shown in Algorithm 4 (Appendix 5).</p><p>We use data collected across all time points and from all patients to infer reliable estimates for selection strengths. However, allele frequencies are correlated across time points within patients (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), and thus, sequential measurements are not independent data points. Our estimates indicate a coalescence time of about <inline-formula><mml:math id="inf366"><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>e</mml:mi></mml:msub><mml:mo>∼</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mn>3</mml:mn></mml:msup></mml:mrow></mml:math></inline-formula> days based on the estimates for the mutation rate <inline-formula><mml:math id="inf367"><mml:mrow><mml:msub><mml:mi>μ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>-</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> /nt/day, and the neutral diversity <inline-formula><mml:math id="inf368"><mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mo>⁢</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>e</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:mrow><mml:mo>=</mml:mo><mml:mn>0.01</mml:mn></mml:mrow></mml:math></inline-formula>. This coalescence time is much longer that the typical separation between sampled time points within a patient (<inline-formula><mml:math id="inf369"><mml:mrow><mml:mi/><mml:mo>∼</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:math></inline-formula> days), suggesting that sequential samples collected from each individual in this data are correlated. Therefore, we treat each patient as effectively a single observation, using the time-averaged likelihood for the (scaled) selection factor <inline-formula><mml:math id="inf370"><mml:mover accent="true"><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:math></inline-formula>:<disp-formula id="equ32"><label>(31)</label><mml:math id="m32"><mml:mrow><mml:mrow><mml:mi mathvariant="script">L</mml:mi></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mover><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mstyle displaystyle="true" scriptlevel="0"><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:munder><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:munder><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:mi>P</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>m</mml:mi><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mrow><mml:mtext>ts</mml:mtext></mml:mrow></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mrow><mml:mover><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf371"><mml:mi>p</mml:mi></mml:math></inline-formula> and <inline-formula><mml:math id="inf372"><mml:mi>t</mml:mi></mml:math></inline-formula> denote patient identity and sampled time points, respectively, and <inline-formula><mml:math id="inf373"><mml:msub><mml:mi>T</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:math></inline-formula> is the total number of time points sampled in patient <inline-formula><mml:math id="inf374"><mml:mi>p</mml:mi></mml:math></inline-formula>. We use the likelihood in <xref ref-type="disp-formula" rid="equ32">Equation 31</xref> to generate samples from the posterior distribution for selection strengths under a flat prior, with a standard Metropolis-Hastings algorithm <xref ref-type="bibr" rid="bib39">Hastings, 1970</xref>. Since the prior is constant, this procedure amounts to simply accepting or rejecting samples based on the likelihood ratio of <xref ref-type="disp-formula" rid="equ32">Equation 31</xref>. We used the centered-normal distribution with standard deviation of 50 (<inline-formula><mml:math id="inf375"><mml:mrow><mml:mi/><mml:mo>×</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:mrow></mml:math></inline-formula> in absolute units) as the proposal density for the jumps in the Markov chain.</p><p>Prior work has also inferred the fitness effect of mutations in HIV, but our approach differs in important aspects. For instance, maximum entropy models have been used to infer the preference of different amino acids in the <italic>Gag</italic> and the <italic>env</italic> proteins of HIV-1 from their prevalences across sequences sampled from different patients( <xref ref-type="bibr" rid="bib57">Louie et al., 2018</xref>; <xref ref-type="bibr" rid="bib28">Ferguson et al., 2013</xref>). The inferred preference values can explain the in-vitro growth rate (fitness) of the associated viral strains, especially for sites that are relatively conserved and are not the drivers of antigenic evolution in HIV-1. However, further modeling would be needed to quantitively map these inferred amino acid preferences onto population genetics measures that can be used to characterize the evolutionary dynamics of an HIV population. Other work has used longitudinal HIV-1 sequence data to infer selection and to characterize the role of selective sweeps due to immune pressure, genetic hitchhiking and recombination in the turnover of HIV-1 populations within patients (<xref ref-type="bibr" rid="bib106">Zanini et al., 2017</xref>; <xref ref-type="bibr" rid="bib67">Neher and Leitner, 2010</xref>; <xref ref-type="bibr" rid="bib42">Illingworth et al., 2020</xref>; <xref ref-type="bibr" rid="bib38">Haddox et al., 2018</xref>). In contrast, our work focuses on the expected composition of the population in a viremic patient prior to the start of treatment as opposed to the history of a viral population. Our approach uses a self-consistent formalism for inference of the population genetics parameters (e.g. population diversity and selection strength) and for the evolutionary simulations used to predict outcomes. Therefore, we can directly interpret the fitted parameters in terms of both the viral dynamics and the pre-treatment state of HIV-1 populations within patients.</p></sec></sec><sec id="s4-8"><title>Predicting trial outcomes from genetically informed evolutionary models</title><sec id="s4-8-1"><title>Predicting rebound times</title><p>We expect different distributions of patient outcomes depending on whether they have been recently infected and thus have relatively low viral diversity, or whether their infection is longstanding with a diverse viral population. To construct the distribution of initial population diversities <inline-formula><mml:math id="inf376"><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:math></inline-formula> for simulating trial outcomes, we apply the <inline-formula><mml:math id="inf377"><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:math></inline-formula> inference procedure (<xref ref-type="disp-formula" rid="equ23">Equation 22</xref>) to pre-treatment sequence datasets available from the clinical trials under consideration. In <xref ref-type="fig" rid="fig2">Figure 2D</xref> this set of pre-trial <inline-formula><mml:math id="inf378"><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:math></inline-formula> is compared to the longitudinal in-patient <inline-formula><mml:math id="inf379"><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:math></inline-formula> from <xref ref-type="bibr" rid="bib106">Zanini et al., 2017</xref>. We used random draws from the inferred <inline-formula><mml:math id="inf380"><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:math></inline-formula> values for patients to generate <inline-formula><mml:math id="inf381"><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:math></inline-formula> for simulations.</p><p>We found that there was considerably more viral escape and non-responders in our simulations than in the observed data as shown in <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3A</xref>. This is <italic>in addition</italic> to the fact that the patients were screened to have only susceptible variants to the antibodies used in trials (<xref ref-type="bibr" rid="bib10">Caskey et al., 2015</xref>; <xref ref-type="bibr" rid="bib12">Caskey et al., 2017</xref>; <xref ref-type="bibr" rid="bib4">Baron et al., 2018</xref>). In theory, there should be zero non-responders, as such patients should have been excluded by screening. The over-prediction of <italic>both</italic> non-responders and late rebounds is a signature of undercounting the effective diversity of the viral populations.</p><p>The failure of both screening and our naive prediction in undercounting the diversity in the viral population can be explained by an effective viral reservoir. Viral variants which mediate rebound can come from compartments such as including bone marrow, lymph nodes, and organ tissues, and can be genetically distinct from those sample from the plasma T-cells during screening (<xref ref-type="bibr" rid="bib13">Chaillon et al., 2020</xref>; <xref ref-type="bibr" rid="bib103">Wong and Yukl, 2016</xref>; <xref ref-type="bibr" rid="bib17">Chun et al., 2005</xref>). This reservoir of viral diversity can reappear in plasma after infusion of a bNAb and could in part contribute to treatment failure (<xref ref-type="bibr" rid="bib2">Avettand-Fenoel et al., 2007</xref>; <xref ref-type="bibr" rid="bib85">Shan and Siliciano, 2013</xref>; <xref ref-type="bibr" rid="bib86">Sharkey et al., 2011</xref>; <xref ref-type="bibr" rid="bib95">Tagarro et al., 2018</xref>).</p></sec><sec id="s4-8-2"><title>Determining patient diversity enhancement due to latent reservoirs</title><p>We model the effect of reservoirs as a simple inflation of the diversity observed by a multiplicative factor <inline-formula><mml:math id="inf382"><mml:mi>ξ</mml:mi></mml:math></inline-formula>. We fit <inline-formula><mml:math id="inf383"><mml:mi>ξ</mml:mi></mml:math></inline-formula> directly to trial observations, using a disparity-based approach by minimizing an empirical divergence estimator <xref ref-type="bibr" rid="bib24">Ekström, 2008</xref> between the observed and simulated data. To do so, we characterize the Hellinger distance <xref ref-type="bibr" rid="bib55">Lindsay, 1994</xref>; <xref ref-type="bibr" rid="bib88">Simpson, 1987</xref> between the true distribution of rebound times <inline-formula><mml:math id="inf384"><mml:mrow><mml:mi>P</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> and the rebound times <inline-formula><mml:math id="inf385"><mml:mrow><mml:mi>Q</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>t</mml:mi><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:mi>ξ</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> generated by simulations with a given reservoir factor <inline-formula><mml:math id="inf386"><mml:mi>ξ</mml:mi></mml:math></inline-formula>,<disp-formula id="equ33"><label>(32)</label><mml:math id="m33"><mml:mrow><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>H</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>P</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mi>Q</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mi>ξ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo>∫</mml:mo><mml:mrow><mml:mtext>d</mml:mtext></mml:mrow><mml:mi>t</mml:mi><mml:mspace width="thinmathspace"/><mml:mo stretchy="false">(</mml:mo><mml:mi>Q</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mi>ξ</mml:mi><mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>P</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac></mml:mrow></mml:msup><mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>≈</mml:mo><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mi>q</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:munderover><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>Q</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>ξ</mml:mi><mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:msubsup><mml:mi>P</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac></mml:mrow></mml:msubsup><mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>Algorithm 5 (Appendix 5) defines the procedure that we use to estimate the Hellinger distance <bold>D</bold><sub>H</sub>(<bold>Q</bold>(t)||<bold>P</bold>(t|ξ)). Specifically, we use n<sub>q</sub> quantiles of the observed data x<sub>(i)</sub> ~ <bold>Q</bold> to partition the space of observations into discrete outcomes<disp-formula id="equ34"><label>(33)</label><mml:math id="m34"><mml:mrow><mml:msub><mml:mi>Q</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>ξ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo>∫</mml:mo><mml:mrow><mml:mtext>d</mml:mtext></mml:mrow><mml:mi>t</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>P</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mi>ξ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo>≤</mml:mo><mml:mi>t</mml:mi><mml:mo>&lt;</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mi>q</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>.</mml:mo></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf387"><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub></mml:math></inline-formula> is a constant by construction, and <inline-formula><mml:math id="inf388"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>ξ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> is estimated by simulations, and <inline-formula><mml:math id="inf389"><mml:mrow><mml:mo>[</mml:mo><mml:mo>⋅</mml:mo><mml:mo>]</mml:mo></mml:mrow></mml:math></inline-formula> is the Iverson bracket <xref ref-type="bibr" rid="bib36">Graham et al., 1989</xref>; see Algorithm 5 (Appendix 5).<disp-formula id="equ35"><label>(34)</label><mml:math id="m35"><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mi>B</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mo>{</mml:mo><mml:mtable columnalign="left left" rowspacing=".2em" columnspacing="1em" displaystyle="false"><mml:mtr><mml:mtd><mml:mn>1</mml:mn><mml:mtext> if </mml:mtext><mml:mi>B</mml:mi><mml:mo>=</mml:mo><mml:mtext>true</mml:mtext></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mn>0</mml:mn><mml:mtext> if </mml:mtext><mml:mi>B</mml:mi><mml:mo>=</mml:mo><mml:mtext>false</mml:mtext></mml:mtd></mml:mtr></mml:mtable><mml:mo fence="true" stretchy="true" symmetric="true"/></mml:mrow></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>To simulate data for this analysis, we generate <inline-formula><mml:math id="inf390"><mml:mi>S</mml:mi></mml:math></inline-formula> rebound times (<inline-formula><mml:math id="inf391"><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>) by simulations, given the scaled diversity values <inline-formula><mml:math id="inf392"><mml:mrow><mml:mi>ξ</mml:mi><mml:mo>⁢</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:mrow></mml:math></inline-formula>. We then find the optimal value <inline-formula><mml:math id="inf393"><mml:msup><mml:mi>ξ</mml:mi><mml:mo>*</mml:mo></mml:msup></mml:math></inline-formula> by minimizing the disparity with the observed rebound times <inline-formula><mml:math id="inf394"><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> by brute-force search,<disp-formula id="equ36"><label>(35)</label><mml:math id="m36"><mml:mrow><mml:mi>R</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ξ</mml:mi><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mstyle displaystyle="true" scriptlevel="0"><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:mrow></mml:munder><mml:mrow><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">y</mml:mi></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mi>ξ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ37"><label>(36)</label><mml:math id="m37"><mml:mrow><mml:msup><mml:mi>ξ</mml:mi><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>arg</mml:mi><mml:mo>⁡</mml:mo><mml:munder><mml:mo movablelimits="true" form="prefix">min</mml:mo><mml:mrow><mml:mi>ξ</mml:mi></mml:mrow></mml:munder><mml:mi>R</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ξ</mml:mi><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>Here, ReboundDisparity is the function defined by Algorithm 5 (Appendix 5); see <xref ref-type="bibr" rid="bib24">Ekström, 2008</xref> for details. We find the optimal reservoir factor to be <inline-formula><mml:math id="inf395"><mml:mrow><mml:msup><mml:mi>ξ</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mo>=</mml:mo><mml:mn>2.1</mml:mn></mml:mrow></mml:math></inline-formula>, which we use in subsequent therapy prediction. The disparity over various values of <inline-formula><mml:math id="inf396"><mml:mi>ξ</mml:mi></mml:math></inline-formula> for different trials is shown in <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>.</p></sec><sec id="s4-8-3"><title>Simulating outcomes of clinal trials</title><p>Given the reservoir-corrected estimate of the diversity <inline-formula><mml:math id="inf397"><mml:mrow><mml:mi>ξ</mml:mi><mml:mo>⁢</mml:mo><mml:mi>θ</mml:mi></mml:mrow></mml:math></inline-formula> and the posterior samples for selection factors <inline-formula><mml:math id="inf398"><mml:mover accent="true"><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:math></inline-formula>, we now summarize how we simulated the outcome of clinical trials.</p><p>For a given bNAb, we draw the selection factor at each of the escape mediating sites from the corresponding Bayesian posterior on <inline-formula><mml:math id="inf399"><mml:mover accent="true"><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:math></inline-formula>; the posterior distributions are shown in <xref ref-type="fig" rid="fig4">Figure 4A</xref>, and summarized in <xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>. We also use the mutational target size (forward <inline-formula><mml:math id="inf400"><mml:mi>μ</mml:mi></mml:math></inline-formula> and backward <inline-formula><mml:math id="inf401"><mml:msup><mml:mi>μ</mml:mi><mml:mo>†</mml:mo></mml:msup></mml:math></inline-formula> rates) associated with each of the escape mediating sites of a given bNAb; see <xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>. The result can be summarized in a mutation / selection matrix <inline-formula><mml:math id="inf402"><mml:msub><mml:mover accent="true"><mml:mi>M</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mi>a</mml:mi></mml:msub></mml:math></inline-formula> for a given bNAb <inline-formula><mml:math id="inf403"><mml:mi>a</mml:mi></mml:math></inline-formula>, where each column corresponds to an escape mediating site <inline-formula><mml:math id="inf404"><mml:mi>i</mml:mi></mml:math></inline-formula> against the bNAb,<disp-formula id="equ38"><label>(37)</label><mml:math id="m38"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>M</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mi>a</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mtable rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:msub><mml:mrow><mml:mover><mml:mi>μ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mtd><mml:mtd><mml:mo>…</mml:mo></mml:mtd><mml:mtd><mml:msub><mml:mrow><mml:mover><mml:mi>μ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msubsup><mml:mrow><mml:mover><mml:mi>μ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mo>†</mml:mo></mml:mrow></mml:msubsup></mml:mtd><mml:mtd><mml:mo>…</mml:mo></mml:mtd><mml:mtd><mml:msubsup><mml:mrow><mml:mover><mml:mi>μ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mo>†</mml:mo></mml:mrow></mml:msubsup></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mrow><mml:mover><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mtd><mml:mtd><mml:mo>…</mml:mo></mml:mtd><mml:mtd><mml:msub><mml:mrow><mml:mover><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mtd></mml:mtr></mml:mtable><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>The elements of the matrix <inline-formula><mml:math id="inf405"><mml:msub><mml:mover accent="true"><mml:mi>M</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mi>a</mml:mi></mml:msub></mml:math></inline-formula> are the scaled mutation and selection factors, i.e., <inline-formula><mml:math id="inf406"><mml:mrow><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>μ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:msub><mml:mi>μ</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:mrow></mml:mrow><mml:mo rspace="4.2pt">,</mml:mo><mml:mrow><mml:mrow><mml:msubsup><mml:mover accent="true"><mml:mi>μ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mi>i</mml:mi><mml:mo>†</mml:mo></mml:msubsup><mml:mo>=</mml:mo><mml:mrow><mml:msub><mml:mi>μ</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:mrow></mml:mrow><mml:mo rspace="4.2pt">,</mml:mo><mml:mrow><mml:mrow><mml:mtext>and </mml:mtext><mml:mo>⁢</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:msub><mml:mi>σ</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:math></inline-formula>, where the absolute value of mutation rate is set to <inline-formula><mml:math id="inf407"><mml:mrow><mml:msub><mml:mi>μ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mn>1.11</mml:mn><mml:mo>×</mml:mo><mml:mpadded width="+1.7pt"><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>-</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:msup></mml:mpadded></mml:mrow><mml:mo>/</mml:mo><mml:mtext>nt</mml:mtext><mml:mo>/</mml:mo><mml:mtext>day</mml:mtext></mml:mrow></mml:mrow></mml:math></inline-formula> from <xref ref-type="bibr" rid="bib106">Zanini et al., 2017</xref>.</p><p>For each patient in our simulated trial, we then draw diversity <inline-formula><mml:math id="inf408"><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:math></inline-formula> from the patient pool, and scale it by our fitted <inline-formula><mml:math id="inf409"><mml:mrow><mml:mi>ξ</mml:mi><mml:mo>=</mml:mo><mml:mn>2.1</mml:mn></mml:mrow></mml:math></inline-formula>, resulting in patient-specific selection and mutation factors,<disp-formula id="equ39"><label>(38)</label><mml:math id="m39"><mml:mtable columnspacing="5pt" displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mrow><mml:mi>ξ</mml:mi><mml:mo>×</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub><mml:mo>×</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>M</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mi>a</mml:mi></mml:msub></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mtable displaystyle="true" rowspacing="0pt"><mml:mtr><mml:mtd columnalign="center"><mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>⁢</mml:mo><mml:mi mathvariant="normal">…</mml:mi><mml:mo>⁢</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="center"><mml:mrow><mml:msubsup><mml:mi>θ</mml:mi><mml:mn>1</mml:mn><mml:mo>†</mml:mo></mml:msubsup><mml:mo>⁢</mml:mo><mml:mi mathvariant="normal">…</mml:mi><mml:mo>⁢</mml:mo><mml:msubsup><mml:mi>θ</mml:mi><mml:mi>i</mml:mi><mml:mo>†</mml:mo></mml:msubsup></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="center"><mml:mrow><mml:msub><mml:mi>σ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>⁢</mml:mo><mml:mi mathvariant="normal">…</mml:mi><mml:mo>⁢</mml:mo><mml:msub><mml:mi>σ</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mtd></mml:mtr></mml:mtable><mml:mo>)</mml:mo></mml:mrow><mml:mo>⁢</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:mrow><mml:mo>×</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>M</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mi>a</mml:mi></mml:msub></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mtable displaystyle="true" rowspacing="0pt"><mml:mtr><mml:mtd columnalign="center"><mml:mrow><mml:msub><mml:mi>μ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>⁢</mml:mo><mml:mi mathvariant="normal">…</mml:mi><mml:mo>⁢</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="center"><mml:mrow><mml:msubsup><mml:mi>μ</mml:mi><mml:mn>1</mml:mn><mml:mo>†</mml:mo></mml:msubsup><mml:mo>⁢</mml:mo><mml:mi mathvariant="normal">…</mml:mi><mml:mo>⁢</mml:mo><mml:msubsup><mml:mi>μ</mml:mi><mml:mi>i</mml:mi><mml:mo>†</mml:mo></mml:msubsup></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="center"><mml:mrow><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>⁢</mml:mo><mml:mi mathvariant="normal">…</mml:mi><mml:mo>⁢</mml:mo><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mtd></mml:mtr></mml:mtable><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mtd><mml:mtd/></mml:mtr></mml:mtable></mml:math></disp-formula></p><p>These parameters are then used to initialize the state of an HIV population within a patient according to (Appendix 5), and to determine the absolute rates in Algorithm 3 (Appendix 5) for the population evolution according to <xref ref-type="disp-formula" rid="equ39">Equation 38</xref>. The decay rate is set to the fitted trial average of <inline-formula><mml:math id="inf410"><mml:mrow><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mpadded width="+1.7pt"><mml:mn>0.31</mml:mn></mml:mpadded><mml:mo>⁢</mml:mo><mml:msup><mml:mtext>days</mml:mtext><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math></inline-formula> (<xref ref-type="disp-formula" rid="equ8">Equation 8</xref>). The carrying capacity <inline-formula><mml:math id="inf411"><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula> is set according to <xref ref-type="disp-formula" rid="equ22">Equation 21</xref>. This determines all parameters of the birth-death process simulating the intra-patient evolution of HIV, which are used in Algorithm 3 (Appendix 5).</p><p>We evolve a population through time until 56 days have elapsed since treatment, or until the escape fraction relative to the carrying capacity <italic>x</italic><sub><italic>t</italic></sub> is above 0.8; see Algorithm 3 (Appendix 5). After <inline-formula><mml:math id="inf412"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>&gt;</mml:mo><mml:mn>.8</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> the evolution is governed by the deterministic equations, and the stochastic simulation ends. The rebound time <inline-formula><mml:math id="inf413"><mml:mi>T</mml:mi></mml:math></inline-formula>, defined as the intersection of the exponential envelope and the carrying capacity, can then be calculated analytically as,<disp-formula id="equ40"><label>(39)</label><mml:math id="m40"><mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mi>γ</mml:mi></mml:mfrac><mml:mo>⁢</mml:mo><mml:mrow><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mrow><mml:mrow><mml:mi>exp</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>γ</mml:mi><mml:mo>⁢</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>⁢</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:mfrac></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>The resulting distribution for rebound times are shown as model predictions in <xref ref-type="fig" rid="fig3">Figure 3B–D</xref>.</p><p>Rebound times generated in this fashion were also used to estimate the probability of late rebound to characterize the efficacy of a given bNAb in curbing viral rebound. The probability of late rebound was estimated from 10<sup>4</sup> simulated patients. The interdecile quantiles (0.1–0.9) of early rebound (<italic>lt</italic><sub>56</sub> days) probability over 200 values of scaled selection coefficients <inline-formula><mml:math id="inf414"><mml:mover accent="true"><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:math></inline-formula> drawn from the posteriors in <xref ref-type="fig" rid="fig4">Figure 4A</xref> are shown in <xref ref-type="fig" rid="fig4">Figure 4C</xref>.</p></sec></sec><sec id="s4-9"><title>Model robustness</title><sec id="s4-9-1"><title>Effect of genomic linkage on the inference of selection</title><p>In our inference of selection (<xref ref-type="disp-formula" rid="equ32">Equation 31</xref>, <xref ref-type="fig" rid="fig4">Figure 4A</xref>), we assume that the escape-mediating sites are at linkage equilibrium and that the distribution of allele frequencies can be approximated by a skewed Beta distribution (<xref ref-type="disp-formula" rid="equ13">Equation 12</xref>), reflecting the equilibrium of allele frequencies. In reality, despite recombination, the HIV genome exhibits linkage effects, especially at nearby sites <xref ref-type="bibr" rid="bib105">Zanini et al., 2015</xref>, and the viral populations experience changing selective pressures by the immune system <xref ref-type="bibr" rid="bib27">Feder et al., 2021</xref>; <xref ref-type="bibr" rid="bib96">Theys et al., 2018</xref>; <xref ref-type="bibr" rid="bib70">Nourmohammad et al., 2019</xref>, and the transient population bottlenecks during therapy <xref ref-type="bibr" rid="bib25">Feder et al., 2016</xref>.</p><p>To test the limits on the validity of our inference procedure, we applied it to in silico populations generated by full-genome forward-time simulations (Appendix 5, Algorithm 3) in the presence and absence of recombination. To do so, we considered an ensemble of ten patients with 100 genomes sampled at 10 time points, and used two diversity parameters <inline-formula><mml:math id="inf415"><mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mn>0.01</mml:mn></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="inf416"><mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mn>0.1</mml:mn></mml:mrow></mml:math></inline-formula>, to cover the range reflected in patient data (<xref ref-type="fig" rid="fig2">Figure 2D</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>).</p><p>One relevant scenario to consider is the impact of other selected sites in the genome on the distribution of alleles at the escape mediating sites against bNAbs. The sites under a strong constant selection are likely to be already fixed (or at a high a frequency) at their favorable state in the population. However, the strong selection on a large fraction of antigenic sites can be thought as time-varying, due to the changing pressure imposed by the immune system or therapy. To capture this effect, we simulated whole genome evolution in which linked sites were under strong selection (<inline-formula><mml:math id="inf417"><mml:mrow><mml:mn>0.1</mml:mn><mml:mo>×</mml:mo><mml:mtext>growth rate</mml:mtext></mml:mrow></mml:math></inline-formula>), and where the sign of selection changed after exponentially distributed waiting times (i.e. as a Poisson process); this model of fluctuating selection has been used in the context of influenza evolution <xref ref-type="bibr" rid="bib94">Strelkowa and Lässig, 2012</xref>, and for somatic evolution of B-cell repertoires in HIV patients <xref ref-type="bibr" rid="bib70">Nourmohammad et al., 2019</xref>. The resulted evolutionary dynamics in this case can involve strong selective sweeps and clonal interference due to the continuous rise of beneficial mutations (in the linked sites) within a population.</p><p>To test the robustness of our selection inference, we evaluated the distribution of maximum likelihood estimates (MLEs) for the selection values <inline-formula><mml:math id="inf418"><mml:mrow><mml:mover accent="true"><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mi>σ</mml:mi><mml:mo>/</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:mrow><mml:mo>⁢</mml:mo><mml:mi>s</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> at the escape mediating sites, inferred from the ensemble of sequences obtain from simulated data with linkage. <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref> shows that even for fully linked genomes (zero recombination) our MLE estimate of selection has little bias relative to the true values used in the simulations. Adding recombination into the simulations only further attenuates the effect of linkage (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>), making the estimates more accurate.</p><p>The reason that selective sweeps of linked beneficial mutations have only minor effects on our inference of selection for the escape mediating sites is two-fold: First, the primary mechanism by which selective sweeps change the strength of selection at linked sites is via a reduction in the effective population size <xref ref-type="bibr" rid="bib40">Hill and Robertson, 2009</xref>; <xref ref-type="bibr" rid="bib18">Comeron et al., 2008</xref>. However, variations in the effective population size are already accounted for in our inference procedure: The selection likelihood in <xref ref-type="disp-formula" rid="equ32">Equation 31</xref> is conditioned on the measured neutral-site diversity, <inline-formula><mml:math id="inf419"><mml:mrow><mml:mi>θ</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mo>⁢</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>e</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mi>μ</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula>. The change in the effective population size impacts the selection coefficient <inline-formula><mml:math id="inf420"><mml:mrow><mml:mi>σ</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mo>⁢</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>e</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> and the diversity <inline-formula><mml:math id="inf421"><mml:mrow><mml:mi>θ</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mo>⁢</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>e</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mi>μ</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> in the same way, and therefore, the (scaled) selection parameter <inline-formula><mml:math id="inf422"><mml:mrow><mml:mover accent="true"><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>/</mml:mo><mml:mi>θ</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> that we infer from data remains insensitive to changes in the effective population size.</p><p>The second reason for the robustness of our selection inference to linkage is due to the fact that a beneficial allele in a linked locus can appear on a genetic background with or without a susceptible variant, leading to the rise of either variants in the population. As a results, the impact of such hitchhiking remains a secondary issue in inference of selection at the escape sites, for which an ensemble of populations from different patients with distinct evolutionary histories of HIV-1are used.</p></sec><sec id="s4-9-2"><title>Robustness of selection inference to intra-patient temporal correlations of HIV alleles</title><p>To infer the selection effect of mutations from the longitudinal deep sequencing data of <xref ref-type="bibr" rid="bib105">Zanini et al., 2015</xref>, we use time averaging of the likelihood (<xref ref-type="disp-formula" rid="equ32">Equation 31</xref>) to avoid conflating our results due to temporal correlations between the circulating alleles within patients (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). We can view this choice as being one choice among two extremes: (i) to treat each patient as effectively one independent data point so that all patients are given the same weight or (ii) to treat each time point as independent, giving patients with more time points a higher weight. These two choices correspond to different log-likelihood functions for the (scaled) selection factor <inline-formula><mml:math id="inf423"><mml:mover accent="true"><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:math></inline-formula>:<disp-formula id="equ41"><label>(40)</label><mml:math id="m41"><mml:mtable columnspacing="5pt" displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mrow><mml:mi class="ltx_font_mathcaligraphic">ℒ</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mover accent="true"><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mtable columnspacing="5pt" displaystyle="true" rowspacing="0pt"><mml:mtr><mml:mtd columnalign="left"><mml:mrow><mml:mstyle displaystyle="false"><mml:msub><mml:mo largeop="true" symmetric="true">∑</mml:mo><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mstyle><mml:mrow><mml:mrow><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>m</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mrow><mml:msub><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:mrow><mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>,</mml:mo><mml:mover accent="true"><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>t</mml:mi><mml:mtext>-independent</mml:mtext></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd/></mml:mtr><mml:mtr><mml:mtd columnalign="left"><mml:mrow><mml:mstyle displaystyle="false"><mml:msub><mml:mo largeop="true" symmetric="true">∑</mml:mo><mml:mi>p</mml:mi></mml:msub></mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>T</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mfrac></mml:mstyle><mml:mo>⁢</mml:mo><mml:mrow><mml:mstyle displaystyle="false"><mml:msub><mml:mo largeop="true" symmetric="true">∑</mml:mo><mml:mi>t</mml:mi></mml:msub></mml:mstyle><mml:mrow><mml:mrow><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>m</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mrow><mml:msub><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:mrow><mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>,</mml:mo><mml:mover accent="true"><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>t</mml:mi><mml:mtext>-averaged</mml:mtext></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:mtd><mml:mtd/></mml:mtr></mml:mtable></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf424"><mml:msub><mml:mi>T</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:math></inline-formula> is the total number of time points from patient <inline-formula><mml:math id="inf425"><mml:mi>p</mml:mi></mml:math></inline-formula>, and <inline-formula><mml:math id="inf426"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>m</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mrow><mml:msub><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:mrow><mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>,</mml:mo><mml:mover accent="true"><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> is the probability to observe <inline-formula><mml:math id="inf427"><mml:mi>m</mml:mi></mml:math></inline-formula> escape mutants, and <inline-formula><mml:math id="inf428"><mml:mi>s</mml:mi></mml:math></inline-formula> susceptible variants at time <inline-formula><mml:math id="inf429"><mml:mi>t</mml:mi></mml:math></inline-formula> in patient <inline-formula><mml:math id="inf430"><mml:mi>p</mml:mi></mml:math></inline-formula>, given the neutral diversity <inline-formula><mml:math id="inf431"><mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> and the scaled selection factor <inline-formula><mml:math id="inf432"><mml:mover accent="true"><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:math></inline-formula>.</p><p>We find that both of these approaches result in similar posteriors for selection <inline-formula><mml:math id="inf433"><mml:mover accent="true"><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:math></inline-formula> (Model robustness <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref> and C), although the <inline-formula><mml:math id="inf434"><mml:mi>t</mml:mi></mml:math></inline-formula>-averaged likelihood has a higher uncertainty due to fewer independent time points. Thus, our inference of selection is insensitive to the exact choice of the likelihood function given in <xref ref-type="disp-formula" rid="equ41">Equation 40</xref>, yet our time-averaged approach remains the more conservative choice between the two.</p></sec><sec id="s4-9-3"><title>Statistical significance of the reservoir-corrected diversity</title><p>In <xref ref-type="disp-formula" rid="equ37">Equation 36</xref>, we introduced the reservoir factor <inline-formula><mml:math id="inf435"><mml:mrow><mml:msup><mml:mi>ξ</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mo>=</mml:mo><mml:mn>2.1</mml:mn></mml:mrow></mml:math></inline-formula> to account for the diversity of HIV-1that is not sampled from a patient’s plasma prior to therapy, which resulted in a better fit of the rebound time distributions (<xref ref-type="fig" rid="fig3">Figure 3</xref>) compared to a reservoir-free model (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3A</xref>). Here, we quantify the importance of the reservoir factor with a statistical test on the null hypothesis, <inline-formula><mml:math id="inf436"><mml:mrow><mml:msub><mml:mi>ξ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>. Specifically, we perform a hypothesis test to test the necessity of using an inflated diversity <inline-formula><mml:math id="inf437"><mml:mrow><mml:mpadded width="+1.7pt"><mml:mi>ξ</mml:mi></mml:mpadded><mml:mo>⁢</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:mrow></mml:math></inline-formula> relative to using the bare diversity observed in pre-trial sequence data <inline-formula><mml:math id="inf438"><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:math></inline-formula>. To do so, we construct a disparity-based test statistic <xref ref-type="bibr" rid="bib24">Ekström, 2008</xref>, which is analogous to the likelihood ratio test statistic.</p><p>Recall that the optimal reservoir factor <inline-formula><mml:math id="inf439"><mml:mrow><mml:msup><mml:mi>ξ</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mi>arg</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:msub><mml:mi>min</mml:mi><mml:mi>ξ</mml:mi></mml:msub><mml:mo>⁡</mml:mo><mml:mi>R</mml:mi></mml:mrow></mml:mrow><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>ξ</mml:mi><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></inline-formula> was obtained by minimizing the disparity function <inline-formula><mml:math id="inf440"><mml:mrow><mml:mi>R</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>ξ</mml:mi><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> across measurements of rebound times <inline-formula><mml:math id="inf441"><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> from all the <inline-formula><mml:math id="inf442"><mml:mi>p</mml:mi></mml:math></inline-formula> patients in data (<xref ref-type="disp-formula" rid="equ37">Equation 36</xref>). We can estimate the test statistic for the reduction in disparity between the null hypothesis, <inline-formula><mml:math id="inf443"><mml:mrow><mml:msub><mml:mi>ξ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> and the fitted reservoir factor <inline-formula><mml:math id="inf444"><mml:msup><mml:mi>ξ</mml:mi><mml:mo>*</mml:mo></mml:msup></mml:math></inline-formula> as,<disp-formula id="equ42"><label>(41)</label><mml:math id="m42"><mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>R</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msub><mml:mi>ξ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>-</mml:mo><mml:mrow><mml:mrow><mml:munder><mml:mi>min</mml:mi><mml:mi>ξ</mml:mi></mml:munder><mml:mo>⁡</mml:mo><mml:mi>R</mml:mi></mml:mrow><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>ξ</mml:mi><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>We can then determine the p-value by estimating the quantile of the observed test statistic <inline-formula><mml:math id="inf445"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>R</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula> relative to that inferred from the distribution of <inline-formula><mml:math id="inf446"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>R</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula> obtained from simulations under null hypothesis <inline-formula><mml:math id="inf447"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>ξ</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> (<xref ref-type="bibr" rid="bib30">Fisher, 1956</xref>). Specifically,<disp-formula id="equ43"><label>(42)</label><mml:math id="m43"><mml:mrow><mml:mtext>p-value</mml:mtext><mml:mo>=</mml:mo><mml:munder><mml:mrow><mml:mi mathvariant="double-struck">E</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:msub><mml:mi>ξ</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:munder><mml:mspace width="thinmathspace"/><mml:mo stretchy="false">(</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:msub><mml:mi>ξ</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>&gt;</mml:mo><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf448"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:munder><mml:mrow><mml:mi mathvariant="double-struck">E</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:msub><mml:mi>ξ</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:munder><mml:mspace width="thinmathspace"/><mml:mo stretchy="false">(</mml:mo><mml:mo>⋅</mml:mo><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula> denotes the expectation over the rebound times <inline-formula><mml:math id="inf449"><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> obtained from 1000 realizations of simulated populations each with <inline-formula><mml:math id="inf450"><mml:mi>p</mml:mi></mml:math></inline-formula> patients, and under the null hypothesis <inline-formula><mml:math id="inf451"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>ξ</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> is the Iverson bracket that takes value 1 when its argument is true and 0, otherwise (<xref ref-type="disp-formula" rid="equ35">Equation 34</xref>). The observed <inline-formula><mml:math id="inf452"><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>R</mml:mi></mml:msub></mml:math></inline-formula> (<xref ref-type="disp-formula" rid="equ42">Equation 41</xref>), the distribution of simulated values of <inline-formula><mml:math id="inf453"><mml:mrow><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>R</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:msub><mml:mi>ξ</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> under the null hypothesis, and the resulting <inline-formula><mml:math id="inf454"><mml:mrow><mml:mtext>p-value</mml:mtext><mml:mo>=</mml:mo><mml:mn>0.004</mml:mn></mml:mrow></mml:math></inline-formula> are shown in <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3B, C</xref>.</p><p>It should be noted that here we use the disparity measure because the corresponding likelihood function for the reservoir factor is inaccessible through forward simulations of populations. However, a general analogy exists between our approach and the more commonly used likelihood approach. Specifically, in an analogous likelihood-ratio test, the test statistic <inline-formula><mml:math id="inf455"><mml:mrow><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>L</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mi>max</mml:mi><mml:mi>ξ</mml:mi></mml:msub><mml:mo>⁡</mml:mo><mml:mrow><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:mi>p</mml:mi></mml:mrow></mml:mrow><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>ξ</mml:mi><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>-</mml:mo><mml:mrow><mml:mrow><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:mi>p</mml:mi></mml:mrow><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msub><mml:mi>ξ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo lspace="2.5pt" rspace="2.5pt" stretchy="false">|</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:math></inline-formula> would be asymptotically <inline-formula><mml:math id="inf456"><mml:msup><mml:mi>χ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:math></inline-formula>-distributed with one degree of freedom under the null hypothesis <xref ref-type="bibr" rid="bib29">Fisher, 1954</xref>, and the quantile under the null-hypothesis (p-value) would be estimated by inverting the <inline-formula><mml:math id="inf457"><mml:msup><mml:mi>χ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:math></inline-formula> cumulative distribution function (i.e. a <inline-formula><mml:math id="inf458"><mml:msup><mml:mi>χ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:math></inline-formula> test).</p></sec><sec id="s4-9-4"><title>Robustness of selection inference to strains from different clades of HIV</title><p>The longitudinal deep sequencing data of <xref ref-type="bibr" rid="bib105">Zanini et al., 2015</xref> is collected from 11 patients, 9 of whom are infected with clade B strains of HIV-1, which is the dominant clade circulating in Europe <xref ref-type="bibr" rid="bib91">Spira et al., 2003</xref>. All of the clinical trials we considered <xref ref-type="bibr" rid="bib10">Caskey et al., 2015</xref>; <xref ref-type="bibr" rid="bib12">Caskey et al., 2017</xref>; <xref ref-type="bibr" rid="bib4">Baron et al., 2018</xref> are from patients carrying clade B strains. For the results presented in the main text, we included all the 11 patients in our analysis. Here, we test wether our inference of selection is sensitive to the choice of including or excluding non-clade B patients in our analysis. We therefore repeated our inference procedure for selection by excluding the two non-clade B patients. Model robustness <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>,B shows a strong agreement between the Bayesian posterior for selection factors in the two cases, with a slight increase in uncertainty for the case with only clade B patients. This increased uncertainty is related to the reduction in sample size by excluding the non-clade B patients from data. Nonetheless, the richness of the intra-patient diversity makes the inference robust to the exclusion of one or two patients.</p></sec><sec id="s4-9-5"><title>Robustness of predictions for trial efficacy to the inferred values of selection strength</title><p>How sensitive are the outcomes of our predictions for the rebound time distributions (<xref ref-type="fig" rid="fig1">Figure 1</xref>) to the exact values of inferred selection strengths we used for our simulations? We addressed this question by performing a disparity analysis similar to that for the diversity <inline-formula><mml:math id="inf459"><mml:mi>θ</mml:mi></mml:math></inline-formula> in <xref ref-type="disp-formula" rid="equ42">Equation 41</xref>. Specifically, we assessed whether we might need to rescale our inferred selection strength <inline-formula><mml:math id="inf460"><mml:mrow><mml:mi>σ</mml:mi><mml:mo>/</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:mrow></mml:math></inline-formula> by a multiplicative factor <inline-formula><mml:math id="inf461"><mml:msub><mml:mi>ξ</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></inline-formula> (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4</xref>).</p><p>In contrast to diversity, the reduction in disparity for adjustment of selection with a factor <inline-formula><mml:math id="inf462"><mml:msub><mml:mi>ξ</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></inline-formula> is small (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4A</xref>) and not statistically significant (<inline-formula><mml:math id="inf463"><mml:mrow><mml:mtext>p-value</mml:mtext><mml:mo>=</mml:mo><mml:mn>0.49</mml:mn></mml:mrow></mml:math></inline-formula>; <xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4B</xref>), and could be attributed to count noise. Still, we cannot discount the possibility that selection was slightly overestimated, possibly due to the effect of compensatory mutations in linked genome, the interplay between the reservoir and the inference of selection, or other biological factors. Nonetheless, in absolute terms, the null hypothesis (i.e. <inline-formula><mml:math id="inf464"><mml:mrow><mml:msub><mml:mi>ξ</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>) cannot be rejected and we have no statistical justification for adding an adjustment factor for selection inferred from untreated patients.</p></sec><sec id="s4-9-6"><title>Robustness of rebound time predictions to methods of identifying escape mutations</title><p>Our predictions rely on identifying escape variants against each bNAb, either based on in vivo trial data and patient surveillance, or in vitro DMS assays. To test the sensitivity of our results to these methods, we compare the predictions of rebound time distributions when identifying escape sites from the DMS data versus the trial data. In Appendix 4, we perform this comparison for the 10–1074 and the PGT121 bNAbs; we do not include the 3BNC117 bNAb in this analysis since it targets the CD4 binding site of HIV-1and the DMS data is unreliable for identifying escape variants against it. As shown in <xref ref-type="fig" rid="app4fig1">Appendix 4—figure 1</xref>, both trial-inferred and DMS-inferred escape sites result in good predictions for rebound time distributions. However, its appears that using the DMS-inferred escape sites could lead to a more optimistic prediction for treatment success (i.e. a later rebound). This inconsistency may be due to the fact that DMS data is collected in vitro, and other biological factors could be influencing the in vivo escape patterns. Moreover, the differences in the genetic composition of the HIV-1strains circulating in patients enrolled in trials and the strains used for the DMS experiments could lead to different epistatic interactions that can enhance or reduce the chances of escape. For a systematic understanding of these differences and limitations, more experiments would be necessary. Nonetheless, DMS data can provides baseline to gauge the efficacy of different bNAbs for therapy and further in vivo investigation.</p></sec></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>Reviewing editor, eLife</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Validation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Writing – original draft, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-76004-mdarchecklist1-v2.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The current manuscript is a computational study, so no data have been generated for this manuscript. Reference to the previously published data used in this manuscript is provided. Modelling code is uploaded on GitHub at <ext-link ext-link-type="uri" xlink:href="https://github.com/StatPhysBio/HIVTreatmentOptimization">https://github.com/StatPhysBio/HIVTreatmentOptimization</ext-link>, (copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:776b6f1495f749cd2e687e53359fdde9593b5a47;origin=https://github.com/StatPhysBio/HIVTreatmentOptimization;visit=swh:1:snp:ac91d9b0c04aa7418b4e7a98db0addd24199f914;anchor=swh:1:rev:0194cf6e554996a066633e99dd53cd5901da552e">swh:1:rev:0194cf6e554996a066633e99dd53cd5901da552e</ext-link>) and in the Julia package <ext-link ext-link-type="uri" xlink:href="https://github.com/StatPhysBio/EscapeSimulator">https://github.com/StatPhysBio/EscapeSimulator</ext-link> (copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:c6cfa184d349a3272b0211efac8fc1f0f3d398e3;origin=https://github.com/StatPhysBio/EscapeSimulator;visit=swh:1:snp:1727701be1d35fdeb61fdd39bc0a9bbc0c1cb90a;anchor=swh:1:rev:9a343f598820bafddfc7ea4547cefa90bf96fd6e">swh:1:rev:9a343f598820bafddfc7ea4547cefa90bf96fd6e</ext-link>).</p><p>The following previously published datasets were used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset1"><person-group person-group-type="author"><collab>Zanini et al</collab></person-group><year iso-8601-date="2015">2015</year><data-title>Project: PRJEB9618</data-title><source>European Nucleotide Archive</source><pub-id pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/ena/browser/view/PRJEB9618?show=reads">PRJEB9618</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset2"><person-group person-group-type="author"><collab>Caskey et al</collab></person-group><year iso-8601-date="2015">2015</year><data-title>HIV-1 isolate 2A1_DB7_02 from USA envelope glycoprotein (env) gene, partial cds</data-title><source>NCBI GenBank</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/KX016803">KX016803</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset3"><person-group person-group-type="author"><collab>Caskey et al</collab></person-group><year iso-8601-date="2017">2017</year><data-title>Antibody 10-1074 suppresses viremia in HIV-1-infected individuals</data-title><source>NCBI GenBank</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/KY323724">KY323724-KY324834</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset4"><person-group person-group-type="author"><collab>Bar-On et al</collab></person-group><year iso-8601-date="2018">2018</year><data-title>Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals</data-title><source>NCBI GenBank</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/MH632763">MH632763</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We are thankful to Jesse Bloom and Adam Dingens for their input on the Deep Mutational Scanning data of HIV, and Michael Lässig and Matthijs Meijers for helpful discussions. This work has been supported by the NSF CAREER award (grant No: 2045054), DFG grant (SFB1310) for Predictability in Evolution, and the MPRG funding through the Max Planck Society.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>LJS</given-names></name></person-group><year iso-8601-date="2010">2010</year><source>An Introduction to Stochastic Processes with Applications to Biology</source><publisher-loc>Boca Raton</publisher-loc><publisher-name>CRC press</publisher-name><pub-id pub-id-type="doi">10.1201/b12537</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avettand-Fenoel</surname><given-names>V</given-names></name><name><surname>Mahlaoui</surname><given-names>N</given-names></name><name><surname>Chaix</surname><given-names>ML</given-names></name><name><surname>Milliancourt</surname><given-names>C</given-names></name><name><surname>Burgard</surname><given-names>M</given-names></name><name><surname>Cavazzana-Calvo</surname><given-names>M</given-names></name><name><surname>Rouzioux</surname><given-names>C</given-names></name><name><surname>Blanche</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Failure of bone marrow transplantation to eradicate HIV reservoir despite efficient HAART</article-title><source>AIDS</source><volume>21</volume><fpage>776</fpage><lpage>777</lpage><pub-id pub-id-type="doi">10.1097/QAD.0b013e3280b01836</pub-id><pub-id pub-id-type="pmid">17413704</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bar</surname><given-names>KJ</given-names></name><name><surname>Sneller</surname><given-names>MC</given-names></name><name><surname>Harrison</surname><given-names>LJ</given-names></name><name><surname>Justement</surname><given-names>JS</given-names></name><name><surname>Overton</surname><given-names>ET</given-names></name><name><surname>Petrone</surname><given-names>ME</given-names></name><name><surname>Salantes</surname><given-names>DB</given-names></name><name><surname>Seamon</surname><given-names>CA</given-names></name><name><surname>Scheinfeld</surname><given-names>B</given-names></name><name><surname>Kwan</surname><given-names>RW</given-names></name><name><surname>Learn</surname><given-names>GH</given-names></name><name><surname>Proschan</surname><given-names>MA</given-names></name><name><surname>Kreider</surname><given-names>EF</given-names></name><name><surname>Blazkova</surname><given-names>J</given-names></name><name><surname>Bardsley</surname><given-names>M</given-names></name><name><surname>Refsland</surname><given-names>EW</given-names></name><name><surname>Messer</surname><given-names>M</given-names></name><name><surname>Clarridge</surname><given-names>KE</given-names></name><name><surname>Tustin</surname><given-names>NB</given-names></name><name><surname>Madden</surname><given-names>PJ</given-names></name><name><surname>Oden</surname><given-names>K</given-names></name><name><surname>O’Dell</surname><given-names>SJ</given-names></name><name><surname>Jarocki</surname><given-names>B</given-names></name><name><surname>Shiakolas</surname><given-names>AR</given-names></name><name><surname>Tressler</surname><given-names>RL</given-names></name><name><surname>Doria-Rose</surname><given-names>NA</given-names></name><name><surname>Bailer</surname><given-names>RT</given-names></name><name><surname>Ledgerwood</surname><given-names>JE</given-names></name><name><surname>Capparelli</surname><given-names>EV</given-names></name><name><surname>Lynch</surname><given-names>RM</given-names></name><name><surname>Graham</surname><given-names>BS</given-names></name><name><surname>Moir</surname><given-names>S</given-names></name><name><surname>Koup</surname><given-names>RA</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name><name><surname>Hoxie</surname><given-names>JA</given-names></name><name><surname>Fauci</surname><given-names>AS</given-names></name><name><surname>Tebas</surname><given-names>P</given-names></name><name><surname>Chun</surname><given-names>T-W</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Effect of HIV antibody VRC01 on viral rebound after treatment interruption</article-title><source>The New England Journal of Medicine</source><volume>375</volume><fpage>2037</fpage><lpage>2050</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1608243</pub-id><pub-id pub-id-type="pmid">27959728</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baron</surname><given-names>Y</given-names></name><name><surname>Gruell</surname><given-names>H</given-names></name><name><surname>Schoofs</surname><given-names>T</given-names></name><name><surname>Pai</surname><given-names>JA</given-names></name><name><surname>Nogueira</surname><given-names>L</given-names></name><name><surname>Butler</surname><given-names>AL</given-names></name><name><surname>Millard</surname><given-names>K</given-names></name><name><surname>Lehmann</surname><given-names>C</given-names></name><name><surname>Suárez</surname><given-names>I</given-names></name><name><surname>Oliveira</surname><given-names>TY</given-names></name><name><surname>Karagounis</surname><given-names>T</given-names></name><name><surname>Cohen</surname><given-names>YZ</given-names></name><name><surname>Wyen</surname><given-names>C</given-names></name><name><surname>Scholten</surname><given-names>S</given-names></name><name><surname>Handl</surname><given-names>L</given-names></name><name><surname>Belblidia</surname><given-names>S</given-names></name><name><surname>Dizon</surname><given-names>JP</given-names></name><name><surname>Vehreschild</surname><given-names>JJ</given-names></name><name><surname>Witmer-Pack</surname><given-names>M</given-names></name><name><surname>Shimeliovich</surname><given-names>I</given-names></name><name><surname>Jain</surname><given-names>K</given-names></name><name><surname>Fiddike</surname><given-names>K</given-names></name><name><surname>Seaton</surname><given-names>KE</given-names></name><name><surname>Yates</surname><given-names>NL</given-names></name><name><surname>Horowitz</surname><given-names>J</given-names></name><name><surname>Gulick</surname><given-names>RM</given-names></name><name><surname>Pfeifer</surname><given-names>N</given-names></name><name><surname>Tomaras</surname><given-names>GD</given-names></name><name><surname>Seaman</surname><given-names>MS</given-names></name><name><surname>Fätkenheuer</surname><given-names>G</given-names></name><name><surname>Caskey</surname><given-names>M</given-names></name><name><surname>Klein</surname><given-names>F</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals</article-title><source>Nature Medicine</source><volume>24</volume><fpage>1701</fpage><lpage>1707</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0186-4</pub-id><pub-id pub-id-type="pmid">30258217</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barouch</surname><given-names>DH</given-names></name><name><surname>Whitney</surname><given-names>JB</given-names></name><name><surname>Moldt</surname><given-names>B</given-names></name><name><surname>Klein</surname><given-names>F</given-names></name><name><surname>Oliveira</surname><given-names>TY</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Stephenson</surname><given-names>KE</given-names></name><name><surname>Chang</surname><given-names>H-W</given-names></name><name><surname>Shekhar</surname><given-names>K</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Nkolola</surname><given-names>JP</given-names></name><name><surname>Seaman</surname><given-names>MS</given-names></name><name><surname>Smith</surname><given-names>KM</given-names></name><name><surname>Borducchi</surname><given-names>EN</given-names></name><name><surname>Cabral</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>JY</given-names></name><name><surname>Blackmore</surname><given-names>S</given-names></name><name><surname>Sanisetty</surname><given-names>S</given-names></name><name><surname>Perry</surname><given-names>JR</given-names></name><name><surname>Beck</surname><given-names>M</given-names></name><name><surname>Lewis</surname><given-names>MG</given-names></name><name><surname>Rinaldi</surname><given-names>W</given-names></name><name><surname>Chakraborty</surname><given-names>AK</given-names></name><name><surname>Poignard</surname><given-names>P</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name><name><surname>Burton</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys</article-title><source>Nature</source><volume>503</volume><fpage>224</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1038/nature12744</pub-id><pub-id pub-id-type="pmid">24172905</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonhoeffer</surname><given-names>S</given-names></name><name><surname>Chappey</surname><given-names>C</given-names></name><name><surname>Parkin</surname><given-names>NT</given-names></name><name><surname>Whitcomb</surname><given-names>JM</given-names></name><name><surname>Petropoulos</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Evidence for positive epistasis in HIV-1</article-title><source>Science</source><volume>306</volume><fpage>1547</fpage><lpage>1550</lpage><pub-id pub-id-type="doi">10.1126/science.1101786</pub-id><pub-id pub-id-type="pmid">15567861</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burton</surname><given-names>DR</given-names></name><name><surname>Poignard</surname><given-names>P</given-names></name><name><surname>Stanfield</surname><given-names>RL</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses</article-title><source>Science</source><volume>337</volume><fpage>183</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1126/science.1225416</pub-id><pub-id pub-id-type="pmid">22798606</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burton</surname><given-names>DR</given-names></name><name><surname>Hangartner</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Broadly neutralizing antibodies to HIV and their role in vaccine design</article-title><source>Annual Review of Immunology</source><volume>34</volume><fpage>635</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-041015-055515</pub-id><pub-id pub-id-type="pmid">27168247</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardozo-Ojeda</surname><given-names>EF</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Modeling HIV-1 Within-Host dynamics after passive infusion of the broadly neutralizing antibody VRC01</article-title><source>Frontiers in Immunology</source><volume>12</volume><elocation-id>710012</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.710012</pub-id><pub-id pub-id-type="pmid">34531859</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caskey</surname><given-names>M</given-names></name><name><surname>Klein</surname><given-names>F</given-names></name><name><surname>Lorenzi</surname><given-names>JCC</given-names></name><name><surname>Seaman</surname><given-names>MS</given-names></name><name><surname>West</surname><given-names>AP</given-names><suffix>Jr</suffix></name><name><surname>Buckley</surname><given-names>N</given-names></name><name><surname>Kremer</surname><given-names>G</given-names></name><name><surname>Nogueira</surname><given-names>L</given-names></name><name><surname>Braunschweig</surname><given-names>M</given-names></name><name><surname>Scheid</surname><given-names>JF</given-names></name><name><surname>Horwitz</surname><given-names>JA</given-names></name><name><surname>Shimeliovich</surname><given-names>I</given-names></name><name><surname>Ben-Avraham</surname><given-names>S</given-names></name><name><surname>Witmer-Pack</surname><given-names>M</given-names></name><name><surname>Platten</surname><given-names>M</given-names></name><name><surname>Lehmann</surname><given-names>C</given-names></name><name><surname>Burke</surname><given-names>LA</given-names></name><name><surname>Hawthorne</surname><given-names>T</given-names></name><name><surname>Gorelick</surname><given-names>RJ</given-names></name><name><surname>Walker</surname><given-names>BD</given-names></name><name><surname>Keler</surname><given-names>T</given-names></name><name><surname>Gulick</surname><given-names>RM</given-names></name><name><surname>Fätkenheuer</surname><given-names>G</given-names></name><name><surname>Schlesinger</surname><given-names>SJ</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117</article-title><source>Nature</source><volume>522</volume><fpage>487</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.1038/nature14411</pub-id><pub-id pub-id-type="pmid">25855300</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caskey</surname><given-names>M</given-names></name><name><surname>Klein</surname><given-names>F</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Broadly neutralizing antibodies for HIV-1 prevention or immunotherapy</article-title><source>The New England Journal of Medicine</source><volume>375</volume><fpage>2019</fpage><lpage>2021</lpage><pub-id pub-id-type="doi">10.1056/NEJMp1613362</pub-id><pub-id pub-id-type="pmid">27959740</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caskey</surname><given-names>M</given-names></name><name><surname>Schoofs</surname><given-names>T</given-names></name><name><surname>Gruell</surname><given-names>H</given-names></name><name><surname>Settler</surname><given-names>A</given-names></name><name><surname>Karagounis</surname><given-names>T</given-names></name><name><surname>Kreider</surname><given-names>EF</given-names></name><name><surname>Murrell</surname><given-names>B</given-names></name><name><surname>Pfeifer</surname><given-names>N</given-names></name><name><surname>Nogueira</surname><given-names>L</given-names></name><name><surname>Oliveira</surname><given-names>TY</given-names></name><name><surname>Learn</surname><given-names>GH</given-names></name><name><surname>Cohen</surname><given-names>YZ</given-names></name><name><surname>Lehmann</surname><given-names>C</given-names></name><name><surname>Gillor</surname><given-names>D</given-names></name><name><surname>Shimeliovich</surname><given-names>I</given-names></name><name><surname>Unson-O’Brien</surname><given-names>C</given-names></name><name><surname>Weiland</surname><given-names>D</given-names></name><name><surname>Robles</surname><given-names>A</given-names></name><name><surname>Kümmerle</surname><given-names>T</given-names></name><name><surname>Wyen</surname><given-names>C</given-names></name><name><surname>Levin</surname><given-names>R</given-names></name><name><surname>Witmer-Pack</surname><given-names>M</given-names></name><name><surname>Eren</surname><given-names>K</given-names></name><name><surname>Ignacio</surname><given-names>C</given-names></name><name><surname>Kiss</surname><given-names>S</given-names></name><name><surname>West</surname><given-names>AP</given-names></name><name><surname>Mouquet</surname><given-names>H</given-names></name><name><surname>Zingman</surname><given-names>BS</given-names></name><name><surname>Gulick</surname><given-names>RM</given-names></name><name><surname>Keler</surname><given-names>T</given-names></name><name><surname>Bjorkman</surname><given-names>PJ</given-names></name><name><surname>Seaman</surname><given-names>MS</given-names></name><name><surname>Hahn</surname><given-names>BH</given-names></name><name><surname>Fätkenheuer</surname><given-names>G</given-names></name><name><surname>Schlesinger</surname><given-names>SJ</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name><name><surname>Klein</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Antibody 10-1074 suppresses viremia in HIV-1-infected individuals</article-title><source>Nature Medicine</source><volume>23</volume><fpage>185</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1038/nm.4268</pub-id><pub-id pub-id-type="pmid">28092665</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaillon</surname><given-names>A</given-names></name><name><surname>Gianella</surname><given-names>S</given-names></name><name><surname>Dellicour</surname><given-names>S</given-names></name><name><surname>Rawlings</surname><given-names>SA</given-names></name><name><surname>Schlub</surname><given-names>TE</given-names></name><name><surname>De Oliveira</surname><given-names>MF</given-names></name><name><surname>Ignacio</surname><given-names>C</given-names></name><name><surname>Porrachia</surname><given-names>M</given-names></name><name><surname>Vrancken</surname><given-names>B</given-names></name><name><surname>Smith</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>HIV persists throughout deep tissues with repopulation from multiple anatomical sources</article-title><source>The Journal of Clinical Investigation</source><volume>130</volume><fpage>1699</fpage><lpage>1712</lpage><pub-id pub-id-type="doi">10.1172/JCI134815</pub-id><pub-id pub-id-type="pmid">31910162</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="software"><person-group person-group-type="author"><collab>Chelate</collab></person-group><year iso-8601-date="2022">2022a</year><data-title>HIVTreatmentOptimization</data-title><version designator="swh:1:rev:0194cf6e554996a066633e99dd53cd5901da552e">swh:1:rev:0194cf6e554996a066633e99dd53cd5901da552e</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:776b6f1495f749cd2e687e53359fdde9593b5a47;origin=https://github.com/StatPhysBio/HIVTreatmentOptimization;visit=swh:1:snp:ac91d9b0c04aa7418b4e7a98db0addd24199f914;anchor=swh:1:rev:0194cf6e554996a066633e99dd53cd5901da552e">https://archive.softwareheritage.org/swh:1:dir:776b6f1495f749cd2e687e53359fdde9593b5a47;origin=https://github.com/StatPhysBio/HIVTreatmentOptimization;visit=swh:1:snp:ac91d9b0c04aa7418b4e7a98db0addd24199f914;anchor=swh:1:rev:0194cf6e554996a066633e99dd53cd5901da552e</ext-link></element-citation></ref><ref id="bib15"><element-citation publication-type="software"><person-group person-group-type="author"><collab>Chelate</collab></person-group><year iso-8601-date="2022">2022b</year><data-title>EscapeSimulator</data-title><version designator="swh:1:rev:9a343f598820bafddfc7ea4547cefa90bf96fd6e">swh:1:rev:9a343f598820bafddfc7ea4547cefa90bf96fd6e</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:c6cfa184d349a3272b0211efac8fc1f0f3d398e3;origin=https://github.com/StatPhysBio/EscapeSimulator;visit=swh:1:snp:1727701be1d35fdeb61fdd39bc0a9bbc0c1cb90a;anchor=swh:1:rev:9a343f598820bafddfc7ea4547cefa90bf96fd6e">https://archive.softwareheritage.org/swh:1:dir:c6cfa184d349a3272b0211efac8fc1f0f3d398e3;origin=https://github.com/StatPhysBio/EscapeSimulator;visit=swh:1:snp:1727701be1d35fdeb61fdd39bc0a9bbc0c1cb90a;anchor=swh:1:rev:9a343f598820bafddfc7ea4547cefa90bf96fd6e</ext-link></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Kwon</surname><given-names>YD</given-names></name><name><surname>Zhou</surname><given-names>T</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>O’Dell</surname><given-names>S</given-names></name><name><surname>Cavacini</surname><given-names>L</given-names></name><name><surname>Hessell</surname><given-names>AJ</given-names></name><name><surname>Pancera</surname><given-names>M</given-names></name><name><surname>Tang</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>ZY</given-names></name><name><surname>Zhang</surname><given-names>MY</given-names></name><name><surname>Arthos</surname><given-names>J</given-names></name><name><surname>Burton</surname><given-names>DR</given-names></name><name><surname>Dimitrov</surname><given-names>DS</given-names></name><name><surname>Nabel</surname><given-names>GJ</given-names></name><name><surname>Posner</surname><given-names>MR</given-names></name><name><surname>Sodroski</surname><given-names>J</given-names></name><name><surname>Wyatt</surname><given-names>R</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name><name><surname>Kwong</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120</article-title><source>Science</source><volume>326</volume><fpage>1123</fpage><lpage>1127</lpage><pub-id pub-id-type="doi">10.1126/science.1175868</pub-id><pub-id pub-id-type="pmid">19965434</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chun</surname><given-names>T-W</given-names></name><name><surname>Nickle</surname><given-names>DC</given-names></name><name><surname>Justement</surname><given-names>JS</given-names></name><name><surname>Large</surname><given-names>D</given-names></name><name><surname>Semerjian</surname><given-names>A</given-names></name><name><surname>Curlin</surname><given-names>ME</given-names></name><name><surname>O’Shea</surname><given-names>MA</given-names></name><name><surname>Hallahan</surname><given-names>CW</given-names></name><name><surname>Daucher</surname><given-names>M</given-names></name><name><surname>Ward</surname><given-names>DJ</given-names></name><name><surname>Moir</surname><given-names>S</given-names></name><name><surname>Mullins</surname><given-names>JI</given-names></name><name><surname>Kovacs</surname><given-names>C</given-names></name><name><surname>Fauci</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir</article-title><source>The Journal of Clinical Investigation</source><volume>115</volume><fpage>3250</fpage><lpage>3255</lpage><pub-id pub-id-type="doi">10.1172/JCI26197</pub-id><pub-id pub-id-type="pmid">16276421</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Comeron</surname><given-names>JM</given-names></name><name><surname>Williford</surname><given-names>A</given-names></name><name><surname>Kliman</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The Hill-Robertson effect: evolutionary consequences of weak selection and linkage in finite populations</article-title><source>Heredity</source><volume>100</volume><fpage>19</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1038/sj.hdy.6801059</pub-id><pub-id pub-id-type="pmid">17878920</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Crow</surname><given-names>JF</given-names></name><name><surname>Kimura</surname><given-names>M.</given-names></name></person-group><source>An Introduction to Population Genetics Theory</source><publisher-loc>Caldwell</publisher-loc><publisher-name>The Blackburn Press</publisher-name><year iso-8601-date="2010">2010</year></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dingens</surname><given-names>AS</given-names></name><name><surname>Haddox</surname><given-names>HK</given-names></name><name><surname>Overbaugh</surname><given-names>J</given-names></name><name><surname>Bloom</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Comprehensive mapping of HIV-1 escape from a broadly neutralizing antibody</article-title><source>Cell Host &amp; Microbe</source><volume>21</volume><fpage>777</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2017.05.003</pub-id><pub-id pub-id-type="pmid">28579254</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dingens</surname><given-names>AS</given-names></name><name><surname>Arenz</surname><given-names>D</given-names></name><name><surname>Weight</surname><given-names>H</given-names></name><name><surname>Overbaugh</surname><given-names>J</given-names></name><name><surname>Bloom</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>An antigenic atlas of HIV-1 escape from broadly neutralizing antibodies distinguishes functional and structural epitopes</article-title><source>Immunity</source><volume>50</volume><fpage>520</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2018.12.017</pub-id><pub-id pub-id-type="pmid">30709739</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durham</surname><given-names>ND</given-names></name><name><surname>Agrawal</surname><given-names>A</given-names></name><name><surname>Waltari</surname><given-names>E</given-names></name><name><surname>Croote</surname><given-names>D</given-names></name><name><surname>Zanini</surname><given-names>F</given-names></name><name><surname>Fouch</surname><given-names>M</given-names></name><name><surname>Davidson</surname><given-names>E</given-names></name><name><surname>Smith</surname><given-names>O</given-names></name><name><surname>Carabajal</surname><given-names>E</given-names></name><name><surname>Pak</surname><given-names>JE</given-names></name><name><surname>Doranz</surname><given-names>BJ</given-names></name><name><surname>Robinson</surname><given-names>M</given-names></name><name><surname>Sanz</surname><given-names>AM</given-names></name><name><surname>Albornoz</surname><given-names>LL</given-names></name><name><surname>Rosso</surname><given-names>F</given-names></name><name><surname>Einav</surname><given-names>S</given-names></name><name><surname>Quake</surname><given-names>SR</given-names></name><name><surname>McCutcheon</surname><given-names>KM</given-names></name><name><surname>Goo</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics</article-title><source>eLife</source><volume>8</volume><elocation-id>e52384</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.52384</pub-id><pub-id pub-id-type="pmid">31820734</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekiert</surname><given-names>DC</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Broadly neutralizing antibodies against influenza virus and prospects for universal therapies</article-title><source>Current Opinion in Virology</source><volume>2</volume><fpage>134</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2012.02.005</pub-id><pub-id pub-id-type="pmid">22482710</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekström</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Alternatives to maximum likelihood estimation based on spacings and the Kullback–Leibler divergence</article-title><source>Journal of Statistical Planning and Inference</source><volume>138</volume><fpage>1778</fpage><lpage>1791</lpage><pub-id pub-id-type="doi">10.1016/j.jspi.2007.06.031</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feder</surname><given-names>AF</given-names></name><name><surname>Rhee</surname><given-names>SY</given-names></name><name><surname>Holmes</surname><given-names>SP</given-names></name><name><surname>Shafer</surname><given-names>RW</given-names></name><name><surname>Petrov</surname><given-names>DA</given-names></name><name><surname>Pennings</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>More effective drugs lead to harder selective sweeps in the evolution of drug resistance in HIV-1</article-title><source>eLife</source><volume>5</volume><elocation-id>e10670</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.10670</pub-id><pub-id pub-id-type="pmid">26882502</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feder</surname><given-names>AF</given-names></name><name><surname>Kline</surname><given-names>C</given-names></name><name><surname>Polacino</surname><given-names>P</given-names></name><name><surname>Cottrell</surname><given-names>M</given-names></name><name><surname>Kashuba</surname><given-names>ADM</given-names></name><name><surname>Keele</surname><given-names>BF</given-names></name><name><surname>Hu</surname><given-names>SL</given-names></name><name><surname>Petrov</surname><given-names>DA</given-names></name><name><surname>Pennings</surname><given-names>PS</given-names></name><name><surname>Ambrose</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A spatio-temporal assessment of simian/human immunodeficiency virus (SHIV) evolution reveals A highly dynamic process within the host</article-title><source>PLOS Pathogens</source><volume>13</volume><elocation-id>e1006358</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006358</pub-id><pub-id pub-id-type="pmid">28542550</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feder</surname><given-names>AF</given-names></name><name><surname>Pennings</surname><given-names>PS</given-names></name><name><surname>Petrov</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The clarifying role of time series data in the population genetics of HIV</article-title><source>PLOS Genetics</source><volume>17</volume><elocation-id>e1009050</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1009050</pub-id><pub-id pub-id-type="pmid">33444376</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferguson</surname><given-names>AL</given-names></name><name><surname>Mann</surname><given-names>JK</given-names></name><name><surname>Omarjee</surname><given-names>S</given-names></name><name><surname>Ndung’u</surname><given-names>T</given-names></name><name><surname>Walker</surname><given-names>BD</given-names></name><name><surname>Chakraborty</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Translating HIV sequences into quantitative fitness landscapes predicts viral vulnerabilities for rational immunogen design</article-title><source>Immunity</source><volume>38</volume><fpage>606</fpage><lpage>617</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.11.022</pub-id><pub-id pub-id-type="pmid">23521886</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>RA.</given-names></name></person-group><source>Statistical Methods for Research Workers</source><edition>Twelfth ed</edition><publisher-loc>New York</publisher-loc><publisher-name>Hafner Publishing</publisher-name><year iso-8601-date="1954">1954</year></element-citation></ref><ref id="bib30"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="1956">1956</year><source>Statistical Methods and Scientific Inference</source><publisher-loc>London</publisher-loc><publisher-name>Oliver and Boyd</publisher-name></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>García</surname><given-names>F</given-names></name><name><surname>Plana</surname><given-names>M</given-names></name><name><surname>Vidal</surname><given-names>C</given-names></name><name><surname>Cruceta</surname><given-names>A</given-names></name><name><surname>O’Brien</surname><given-names>WA</given-names></name><name><surname>Pantaleo</surname><given-names>G</given-names></name><name><surname>Pumarola</surname><given-names>T</given-names></name><name><surname>Gallart</surname><given-names>T</given-names></name><name><surname>Miró</surname><given-names>JM</given-names></name><name><surname>Gatell</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy</article-title><source>AIDS</source><volume>13</volume><fpage>F79</fpage><lpage>F86</lpage><pub-id pub-id-type="doi">10.1097/00002030-199907300-00002</pub-id><pub-id pub-id-type="pmid">10449278</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>García</surname><given-names>F</given-names></name><name><surname>Plana</surname><given-names>M</given-names></name><name><surname>Ortiz</surname><given-names>GM</given-names></name><name><surname>Bonhoeffer</surname><given-names>S</given-names></name><name><surname>Soriano</surname><given-names>A</given-names></name><name><surname>Vidal</surname><given-names>C</given-names></name><name><surname>Cruceta</surname><given-names>A</given-names></name><name><surname>Arnedo</surname><given-names>M</given-names></name><name><surname>Gil</surname><given-names>C</given-names></name><name><surname>Pantaleo</surname><given-names>G</given-names></name><name><surname>Pumarola</surname><given-names>T</given-names></name><name><surname>Gallart</surname><given-names>T</given-names></name><name><surname>Nixon</surname><given-names>DF</given-names></name><name><surname>Miró</surname><given-names>JM</given-names></name><name><surname>Gatell</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection</article-title><source>AIDS</source><volume>15</volume><fpage>F29</fpage><lpage>F40</lpage><pub-id pub-id-type="doi">10.1097/00002030-200106150-00002</pub-id><pub-id pub-id-type="pmid">11416735</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaschen</surname><given-names>B</given-names></name><name><surname>Kuiken</surname><given-names>C</given-names></name><name><surname>Korber</surname><given-names>B</given-names></name><name><surname>Foley</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Retrieval and on-the-fly alignment of sequence fragments from the HIV database</article-title><source>Bioinformatics</source><volume>17</volume><fpage>415</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/17.5.415</pub-id><pub-id pub-id-type="pmid">11331235</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geman</surname><given-names>S</given-names></name><name><surname>Geman</surname><given-names>D</given-names></name></person-group><year iso-8601-date="1984">1984</year><article-title>Stochastic relaxation, gibbs distributions, and the bayesian restoration of images</article-title><source>IEEE Transactions on Pattern Analysis and Machine Intelligence</source><volume>6</volume><fpage>721</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.1109/tpami.1984.4767596</pub-id><pub-id pub-id-type="pmid">22499653</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillespie</surname><given-names>DT</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Exact stochastic simulation of coupled chemical reactions</article-title><source>The Journal of Physical Chemistry</source><volume>81</volume><fpage>2340</fpage><lpage>2361</lpage><pub-id pub-id-type="doi">10.1021/j100540a008</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>RL</given-names></name><name><surname>Knuth</surname><given-names>DE</given-names></name><name><surname>Patashnik</surname><given-names>O</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Concrete mathematics: A foundation for computer science</article-title><source>Computers in Physics</source><volume>3</volume><elocation-id>106</elocation-id><pub-id pub-id-type="doi">10.1063/1.4822863</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gruell</surname><given-names>H</given-names></name><name><surname>Klein</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Antibody-mediated prevention and treatment of HIV-1 infection</article-title><source>Retrovirology</source><volume>15</volume><elocation-id>73</elocation-id><pub-id pub-id-type="doi">10.1186/s12977-018-0455-9</pub-id><pub-id pub-id-type="pmid">30445968</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haddox</surname><given-names>HK</given-names></name><name><surname>Dingens</surname><given-names>AS</given-names></name><name><surname>Hilton</surname><given-names>SK</given-names></name><name><surname>Overbaugh</surname><given-names>J</given-names></name><name><surname>Bloom</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mapping mutational effects along the evolutionary landscape of HIV envelope</article-title><source>eLife</source><volume>7</volume><elocation-id>e34420</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.34420</pub-id><pub-id pub-id-type="pmid">29590010</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hastings</surname><given-names>WK</given-names></name></person-group><year iso-8601-date="1970">1970</year><article-title>Monte Carlo sampling methods using Markov chains and their applications</article-title><source>Biometrika</source><volume>57</volume><fpage>97</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1093/biomet/57.1.97</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>WG</given-names></name><name><surname>Robertson</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The effect of linkage on limits to artificial selection</article-title><source>Genetical Research</source><volume>8</volume><fpage>269</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1017/S0016672300010156</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horwitz</surname><given-names>JA</given-names></name><name><surname>Halper-Stromberg</surname><given-names>A</given-names></name><name><surname>Mouquet</surname><given-names>H</given-names></name><name><surname>Gitlin</surname><given-names>AD</given-names></name><name><surname>Tretiakova</surname><given-names>A</given-names></name><name><surname>Eisenreich</surname><given-names>TR</given-names></name><name><surname>Malbec</surname><given-names>M</given-names></name><name><surname>Gravemann</surname><given-names>S</given-names></name><name><surname>Billerbeck</surname><given-names>E</given-names></name><name><surname>Dorner</surname><given-names>M</given-names></name><name><surname>Büning</surname><given-names>H</given-names></name><name><surname>Schwartz</surname><given-names>O</given-names></name><name><surname>Knops</surname><given-names>E</given-names></name><name><surname>Kaiser</surname><given-names>R</given-names></name><name><surname>Seaman</surname><given-names>MS</given-names></name><name><surname>Wilson</surname><given-names>JM</given-names></name><name><surname>Rice</surname><given-names>CM</given-names></name><name><surname>Ploss</surname><given-names>A</given-names></name><name><surname>Bjorkman</surname><given-names>PJ</given-names></name><name><surname>Klein</surname><given-names>F</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice</article-title><source>PNAS</source><volume>110</volume><fpage>16538</fpage><lpage>16543</lpage><pub-id pub-id-type="doi">10.1073/pnas.1315295110</pub-id><pub-id pub-id-type="pmid">24043801</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Illingworth</surname><given-names>CJR</given-names></name><name><surname>Raghwani</surname><given-names>J</given-names></name><name><surname>Serwadda</surname><given-names>D</given-names></name><name><surname>Sewankambo</surname><given-names>NK</given-names></name><name><surname>Robb</surname><given-names>ML</given-names></name><name><surname>Eller</surname><given-names>MA</given-names></name><name><surname>Redd</surname><given-names>AR</given-names></name><name><surname>Quinn</surname><given-names>TC</given-names></name><name><surname>Lythgoe</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A de novo approach to inferring within-host fitness effects during untreated HIV-1 infection</article-title><source>PLOS Pathogens</source><volume>16</volume><elocation-id>e1008171</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1008171</pub-id><pub-id pub-id-type="pmid">32492061</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ioannidis</surname><given-names>JP</given-names></name><name><surname>Havlir</surname><given-names>DV</given-names></name><name><surname>Tebas</surname><given-names>P</given-names></name><name><surname>Hirsch</surname><given-names>MS</given-names></name><name><surname>Collier</surname><given-names>AC</given-names></name><name><surname>Richman</surname><given-names>DD</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication</article-title><source>AIDS</source><volume>14</volume><fpage>1481</fpage><lpage>1488</lpage><pub-id pub-id-type="doi">10.1097/00002030-200007280-00003</pub-id><pub-id pub-id-type="pmid">10983634</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Julg</surname><given-names>B</given-names></name><name><surname>Pegu</surname><given-names>A</given-names></name><name><surname>Abbink</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Brinkman</surname><given-names>A</given-names></name><name><surname>Molloy</surname><given-names>K</given-names></name><name><surname>Mojta</surname><given-names>S</given-names></name><name><surname>Chandrashekar</surname><given-names>A</given-names></name><name><surname>Callow</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Schmidt</surname><given-names>SD</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Koup</surname><given-names>RA</given-names></name><name><surname>Seaman</surname><given-names>MS</given-names></name><name><surname>Keele</surname><given-names>BF</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name><name><surname>Connors</surname><given-names>M</given-names></name><name><surname>Barouch</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Virological control by the CD4-Binding site antibody n6 in simian-human immunodeficiency virus-infected rhesus monkeys</article-title><source>Journal of Virology</source><volume>91</volume><elocation-id>e00498-17</elocation-id><pub-id pub-id-type="doi">10.1128/JVI.00498-17</pub-id><pub-id pub-id-type="pmid">28539448</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1981">1981</year><article-title>Estimation of evolutionary distances between homologous nucleotide sequences</article-title><source>PNAS</source><volume>78</volume><fpage>454</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1073/pnas.78.1.454</pub-id><pub-id pub-id-type="pmid">6165991</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>F</given-names></name><name><surname>Halper-Stromberg</surname><given-names>A</given-names></name><name><surname>Horwitz</surname><given-names>JA</given-names></name><name><surname>Gruell</surname><given-names>H</given-names></name><name><surname>Scheid</surname><given-names>JF</given-names></name><name><surname>Bournazos</surname><given-names>S</given-names></name><name><surname>Mouquet</surname><given-names>H</given-names></name><name><surname>Spatz</surname><given-names>LA</given-names></name><name><surname>Diskin</surname><given-names>R</given-names></name><name><surname>Abadir</surname><given-names>A</given-names></name><name><surname>Zang</surname><given-names>T</given-names></name><name><surname>Dorner</surname><given-names>M</given-names></name><name><surname>Billerbeck</surname><given-names>E</given-names></name><name><surname>Labitt</surname><given-names>RN</given-names></name><name><surname>Gaebler</surname><given-names>C</given-names></name><name><surname>Marcovecchio</surname><given-names>P</given-names></name><name><surname>Incesu</surname><given-names>RB</given-names></name><name><surname>Eisenreich</surname><given-names>TR</given-names></name><name><surname>Bieniasz</surname><given-names>PD</given-names></name><name><surname>Seaman</surname><given-names>MS</given-names></name><name><surname>Bjorkman</surname><given-names>PJ</given-names></name><name><surname>Ravetch</surname><given-names>JV</given-names></name><name><surname>Ploss</surname><given-names>A</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>HIV therapy by a combination of broadly neutralizing antibodies in humanized mice</article-title><source>Nature</source><volume>492</volume><fpage>118</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1038/nature11604</pub-id><pub-id pub-id-type="pmid">23103874</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>F</given-names></name><name><surname>Mouquet</surname><given-names>H</given-names></name><name><surname>Dosenovic</surname><given-names>P</given-names></name><name><surname>Scheid</surname><given-names>JF</given-names></name><name><surname>Scharf</surname><given-names>L</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Antibodies in HIV-1 vaccine development and therapy</article-title><source>Science</source><volume>341</volume><fpage>1199</fpage><lpage>1204</lpage><pub-id pub-id-type="doi">10.1126/science.1241144</pub-id><pub-id pub-id-type="pmid">24031012</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>R</given-names></name><name><surname>Louder</surname><given-names>MK</given-names></name><name><surname>Wagh</surname><given-names>K</given-names></name><name><surname>Bailer</surname><given-names>RT</given-names></name><name><surname>deCamp</surname><given-names>A</given-names></name><name><surname>Greene</surname><given-names>K</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Taft</surname><given-names>JD</given-names></name><name><surname>Gazumyan</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name><name><surname>Korber</surname><given-names>B</given-names></name><name><surname>Montefiori</surname><given-names>DC</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes</article-title><source>Journal of Virology</source><volume>89</volume><fpage>2659</fpage><lpage>2671</lpage><pub-id pub-id-type="doi">10.1128/JVI.03136-14</pub-id><pub-id pub-id-type="pmid">25520506</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>YD</given-names></name><name><surname>Georgiev</surname><given-names>IS</given-names></name><name><surname>Ofek</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Asokan</surname><given-names>M</given-names></name><name><surname>Bailer</surname><given-names>RT</given-names></name><name><surname>Bao</surname><given-names>A</given-names></name><name><surname>Caruso</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Choe</surname><given-names>M</given-names></name><name><surname>Druz</surname><given-names>A</given-names></name><name><surname>Ko</surname><given-names>S-Y</given-names></name><name><surname>Louder</surname><given-names>MK</given-names></name><name><surname>McKee</surname><given-names>K</given-names></name><name><surname>O’Dell</surname><given-names>S</given-names></name><name><surname>Pegu</surname><given-names>A</given-names></name><name><surname>Rudicell</surname><given-names>RS</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Alger</surname><given-names>M</given-names></name><name><surname>Bender</surname><given-names>MF</given-names></name><name><surname>Carlton</surname><given-names>K</given-names></name><name><surname>Cooper</surname><given-names>JW</given-names></name><name><surname>Blinn</surname><given-names>J</given-names></name><name><surname>Eudailey</surname><given-names>J</given-names></name><name><surname>Lloyd</surname><given-names>K</given-names></name><name><surname>Parks</surname><given-names>R</given-names></name><name><surname>Alam</surname><given-names>SM</given-names></name><name><surname>Haynes</surname><given-names>BF</given-names></name><name><surname>Padte</surname><given-names>NN</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Ho</surname><given-names>DD</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Connors</surname><given-names>M</given-names></name><name><surname>Schwartz</surname><given-names>RM</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name><name><surname>Kwong</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Optimization of the solubility of HIV-1-Neutralizing antibody 10E8 through somatic variation and structure-based design</article-title><source>Journal of Virology</source><volume>90</volume><fpage>5899</fpage><lpage>5914</lpage><pub-id pub-id-type="doi">10.1128/JVI.03246-15</pub-id><pub-id pub-id-type="pmid">27053554</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwong</surname><given-names>PD</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name><name><surname>Nabel</surname><given-names>GJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning</article-title><source>Nature Reviews Immunology</source><volume>13</volume><fpage>693</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1038/nri3516</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LaBranche</surname><given-names>CC</given-names></name><name><surname>McGuire</surname><given-names>AT</given-names></name><name><surname>Gray</surname><given-names>MD</given-names></name><name><surname>Behrens</surname><given-names>S</given-names></name><name><surname>Kwong</surname><given-names>PD</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>T</given-names></name><name><surname>Sattentau</surname><given-names>QJ</given-names></name><name><surname>Peacock</surname><given-names>J</given-names></name><name><surname>Eaton</surname><given-names>A</given-names></name><name><surname>Greene</surname><given-names>K</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Perez</surname><given-names>LG</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Saunders</surname><given-names>KO</given-names></name><name><surname>Kwong</surname><given-names>PD</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name><name><surname>Haynes</surname><given-names>BF</given-names></name><name><surname>Stamatatos</surname><given-names>L</given-names></name><name><surname>Montefiori</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies</article-title><source>PLOS Pathogens</source><volume>14</volume><elocation-id>e1007431</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1007431</pub-id><pub-id pub-id-type="pmid">30395637</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemey</surname><given-names>P</given-names></name><name><surname>Rambaut</surname><given-names>A</given-names></name><name><surname>Pybus</surname><given-names>OG</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>HIV evolutionary dynamics within and among hosts</article-title><source>AIDS Reviews</source><volume>8</volume><fpage>125</fpage><lpage>140</lpage><pub-id pub-id-type="pmid">17078483</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>H-X</given-names></name><name><surname>Lynch</surname><given-names>R</given-names></name><name><surname>Zhou</surname><given-names>T</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Alam</surname><given-names>SM</given-names></name><name><surname>Boyd</surname><given-names>SD</given-names></name><name><surname>Fire</surname><given-names>AZ</given-names></name><name><surname>Roskin</surname><given-names>KM</given-names></name><name><surname>Schramm</surname><given-names>CA</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Shapiro</surname><given-names>L</given-names></name><collab>NISC Comparative Sequencing Program</collab><name><surname>Mullikin</surname><given-names>JC</given-names></name><name><surname>Gnanakaran</surname><given-names>S</given-names></name><name><surname>Hraber</surname><given-names>P</given-names></name><name><surname>Wiehe</surname><given-names>K</given-names></name><name><surname>Kelsoe</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Xia</surname><given-names>S-M</given-names></name><name><surname>Montefiori</surname><given-names>DC</given-names></name><name><surname>Parks</surname><given-names>R</given-names></name><name><surname>Lloyd</surname><given-names>KE</given-names></name><name><surname>Scearce</surname><given-names>RM</given-names></name><name><surname>Soderberg</surname><given-names>KA</given-names></name><name><surname>Cohen</surname><given-names>M</given-names></name><name><surname>Kamanga</surname><given-names>G</given-names></name><name><surname>Louder</surname><given-names>MK</given-names></name><name><surname>Tran</surname><given-names>LM</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Moquin</surname><given-names>S</given-names></name><name><surname>Du</surname><given-names>X</given-names></name><name><surname>Joyce</surname><given-names>MG</given-names></name><name><surname>Srivatsan</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Zheng</surname><given-names>A</given-names></name><name><surname>Shaw</surname><given-names>GM</given-names></name><name><surname>Hahn</surname><given-names>BH</given-names></name><name><surname>Kepler</surname><given-names>TB</given-names></name><name><surname>Korber</surname><given-names>BTM</given-names></name><name><surname>Kwong</surname><given-names>PD</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name><name><surname>Haynes</surname><given-names>BF</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus</article-title><source>Nature</source><volume>496</volume><fpage>469</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1038/nature12053</pub-id><pub-id pub-id-type="pmid">23552890</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lienhardt</surname><given-names>C</given-names></name><name><surname>Raviglione</surname><given-names>M</given-names></name><name><surname>Spigelman</surname><given-names>M</given-names></name><name><surname>Hafner</surname><given-names>R</given-names></name><name><surname>Jaramillo</surname><given-names>E</given-names></name><name><surname>Hoelscher</surname><given-names>M</given-names></name><name><surname>Zumla</surname><given-names>A</given-names></name><name><surname>Gheuens</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future</article-title><source>The Journal of Infectious Diseases</source><volume>205</volume><fpage>S241</fpage><lpage>S249</lpage><pub-id pub-id-type="doi">10.1093/infdis/jis034</pub-id><pub-id pub-id-type="pmid">22448022</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindsay</surname><given-names>BG</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Efficiency versus robustness: the case for minimum hellinger distance and related methods</article-title><source>The Annals of Statistics</source><volume>22</volume><fpage>1081</fpage><lpage>1114</lpage><pub-id pub-id-type="doi">10.1214/aos/1176325512</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Development of CAR-T cells for long-term eradication and surveillance of HIV-1 reservoir</article-title><source>Current Opinion in Virology</source><volume>38</volume><fpage>21</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2019.04.004</pub-id><pub-id pub-id-type="pmid">31132749</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louie</surname><given-names>RHY</given-names></name><name><surname>Kaczorowski</surname><given-names>KJ</given-names></name><name><surname>Barton</surname><given-names>JP</given-names></name><name><surname>Chakraborty</surname><given-names>AK</given-names></name><name><surname>McKay</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Fitness landscape of the human immunodeficiency virus envelope protein that is targeted by antibodies</article-title><source>PNAS</source><volume>115</volume><fpage>E564</fpage><lpage>E573</lpage><pub-id pub-id-type="doi">10.1073/pnas.1717765115</pub-id><pub-id pub-id-type="pmid">29311326</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>CL</given-names></name><name><surname>Murakowski</surname><given-names>DK</given-names></name><name><surname>Bournazos</surname><given-names>S</given-names></name><name><surname>Schoofs</surname><given-names>T</given-names></name><name><surname>Sarkar</surname><given-names>D</given-names></name><name><surname>Halper-Stromberg</surname><given-names>A</given-names></name><name><surname>Horwitz</surname><given-names>JA</given-names></name><name><surname>Nogueira</surname><given-names>L</given-names></name><name><surname>Golijanin</surname><given-names>J</given-names></name><name><surname>Gazumyan</surname><given-names>A</given-names></name><name><surname>Ravetch</surname><given-names>JV</given-names></name><name><surname>Caskey</surname><given-names>M</given-names></name><name><surname>Chakraborty</surname><given-names>AK</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo</article-title><source>Science</source><volume>352</volume><fpage>1001</fpage><lpage>1004</lpage><pub-id pub-id-type="doi">10.1126/science.aaf1279</pub-id><pub-id pub-id-type="pmid">27199430</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>RM</given-names></name><name><surname>Wong</surname><given-names>P</given-names></name><name><surname>Tran</surname><given-names>L</given-names></name><name><surname>O’Dell</surname><given-names>S</given-names></name><name><surname>Nason</surname><given-names>MC</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies</article-title><source>Journal of Virology</source><volume>89</volume><fpage>4201</fpage><lpage>4213</lpage><pub-id pub-id-type="doi">10.1128/JVI.03608-14</pub-id><pub-id pub-id-type="pmid">25631091</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Margolis</surname><given-names>DM</given-names></name><name><surname>Koup</surname><given-names>RA</given-names></name><name><surname>Ferrari</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>HIV antibodies for treatment of HIV infection</article-title><source>Immunological Reviews</source><volume>275</volume><fpage>313</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1111/imr.12506</pub-id><pub-id pub-id-type="pmid">28133794</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayer</surname><given-names>BT</given-names></name><name><surname>deCamp</surname><given-names>AC</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Schiffer</surname><given-names>JT</given-names></name><name><surname>Gottardo</surname><given-names>R</given-names></name><name><surname>Gilbert</surname><given-names>PB</given-names></name><name><surname>Reeves</surname><given-names>DB</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention</article-title><source>PLOS Computational Biology</source><volume>18</volume><elocation-id>e1010003</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1010003</pub-id><pub-id pub-id-type="pmid">35385469</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>McCullagh</surname><given-names>P</given-names></name><name><surname>Nelder</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2019">2019</year><source>Generalized Linear Models</source><publisher-loc>Boca Raton</publisher-loc><publisher-name>Routledge</publisher-name><pub-id pub-id-type="doi">10.1201/9780203753736</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meijers</surname><given-names>M</given-names></name><name><surname>Vanshylla</surname><given-names>K</given-names></name><name><surname>Gruell</surname><given-names>H</given-names></name><name><surname>Klein</surname><given-names>F</given-names></name><name><surname>Lässig</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Predicting in vivo escape dynamics of HIV-1 from a broadly neutralizing antibody</article-title><source>PNAS</source><volume>118</volume><elocation-id>e2104651118</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2104651118</pub-id><pub-id pub-id-type="pmid">34301904</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meintjes</surname><given-names>PL</given-names></name><name><surname>Rodrigo</surname><given-names>AG</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Evolution of relative synonymous codon usage in Human Immunodeficiency Virus type-1</article-title><source>Journal of Bioinformatics and Computational Biology</source><volume>3</volume><fpage>157</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1142/s0219720005000953</pub-id><pub-id pub-id-type="pmid">15751118</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendoza</surname><given-names>P</given-names></name><name><surname>Gruell</surname><given-names>H</given-names></name><name><surname>Nogueira</surname><given-names>L</given-names></name><name><surname>Pai</surname><given-names>JA</given-names></name><name><surname>Butler</surname><given-names>AL</given-names></name><name><surname>Millard</surname><given-names>K</given-names></name><name><surname>Lehmann</surname><given-names>C</given-names></name><name><surname>Suárez</surname><given-names>I</given-names></name><name><surname>Oliveira</surname><given-names>TY</given-names></name><name><surname>Lorenzi</surname><given-names>JCC</given-names></name><name><surname>Cohen</surname><given-names>YZ</given-names></name><name><surname>Wyen</surname><given-names>C</given-names></name><name><surname>Kümmerle</surname><given-names>T</given-names></name><name><surname>Karagounis</surname><given-names>T</given-names></name><name><surname>Lu</surname><given-names>C-L</given-names></name><name><surname>Handl</surname><given-names>L</given-names></name><name><surname>Unson-O’Brien</surname><given-names>C</given-names></name><name><surname>Patel</surname><given-names>R</given-names></name><name><surname>Ruping</surname><given-names>C</given-names></name><name><surname>Schlotz</surname><given-names>M</given-names></name><name><surname>Witmer-Pack</surname><given-names>M</given-names></name><name><surname>Shimeliovich</surname><given-names>I</given-names></name><name><surname>Kremer</surname><given-names>G</given-names></name><name><surname>Thomas</surname><given-names>E</given-names></name><name><surname>Seaton</surname><given-names>KE</given-names></name><name><surname>Horowitz</surname><given-names>J</given-names></name><name><surname>West</surname><given-names>AP</given-names><suffix>Jr</suffix></name><name><surname>Bjorkman</surname><given-names>PJ</given-names></name><name><surname>Tomaras</surname><given-names>GD</given-names></name><name><surname>Gulick</surname><given-names>RM</given-names></name><name><surname>Pfeifer</surname><given-names>N</given-names></name><name><surname>Fätkenheuer</surname><given-names>G</given-names></name><name><surname>Seaman</surname><given-names>MS</given-names></name><name><surname>Klein</surname><given-names>F</given-names></name><name><surname>Caskey</surname><given-names>M</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Combination therapy with anti-HIV-1 antibodies maintains viral suppression</article-title><source>Nature</source><volume>561</volume><fpage>479</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0531-2</pub-id><pub-id pub-id-type="pmid">30258136</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mouquet</surname><given-names>H</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>HIV: Roadmaps to a vaccine</article-title><source>Nature</source><volume>496</volume><fpage>441</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1038/nature12091</pub-id><pub-id pub-id-type="pmid">23552894</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neher</surname><given-names>RA</given-names></name><name><surname>Leitner</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Recombination rate and selection strength in HIV intra-patient evolution</article-title><source>PLOS Computational Biology</source><volume>6</volume><elocation-id>e1000660</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1000660</pub-id><pub-id pub-id-type="pmid">20126527</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2006">2006</year><source>Statistical Methods in Molecular Evolution</source><publisher-loc>New York</publisher-loc><publisher-name>Springer</publisher-name><pub-id pub-id-type="doi">10.1007/0-387-27733-1</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nourmohammad</surname><given-names>A</given-names></name><name><surname>Otwinowski</surname><given-names>J</given-names></name><name><surname>Plotkin</surname><given-names>JB</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Host-Pathogen coevolution and the emergence of broadly neutralizing antibodies in chronic infections</article-title><source>PLOS Genetics</source><volume>12</volume><elocation-id>e1006171</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1006171</pub-id><pub-id pub-id-type="pmid">27442127</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nourmohammad</surname><given-names>A</given-names></name><name><surname>Otwinowski</surname><given-names>J</given-names></name><name><surname>Łuksza</surname><given-names>M</given-names></name><name><surname>Mora</surname><given-names>T</given-names></name><name><surname>Walczak</surname><given-names>AM</given-names></name><name><surname>Leitner</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Fierce selection and interference in b-cell repertoire response to chronic HIV-1</article-title><source>Molecular Biology and Evolution</source><volume>36</volume><fpage>2184</fpage><lpage>2194</lpage><pub-id pub-id-type="doi">10.1093/molbev/msz143</pub-id><pub-id pub-id-type="pmid">31209469</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otsuka</surname><given-names>Y</given-names></name><name><surname>Schmitt</surname><given-names>K</given-names></name><name><surname>Quinlan</surname><given-names>BD</given-names></name><name><surname>Gardner</surname><given-names>MR</given-names></name><name><surname>Alfant</surname><given-names>B</given-names></name><name><surname>Reich</surname><given-names>A</given-names></name><name><surname>Farzan</surname><given-names>M</given-names></name><name><surname>Choe</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Diverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodies</article-title><source>PLOS Pathogens</source><volume>14</volume><elocation-id>e1007238</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1007238</pub-id><pub-id pub-id-type="pmid">30125330</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owen</surname><given-names>A</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Safe and effective importance sampling</article-title><source>Journal of the American Statistical Association</source><volume>95</volume><fpage>135</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1080/01621459.2000.10473909</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pancera</surname><given-names>M</given-names></name><name><surname>Changela</surname><given-names>A</given-names></name><name><surname>Kwong</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design</article-title><source>Current Opinion in HIV and AIDS</source><volume>12</volume><fpage>229</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1097/COH.0000000000000360</pub-id><pub-id pub-id-type="pmid">28422787</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perelson</surname><given-names>AS</given-names></name><name><surname>Neumann</surname><given-names>AU</given-names></name><name><surname>Markowitz</surname><given-names>M</given-names></name><name><surname>Leonard</surname><given-names>JM</given-names></name><name><surname>Ho</surname><given-names>DD</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time</article-title><source>Science</source><volume>271</volume><fpage>1582</fpage><lpage>1586</lpage><pub-id pub-id-type="doi">10.1126/science.271.5255.1582</pub-id><pub-id pub-id-type="pmid">8599114</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perelson</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Modelling viral and immune system dynamics</article-title><source>Nature Reviews. Immunology</source><volume>2</volume><fpage>28</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1038/nri700</pub-id><pub-id pub-id-type="pmid">11905835</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reeves</surname><given-names>DB</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Duke</surname><given-names>ER</given-names></name><name><surname>Mayer</surname><given-names>BT</given-names></name><name><surname>Cardozo-Ojeda</surname><given-names>EF</given-names></name><name><surname>Boshier</surname><given-names>FA</given-names></name><name><surname>Swan</surname><given-names>DA</given-names></name><name><surname>Rolland</surname><given-names>M</given-names></name><name><surname>Robb</surname><given-names>ML</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name><name><surname>Cohen</surname><given-names>MS</given-names></name><name><surname>Corey</surname><given-names>L</given-names></name><name><surname>Gilbert</surname><given-names>PB</given-names></name><name><surname>Schiffer</surname><given-names>JT</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials</article-title><source>PLOS Computational Biology</source><volume>16</volume><elocation-id>e1007626</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1007626</pub-id><pub-id pub-id-type="pmid">32084132</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro</surname><given-names>RM</given-names></name><name><surname>Bonhoeffer</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Production of resistant HIV mutants during antiretroviral therapy</article-title><source>PNAS</source><volume>97</volume><fpage>7681</fpage><lpage>7686</lpage><pub-id pub-id-type="doi">10.1073/pnas.97.14.7681</pub-id><pub-id pub-id-type="pmid">10884399</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Risken</surname><given-names>H</given-names></name></person-group><year iso-8601-date="1989">1989</year><source>The Fokker-Planck Equation</source><publisher-loc>Berlin, Heidelberg</publisher-loc><publisher-name>Springer-Verlag</publisher-name><pub-id pub-id-type="doi">10.1007/978-3-642-61544-3</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rong</surname><given-names>L</given-names></name><name><surname>Feng</surname><given-names>Z</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Emergence of HIV-1 drug resistance during antiretroviral treatment</article-title><source>Bulletin of Mathematical Biology</source><volume>69</volume><fpage>2027</fpage><lpage>2060</lpage><pub-id pub-id-type="doi">10.1007/s11538-007-9203-3</pub-id><pub-id pub-id-type="pmid">17450401</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rong</surname><given-names>L</given-names></name><name><surname>Dahari</surname><given-names>H</given-names></name><name><surname>Ribeiro</surname><given-names>RM</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Rapid emergence of protease inhibitor resistance in hepatitis C virus</article-title><source>Science Translational Medicine</source><volume>2</volume><elocation-id>30ra32</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.3000544</pub-id><pub-id pub-id-type="pmid">20445200</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saha</surname><given-names>A</given-names></name><name><surname>Dixit</surname><given-names>NM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Pre-existing resistance in the latent reservoir can compromise VRC01 therapy during chronic HIV-1 infection</article-title><source>PLOS Computational Biology</source><volume>16</volume><elocation-id>11</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1008434</pub-id><pub-id pub-id-type="pmid">33253162</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheid</surname><given-names>JF</given-names></name><name><surname>Horwitz</surname><given-names>JA</given-names></name><name><surname>Bar-On</surname><given-names>Y</given-names></name><name><surname>Kreider</surname><given-names>EF</given-names></name><name><surname>Lu</surname><given-names>C-L</given-names></name><name><surname>Lorenzi</surname><given-names>JCC</given-names></name><name><surname>Feldmann</surname><given-names>A</given-names></name><name><surname>Braunschweig</surname><given-names>M</given-names></name><name><surname>Nogueira</surname><given-names>L</given-names></name><name><surname>Oliveira</surname><given-names>T</given-names></name><name><surname>Shimeliovich</surname><given-names>I</given-names></name><name><surname>Patel</surname><given-names>R</given-names></name><name><surname>Burke</surname><given-names>L</given-names></name><name><surname>Cohen</surname><given-names>YZ</given-names></name><name><surname>Hadrigan</surname><given-names>S</given-names></name><name><surname>Settler</surname><given-names>A</given-names></name><name><surname>Witmer-Pack</surname><given-names>M</given-names></name><name><surname>West</surname><given-names>AP</given-names><suffix>Jr</suffix></name><name><surname>Juelg</surname><given-names>B</given-names></name><name><surname>Keler</surname><given-names>T</given-names></name><name><surname>Hawthorne</surname><given-names>T</given-names></name><name><surname>Zingman</surname><given-names>B</given-names></name><name><surname>Gulick</surname><given-names>RM</given-names></name><name><surname>Pfeifer</surname><given-names>N</given-names></name><name><surname>Learn</surname><given-names>GH</given-names></name><name><surname>Seaman</surname><given-names>MS</given-names></name><name><surname>Bjorkman</surname><given-names>PJ</given-names></name><name><surname>Klein</surname><given-names>F</given-names></name><name><surname>Schlesinger</surname><given-names>SJ</given-names></name><name><surname>Walker</surname><given-names>BD</given-names></name><name><surname>Hahn</surname><given-names>BH</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name><name><surname>Caskey</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption</article-title><source>Nature</source><volume>535</volume><fpage>556</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1038/nature18929</pub-id><pub-id pub-id-type="pmid">27338952</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schommers</surname><given-names>P</given-names></name><name><surname>Gruell</surname><given-names>H</given-names></name><name><surname>Abernathy</surname><given-names>ME</given-names></name><name><surname>Tran</surname><given-names>MK</given-names></name><name><surname>Dingens</surname><given-names>AS</given-names></name><name><surname>Gristick</surname><given-names>HB</given-names></name><name><surname>Barnes</surname><given-names>CO</given-names></name><name><surname>Schoofs</surname><given-names>T</given-names></name><name><surname>Schlotz</surname><given-names>M</given-names></name><name><surname>Vanshylla</surname><given-names>K</given-names></name><name><surname>Kreer</surname><given-names>C</given-names></name><name><surname>Weiland</surname><given-names>D</given-names></name><name><surname>Holtick</surname><given-names>U</given-names></name><name><surname>Scheid</surname><given-names>C</given-names></name><name><surname>Valter</surname><given-names>MM</given-names></name><name><surname>van Gils</surname><given-names>MJ</given-names></name><name><surname>Sanders</surname><given-names>RW</given-names></name><name><surname>Vehreschild</surname><given-names>JJ</given-names></name><name><surname>Cornely</surname><given-names>OA</given-names></name><name><surname>Lehmann</surname><given-names>C</given-names></name><name><surname>Fätkenheuer</surname><given-names>G</given-names></name><name><surname>Seaman</surname><given-names>MS</given-names></name><name><surname>Bloom</surname><given-names>JD</given-names></name><name><surname>Bjorkman</surname><given-names>PJ</given-names></name><name><surname>Klein</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Restriction of HIV-1 escape by a highly broad and potent neutralizing antibody</article-title><source>Cell</source><volume>180</volume><fpage>471</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.01.010</pub-id><pub-id pub-id-type="pmid">32004464</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoofs</surname><given-names>T</given-names></name><name><surname>Klein</surname><given-names>F</given-names></name><name><surname>Braunschweig</surname><given-names>M</given-names></name><name><surname>Kreider</surname><given-names>EF</given-names></name><name><surname>Feldmann</surname><given-names>A</given-names></name><name><surname>Nogueira</surname><given-names>L</given-names></name><name><surname>Oliveira</surname><given-names>T</given-names></name><name><surname>Lorenzi</surname><given-names>JCC</given-names></name><name><surname>Parrish</surname><given-names>EH</given-names></name><name><surname>Learn</surname><given-names>GH</given-names></name><name><surname>West</surname><given-names>AP</given-names></name><name><surname>Bjorkman</surname><given-names>PJ</given-names></name><name><surname>Schlesinger</surname><given-names>SJ</given-names></name><name><surname>Seaman</surname><given-names>MS</given-names></name><name><surname>Czartoski</surname><given-names>J</given-names></name><name><surname>McElrath</surname><given-names>MJ</given-names></name><name><surname>Pfeifer</surname><given-names>N</given-names></name><name><surname>Hahn</surname><given-names>BH</given-names></name><name><surname>Caskey</surname><given-names>M</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1</article-title><source>Science</source><volume>352</volume><fpage>997</fpage><lpage>1001</lpage><pub-id pub-id-type="doi">10.1126/science.aaf0972</pub-id><pub-id pub-id-type="pmid">27199429</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shan</surname><given-names>L</given-names></name><name><surname>Siliciano</surname><given-names>RF</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication</article-title><source>BioEssays</source><volume>35</volume><fpage>544</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1002/bies.201200170</pub-id><pub-id pub-id-type="pmid">23613347</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharkey</surname><given-names>M</given-names></name><name><surname>Babic</surname><given-names>DZ</given-names></name><name><surname>Greenough</surname><given-names>T</given-names></name><name><surname>Gulick</surname><given-names>R</given-names></name><name><surname>Kuritzkes</surname><given-names>DR</given-names></name><name><surname>Stevenson</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure</article-title><source>PLOS Pathogens</source><volume>7</volume><elocation-id>e1001303</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1001303</pub-id><pub-id pub-id-type="pmid">21383975</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shingai</surname><given-names>M</given-names></name><name><surname>Nishimura</surname><given-names>Y</given-names></name><name><surname>Klein</surname><given-names>F</given-names></name><name><surname>Mouquet</surname><given-names>H</given-names></name><name><surname>Donau</surname><given-names>OK</given-names></name><name><surname>Plishka</surname><given-names>R</given-names></name><name><surname>Buckler-White</surname><given-names>A</given-names></name><name><surname>Seaman</surname><given-names>M</given-names></name><name><surname>Piatak</surname><given-names>M</given-names></name><name><surname>Lifson</surname><given-names>JD</given-names></name><name><surname>Dimitrov</surname><given-names>DS</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name><name><surname>Martin</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia</article-title><source>Nature</source><volume>503</volume><fpage>277</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1038/nature12746</pub-id><pub-id pub-id-type="pmid">24172896</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simpson</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>Minimum hellinger distance estimation for the analysis of count data</article-title><source>Journal of the American Statistical Association</source><volume>82</volume><fpage>802</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1080/01621459.1987.10478501</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sok</surname><given-names>D</given-names></name><name><surname>Burton</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Recent progress in broadly neutralizing antibodies to HIV</article-title><source>Nature Immunology</source><volume>19</volume><fpage>1179</fpage><lpage>1188</lpage><pub-id pub-id-type="doi">10.1038/s41590-018-0235-7</pub-id><pub-id pub-id-type="pmid">30333615</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sparrow</surname><given-names>E</given-names></name><name><surname>Friede</surname><given-names>M</given-names></name><name><surname>Sheikh</surname><given-names>M</given-names></name><name><surname>Torvaldsen</surname><given-names>S</given-names></name><name><surname>Newall</surname><given-names>AT</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications</article-title><source>Vaccine</source><volume>34</volume><fpage>5442</fpage><lpage>5448</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.08.057</pub-id><pub-id pub-id-type="pmid">27622299</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spira</surname><given-names>S</given-names></name><name><surname>Wainberg</surname><given-names>MA</given-names></name><name><surname>Loemba</surname><given-names>H</given-names></name><name><surname>Turner</surname><given-names>D</given-names></name><name><surname>Brenner</surname><given-names>BG</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance</article-title><source>The Journal of Antimicrobial Chemotherapy</source><volume>51</volume><fpage>229</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1093/jac/dkg079</pub-id><pub-id pub-id-type="pmid">12562686</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stephenson</surname><given-names>KE</given-names></name><name><surname>Julg</surname><given-names>B</given-names></name><name><surname>Tan</surname><given-names>CS</given-names></name><name><surname>Zash</surname><given-names>R</given-names></name><name><surname>Walsh</surname><given-names>SR</given-names></name><name><surname>Rolle</surname><given-names>C-P</given-names></name><name><surname>Monczor</surname><given-names>AN</given-names></name><name><surname>Lupo</surname><given-names>S</given-names></name><name><surname>Gelderblom</surname><given-names>HC</given-names></name><name><surname>Ansel</surname><given-names>JL</given-names></name><name><surname>Kanjilal</surname><given-names>DG</given-names></name><name><surname>Maxfield</surname><given-names>LF</given-names></name><name><surname>Nkolola</surname><given-names>J</given-names></name><name><surname>Borducchi</surname><given-names>EN</given-names></name><name><surname>Abbink</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Peter</surname><given-names>L</given-names></name><name><surname>Chandrashekar</surname><given-names>A</given-names></name><name><surname>Nityanandam</surname><given-names>R</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Setaro</surname><given-names>A</given-names></name><name><surname>Sapiente</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Sunner</surname><given-names>L</given-names></name><name><surname>Cassidy</surname><given-names>T</given-names></name><name><surname>Bennett</surname><given-names>C</given-names></name><name><surname>Sato</surname><given-names>A</given-names></name><name><surname>Mayer</surname><given-names>B</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name><name><surname>deCamp</surname><given-names>A</given-names></name><name><surname>Priddy</surname><given-names>FH</given-names></name><name><surname>Wagh</surname><given-names>K</given-names></name><name><surname>Giorgi</surname><given-names>EE</given-names></name><name><surname>Yates</surname><given-names>NL</given-names></name><name><surname>Arduino</surname><given-names>RC</given-names></name><name><surname>DeJesus</surname><given-names>E</given-names></name><name><surname>Tomaras</surname><given-names>GD</given-names></name><name><surname>Seaman</surname><given-names>MS</given-names></name><name><surname>Korber</surname><given-names>B</given-names></name><name><surname>Barouch</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Safety, pharmacokinetics and antiviral activity of PGT121, A broadly neutralizing monoclonal antibody against HIV-1: A randomized, placebo-controlled, phase 1 clinical trial</article-title><source>Nature Medicine</source><volume>27</volume><fpage>1718</fpage><lpage>1724</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01509-0</pub-id><pub-id pub-id-type="pmid">34621054</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoddart</surname><given-names>JA</given-names></name><name><surname>Taylor</surname><given-names>JF</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Genotypic diversity: estimation and prediction in samples</article-title><source>Genetics</source><volume>118</volume><fpage>705</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1093/genetics/118.4.705</pub-id><pub-id pub-id-type="pmid">17246421</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strelkowa</surname><given-names>N</given-names></name><name><surname>Lässig</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Clonal interference in the evolution of influenza</article-title><source>Genetics</source><volume>192</volume><fpage>671</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1534/genetics.112.143396</pub-id><pub-id pub-id-type="pmid">22851649</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tagarro</surname><given-names>A</given-names></name><name><surname>Chan</surname><given-names>M</given-names></name><name><surname>Zangari</surname><given-names>P</given-names></name><name><surname>Ferns</surname><given-names>B</given-names></name><name><surname>Foster</surname><given-names>C</given-names></name><name><surname>De Rossi</surname><given-names>A</given-names></name><name><surname>Nastouli</surname><given-names>E</given-names></name><name><surname>Muñoz-Fernández</surname><given-names>MA</given-names></name><name><surname>Gibb</surname><given-names>D</given-names></name><name><surname>Rossi</surname><given-names>P</given-names></name><name><surname>Giaquinto</surname><given-names>C</given-names></name><name><surname>Babiker</surname><given-names>A</given-names></name><name><surname>Fortuny</surname><given-names>C</given-names></name><name><surname>Freguja</surname><given-names>R</given-names></name><name><surname>Cotugno</surname><given-names>N</given-names></name><name><surname>Judd</surname><given-names>A</given-names></name><name><surname>Noguera-Julian</surname><given-names>A</given-names></name><name><surname>Navarro</surname><given-names>ML</given-names></name><name><surname>Mellado</surname><given-names>MJ</given-names></name><name><surname>Klein</surname><given-names>N</given-names></name><name><surname>Palma</surname><given-names>P</given-names></name><name><surname>Rojo</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Early and highly suppressive antiretroviral therapy are main factors associated with low viral reservoir in european perinatally HIV-Infected children</article-title><source>JAIDS Journal of Acquired Immune Deficiency Syndromes</source><volume>79</volume><fpage>269</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1097/QAI.0000000000001789</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theys</surname><given-names>K</given-names></name><name><surname>Feder</surname><given-names>AF</given-names></name><name><surname>Gelbart</surname><given-names>M</given-names></name><name><surname>Hartl</surname><given-names>M</given-names></name><name><surname>Stern</surname><given-names>A</given-names></name><name><surname>Pennings</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Within-patient mutation frequencies reveal fitness costs of CpG dinucleotides and drastic amino acid changes in HIV</article-title><source>PLOS Genetics</source><volume>14</volume><elocation-id>e1007420</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1007420</pub-id><pub-id pub-id-type="pmid">29953449</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomaras</surname><given-names>GD</given-names></name><name><surname>Yates</surname><given-names>NL</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Qin</surname><given-names>L</given-names></name><name><surname>Fouda</surname><given-names>GG</given-names></name><name><surname>Chavez</surname><given-names>LL</given-names></name><name><surname>Decamp</surname><given-names>AC</given-names></name><name><surname>Parks</surname><given-names>RJ</given-names></name><name><surname>Ashley</surname><given-names>VC</given-names></name><name><surname>Lucas</surname><given-names>JT</given-names></name><name><surname>Cohen</surname><given-names>M</given-names></name><name><surname>Eron</surname><given-names>J</given-names></name><name><surname>Hicks</surname><given-names>CB</given-names></name><name><surname>Liao</surname><given-names>H-X</given-names></name><name><surname>Self</surname><given-names>SG</given-names></name><name><surname>Landucci</surname><given-names>G</given-names></name><name><surname>Forthal</surname><given-names>DN</given-names></name><name><surname>Weinhold</surname><given-names>KJ</given-names></name><name><surname>Keele</surname><given-names>BF</given-names></name><name><surname>Hahn</surname><given-names>BH</given-names></name><name><surname>Greenberg</surname><given-names>ML</given-names></name><name><surname>Morris</surname><given-names>L</given-names></name><name><surname>Karim</surname><given-names>SSA</given-names></name><name><surname>Blattner</surname><given-names>WA</given-names></name><name><surname>Montefiori</surname><given-names>DC</given-names></name><name><surname>Shaw</surname><given-names>GM</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name><name><surname>Haynes</surname><given-names>BF</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia</article-title><source>Journal of Virology</source><volume>82</volume><fpage>12449</fpage><lpage>12463</lpage><pub-id pub-id-type="doi">10.1128/JVI.01708-08</pub-id><pub-id pub-id-type="pmid">18842730</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagh</surname><given-names>K</given-names></name><name><surname>Bhattacharya</surname><given-names>T</given-names></name><name><surname>Williamson</surname><given-names>C</given-names></name><name><surname>Robles</surname><given-names>A</given-names></name><name><surname>Bayne</surname><given-names>M</given-names></name><name><surname>Garrity</surname><given-names>J</given-names></name><name><surname>Rist</surname><given-names>M</given-names></name><name><surname>Rademeyer</surname><given-names>C</given-names></name><name><surname>Yoon</surname><given-names>H</given-names></name><name><surname>Lapedes</surname><given-names>A</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Greene</surname><given-names>K</given-names></name><name><surname>Louder</surname><given-names>MK</given-names></name><name><surname>Kong</surname><given-names>R</given-names></name><name><surname>Karim</surname><given-names>SA</given-names></name><name><surname>Burton</surname><given-names>DR</given-names></name><name><surname>Barouch</surname><given-names>DH</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name><name><surname>Morris</surname><given-names>L</given-names></name><name><surname>Montefiori</surname><given-names>DC</given-names></name><name><surname>Korber</surname><given-names>B</given-names></name><name><surname>Seaman</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Optimal combinations of broadly neutralizing antibodies for prevention and treatment of HIV-1 clade c infection</article-title><source>PLOS Pathogens</source><volume>12</volume><elocation-id>e1005520</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1005520</pub-id><pub-id pub-id-type="pmid">27028935</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>LM</given-names></name><name><surname>Phogat</surname><given-names>SK</given-names></name><name><surname>Chan-Hui</surname><given-names>PY</given-names></name><name><surname>Wagner</surname><given-names>D</given-names></name><name><surname>Phung</surname><given-names>P</given-names></name><name><surname>Goss</surname><given-names>JL</given-names></name><name><surname>Wrin</surname><given-names>T</given-names></name><name><surname>Simek</surname><given-names>MD</given-names></name><name><surname>Fling</surname><given-names>S</given-names></name><name><surname>Mitcham</surname><given-names>JL</given-names></name><name><surname>Lehrman</surname><given-names>JK</given-names></name><name><surname>Priddy</surname><given-names>FH</given-names></name><name><surname>Olsen</surname><given-names>OA</given-names></name><name><surname>Frey</surname><given-names>SM</given-names></name><name><surname>Hammond</surname><given-names>PW</given-names></name><name><surname>Kaminsky</surname><given-names>S</given-names></name><name><surname>Zamb</surname><given-names>T</given-names></name><name><surname>Moyle</surname><given-names>M</given-names></name><name><surname>Koff</surname><given-names>WC</given-names></name><name><surname>Poignard</surname><given-names>P</given-names></name><name><surname>Burton</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target</article-title><source>Science</source><volume>326</volume><fpage>285</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1126/science.1178746</pub-id><pub-id pub-id-type="pmid">19729618</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>LM</given-names></name><name><surname>Huber</surname><given-names>M</given-names></name><name><surname>Doores</surname><given-names>KJ</given-names></name><name><surname>Falkowska</surname><given-names>E</given-names></name><name><surname>Pejchal</surname><given-names>R</given-names></name><name><surname>Julien</surname><given-names>JP</given-names></name><name><surname>Wang</surname><given-names>SK</given-names></name><name><surname>Ramos</surname><given-names>A</given-names></name><name><surname>Chan-Hui</surname><given-names>PY</given-names></name><name><surname>Moyle</surname><given-names>M</given-names></name><name><surname>Mitcham</surname><given-names>JL</given-names></name><name><surname>Hammond</surname><given-names>PW</given-names></name><name><surname>Olsen</surname><given-names>OA</given-names></name><name><surname>Phung</surname><given-names>P</given-names></name><name><surname>Fling</surname><given-names>S</given-names></name><name><surname>Wong</surname><given-names>CH</given-names></name><name><surname>Phogat</surname><given-names>S</given-names></name><name><surname>Wrin</surname><given-names>T</given-names></name><name><surname>Simek</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Broad neutralization coverage of HIV by multiple highly potent antibodies</article-title><source>Nature</source><volume>477</volume><fpage>466</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1038/nature10373</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>West</surname><given-names>AP</given-names></name><name><surname>Scharf</surname><given-names>L</given-names></name><name><surname>Scheid</surname><given-names>JF</given-names></name><name><surname>Klein</surname><given-names>F</given-names></name><name><surname>Bjorkman</surname><given-names>PJ</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Structural insights on the role of antibodies in HIV-1 vaccine and therapy</article-title><source>Cell</source><volume>156</volume><fpage>633</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.01.052</pub-id><pub-id pub-id-type="pmid">24529371</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wilkinson</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><source>Stochastic Modelling for Systems Biology</source><edition>Third ed</edition><publisher-loc>Boca Raton</publisher-loc><publisher-name>CRC Press</publisher-name></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>JK</given-names></name><name><surname>Yukl</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Tissue reservoirs of HIV</article-title><source>Current Opinion in HIV and AIDS</source><volume>11</volume><fpage>362</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1097/COH.0000000000000293</pub-id><pub-id pub-id-type="pmid">27259045</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>WH</given-names></name><name><surname>Su</surname><given-names>D</given-names></name><name><surname>Torabi</surname><given-names>J</given-names></name><name><surname>Fennessey</surname><given-names>CM</given-names></name><name><surname>Shiakolas</surname><given-names>A</given-names></name><name><surname>Lynch</surname><given-names>R</given-names></name><name><surname>Chun</surname><given-names>TW</given-names></name><name><surname>Doria-Rose</surname><given-names>N</given-names></name><name><surname>Alter</surname><given-names>G</given-names></name><name><surname>Seaman</surname><given-names>MS</given-names></name><name><surname>Keele</surname><given-names>BF</given-names></name><name><surname>Lauffenburger</surname><given-names>DA</given-names></name><name><surname>Julg</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Predicting the broadly neutralizing antibody susceptibility of the HIV reservoir</article-title><source>JCI Insight</source><volume>4</volume><elocation-id>130153</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.130153</pub-id><pub-id pub-id-type="pmid">31484826</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanini</surname><given-names>F</given-names></name><name><surname>Brodin</surname><given-names>J</given-names></name><name><surname>Thebo</surname><given-names>L</given-names></name><name><surname>Lanz</surname><given-names>C</given-names></name><name><surname>Bratt</surname><given-names>G</given-names></name><name><surname>Albert</surname><given-names>J</given-names></name><name><surname>Neher</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Population genomics of intrapatient HIV-1 evolution</article-title><source>eLife</source><volume>4</volume><elocation-id>e11282</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.11282</pub-id><pub-id pub-id-type="pmid">26652000</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanini</surname><given-names>F</given-names></name><name><surname>Puller</surname><given-names>V</given-names></name><name><surname>Brodin</surname><given-names>J</given-names></name><name><surname>Albert</surname><given-names>J</given-names></name><name><surname>Neher</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title><italic>In vivo</italic> mutation rates and the landscape of fitness costs of HIV-1</article-title><source>Virus Evolution</source><volume>3</volume><elocation-id>vex003</elocation-id><pub-id pub-id-type="doi">10.1093/ve/vex003</pub-id><pub-id pub-id-type="pmid">28458914</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Dai</surname><given-names>L</given-names></name><name><surname>Barton</surname><given-names>JP</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Tan</surname><given-names>Y</given-names></name><name><surname>Pang</surname><given-names>W</given-names></name><name><surname>Chakraborty</surname><given-names>AK</given-names></name><name><surname>Lloyd-Smith</surname><given-names>JO</given-names></name><name><surname>Sun</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Predominance of positive epistasis among drug resistance-associated mutations in HIV-1 protease</article-title><source>PLOS Genetics</source><volume>16</volume><elocation-id>e1009009</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1009009</pub-id><pub-id pub-id-type="pmid">33085662</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>T</given-names></name><name><surname>Georgiev</surname><given-names>I</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>Z-Y</given-names></name><name><surname>Dai</surname><given-names>K</given-names></name><name><surname>Finzi</surname><given-names>A</given-names></name><name><surname>Do Kwon</surname><given-names>Y</given-names></name><name><surname>Scheid</surname><given-names>JF</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name><name><surname>Sodroski</surname><given-names>J</given-names></name><name><surname>Shapiro</surname><given-names>L</given-names></name><name><surname>Nabel</surname><given-names>GJ</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name><name><surname>Kwong</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01</article-title><source>Science</source><volume>329</volume><fpage>811</fpage><lpage>817</lpage><pub-id pub-id-type="doi">10.1126/science.1192819</pub-id><pub-id pub-id-type="pmid">20616231</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>T</given-names></name><name><surname>Lynch</surname><given-names>RM</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Acharya</surname><given-names>P</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Doria-Rose</surname><given-names>NA</given-names></name><name><surname>Joyce</surname><given-names>MG</given-names></name><name><surname>Lingwood</surname><given-names>D</given-names></name><name><surname>Soto</surname><given-names>C</given-names></name><name><surname>Bailer</surname><given-names>RT</given-names></name><name><surname>Ernandes</surname><given-names>MJ</given-names></name><name><surname>Kong</surname><given-names>R</given-names></name><name><surname>Longo</surname><given-names>NS</given-names></name><name><surname>Louder</surname><given-names>MK</given-names></name><name><surname>McKee</surname><given-names>K</given-names></name><name><surname>O’Dell</surname><given-names>S</given-names></name><name><surname>Schmidt</surname><given-names>SD</given-names></name><name><surname>Tran</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Druz</surname><given-names>A</given-names></name><name><surname>Luongo</surname><given-names>TS</given-names></name><name><surname>Moquin</surname><given-names>S</given-names></name><name><surname>Srivatsan</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Zheng</surname><given-names>A</given-names></name><name><surname>Pancera</surname><given-names>M</given-names></name><name><surname>Kirys</surname><given-names>T</given-names></name><name><surname>Georgiev</surname><given-names>IS</given-names></name><name><surname>Gindin</surname><given-names>T</given-names></name><name><surname>Peng</surname><given-names>HP</given-names></name><name><surname>Yang</surname><given-names>AS</given-names></name><name><surname>Mullikin</surname><given-names>JC</given-names></name><name><surname>Gray</surname><given-names>MD</given-names></name><name><surname>Stamatatos</surname><given-names>L</given-names></name><name><surname>Burton</surname><given-names>DR</given-names></name><name><surname>Koff</surname><given-names>WC</given-names></name><name><surname>Cohen</surname><given-names>MS</given-names></name><name><surname>Haynes</surname><given-names>BF</given-names></name><name><surname>Casazza</surname><given-names>JP</given-names></name><name><surname>Connors</surname><given-names>M</given-names></name><name><surname>Corti</surname><given-names>D</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name><name><surname>Sattentau</surname><given-names>QJ</given-names></name><name><surname>Weiss</surname><given-names>RA</given-names></name><name><surname>West</surname><given-names>AP</given-names></name><name><surname>Bjorkman</surname><given-names>PJ</given-names></name><name><surname>Scheid</surname><given-names>JF</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name><name><surname>Shapiro</surname><given-names>L</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name><name><surname>Kwong</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Structural repertoire of HIV-1-Neutralizing antibodies targeting the CD4 supersite in 14 donors</article-title><source>Cell</source><volume>161</volume><fpage>1280</fpage><lpage>1292</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.05.007</pub-id><pub-id pub-id-type="pmid">26004070</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zwick</surname><given-names>MB</given-names></name><name><surname>Labrijn</surname><given-names>AF</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Spenlehauer</surname><given-names>C</given-names></name><name><surname>Saphire</surname><given-names>EO</given-names></name><name><surname>Binley</surname><given-names>JM</given-names></name><name><surname>Moore</surname><given-names>JP</given-names></name><name><surname>Stiegler</surname><given-names>G</given-names></name><name><surname>Katinger</surname><given-names>H</given-names></name><name><surname>Burton</surname><given-names>DR</given-names></name><name><surname>Parren</surname><given-names>PWHI</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus Type 1 glycoprotein gp41</article-title><source>Journal of Virology</source><volume>75</volume><fpage>10892</fpage><lpage>10905</lpage><pub-id pub-id-type="doi">10.1128/JVI.75.22.10892-10905.2001</pub-id><pub-id pub-id-type="pmid">11602729</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><table-wrap id="app1table1" position="float"><label>Appendix 1—table 1.</label><caption><title>Selection and mutational target size for escape-mediating sites against each bNAb.</title><p>Shown are the sites (column 1) and the susceptible and the escape amino acids (column 2) for each bNAb. We called patterns for 10–1074 and CD4 binding site targetting antibodies VRC01 and 3BNC117 using genetic trial data and the remainder using DMS data. The inferred mutational target size of escape at each site (forward <inline-formula><mml:math id="inf465"><mml:mi>μ</mml:mi></mml:math></inline-formula> and backward <inline-formula><mml:math id="inf466"><mml:msup><mml:mi>μ</mml:mi><mml:mo>†</mml:mo></mml:msup></mml:math></inline-formula> mutation rates) is shown in column 3. The major quantiles (<inline-formula><mml:math id="inf467"><mml:mrow><mml:mn>10</mml:mn><mml:mo>%</mml:mo><mml:mo>,</mml:mo><mml:mn> 50</mml:mn><mml:mo rspace="4.2pt">%</mml:mo><mml:mtext>(median)</mml:mtext><mml:mo>,</mml:mo><mml:mn>90</mml:mn><mml:mo>%</mml:mo><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula> associated with the inferred site-specific Bayesian posterior of the scaled selection strength <inline-formula><mml:math id="inf468"><mml:mrow><mml:mover accent="true"><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>/</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> are shown in column 4. The corresponding quantiles for the strength of selection,<inline-formula><mml:math id="inf469"><mml:mrow><mml:mi>σ</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mover accent="true"><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mo>⁢</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> after convolving the posterior for the scaled selection <inline-formula><mml:math id="inf470"><mml:mover accent="true"><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:math></inline-formula> with the reservoir-corrected intra-patient diversity of HIV-1 <inline-formula><mml:math id="inf471"><mml:mrow><mml:mi>ξ</mml:mi><mml:mo>⁢</mml:mo><mml:mi>θ</mml:mi></mml:mrow></mml:math></inline-formula> are shown in column 5.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom"/><th align="left" valign="bottom"/><th align="left" valign="bottom"/><th align="left" valign="bottom"/><th align="left" valign="bottom"/><th align="left" valign="bottom" colspan="3"><inline-formula><mml:math id="inf472"><mml:mrow><mml:mi>σ</mml:mi><mml:mo>/</mml:mo><mml:mi>θ</mml:mi></mml:mrow></mml:math></inline-formula> quantiles</th><th align="left" valign="bottom" colspan="3"><inline-formula><mml:math id="inf473"><mml:mi>σ</mml:mi></mml:math></inline-formula> quantiles</th></tr><tr><th align="left" valign="bottom">bNAb</th><th align="left" valign="bottom">site</th><th align="left" valign="bottom">susceptible AA</th><th align="left" valign="bottom">escape AA</th><th align="left" valign="bottom"><inline-formula><mml:math id="inf474"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>μ</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula></th><th align="left" valign="bottom"><inline-formula><mml:math id="inf475"><mml:msup><mml:mi>μ</mml:mi><mml:mo>†</mml:mo></mml:msup></mml:math></inline-formula></th><th align="left" valign="bottom">0.1</th><th align="left" valign="bottom">0.5</th><th align="left" valign="bottom">0.9</th><th align="left" valign="bottom">0.1</th><th align="left" valign="bottom">0.5</th><th align="left" valign="bottom">0.9</th></tr></thead><tbody><tr><td align="char" char="ndash" valign="middle" rowspan="3">10–1074</td><td align="char" char="." valign="bottom">325</td><td align="left" valign="bottom">DN</td><td align="left" valign="bottom">EGK</td><td align="char" char="." valign="bottom">0.76</td><td align="char" char="." valign="bottom">0.51</td><td align="char" char="." valign="bottom">560</td><td align="char" char="." valign="bottom">1,100</td><td align="char" char="." valign="bottom">2,900</td><td align="char" char="." valign="bottom">8.8</td><td align="char" char="." valign="bottom">29</td><td align="char" char="." valign="bottom">93</td></tr><tr><td align="char" char="." valign="bottom">332</td><td align="left" valign="bottom">N</td><td align="left" valign="bottom">DHIKSTY</td><td align="char" char="." valign="bottom">2.8</td><td align="char" char="." valign="bottom">0.4</td><td align="char" char="." valign="bottom">190</td><td align="char" char="." valign="bottom">290</td><td align="char" char="." valign="bottom">450</td><td align="char" char="." valign="bottom">2.6</td><td align="char" char="." valign="bottom">7.1</td><td align="char" char="." valign="bottom">16</td></tr><tr><td align="char" char="." valign="bottom">334</td><td align="left" valign="bottom">S</td><td align="left" valign="bottom">AFGINRY</td><td align="char" char="." valign="bottom">1.3</td><td align="char" char="." valign="bottom">0.44</td><td align="char" char="." valign="bottom">100</td><td align="char" char="." valign="bottom">170</td><td align="char" char="." valign="bottom">250</td><td align="char" char="." valign="bottom">1.4</td><td align="char" char="." valign="bottom">4</td><td align="char" char="." valign="bottom">9.5</td></tr><tr><td align="char" char="." valign="middle" rowspan="2">10E8</td><td align="char" char="." valign="bottom">671</td><td align="left" valign="bottom">KNS</td><td align="left" valign="bottom">RT</td><td align="char" char="." valign="bottom">0.41</td><td align="char" char="." valign="bottom">0.51</td><td align="char" char="." valign="bottom">38</td><td align="char" char="." valign="bottom">110</td><td align="char" char="." valign="bottom">220</td><td align="char" char="." valign="bottom">0.68</td><td align="char" char="." valign="bottom">2.5</td><td align="char" char="." valign="bottom">7.3</td></tr><tr><td align="char" char="." valign="bottom">673</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">LV</td><td align="char" char="." valign="bottom">1.4</td><td align="char" char="." valign="bottom">0.47</td><td align="char" char="." valign="bottom">150</td><td align="char" char="." valign="bottom">290</td><td align="char" char="." valign="bottom">510</td><td align="char" char="." valign="bottom">2.4</td><td align="char" char="." valign="bottom">7</td><td align="char" char="." valign="bottom">18</td></tr><tr><td align="char" char="." valign="middle" rowspan="4">3BNC117</td><td align="char" char="." valign="bottom">279</td><td align="left" valign="bottom">DN</td><td align="left" valign="bottom">AHK</td><td align="char" char="." valign="bottom">0.33</td><td align="char" char="." valign="bottom">0.22</td><td align="char" char="." valign="bottom">190</td><td align="char" char="." valign="bottom">470</td><td align="char" char="." valign="bottom">930</td><td align="char" char="." valign="bottom">3.4</td><td align="char" char="." valign="bottom">11</td><td align="char" char="." valign="bottom">31</td></tr><tr><td align="char" char="." valign="bottom">281</td><td align="left" valign="bottom">AP</td><td align="left" valign="bottom">TV</td><td align="char" char="." valign="bottom">1.1</td><td align="char" char="." valign="bottom">1.1</td><td align="char" char="." valign="bottom">62</td><td align="char" char="." valign="bottom">140</td><td align="char" char="." valign="bottom">250</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom">3.2</td><td align="char" char="." valign="bottom">8.6</td></tr><tr><td align="char" char="." valign="bottom">282</td><td align="left" valign="bottom">KY</td><td align="left" valign="bottom">ENR</td><td align="char" char="." valign="bottom">1.2</td><td align="char" char="." valign="bottom">0.8</td><td align="char" char="." valign="bottom">120</td><td align="char" char="." valign="bottom">230</td><td align="char" char="." valign="bottom">400</td><td align="char" char="." valign="bottom">1.9</td><td align="char" char="." valign="bottom">5.6</td><td align="char" char="." valign="bottom">14</td></tr><tr><td align="char" char="." valign="bottom">459</td><td align="left" valign="bottom">G</td><td align="left" valign="bottom">DN</td><td align="char" char="." valign="bottom">0.5</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">54</td><td align="char" char="." valign="bottom">140</td><td align="char" char="." valign="bottom">270</td><td align="char" char="." valign="bottom">0.91</td><td align="char" char="." valign="bottom">3.3</td><td align="char" char="." valign="bottom">9.5</td></tr><tr><td align="left" valign="middle" rowspan="4">PG9</td><td align="char" char="." valign="bottom">160</td><td align="left" valign="bottom">N</td><td align="left" valign="bottom">KY</td><td align="char" char="." valign="bottom">0.4</td><td align="char" char="." valign="bottom">0.2</td><td align="char" char="." valign="bottom">150</td><td align="char" char="." valign="bottom">280</td><td align="char" char="." valign="bottom">480</td><td align="char" char="." valign="bottom">2.3</td><td align="char" char="." valign="bottom">6.7</td><td align="char" char="." valign="bottom">17</td></tr><tr><td align="char" char="." valign="bottom">162</td><td align="left" valign="bottom">ST</td><td align="left" valign="bottom">AIP</td><td align="char" char="." valign="bottom">1.2</td><td align="char" char="." valign="bottom">1.1</td><td align="char" char="." valign="bottom">540</td><td align="char" char="." valign="bottom">1600</td><td align="char" char="." valign="bottom">2600</td><td align="char" char="." valign="bottom">9.5</td><td align="char" char="." valign="bottom">34</td><td align="char" char="." valign="bottom">98</td></tr><tr><td align="char" char="." valign="bottom">169</td><td align="left" valign="bottom">GIKMRVW</td><td align="left" valign="bottom">ELT</td><td align="char" char="." valign="bottom">0.53</td><td align="char" char="." valign="bottom">0.92</td><td align="char" char="." valign="bottom">240</td><td align="char" char="." valign="bottom">590</td><td align="char" char="." valign="bottom">1200</td><td align="char" char="." valign="bottom">4.1</td><td align="char" char="." valign="bottom">14</td><td align="char" char="." valign="bottom">41</td></tr><tr><td align="char" char="." valign="bottom">171</td><td align="left" valign="bottom">KPR</td><td align="left" valign="bottom">AEGHNQST</td><td align="char" char="." valign="bottom">1.4</td><td align="char" char="." valign="bottom">0.62</td><td align="char" char="." valign="bottom">100</td><td align="char" char="." valign="bottom">190</td><td align="char" char="." valign="bottom">310</td><td align="char" char="." valign="bottom">1.5</td><td align="char" char="." valign="bottom">4.5</td><td align="char" char="." valign="bottom">11</td></tr><tr><td align="left" valign="middle" rowspan="3">PGT121</td><td align="char" char="." valign="bottom">330</td><td align="left" valign="bottom">FHLRSY</td><td align="left" valign="bottom">Q</td><td align="char" char="." valign="bottom">0.12</td><td align="char" char="." valign="bottom">1.4</td><td align="char" char="." valign="bottom">7.4</td><td align="char" char="." valign="bottom">160</td><td align="char" char="." valign="bottom">530</td><td align="char" char="." valign="bottom">0.15</td><td align="char" char="." valign="bottom">3.6</td><td align="char" char="." valign="bottom">16</td></tr><tr><td align="char" char="." valign="bottom">332</td><td align="left" valign="bottom">AENV</td><td align="left" valign="bottom">DIKT</td><td align="char" char="." valign="bottom">1.1</td><td align="char" char="." valign="bottom">1.2</td><td align="char" char="." valign="bottom">80</td><td align="char" char="." valign="bottom">180</td><td align="char" char="." valign="bottom">320</td><td align="char" char="." valign="bottom">1.3</td><td align="char" char="." valign="bottom">4.2</td><td align="char" char="." valign="bottom">11</td></tr><tr><td align="char" char="." valign="bottom">334</td><td align="left" valign="bottom">DS</td><td align="left" valign="bottom">GN</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">2</td><td align="char" char="." valign="bottom">15</td><td align="char" char="." valign="bottom">80</td><td align="char" char="." valign="bottom">170</td><td align="char" char="." valign="bottom">0.26</td><td align="char" char="." valign="bottom">1.8</td><td align="char" char="." valign="bottom">5.9</td></tr><tr><td align="left" valign="middle" rowspan="5">PGT145</td><td align="char" char="." valign="bottom">121</td><td align="left" valign="bottom">K</td><td align="left" valign="bottom">E</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">34</td><td align="char" char="." valign="bottom">92</td><td align="char" char="." valign="bottom">170</td><td align="char" char="." valign="bottom">0.58</td><td align="char" char="." valign="bottom">2.1</td><td align="char" char="." valign="bottom">5.8</td></tr><tr><td align="char" char="." valign="bottom">160</td><td align="left" valign="bottom">N</td><td align="left" valign="bottom">KY</td><td align="char" char="." valign="bottom">0.4</td><td align="char" char="." valign="bottom">0.2</td><td align="char" char="." valign="bottom">140</td><td align="char" char="." valign="bottom">250</td><td align="char" char="." valign="bottom">440</td><td align="char" char="." valign="bottom">2.1</td><td align="char" char="." valign="bottom">6.2</td><td align="char" char="." valign="bottom">15</td></tr><tr><td align="char" char="." valign="bottom">162</td><td align="left" valign="bottom">ST</td><td align="left" valign="bottom">AIP</td><td align="char" char="." valign="bottom">1.2</td><td align="char" char="." valign="bottom">1.1</td><td align="char" char="." valign="bottom">680</td><td align="char" char="." valign="bottom">1200</td><td align="char" char="." valign="bottom">2000</td><td align="char" char="." valign="bottom">11</td><td align="char" char="." valign="bottom">29</td><td align="char" char="." valign="bottom">73</td></tr><tr><td align="char" char="." valign="bottom">166</td><td align="left" valign="bottom">KR</td><td align="left" valign="bottom">AEGST</td><td align="char" char="." valign="bottom">0.73</td><td align="char" char="." valign="bottom">0.58</td><td align="char" char="." valign="bottom">58</td><td align="char" char="." valign="bottom">120</td><td align="char" char="." valign="bottom">200</td><td align="char" char="." valign="bottom">0.9</td><td align="char" char="." valign="bottom">2.8</td><td align="char" char="." valign="bottom">7.2</td></tr><tr><td align="char" char="." valign="bottom">169</td><td align="left" valign="bottom">GIKLTV</td><td align="left" valign="bottom">EMRW</td><td align="char" char="." valign="bottom">0.59</td><td align="char" char="." valign="bottom">1.4</td><td align="char" char="." valign="bottom">8.8</td><td align="char" char="." valign="bottom">80</td><td align="char" char="." valign="bottom">190</td><td align="char" char="." valign="bottom">0.16</td><td align="char" char="." valign="bottom">1.8</td><td align="char" char="." valign="bottom">6.1</td></tr><tr><td align="left" valign="middle" rowspan="5">PGT151</td><td align="char" char="." valign="bottom">512</td><td align="left" valign="bottom">A</td><td align="left" valign="bottom">GT</td><td align="char" char="." valign="bottom">1.1</td><td align="char" char="." valign="bottom">0.57</td><td align="char" char="." valign="bottom">860</td><td align="char" char="." valign="bottom">2,700</td><td align="char" char="." valign="bottom">4100</td><td align="char" char="." valign="bottom">16</td><td align="char" char="." valign="bottom">59</td><td align="char" char="." valign="bottom">160</td></tr><tr><td align="char" char="." valign="bottom">611</td><td align="left" valign="bottom">GN</td><td align="left" valign="bottom">DS</td><td align="char" char="." valign="bottom">1.3</td><td align="char" char="." valign="bottom">2</td><td align="char" char="." valign="bottom">360</td><td align="char" char="." valign="bottom">890</td><td align="char" char="." valign="bottom">1300</td><td align="char" char="." valign="bottom">6.5</td><td align="char" char="." valign="bottom">20</td><td align="char" char="." valign="bottom">50</td></tr><tr><td align="char" char="." valign="bottom">613</td><td align="left" valign="bottom">ST</td><td align="left" valign="bottom">CN</td><td align="char" char="." valign="bottom">0.28</td><td align="char" char="." valign="bottom">0.7</td><td align="char" char="." valign="bottom">1200</td><td align="char" char="." valign="bottom">2,800</td><td align="char" char="." valign="bottom">3500</td><td align="char" char="." valign="bottom">21</td><td align="char" char="." valign="bottom">58</td><td align="char" char="." valign="bottom">140</td></tr><tr><td align="char" char="." valign="bottom">637</td><td align="left" valign="bottom">DN</td><td align="left" valign="bottom">EKST</td><td align="char" char="." valign="bottom">0.83</td><td align="char" char="." valign="bottom">0.41</td><td align="char" char="." valign="bottom">120</td><td align="char" char="." valign="bottom">210</td><td align="char" char="." valign="bottom">350</td><td align="char" char="." valign="bottom">1.8</td><td align="char" char="." valign="bottom">5.1</td><td align="char" char="." valign="bottom">13</td></tr><tr><td align="char" char="." valign="bottom">639</td><td align="left" valign="bottom">T</td><td align="left" valign="bottom">IM</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1100</td><td align="char" char="." valign="bottom">1600</td><td align="char" char="." valign="bottom">2600</td><td align="char" char="." valign="bottom">16</td><td align="char" char="." valign="bottom">42</td><td align="char" char="." valign="bottom">96</td></tr><tr><td align="left" valign="middle" rowspan="5">VRC01</td><td align="char" char="." valign="bottom">197</td><td align="left" valign="bottom">DN</td><td align="left" valign="bottom">S</td><td align="char" char="." valign="bottom">0.5</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">730</td><td align="char" char="." valign="bottom">1600</td><td align="char" char="." valign="bottom">2300</td><td align="char" char="." valign="bottom">12</td><td align="char" char="." valign="bottom">35</td><td align="char" char="." valign="bottom">88</td></tr><tr><td align="char" char="." valign="bottom">279</td><td align="left" valign="bottom">DN</td><td align="left" valign="bottom">AHK</td><td align="char" char="." valign="bottom">0.33</td><td align="char" char="." valign="bottom">0.22</td><td align="char" char="." valign="bottom">200</td><td align="char" char="." valign="bottom">420</td><td align="char" char="." valign="bottom">940</td><td align="char" char="." valign="bottom">3.2</td><td align="char" char="." valign="bottom">10</td><td align="char" char="." valign="bottom">30</td></tr><tr><td align="char" char="." valign="bottom">280</td><td align="left" valign="bottom">N</td><td align="left" valign="bottom">D</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">440</td><td align="char" char="." valign="bottom">1000</td><td align="char" char="." valign="bottom">1800</td><td align="char" char="." valign="bottom">7.3</td><td align="char" char="." valign="bottom">24</td><td align="char" char="." valign="bottom">63</td></tr><tr><td align="char" char="." valign="bottom">281</td><td align="left" valign="bottom">AP</td><td align="left" valign="bottom">TV</td><td align="char" char="." valign="bottom">1.1</td><td align="char" char="." valign="bottom">1.1</td><td align="char" char="." valign="bottom">52</td><td align="char" char="." valign="bottom">130</td><td align="char" char="." valign="bottom">250</td><td align="char" char="." valign="bottom">0.9</td><td align="char" char="." valign="bottom">3.1</td><td align="char" char="." valign="bottom">8.6</td></tr><tr><td align="char" char="." valign="bottom">458</td><td align="left" valign="bottom">G</td><td align="left" valign="bottom">D</td><td align="char" char="." valign="bottom">0.5</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">290</td><td align="char" char="." valign="bottom">1200</td><td align="char" char="." valign="bottom">2200</td><td align="char" char="." valign="bottom">6</td><td align="char" char="." valign="bottom">26</td><td align="char" char="." valign="bottom">75</td></tr><tr><td align="left" valign="middle" rowspan="4">VRC34</td><td align="char" char="." valign="bottom">512</td><td align="left" valign="bottom">A</td><td align="left" valign="bottom">GT</td><td align="char" char="." valign="bottom">1.1</td><td align="char" char="." valign="bottom">0.57</td><td align="char" char="." valign="bottom">720</td><td align="char" char="." valign="bottom">1400</td><td align="char" char="." valign="bottom">2900</td><td align="char" char="." valign="bottom">11</td><td align="char" char="." valign="bottom">34</td><td align="char" char="." valign="bottom">92</td></tr><tr><td align="left" valign="bottom">524</td><td align="char" char="." valign="bottom">GP</td><td align="left" valign="bottom">AERS</td><td align="left" valign="bottom">1.5</td><td align="char" char="." valign="bottom">0.67</td><td align="char" char="." valign="bottom">45</td><td align="char" char="." valign="bottom">95</td><td align="char" char="." valign="bottom">150</td><td align="char" char="." valign="bottom">0.71</td><td align="char" char="." valign="bottom">2.2</td><td align="char" char="." valign="bottom">5.6</td></tr><tr><td align="left" valign="bottom">88</td><td align="char" char="." valign="bottom">N</td><td align="left" valign="bottom">K</td><td align="left" valign="bottom">0.26</td><td align="char" char="." valign="bottom">0.26</td><td align="char" char="." valign="bottom">570</td><td align="char" char="." valign="bottom">1400</td><td align="char" char="." valign="bottom">1900</td><td align="char" char="." valign="bottom">9.8</td><td align="char" char="." valign="bottom">30</td><td align="char" char="." valign="bottom">74</td></tr><tr><td align="left" valign="bottom">90</td><td align="char" char="." valign="bottom">ST</td><td align="left" valign="bottom">AEK</td><td align="left" valign="bottom">0.48</td><td align="char" char="." valign="bottom">0.8</td><td align="char" char="." valign="bottom">1400</td><td align="char" char="." valign="bottom">2500</td><td align="char" char="." valign="bottom">3300</td><td align="char" char="." valign="bottom">19</td><td align="char" char="." valign="bottom">57</td><td align="char" char="." valign="bottom">130</td></tr></tbody></table></table-wrap></app><app id="appendix-2"><title>Appendix 2</title><sec sec-type="appendix" id="s8"><title>Fokker-Planck description of the birth-death process</title><p>The individual-based birth-death model introduced above specifies the stochastic dynamics of a population state over time. We characterize the state of a population by vector <inline-formula><mml:math id="inf476"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="bold-italic">n</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mi>M</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula>, where <italic>n</italic><sub><italic>a</italic></sub> is the number of type <inline-formula><mml:math id="inf477"><mml:mi>a</mml:mi></mml:math></inline-formula> variants within the population. Using the concept of chemical reactions, suitable for Gillespie algorithm <xref ref-type="bibr" rid="bib102">Wilkinson, 2019</xref>; <xref ref-type="bibr" rid="bib35">Gillespie, 2002</xref>, we can determine the propensity <inline-formula><mml:math id="inf478"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>a</mml:mi><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">n</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula> for a given reaction <inline-formula><mml:math id="inf479"><mml:mi>r</mml:mi></mml:math></inline-formula> (i.e., birth, death, or mutation) in a population of state <inline-formula><mml:math id="inf480"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="bold-italic">n</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>, which in turn determines the rate at which the reactions occur (<xref ref-type="disp-formula" rid="equ10">Equation 9</xref>). We denote the resulting change in the state of a population due to reaction <inline-formula><mml:math id="inf481"><mml:mi>r</mml:mi></mml:math></inline-formula> by <inline-formula><mml:math id="inf482"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi mathvariant="bold-italic">ν</mml:mi><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>. Taken together, the impact of the reactions in the birth-death model can be summarized as, Reaction Rate parameter Propensity State change<disp-formula id="equ44"><label>(43)</label><mml:math id="m44"><mml:mrow><mml:mtable rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mrow><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">y</mml:mi><mml:mspace width="thinmathspace"/><mml:msub><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi mathvariant="bold">n</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mspace width="thinmathspace"/><mml:msub><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">h</mml:mi></mml:mrow></mml:mtd><mml:mtd><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>λ</mml:mi><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:mfrac></mml:mtd><mml:mtd><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mtd><mml:mtd><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mi>e</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">h</mml:mi></mml:mrow></mml:mtd><mml:mtd><mml:msub><mml:mi>δ</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>λ</mml:mi><mml:mo>−</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:mfrac></mml:mtd><mml:mtd><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>δ</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mtd><mml:mtd><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mi>e</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mi>μ</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mo stretchy="false">→</mml:mo><mml:mi>b</mml:mi></mml:mrow></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi>μ</mml:mi><mml:mo>†</mml:mo></mml:msup><mml:mo>=</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mrow><mml:mi>b</mml:mi><mml:mo stretchy="false">→</mml:mo><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mtd><mml:mtd><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>μ</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mo stretchy="false">→</mml:mo><mml:mi>b</mml:mi></mml:mrow></mml:msub></mml:mtd><mml:mtd><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mi>e</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>b</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mi>e</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf483"><mml:msub><mml:mover accent="true"><mml:mi>e</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub></mml:math></inline-formula> is a vector of size <inline-formula><mml:math id="inf484"><mml:mi>M</mml:mi></mml:math></inline-formula> equal to size of the population state vector, in which the <inline-formula><mml:math id="inf485"><mml:msup><mml:mi>i</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mo>⁢</mml:mo><mml:mi>h</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> element equal to one and the rest are zero. For example, a mutation reaction <inline-formula><mml:math id="inf486"><mml:mrow><mml:mi>μ</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>a</mml:mi><mml:mo>→</mml:mo><mml:mi>b</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> destroys a variant <inline-formula><mml:math id="inf487"><mml:mi>a</mml:mi></mml:math></inline-formula> and creates a variant <inline-formula><mml:math id="inf488"><mml:mi>b</mml:mi></mml:math></inline-formula>, resulting in the following change in the state vector,<disp-formula id="equ45"><label>(44)</label><mml:math id="m45"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">v</mml:mi></mml:mrow><mml:mrow><mml:mi>μ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo stretchy="false">→</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mi>e</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mi>e</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:math></disp-formula></p><p>The reactions in <xref ref-type="disp-formula" rid="equ44">Equation 43</xref> specify a Master equation for the change in the probability of the population state <inline-formula><mml:math id="inf489"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">n</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula>,<disp-formula id="equ46"><label>(45)</label><mml:math id="m46"><mml:mrow><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo>˙</mml:mo></mml:mover></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">n</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:munder><mml:msub><mml:mi>a</mml:mi><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">n</mml:mi><mml:mo>−</mml:mo><mml:msub><mml:mi mathvariant="bold-italic">ν</mml:mi><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mi>p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">n</mml:mi><mml:mo>−</mml:mo><mml:msub><mml:mi mathvariant="bold-italic">ν</mml:mi><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mi>a</mml:mi><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">n</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mi>p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">n</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf490"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="bold-italic">n</mml:mi><mml:mo>=</mml:mo><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:munder><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mover><mml:mi>e</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> is the state vector. Using a Kramers-Moyal expansion <xref ref-type="bibr" rid="bib78">Risken, 1989</xref>, we arrive at a Fokker-Planck approximation for the change in the probability distribution of the population state <inline-formula><mml:math id="inf491"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">n</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula>,<disp-formula id="equ47"><label>(46)</label><mml:math id="m47"><mml:mrow><mml:mfrac><mml:mrow><mml:mtext>d</mml:mtext></mml:mrow><mml:mrow><mml:mrow><mml:mtext>d</mml:mtext></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">n</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:munder><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:munder><mml:mfrac><mml:mi mathvariant="normal">∂</mml:mi><mml:mrow><mml:mi mathvariant="normal">∂</mml:mi><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mfrac><mml:mi mathvariant="normal">∂</mml:mi><mml:mrow><mml:mi mathvariant="normal">∂</mml:mi><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:msubsup><mml:mi>ν</mml:mi><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup><mml:msubsup><mml:mi>ν</mml:mi><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>a</mml:mi><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">n</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>−</mml:mo><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:munder><mml:mfrac><mml:mi mathvariant="normal">∂</mml:mi><mml:mrow><mml:mi mathvariant="normal">∂</mml:mi><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:msubsup><mml:mi>ν</mml:mi><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>a</mml:mi><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">n</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mi>p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">n</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></disp-formula></p><p>We can identify the drift (i.e. the deterministic force) and diffusion tensors of the Fokker-Planck operator:<disp-formula id="equ48"><label>(47)</label><mml:math id="m48"><mml:mrow><mml:mtable columnalign="right left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mi mathvariant="bold-italic">b</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">n</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:munder><mml:msub><mml:mi mathvariant="bold-italic">ν</mml:mi><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>a</mml:mi><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">n</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mi mathvariant="bold">Σ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">n</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:munder><mml:msubsup><mml:mi mathvariant="bold-italic">ν</mml:mi><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:msub><mml:mi>a</mml:mi><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">n</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula></p><p>To better demonstrate the structure of this birth-death operator, consider a bi-allelic case (e.g. susceptible and resistant) with a two-dimensional state vector, <inline-formula><mml:math id="inf492"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="bold-italic">n</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mtable rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mtd></mml:mtr></mml:mtable><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula>. The drift and the diffusion tensors associated with this process follow,<disp-formula id="equ49"><label>(48)</label><mml:math id="m49"><mml:mrow><mml:mtable columnalign="right left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mi mathvariant="bold-italic">b</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">n</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mtable rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>−</mml:mo><mml:mi>μ</mml:mi></mml:mtd><mml:mtd><mml:msup><mml:mi>μ</mml:mi><mml:mrow><mml:mo>†</mml:mo></mml:mrow></mml:msup></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>μ</mml:mi></mml:mtd><mml:mtd><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>−</mml:mo><mml:msup><mml:mi>μ</mml:mi><mml:mrow><mml:mo>†</mml:mo></mml:mrow></mml:msup></mml:mtd></mml:mtr></mml:mtable><mml:mo>)</mml:mo></mml:mrow><mml:mo>⋅</mml:mo><mml:mi mathvariant="bold-italic">n</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula><disp-formula id="equ50"><label>(49)</label><mml:math id="m50"><mml:mrow><mml:mtable columnalign="right left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mi mathvariant="bold">Σ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">n</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:mi>λ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mtable rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mtd></mml:mtr></mml:mtable><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mi mathvariant="script">O</mml:mi></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>μ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula></p><p>Note that in <xref ref-type="disp-formula" rid="equ50">Equation 49</xref> we neglect the stochasticity due to mutations since the magnitude of the associated noise is much smaller than the noise due to the birth and death (i.e., genetic drift). From this Fokker-planck equation we directly recover the equilibrium distribution which links the parameters of our model to the genetic observables.</p><p>In the steady state, the population is fluctuating around carrying capacity <inline-formula><mml:math id="inf493"><mml:mrow><mml:mrow><mml:msub><mml:mo largeop="true" symmetric="true">∑</mml:mo><mml:mi>a</mml:mi></mml:msub><mml:msub><mml:mi>n</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:mrow><mml:mo>≈</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> and we can represent the population state via allele frequencies <inline-formula><mml:math id="inf494"><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>. In the simple case of a bi-allelic problem, the equilibrium allele frequency distribution <inline-formula><mml:math id="inf495"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mtext>eq</mml:mtext></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> follows the Wright-equilibrium distribution <xref ref-type="bibr" rid="bib19">Crow and Kimura, 2010</xref> with modified rates,<disp-formula id="equ51"><label>(50)</label><mml:math id="m51"><mml:mrow><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mtext>eq</mml:mtext></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mi>Z</mml:mi></mml:mfrac><mml:mo>⁢</mml:mo><mml:mfrac><mml:mrow><mml:mpadded width="+3.3pt"><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:mo>⁢</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mrow><mml:mi>λ</mml:mi></mml:mfrac><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>⁢</mml:mo><mml:mi>x</mml:mi></mml:mrow></mml:msup></mml:mpadded><mml:mo>⁢</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>x</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:mo>⁢</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mrow><mml:mi>λ</mml:mi></mml:mfrac><mml:mo>⁢</mml:mo><mml:msup><mml:mi>μ</mml:mi><mml:mo>†</mml:mo></mml:msup></mml:mrow></mml:msup><mml:mo>⁢</mml:mo><mml:msup><mml:mi>x</mml:mi><mml:mrow><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:mo>⁢</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mrow><mml:mi>λ</mml:mi></mml:mfrac><mml:mo>⁢</mml:mo><mml:mi>μ</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>x</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>⁢</mml:mo><mml:mi>x</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mo>≡</mml:mo><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mi>Z</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>σ</mml:mi><mml:mo>,</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>⁢</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>⁢</mml:mo><mml:mi>x</mml:mi></mml:mrow></mml:mrow></mml:msup><mml:mo>⁢</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>x</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup></mml:msup><mml:mo>⁢</mml:mo><mml:msup><mml:mi>x</mml:mi><mml:mi>θ</mml:mi></mml:msup></mml:mrow><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>x</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>⁢</mml:mo><mml:mi>x</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:math></disp-formula></p></sec></app><app id="appendix-3"><title>Appendix 3</title><sec sec-type="appendix" id="s9"><title>Incomplete escape of HIV-1 from bNAbs</title><p>In our model, we assume that during therapy the susceptible HIV-1 sub-population is completely neutralized by bNAbs and is removed at an exponential rate from the viral population. On the other hand, the resistant variants grow in accordance with their intrinsic fitness in the presence of bNAbs. However, this binary categorization is an approximation, and binding kinetics between viral epitopes and bNAbs implies that neutralization is a probabilistic process and could be incomplete, resulting in the removal of only a fraction of the susceptible variants. The degree of this neutralization depends on the concentration of the infused bNAbs in a patient’s serum, and the binding affinity between bNAbs and the susceptible viral epitopes. In a simple model of binding kinetics, the binding affinity is characterized by the half maximal inhibitory concentration, or IC<sub>50</sub>. The probability that a (susceptible) viral variant ‘<inline-formula><mml:math id="inf496"><mml:mi>i</mml:mi></mml:math></inline-formula>’ does not bind to a neutralizing bNAb with serum concentration [A] is given by,<disp-formula id="equ52"><label>(51)</label><mml:math id="m52"><mml:mrow><mml:msub><mml:mi>u</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mtext>[A]</mml:mtext></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mtext>[A]</mml:mtext></mml:mrow><mml:msubsup><mml:mtext>IC</mml:mtext><mml:mrow><mml:mn>50</mml:mn></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup></mml:mfrac></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf497"><mml:msubsup><mml:mtext>IC</mml:mtext><mml:mn>50</mml:mn><mml:mi>i</mml:mi></mml:msubsup></mml:math></inline-formula> is the half maximal inhibitory concentration of the bNAb against viral variant <inline-formula><mml:math id="inf498"><mml:mi>i</mml:mi></mml:math></inline-formula>. We model the growth rate <inline-formula><mml:math id="inf499"><mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mtext>[A]</mml:mtext><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> of the susceptible variant <inline-formula><mml:math id="inf500"><mml:mi>i</mml:mi></mml:math></inline-formula> in the presence of a neutralizing bNAb with concentration [A] as a weighted sum of the viral growth rate in the absence of bNAbs <inline-formula><mml:math id="inf501"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>, and the decay rate <inline-formula><mml:math id="inf502"><mml:mi>r</mml:mi></mml:math></inline-formula> of the virus due to neutralization; the respective weights are set according to the probability that a viral variant is bound (or unbound) to a bNAb (<xref ref-type="disp-formula" rid="equ52">Equation 51</xref>), which results in,<disp-formula id="equ53"><label>(52)</label><mml:math id="m53"><mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mtext>[A]</mml:mtext></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mtext>[A]</mml:mtext></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mtext>[A]</mml:mtext></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mi>r</mml:mi><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>In the course of a trial, the concentration of an infused bNAb decays exponentially <inline-formula><mml:math id="inf503"><mml:mrow><mml:mrow><mml:mtext>[A]</mml:mtext><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:msub><mml:mtext>[A]</mml:mtext><mml:mn>0</mml:mn></mml:msub><mml:mo>⁢</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:mfrac><mml:mi>t</mml:mi><mml:msub><mml:mi>τ</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:mfrac></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math></inline-formula>, with a characteristic time of about <inline-formula><mml:math id="inf504"><mml:mrow><mml:msub><mml:mi>τ</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo>≃</mml:mo><mml:mrow><mml:mn>20</mml:mn><mml:mo>⁢</mml:mo><mml:mtext> days</mml:mtext></mml:mrow></mml:mrow></mml:math></inline-formula><xref ref-type="bibr" rid="bib92">Stephenson et al., 2021</xref>; here <inline-formula><mml:math id="inf505"><mml:msub><mml:mtext>[A]</mml:mtext><mml:mn>0</mml:mn></mml:msub></mml:math></inline-formula> is the concentration of the bNAb upon infusion. By combining <xref ref-type="disp-formula" rid="equ53">Equation 52</xref> with the bNAb’s exponential decay over time, we find that the growth rate of variant <inline-formula><mml:math id="inf506"><mml:mi>i</mml:mi></mml:math></inline-formula> over time is given by<disp-formula id="equ54"><label>(53)</label><mml:math id="m54"><mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:msub><mml:mrow><mml:mtext>[A]</mml:mtext></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:msubsup><mml:mtext>IC</mml:mtext><mml:mrow><mml:mn>50</mml:mn></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup></mml:mfrac><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mfrac><mml:mi>t</mml:mi><mml:msub><mml:mi>τ</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:mi>r</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mi>r</mml:mi><mml:mo>.</mml:mo></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>The growth rate of the susceptible variant is determined by the ratio <inline-formula><mml:math id="inf507"><mml:mrow><mml:msub><mml:mtext>[A]</mml:mtext><mml:mn>0</mml:mn></mml:msub><mml:mo>/</mml:mo><mml:msubsup><mml:mtext>IC</mml:mtext><mml:mn>50</mml:mn><mml:mi>i</mml:mi></mml:msubsup></mml:mrow></mml:math></inline-formula> between the initial antibody concentration and the half maximal inhibitory concentration of the bNAb.</p><fig id="app3fig1" position="float"><label>Appendix 3—figure 1.</label><caption><title>The effect of incomplete neutralization.</title><p>Viral load curves, simulated under the noise-averaged model (deterministic limit) <xref ref-type="disp-formula" rid="equ4">Equation 4</xref>, are plotted under the assumption of incomplete neutralization for different values of <inline-formula><mml:math id="inf508"><mml:mrow><mml:msub><mml:mtext>[A]</mml:mtext><mml:mn>0</mml:mn></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mtext>IC</mml:mtext><mml:mn>50</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> (colors); incomplete neutralization is defined by a changing growth rate given by <xref ref-type="disp-formula" rid="equ54">Equation 53</xref>. Small values of <inline-formula><mml:math id="inf509"><mml:mrow><mml:mrow><mml:msub><mml:mtext>[A]</mml:mtext><mml:mn>0</mml:mn></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mtext>IC</mml:mtext><mml:mn>50</mml:mn></mml:msub></mml:mrow><mml:mo>≪</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> (red) lead to similar trajectories to the perfectly resistant variant (solid black line), while large <inline-formula><mml:math id="inf510"><mml:mrow><mml:mrow><mml:msub><mml:mtext>[A]</mml:mtext><mml:mn>0</mml:mn></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mtext>IC</mml:mtext><mml:mn>50</mml:mn></mml:msub></mml:mrow><mml:mo>≫</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> (green line) is indistinguishable from the fully susceptible variants (dotted black line). For all curves, the escaping virus has an initial frequency <inline-formula><mml:math id="inf511"><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mo>⁢</mml:mo><mml:mi>e</mml:mi><mml:mo>⁢</mml:mo><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>-</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>, with decay rate <inline-formula><mml:math id="inf512"><mml:mi>r</mml:mi></mml:math></inline-formula> and free growth rate <inline-formula><mml:math id="inf513"><mml:msup><mml:mi>γ</mml:mi><mml:mn>0</mml:mn></mml:msup></mml:math></inline-formula>, <inline-formula><mml:math id="inf514"><mml:mrow><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mn>0</mml:mn></mml:msup><mml:mo>=</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> days.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76004-app3-fig1-v2.tif"/></fig><p>As shown in <xref ref-type="fig" rid="app3fig1">Appendix 3—figure 1</xref>, if the initial antibody concentration is an order of magnitude below the IC<sub>50</sub>(orange line), the dynamics of a patient’s viremia closely resembles that of a fully resistant population (solid black line). On the other hand, if the initial bNAb dosage is an order of magnitude above the IC<sub>50</sub>(blue line), the dynamics behaves as though the viral population is completely susceptible (dotted line), resulting in a late viral rebound (more than 8 weeks). We find that incomplete neutralization is most relevant when the initial bNAb concentration is roughly similar to IC<sub>50</sub>, that is, <inline-formula><mml:math id="inf515"><mml:mrow><mml:mrow><mml:msub><mml:mtext>[A]</mml:mtext><mml:mn>0</mml:mn></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mtext>IC</mml:mtext><mml:mn>50</mml:mn></mml:msub></mml:mrow><mml:mo>≈</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> (green line). Therefore, our binary categorization is applicable so long as the distribution of <inline-formula><mml:math id="inf516"><mml:msubsup><mml:mtext>IC</mml:mtext><mml:mn>50</mml:mn><mml:mi>i</mml:mi></mml:msubsup></mml:math></inline-formula> has low density around initial serum concentrations <inline-formula><mml:math id="inf517"><mml:msub><mml:mtext>[A]</mml:mtext><mml:mn>0</mml:mn></mml:msub></mml:math></inline-formula>. The likelihood of <inline-formula><mml:math id="inf518"><mml:msubsup><mml:mtext>IC</mml:mtext><mml:mn>50</mml:mn><mml:mi>i</mml:mi></mml:msubsup></mml:math></inline-formula> matching the antibody dose determines the rate at which our results will be biased by incomplete neutralization.</p><p>To compare IC<sub>50</sub>with the initial bNAb concentration, we use the neutralization data from the 10–1074 bNAb trial <xref ref-type="bibr" rid="bib12">Caskey et al., 2017</xref>. For this trial, TZM-bl neutralization assays against different bNAbs were obtained on 114 pseudoviruses expressing envelope proteins derived from circulating viruses in patients on day 0 (55 pseudoviruses) and week 4 (59 pseudoviruses) after 10–1074 infusion. Expectantly, a fraction of viruses from week 4 were resistant (i.e. large IC<sub>50</sub>) to the 10–1074 bNAb used in the trial (orange histogram in <xref ref-type="fig" rid="app3fig2">Appendix 3—figure 2A</xref>). However, almost all viruses were susceptible to the (control) 3BNC117 bNAb, which the viruses had not been previously exposed to (orange histogram in <xref ref-type="fig" rid="app3fig2">Appendix 3—figure 2B</xref>).</p><p>For comparison, the distribution for the initial concentration <inline-formula><mml:math id="inf519"><mml:msub><mml:mtext>[A]</mml:mtext><mml:mn>0</mml:mn></mml:msub></mml:math></inline-formula> (or equivalently the maximum concentration) of the infused 10–1074 bNAb in patients enrolled in this trial is shown in <xref ref-type="fig" rid="app3fig2">Appendix 3—figure 2</xref> (blue histograms), and is peaked around <inline-formula><mml:math id="inf520"><mml:mrow><mml:mn>200</mml:mn><mml:mo>⁢</mml:mo><mml:mi>μ</mml:mi><mml:mo>⁢</mml:mo><mml:mtext>g/ml</mml:mtext></mml:mrow></mml:math></inline-formula>. The IC<sub>50</sub>values in this trial are much lower (higher) for susceptible (resistant) variants compared to the initial bNAb concentrations. Therefore, our simplified model assuming that a viral variant is either fully resistant or susceptible to a bNAb (i.e. no incomplete escape) is a reasonable approach for capturing the statistics of treatment failure at the concentrations tested in these trials. Nonetheless, developing a genotype-to-neutralization model such as the ones developed by <xref ref-type="bibr" rid="bib98">Wagh et al., 2016</xref>; <xref ref-type="bibr" rid="bib104">Yu et al., 2019</xref>, may allow for a more nuanced approach to modeling of neutralization in future work.</p><fig id="app3fig2" position="float"><label>Appendix 3—figure 2.</label><caption><title>The distribution of <inline-formula><mml:math id="inf521"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mtext>IC</mml:mtext><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf522"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mtext>[A]</mml:mtext></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>.</title><p>The distribution of IC<sub>50</sub>for envelope proteins derived from circulating viruses in patients after 10–1074 infusion is shown against (<bold>A</bold>) 10–1074, (<bold>B</bold>) 3BNC117 as a control. For comparison, the distribution of the maximum (initial) 10–1074 bNAb concentration used in the trial is shown in blue. The maximum measurable <inline-formula><mml:math id="inf523"><mml:mrow><mml:msub><mml:mtext>IC</mml:mtext><mml:mn>50</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mpadded width="+1.7pt"><mml:mn>50</mml:mn></mml:mpadded><mml:mo>⁢</mml:mo><mml:mi>μ</mml:mi><mml:mo>⁢</mml:mo><mml:mtext>g /ml</mml:mtext></mml:mrow></mml:mrow></mml:math></inline-formula> associated with the TZM-bl neutralization assays used in these experiments is indicated in each panel.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76004-app3-fig2-v2.tif"/></fig></sec></app><app id="appendix-4"><title>Appendix 4</title><sec sec-type="appendix" id="s10"><title>Comparison of DMS-inferred and trial-inferred escape pathways</title><p>In this appendix we compare the sensitivity of our rebound time predictions to the methodology used to identify sites of escape (i.e., data from DMS experiments versus therapy trials). To do so, we focus on two bNAbs, 10–1074 and PGT121 for which we have access to both the trial <xref ref-type="bibr" rid="bib12">Caskey et al., 2017</xref>; <xref ref-type="bibr" rid="bib92">Stephenson et al., 2021</xref> and the DMS data <xref ref-type="bibr" rid="bib21">Dingens et al., 2019</xref>; <xref ref-type="bibr" rid="bib20">Dingens et al., 2017</xref>; <xref ref-type="bibr" rid="bib83">Schommers et al., 2020</xref>. The inferred resistant and susceptible variants at the identified sites for both of these bNAbs based on their respective trials and the DMS data are reported in <xref ref-type="table" rid="app4table1">Appendix 4—table 1</xref>.</p><p>Although there is a lot of commonalities among the two approaches, the two methods can be sensitive to different mutational pathways in certain sites. This is in part expected as the DMS procedure can generate many rare variants, but all on a common genetic background background; in this case the experiments scan only single point mutations away from the HIV-1 strain BF520.W14M.C2 <xref ref-type="bibr" rid="bib20">Dingens et al., 2017</xref>. On the other hand, the clinical trial data shows escape variants on the genetic background of a diverse viral population circulating in a patient, and the fate of a mutation can be strongly determined by the epistatic interactions with the background genome that it appears on.</p><table-wrap id="app4table1" position="float"><label>Appendix 4—table 1.</label><caption><title>Escape variants inferred from trial and DMS data.</title><p>Tables show the sites mediating escape of HIV-1 from the 10–1074 and the PGT121 bNAbs, using the respective trial data <xref ref-type="bibr" rid="bib12">Caskey et al., 2017</xref>; <xref ref-type="bibr" rid="bib92">Stephenson et al., 2021</xref> (left) and the DMS data <xref ref-type="bibr" rid="bib20">Dingens et al., 2017</xref> (right). The susceptible (sus) and resistant (res) variants at each site are identified according to the procedure detailed in the Methods. Sites that are identified as escape-mediating by only one of the methods are marked with (*). While substitutions at site 325 were called as escape mediating based on the PGT121 trial data <xref ref-type="bibr" rid="bib92">Stephenson et al., 2021</xref> but are missed by the DMS data, this site was only inconsistently associated with escape, and its associated escape variants usually co-occur with other escape substitutions; see the Extended Data Figure 3 in <xref ref-type="bibr" rid="bib92">Stephenson et al., 2021</xref>. Sites are numbered according to HXB2.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top"/><th align="left" valign="top" colspan="2">10–1074 trial</th><th align="left" valign="top"/><th align="left" valign="top"/><th align="left" valign="top" colspan="2">10–1074 trial</th></tr></thead><tbody><tr><td align="left" valign="top">HXB2 site</td><td align="left" valign="top">sus</td><td align="left" valign="top">res</td><td align="left" valign="top"/><td align="left" valign="top">HXB2 site</td><td align="left" valign="top">sus</td><td align="left" valign="top">res</td></tr><tr><td align="left" valign="top">325</td><td align="left" valign="top">DN</td><td align="left" valign="top">EGK</td><td align="left" valign="top"/><td align="left" valign="top">325</td><td align="left" valign="top">DN</td><td align="left" valign="top">EGK</td></tr><tr><td align="left" valign="top">330*</td><td align="left" valign="top">FHLQSYR</td><td align="left" valign="top">*1,731</td><td align="left" valign="top"/><td align="left" valign="top">330</td><td align="left" valign="top">FHLQSYR</td><td align="left" valign="top">R</td></tr><tr><td align="left" valign="top">332</td><td align="left" valign="top">N</td><td align="left" valign="top">DHIKSTY</td><td align="left" valign="top"/><td align="left" valign="top">332</td><td align="left" valign="top">N</td><td align="left" valign="top">ADEIKTV</td></tr><tr><td align="left" valign="top">334</td><td align="left" valign="top">S</td><td align="left" valign="top">AFGINRY</td><td align="left" valign="top"/><td align="left" valign="top">334</td><td align="left" valign="top">S</td><td align="left" valign="top">DGN</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top"/><td align="left" valign="top" colspan="2"><bold>PGT121 trial</bold></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top" colspan="2"><bold>PGT121 DMS</bold></td></tr><tr><td align="left" valign="top">HXB2 site</td><td align="left" valign="top">sus</td><td align="left" valign="top">res</td><td align="left" valign="top"/><td align="left" valign="top">HXB2 site</td><td align="left" valign="top">sus</td><td align="left" valign="top">res</td></tr><tr><td align="left" valign="top">325</td><td align="left" valign="top">D</td><td align="left" valign="top">NKT</td><td align="left" valign="top"/><td align="left" valign="top">325*</td><td align="left" valign="top">DNKT</td><td align="left" valign="top">*</td></tr><tr><td align="left" valign="top">330*</td><td align="left" valign="top">FHLQSYR</td><td align="left" valign="top">*1,733</td><td align="left" valign="top"/><td align="left" valign="top">330</td><td align="left" valign="top">FHLRSY</td><td align="left" valign="top">Q</td></tr><tr><td align="left" valign="top">332</td><td align="left" valign="top">NV</td><td align="left" valign="top">DSRTI</td><td align="left" valign="top"/><td align="left" valign="top">332</td><td align="left" valign="top">AENV</td><td align="left" valign="top">DIKT</td></tr><tr><td align="left" valign="top">334</td><td align="left" valign="top">TS</td><td align="left" valign="top">RND</td><td align="left" valign="top"/><td align="left" valign="top">334</td><td align="left" valign="top">DS</td><td align="left" valign="top">GN</td></tr></tbody></table></table-wrap><p>To assess the sensitivity of our analyses, we make predictions for the distribution of rebound times, using the escape pathways identified based on the DMS versus the trial data in <xref ref-type="table" rid="app4table1">Appendix 4—table 1</xref>. Overall, we see good agreements between the two approaches, but DMS-inferred escape pathways predict slightly too many patients with late rebound (<inline-formula><mml:math id="inf524"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>&gt;</mml:mo><mml:mn>56</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> days) compared to the trial-based inference, i.e., DMS-based predictions are more optimistic (<xref ref-type="fig" rid="app4fig1">Appendix 4—figure 1</xref>). This deviation is likely to be related to the diversity of viral genetic backgrounds in clinical trials, since more escape pathways could be realized through positive epistasis, leading to a faster viral rebound.</p><fig id="app4fig1" position="float"><label>Appendix 4—figure 1.</label><caption><title>Statistics of viral rebound with using escape pathways inferred from the DMS and the trial data.</title><p>We compare the distribution of rebound times in patients from the clinical trials with 10–1074 <xref ref-type="bibr" rid="bib12">Caskey et al., 2017</xref> (top) and PGT121 <xref ref-type="bibr" rid="bib92">Stephenson et al., 2021</xref> (bottom) bNAbs, using escape pathways inferred from the respective trial data (left) and the DMS data <xref ref-type="bibr" rid="bib20">Dingens et al., 2017</xref> (right). The error bars show the inter decile range (0.1–0.9 quantiles) generated by the simulations for the corresponding trial. The PGT121 trial predictions relied on the neutral diversity estimates <inline-formula><mml:math id="inf525"><mml:msub><mml:mi>θ</mml:mi><mml:mtext>ts</mml:mtext></mml:msub></mml:math></inline-formula> from the other three trials <xref ref-type="bibr" rid="bib10">Caskey et al., 2015</xref>; <xref ref-type="bibr" rid="bib12">Caskey et al., 2017</xref>; <xref ref-type="bibr" rid="bib4">Baron et al., 2018</xref> due to the relatively limited genetic data available from this study. The fitted reservoir value of <inline-formula><mml:math id="inf526"><mml:mrow><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mo>⁢</mml:mo><mml:mi>e</mml:mi><mml:mo>⁢</mml:mo><mml:mi>s</mml:mi><mml:mo>⁢</mml:mo><mml:mi>v</mml:mi></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>2.07</mml:mn></mml:mrow></mml:math></inline-formula> is used for all predictions.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76004-app4-fig1-v2.tif"/></fig></sec></app><app id="appendix-5"><title>Appendix 5</title><sec sec-type="appendix" id="s11"><title>Simulation algorithms</title><table-wrap id="inlinetable1" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Algorithm 1. Population initialization</th></tr></thead><tbody><tr><td align="left" valign="top"><bold>procedure</bold> Population Initialization (<inline-formula><mml:math id="inf527"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>σ</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>L</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>L</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msubsup><mml:mi>θ</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mo>†</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>)<break/><break/>⊳ Generates a population of size of <inline-formula><mml:math id="inf528"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> from equilibrium. <inline-formula><mml:math id="inf529"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>θ</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>, and <inline-formula><mml:math id="inf530"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>σ</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> are the parameters defining the equilibrium values of the population state. Returns the initial vector of genotypes<break/><bold>  for</bold> <inline-formula><mml:math id="inf531"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>i</mml:mi><mml:mo>∈</mml:mo><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>L</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> <bold>do</bold><break/>     <inline-formula><mml:math id="inf532"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>∼</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mtext>eq</mml:mtext></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:msub><mml:mi>σ</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msubsup><mml:mi>θ</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mo>†</mml:mo></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula><break/><bold>   end for</bold><break/><bold>  for</bold> <inline-formula><mml:math id="inf533"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>v</mml:mi><mml:mo>∈</mml:mo><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> <bold>do</bold> <inline-formula><mml:math id="inf534"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>ρ</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi>v</mml:mi></mml:mrow></mml:msubsup><mml:mo>∼</mml:mo><mml:mtext>Bernoulli</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula><bold><break/>  end for</bold><break/><bold>return</bold> <inline-formula><mml:math id="inf535"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mi>ρ</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math></inline-formula><break/><bold>end procedure</bold></td></tr></tbody></table></table-wrap><table-wrap id="inlinetable2" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Algorithm 2. Gibbs Sampler for Allele Frequencies</th></tr></thead><tbody><tr><td align="left" valign="top"><bold>procedure</bold> Equlibrium Sampler (<inline-formula><mml:math id="inf536"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>σ</mml:mi><mml:mo>,</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mrow><mml:mo>†</mml:mo></mml:mrow></mml:msup><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mtext>Samples</mml:mtext></mml:mrow></mml:mstyle></mml:math></inline-formula>)<break/><break/>⊳Generates a stream of non-independent but rapidly mixing samples <inline-formula><mml:math id="inf537"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>X</mml:mi><mml:mo>∼</mml:mo><mml:mi>p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mi>σ</mml:mi><mml:mo>,</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mrow><mml:mo>†</mml:mo></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula>. Default BurnIn is 10.<break/> <break/>   <inline-formula><mml:math id="inf538"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>N</mml:mi><mml:mo stretchy="false">←</mml:mo><mml:mtext>Samples</mml:mtext><mml:mo>+</mml:mo><mml:mtext>BurnIn</mml:mtext></mml:mrow></mml:mstyle></mml:math></inline-formula> <break/>   <inline-formula><mml:math id="inf539"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">←</mml:mo><mml:mtext>Round</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mi>σ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula><break/>   <bold>for</bold> <inline-formula><mml:math id="inf540"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>N</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> <bold>do</bold> <break/>    <inline-formula><mml:math id="inf541"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>∼</mml:mo><mml:mtext>Beta</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup><mml:mo>+</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula>                          ⊳Sample the mutant fraction<break/>     <inline-formula><mml:math id="inf542"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>∼</mml:mo><mml:mtext>Poisson</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mi>σ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula>                     ⊳Sample the auxiliary parameter<break/>  <bold>end for</bold> <break/><bold>return</bold> <inline-formula><mml:math id="inf543"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mtext>BurnIn</mml:mtext><mml:mo>:</mml:mo><mml:mi>N</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>     ⊳Return only the mutant frequency <inline-formula><mml:math id="inf544"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>X</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> part of the chain (marginalize over <inline-formula><mml:math id="inf545"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>)<break/><bold>end procedure</bold></td></tr></tbody></table></table-wrap><table-wrap id="inlinetable3" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Algorithm 3. Population time step</th></tr></thead><tbody><tr><td align="left" valign="top"><bold>procedure</bold> EvolvePopulation (<inline-formula><mml:math id="inf546"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>t</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>ρ</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>N</mml:mi></mml:mrow></mml:msup><mml:mo fence="false" stretchy="false">|</mml:mo><mml:mi>λ</mml:mi><mml:mo>,</mml:mo><mml:mi>γ</mml:mi><mml:mo>,</mml:mo><mml:mi>r</mml:mi><mml:mo>,</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula>) <break/>⊳ Acts on a time <inline-formula><mml:math id="inf547"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> and a list of <inline-formula><mml:math id="inf548"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> genotypes <inline-formula><mml:math id="inf549"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mi>ρ</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>N</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math></inline-formula>. Inherits dependency on other parameters from the fitness function <inline-formula><mml:math id="inf550"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>F</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>G</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula> and the <inline-formula><mml:math id="inf551"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mtext>Mutate</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mi>G</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula> operator which depend on <inline-formula><mml:math id="inf552"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>L</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>L</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msubsup><mml:mi>μ</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mo>†</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf553"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>γ</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> and the population diversity measure <inline-formula><mml:math id="inf554"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>.<break/><break/>  <inline-formula><mml:math id="inf555"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">←</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>N</mml:mi></mml:mfrac><mml:munder><mml:mo>∑</mml:mo><mml:mi>i</mml:mi></mml:munder><mml:mi>F</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>g</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msup><mml:mi>t</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mo stretchy="false">←</mml:mo><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mfrac><mml:mtext>RandExp()</mml:mtext><mml:mrow><mml:mi>λ</mml:mi><mml:mi>N</mml:mi></mml:mrow></mml:mfrac></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>i</mml:mi><mml:mo>∼</mml:mo><mml:mtext>Rand</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>G</mml:mi><mml:mo stretchy="false">←</mml:mo><mml:msup><mml:mi>ρ</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msup></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mstyle></mml:math></inline-formula>                                     <bold><break/>  if</bold> <inline-formula><mml:math id="inf556"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mtext>IsEscaped</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mi>G</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula> <bold>then</bold>                                    ⊳ If the virus is escaped<break/>     <inline-formula><mml:math id="inf557"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>D</mml:mi><mml:mo>∼</mml:mo><mml:mtext>Bernoulli</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mfrac><mml:mrow><mml:mi>λ</mml:mi><mml:mo>−</mml:mo><mml:mi>F</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>G</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mi>ϕ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>λ</mml:mi></mml:mrow></mml:mfrac><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula>                  ⊳ Determine if the virus dies (<inline-formula><mml:math id="inf558"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>D</mml:mi><mml:mo>=</mml:mo><mml:mtext>true</mml:mtext></mml:mrow></mml:mstyle></mml:math></inline-formula>) or lives (<inline-formula><mml:math id="inf559"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>D</mml:mi><mml:mo>=</mml:mo><mml:mtext>false</mml:mtext></mml:mrow></mml:mstyle></mml:math></inline-formula>).<break/><bold>   if</bold> <inline-formula><mml:math id="inf560"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>D</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> <bold>then</bold><break/>      <inline-formula><mml:math id="inf561"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:msup><mml:mi>N</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mo stretchy="false">←</mml:mo><mml:mi>N</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msup><mml:mi>ρ</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:msup><mml:mi>N</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:msup><mml:mo stretchy="false">←</mml:mo><mml:msup><mml:mi>ρ</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mrow><mml:mover><mml:mi>i</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover></mml:mrow><mml:mo>:</mml:mo><mml:mi>N</mml:mi></mml:mrow></mml:msup></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mstyle></mml:math></inline-formula>                            ⊳ Delete genotype at position <inline-formula><mml:math id="inf562"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula><break/><bold>   else</bold><break/>      <inline-formula><mml:math id="inf563"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:msup><mml:mi>N</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mo stretchy="false">←</mml:mo><mml:mi>N</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msup><mml:mi>ρ</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:msup><mml:mi>N</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:msup><mml:mo stretchy="false">←</mml:mo><mml:mtext>Append</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi>ρ</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>N</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:mi>G</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mstyle></mml:math></inline-formula>                   ⊳ Duplicate genotype at position <inline-formula><mml:math id="inf564"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula><break/><bold>   end if</bold><break/><bold>  else</bold>                                              ⊳ If the virus is neutralized <break/>   <inline-formula><mml:math id="inf565"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>D</mml:mi><mml:mo>∼</mml:mo><mml:mtext>Bernoulli</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mfrac><mml:mi>r</mml:mi><mml:mi>λ</mml:mi></mml:mfrac><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula>                                ⊳ remove it at the appropriate rate<break/><bold>   if</bold> <inline-formula><mml:math id="inf566"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>D</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> <bold>then</bold><break/>     <inline-formula><mml:math id="inf567"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:msup><mml:mi>N</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mo stretchy="false">←</mml:mo><mml:mi>N</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msup><mml:mi>ρ</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:msup><mml:mi>N</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:msup><mml:mo stretchy="false">←</mml:mo><mml:msup><mml:mi>ρ</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mrow><mml:mover><mml:mi>i</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover></mml:mrow><mml:mo>:</mml:mo><mml:mi>N</mml:mi></mml:mrow></mml:msup></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mstyle></mml:math></inline-formula>                               ⊳ Delete genotype at position <inline-formula><mml:math id="inf568"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula><break/><bold>   end if</bold><break/><bold>  end if</bold><break/>   <inline-formula><mml:math id="inf569"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>j</mml:mi><mml:mo>∼</mml:mo><mml:mtext>Rand</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:msup><mml:mi>N</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula>                                ⊳ Choose a random virus to mutate<break/>   <inline-formula><mml:math id="inf570"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mi>ρ</mml:mi><mml:mi>j</mml:mi></mml:msup><mml:mo stretchy="false">←</mml:mo><mml:mtext>Mutate</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi>ρ</mml:mi><mml:mi>j</mml:mi></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula>                           ⊳ Apply mutation operator with intensity <inline-formula><mml:math id="inf571"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>μ</mml:mi><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>λ</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula><break/><bold>return</bold> <inline-formula><mml:math id="inf572"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi>t</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mo>,</mml:mo><mml:msup><mml:mi>ρ</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:msup><mml:mi>N</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula>                            ⊳ Return the new time and the new population.<break/><bold>end procedure</bold></td></tr></tbody></table></table-wrap></sec><sec sec-type="appendix" id="s12"><title>Inference algorithms</title><table-wrap id="inlinetable4" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Algorithm 4. Importance sampled log-likelihood given a single datapoint</th></tr></thead><tbody><tr><td align="left" valign="top"><bold>procedure</bold> SigmaLikelihood (<inline-formula><mml:math id="inf573"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mover><mml:mi>μ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mo>,</mml:mo><mml:msup><mml:mrow><mml:mover><mml:mi>μ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mo>†</mml:mo></mml:msup><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>N</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>)           ⊳ Takes mutant <inline-formula><mml:math id="inf574"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> and susceptible <inline-formula><mml:math id="inf575"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> counts for a particular site at a single timepoint. Returns an approximate log-likelihood function <inline-formula><mml:math id="inf576"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>l</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mover><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:mi>P</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mrow><mml:mover><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>, up to an additive constant. SigmaLikelihood is a <italic>closure</italic> that returns a one-parameter function. We used N =103 samples. <break/>   <inline-formula><mml:math id="inf577"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mi>θ</mml:mi><mml:mo stretchy="false">←</mml:mo><mml:mrow><mml:mover><mml:mi>μ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup><mml:mo stretchy="false">←</mml:mo><mml:msup><mml:mrow><mml:mover><mml:mi>μ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mo>†</mml:mo></mml:msup><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mstyle></mml:math></inline-formula> <break/><bold>  for</bold> <inline-formula><mml:math id="inf578"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>i</mml:mi><mml:mo>∈</mml:mo><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>N</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> <bold>do</bold> <break/>     <inline-formula><mml:math id="inf579"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>∼</mml:mo><mml:mtext>Beta</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula>                           ⊳ Sample from the neutral distribution <break/>     <inline-formula><mml:math id="inf580"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>w</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">←</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mi mathvariant="script">B</mml:mi></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>θ</mml:mi><mml:mo>+</mml:mo><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup><mml:mo>+</mml:mo><mml:mi>s</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="script">B</mml:mi></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msubsup><mml:mi>x</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi></mml:msubsup><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mi>w</mml:mi></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula>                         ⊳ Importance weight ratio <break/>    <inline-formula><mml:math id="inf581"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>y</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>∼</mml:mo><mml:mtext>Beta</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mi>θ</mml:mi><mml:mo>+</mml:mo><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup><mml:mo>+</mml:mo><mml:mi>s</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula>                    ⊳ sample from the neutral distribution, conditioned on the observations <break/>     <inline-formula><mml:math id="inf582"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>v</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">←</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mi mathvariant="script">B</mml:mi></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>θ</mml:mi><mml:mo>+</mml:mo><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup><mml:mo>+</mml:mo><mml:mi>s</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="script">B</mml:mi></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mo>†</mml:mo></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msubsup><mml:mi>y</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi></mml:msubsup><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mi>w</mml:mi></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula>                          ⊳ Importance weight ratio <break/><bold>  end for</bold> <break/>  <inline-formula><mml:math id="inf583"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>Z</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mover><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo>:=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>N</mml:mi></mml:mfrac><mml:munder><mml:mo>∑</mml:mo><mml:mi>i</mml:mi></mml:munder><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mover><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:msup><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>N</mml:mi></mml:mfrac><mml:munder><mml:mo>∑</mml:mo><mml:mi>i</mml:mi></mml:munder><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mrow><mml:mover><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>y</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:msup><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>v</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula>         ⊳ importance sampling mean <break/>  <inline-formula><mml:math id="inf584"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>Z</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mover><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo>:=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>N</mml:mi></mml:mfrac><mml:munder><mml:mo>∑</mml:mo><mml:mi>i</mml:mi></mml:munder><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mover><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:msup><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msubsup><mml:mi>w</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>N</mml:mi></mml:mfrac><mml:munder><mml:mo>∑</mml:mo><mml:mi>i</mml:mi></mml:munder><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mrow><mml:mover><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>y</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:msup><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msubsup><mml:mi>v</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula>            ⊳ Note the inversion in the weighting factor compared to Z<sub>0</sub>. <break/><bold>return</bold> <inline-formula><mml:math id="inf585"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>l</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mover><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo>:=</mml:mo><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:msub><mml:mi>Z</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mover><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo>−</mml:mo><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:msub><mml:mi>Z</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mover><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula> ⊳ Return a log-likelihood function. The same random variable realizations <inline-formula><mml:math id="inf586"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>N</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf587"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>y</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>N</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> are cached in memory and used for each function evaluation, making <inline-formula><mml:math id="inf588"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>l</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mover><mml:mi>σ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula> continuous and differentiable. <break/><bold>end procedure</bold></td></tr></tbody></table></table-wrap><table-wrap id="inlinetable5" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Algorithm 5. Rebound-time Disparity</th></tr></thead><tbody><tr><td align="left" valign="top"><bold>procedure</bold> ReboundDisparity (<inline-formula><mml:math id="inf589"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>) <break/> ⊳ Takes the observed rebound times <inline-formula><mml:math id="inf590"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>∼</mml:mo><mml:mi>Q</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> from a set of trial patients and simulated late rebound times <inline-formula><mml:math id="inf591"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>∼</mml:mo><mml:mi>P</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> and returns a disparity estimator. <break/>   ⊳ First estimate the probabilities in the truncated observation categories <break/>  <inline-formula><mml:math id="inf592"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>N</mml:mi><mml:mi>R</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo stretchy="false">←</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>P</mml:mi></mml:mfrac><mml:munder><mml:mo>∑</mml:mo><mml:mi>p</mml:mi></mml:munder><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>&lt;</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">y</mml:mi></mml:mrow><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula>                ⊳ Count the fraction of non-responders in trial <break/>   <inline-formula><mml:math id="inf593"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>Q</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>N</mml:mi><mml:mi>R</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo stretchy="false">←</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>S</mml:mi></mml:mfrac><mml:munder><mml:mo>∑</mml:mo><mml:mi>s</mml:mi></mml:munder><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo>&lt;</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">y</mml:mi></mml:mrow><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula>                              ⊳... and in simulation <break/>   <inline-formula><mml:math id="inf594"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>L</mml:mi><mml:mi>R</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo stretchy="false">←</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>P</mml:mi></mml:mfrac><mml:munder><mml:mo>∑</mml:mo><mml:mi>p</mml:mi></mml:munder><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>≥</mml:mo><mml:mn>56</mml:mn><mml:mtext> days</mml:mtext><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula>              ⊳ Count the fraction of late rebounds in trial <break/>   <inline-formula><mml:math id="inf595"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>Q</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>L</mml:mi><mml:mi>R</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo stretchy="false">←</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>S</mml:mi></mml:mfrac><mml:munder><mml:mo>∑</mml:mo><mml:mi>s</mml:mi></mml:munder><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo>≥</mml:mo><mml:mn>56</mml:mn><mml:mtext> days</mml:mtext><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula>                           ⊳... and in simulation <break/>   ⊳ Then construct a histogram over the continuous data-points (i.e. <italic>t</italic> ∈ [0, 56]) and estimate the probability in each bin <break/>  <inline-formula><mml:math id="inf596"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:msup><mml:mi>P</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mtext>SortAscending</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mi>F</mml:mi><mml:mi>i</mml:mi><mml:mi>l</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mo stretchy="false">[</mml:mo><mml:mn>1</mml:mn><mml:mo>≤</mml:mo><mml:mi>t</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>56</mml:mn><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula> ⊳ Select only the observed rebound times <break/>   <inline-formula><mml:math id="inf597"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">←</mml:mo><mml:mo>−</mml:mo><mml:mi mathvariant="normal">∞</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf598"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:msup><mml:mi>P</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">←</mml:mo><mml:mi mathvariant="normal">∞</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> <break/><bold>  for</bold> <inline-formula><mml:math id="inf599"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>p</mml:mi><mml:mo>∈</mml:mo><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:msup><mml:mi>P</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:mstyle></mml:math></inline-formula> <bold>do</bold> <break/>     <inline-formula><mml:math id="inf600"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>Q</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>p</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo stretchy="false">←</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>P</mml:mi></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula>      ⊳ By design, each histogram bin contains one observed data point, and gets 1 <italic>/</italic>P mass <break/>     <inline-formula><mml:math id="inf601"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>p</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo stretchy="false">←</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>S</mml:mi></mml:mfrac><mml:munder><mml:mo>∑</mml:mo><mml:mi>s</mml:mi></mml:munder><mml:mo stretchy="false">[</mml:mo><mml:mo movablelimits="true" form="prefix">max</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>≤</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo>&lt;</mml:mo><mml:mo movablelimits="true" form="prefix">min</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>56</mml:mn><mml:mo>,</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mtext> days</mml:mtext><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula>     ⊳ Use the midpoints of adjacent points to construct the boundaries of histogram bins, and determine probability mass in each bin. <break/><bold>  end for</bold> <break/><bold>return</bold> <inline-formula><mml:math id="inf602"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>P</mml:mi><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>∈</mml:mo><mml:mi>N</mml:mi><mml:mi>R</mml:mi><mml:mo>,</mml:mo><mml:mi>L</mml:mi><mml:mi>R</mml:mi><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:msup><mml:mi>P</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:munder><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>Q</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msubsup><mml:mi>P</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mstyle></mml:math></inline-formula>    ⊳ Return the discretized estimate of the Hellinger distance, scaled by the number of patients <break/><bold>end procedure</bold></td></tr></tbody></table></table-wrap></sec></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.76004.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sprenger</surname><given-names>Kayla</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/042nb2s44</institution-id><institution>Massachusetts Institute of Technology</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2021.12.03.21267269" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2021.12.03.21267269"/></front-stub><body><p>This paper will be of interest to scientists within the fields of statistical and biological physics, immunology, and vaccinology. The mathematical/statistical framework is rigorously constructed based on key concepts from population genetics and high-throughput viral genetic sequence data. The results provide important insights into the failures of past treatment regimens with broadly neutralizing antibodies to suppress viral escape in clinical trial participants. The results also present exciting and highly testable predictions of improved treatment strategies for combatting HIV through passive bnAb immunization.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.76004.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Sprenger</surname><given-names>Kayla</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/042nb2s44</institution-id><institution>Massachusetts Institute of Technology</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Sprenger</surname><given-names>Kayla</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/042nb2s44</institution-id><institution>Massachusetts Institute of Technology</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.12.03.21267269">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2021.12.03.21267269v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Design of an optimal combination therapy with broadly neutralizing antibodies to suppress HIV-1&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including Kayla Sprenger as Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Miles Davenport as the Senior Editor.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) The text should be modified to more clearly convey the novelty of the current work, and to better place the current work within the context of the existing literature on bnAb therapy design both from an experimental and computational perspective. Specifically, the conceptual advances that this work offers in terms of methodology and/or success in therapy design over past studies should be made more clear, and additional citations/discussion of existing literature is warranted.</p><p>For example, combination therapy with more than two bnAbs vs. fewer has long been shown to be more effective in suppressing early rebound. A suggestion is to note this fact and discuss the benefits of clinical corroboration of the model's results – i.e., that this corroboration provides a basis for using the model to interrogate new bnAbs (for which DMS data is available), and/or the combinatorial explosion of higher order cocktails for which we cannot possibly test all combinations.</p><p>2) Related to the above note, the non-independence of bnAbs is an important point that should be discussed/acknowledged as a potential shortcoming of the model.</p><p>3) As presented, the deep mutational scanning data is not convincing in its ability to fully characterize the spectrum of escape mutations, given the typical inability of DMS data to probe the low-frequency variants that primarily mediate rebound. More work needs to be done here to ensure/make clear that the predictive power of the approach is strong in this regard.</p><p>4) More discussion should be focused around specific use cases of the work. Particularly, since the framework is most predictive for early rebound times, it should be emphasized that the results from this work would best translate to, e.g., the design of short term suppressive treatments, rather than therapy efficacy over longer timescales, which would require a more complete characterization.</p><p>5) More discussion of how the predicted fitness costs compare to the older fitness landscape work would be useful context in the discussion.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>General comments/questions:</p><p>In the Abstract (and Discussion), it is stated that bnAbs may serve as an alternative strategy to antiretroviral therapy against HIV, yet in the Introduction it is stated that augmenting antiretroviral therapy with bnAbs may be a fruitful strategy against HIV. Perhaps highlight the more promising approach of the two for consistency?</p><p>Line 52 states that prior work on designing bnAb therapies did not consider viral dynamics, yet the following sentence appears to give theoretical examples of just this (&quot;dynamics of viremia&quot;). Was the first sentence referring to prior experimental work?</p><p>In general, I find the paragraph in the Introduction between lines 52-72 to be a bit unfocused; what are the authors wishing to communicate here? Specifically, regarding lines 58-72, it seems like one could skip straight from line 57 to 73 and it would flow just as well.</p><p>Line 93: are the authors referring to cancer cells, or cancer-causing pathogens? Do such extensive longitudinal sequence datasets also exist for resistant bacteria and cancer-causing pathogens as for HIV, that would enable translation of this approach to those settings?</p><p>Line 106-107, Equation 1 appears to model the virus population size as a function of time (N(t)), rather than the rebound time explicitly (perhaps reword slightly?).</p><p>Line 119: in defining the actual rebound time, T=-γ^-1*logx, it would seem that this is a constant, since γ is a constant, and x is also an inferred constant. If this is correct, why is equation 1 needed? Likely, I am just missing something here!</p><p>Line 135: it might be helpful to talk more physically about what is meant by the 'birth' and 'death' of a variant (variant completely dies out? Or the variant population declines as a result of bnAb infusion?). Does a single amino acid mutation move a variant a to another type b?</p><p>Line 155: Is not the mutation rate of HIV well known already? Is the rate inferred by the authors in line with past estimates?</p><p>Line 156-157: The authors state that the 'fastest process in the dynamics…is the growth rate of susceptible viruses&quot;. Should this not say 'resistant viruses&quot;, since γ = 1/3 days<sup>-1</sup> vs. 3 days<sup>-1</sup> for susceptible viruses, or &quot;slowest process&quot;?</p><p>Line 174: &quot;mutational target size&quot; is not very intuitive for me. I know it is defined later on lines 211-213, but perhaps this can be summarized or stated more intuitively here, as well as in the Discussion?</p><p>Lines 178-182: the authors propose to infer mutation and fitness characteristics of escape-mediating HIV variants via sequence data. Work out of Arup Chakraborty's lab at MIT comes to mind on developing HIV fitness landscapes. Would this not offer the same information for parameterizing the birth-death model? Perhaps the potential relevance/connection between those past works and the current work could be briefly discussed.</p><p>In the section on 'Diversity of the viral population', it seems counterintuitive to me that characterizing only synonymous mutations as a measure of neutral genetic diversity would allow one to determine the 'chance to observe a rare (e.g., resistant) mutation' (line 185), since this implies a change in the amino acid sequence of the protein. I must not be thinking about this correctly; can the authors please clarify this for me?</p><p>Lines 222-223: The footprint of a bnAb is often larger than the actual epitope, which may contain both variable and conserved sites (e.g., the CD4 binding site). Thus, bnAbs must bind to both residue types. Given this, why do the authors expect HIV escape mutations to be intrinsically deleterious for the virus (implying they occur mostly at conserved sites), vs. occurring at the nearby variable sites that bnAbs also contact? For example, the following paper, https://www.pnas.org/content/115/4/E564, states that &quot;Even for the relatively &quot;conserved&quot; CD4 binding-site region, only mutations at some residues are predicted to incur large fitness costs upon mutations.&quot;</p><p>Line 314: what do the authors classify as 'early rebound'? Below 56 days?</p><p>Line 330-332: the first part of this statement makes sense to me (that fitness-limiting bnAbs like PGT151 are best against high-diversity viral populations), but I am not certain about the second part. Wouldn't fitness-limiting and mutation-limiting bnAbs be equally good against low-diversity viral populations?</p><p>Lines 378-379: Might it be possible for the authors to speculate on how the exclusion of the dynamics of Ab concentration and IC50 neutralization during treatments could affect their results/conclusions?</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>In Appendix 1, the authors might consider coloring the resistant and susceptible amino acid identities based on the data source (DMS, patient-derived, crystallography).</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.76004.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) The text should be modified to more clearly convey the novelty of the current work, and to better place the current work within the context of the existing literature on bnAb therapy design both from an experimental and computational perspective. Specifically, the conceptual advances that this work offers in terms of methodology and/or success in therapy design over past studies should be made more clear, and additional citations/discussion of existing literature is warranted.</p><p>For example, combination therapy with more than two bnAbs vs. fewer has long been shown to be more effective in suppressing early rebound. A suggestion is to note this fact and discuss the benefits of clinical corroboration of the model's results – i.e., that this corroboration provides a basis for using the model to interrogate new bnAbs (for which DMS data is available), and/or the combinatorial explosion of higher order cocktails for which we cannot possibly test all combinations.</p></disp-quote><p>We thank the reviewers for this comment. We have now reorganized and extended the introduction and the discussion to better reflect prior work in both fitness inference and therapy optimization.</p><p>In the introduction, we elaborate on various modeling and experimental approaches for bNAb mono and combo therapy design, and describe how our approach is distinguished from the existing work. We have made the following changes in the introduction:</p><p>“We discuss the modeling and machine learning techniques trained on experimental data from neutralization assays against pseudo-viruses to characterize the efficacy of bNAbs and their combinations against different variants of HIV [R1–R3]. These modeling approaches to optimization view the infection as a static collection of viral strains to be neutralized as opposed to an actively evolving population. We then discuss the mechanistic models that have been developed to explain the dynamics of viremia in patients following passive infusion of bNAbs [R4–R9]. These detailed models use trial data to fit parameters in relation to a bNAb’s efficacy in clearing virions, reducing viral load, etc. These detailed mechanistic models cannot easily generalize from one trial to another in order to predict the efficacy of a new bNAb mono- or combination therapy. We describe how evolution of the HIV population is another key factor to consider in modeling the dynamics of viremia in response to therapy with ART or bNAb. We then present our approach as a coarse-grained evolutionary model of viral response to bNAb infusion that uses genetic data of HIV-1 in untreated patients to predict bNAb therapy outcome by characterizing the chances of viral escape from a given bNAb. Although our model does not accurately reproduce the detailed dynamics of viremia in each patient and lacks the mechanistic insight of richer models proposed previously, it can accurately predict the distribution of viral rebound times in response to passive bNAb infusions – a key measure of efficacy for a bNAb therapy trial. We then emphasize that our prediction for the viral rebound time in response to a bNAb relies on only a few patient-specific parameters (i.e., the genetic diversity of patients prior to treatment), and is primarily done based on the inferred genetic parameters from the deep sequencing of HIV-1 populations in a separate cohort of ART-naive patient. Therefore, we argue that our model could be used to guide therapy trial design by identifying optimal combinations of bNAbs to suppress evolutionary escape of HIV-1 in patients.”</p><p>In the Discussion we have added the reviewer’s suggestion to the text to argue how our approach can be used to identify combo therapies. From the Discussion section (lines 419-426):</p><p>“Combination therapy with more than two bNAbs (or drugs in ART) has long been shown to be more effective in suppressing early HIV rebound, both in theory and practice [R1,R2,R4,R10–R12]. In addition to corroborating this conclusion quantitatively, we provide a method for assessing new bNAbs for which escape mutations are known. Our method can be understood as a tool to navigate the combinatorial explosion of higher order cocktails for which we cannot possibly test all combinations. By assessing the evolvability of resistance against different combinations we can identify the best therapies to target for clinical trial. Specifically, we show that to suppress the chance of viral rebound to below 1%, we show that a combo-therapy with 3 bNAbs with a mixture of mutation- and selection-limited strategies that target different regions of the viral envelope is necessary. Such combination can counter the full variation of viral diversity observed in patients. We found that PG9, PG151, and VRC01, which respectively target V2 loop, Interface, and CD4 binding site of HIV envelope, form an optimal combination for a 3-bNAb therapy to limit HIV-1 escape in patients infected with clade B of the virus.”</p><disp-quote content-type="editor-comment"><p>2) Related to the above note, the non-independence of bnAbs is an important point that should be discussed/acknowledged as a potential shortcoming of the model.</p></disp-quote><p>We thank the reviewers for pointing this out. Indeed, using bNAbs that target the same (or structurally adjacent) epitopes in a therapy could lead to physical interference during neutralization, and in those cases the assumption of independence can well be violated. The sharing of mutational pathways invalidates the assumption of independence and may make our predictions too optimistic. Still, our model correctly finds that escape from combinations of bNAbs that target the same epitope is easier due to the fewer necessary mutations. We have now expanded our discussions on this matter in the manuscript:</p><p>From section Devising optimal bNAb therapy cocktails in the main text (lines 375-386):</p><p>“Escape from bNAbs in multivalent therapy is also influenced by the non-independence of escape pathways. Several of the bNAbs (e.g. 10-1074 and PG121) in this study target the same (or structurally adjacent) epitopes and escape from them is mediated by the same mutations. The sharing of mutational pathways invalidates the assumption of independence and may make our predictions too optimistic. However, the best performing antibody combinations in Figure 4C target multiple epitopes to reduce the chances of collective escape. Therefore, the assumptions of independent fitness effects and independent mutational pathways in this case are not consequential for the main predictions of our model (i.e., the choice of bNAb combinations). in vitro data shown in [R13] suggest that additive and independent effects are the norm, but that small but consistent synergistic effects may imply that our assumption of site-wise independence is conservative. More data on HIV escape from combinations of bNAbs would be informative for further modeling efforts and relevant for long-term therapy design.”</p><disp-quote content-type="editor-comment"><p>3) As presented, the deep mutational scanning data is not convincing in its ability to fully characterize the spectrum of escape mutations, given the typical inability of DMS data to probe the low-frequency variants that primarily mediate rebound. More work needs to be done here to ensure/make clear that the predictive power of the approach is strong in this regard.</p></disp-quote><p>We agree with the reviewers that the utility and limitations of the DMS data should be more clearly demonstrated. We have included a new Appendix (Appendix 4; Appendix 4 Figure 1; Appendix 4 Table 1) to compare predictions of rebound time distributions when identifying escape sites from the DMS data versus the trial data. We performed this comparison for the 10-1074 bNAb for which we have access to both the DMS and the trial data. We also included an analysis for a new therapy trial dataset with the PGT121 bNAb [R9]; in the previous version of this manuscript we only had access to the DMS data to characterize escape against PGT121. We should note that two other trial datasets are available for the 3BNC117 and VRC01 bNAbs. However, both of these bNAbs target the CD4 binding site of the env protein and, as noted in the manuscript, the DMS experiments in the presence of these bNAbs are very noisy and cannot be used to reliably identify the escape sites; see Appendix 4 for details.</p><p>In addition, we have included a discussion on this matter in the Methods section Model robustness, subsection Robustness of rebound time predictions to methods of identifying escape mutations (lines 1104-1121):</p><p>“Our predictions rely on identifying escape variants against each bNAb, either based on in-vivo trial data and patient surveillance, or in-vitro DMS assays. To test the sensitivity of our results to these methods, we compare the predictions of rebound time distributions when identifying escape sites from the DMS data versus the trial data. In Appendix 4 we perform this comparison for the 10-1074 and the PGT121 bNAbs; we do not include the 3BNC117 bNAb in this analysis since it targets the CD4 binding site of HIV-1and the DMS data is unreliable for identifying escape variants against it. As shown in Appendix 4-Figure 1, both trial-inferred and DMS-inferred escape sites result in good predictions for rebound time distributions. However, its appears that using the DMS-inferred escape sites could lead to a more optimistic prediction for treatment success (i.e., a later rebound). This inconsistency may be due to the fact that DMS data is collected in-vitro, and other biological factors could be influencing the in-vivo escape patterns. Moreover, the differences in the genetic composition of the HIV-1strains circulating in patients enrolled in trials and the strains used for the DMS experiments could lead to different epistatic interactions that can enhance or reduce the chances of escape. For a systematic understanding of these differences and limitations, more experiments would be necessary. Nonetheless, DMS data can provides baseline to gauge the efficacy of different bNAbs for therapy and further in-vivo investigation.”</p><p>We have also included a paragraph in the Discussion section, Limitations subsection on this point (lines 472490):</p><p>“Our predictions are limited by our ability to identify the escape variants for each bNAb, either based on the in-vivo trial data and patient surveillance, or in-vitro assays such as DMS experiments. In Appendix 4 we compare the accuracy of our predictions for the rebound time distributions of HIV using DMS-inferred versus trial-inferred escape variants against the 10-1074 and the PGT121 bNAbs, and we find good agreements between the two approaches in both cases. However, it should be noted that identifying escape variants from DMS experiments lead to a more optimistic prediction for treatment success during the first 8 weeks of trials (i.e., they suggest a later rebound). One reason for this discrepancy may be related to the distinct genetic composition of viruses in the two approaches. DMS experiments characterize HIV escape by introducing mutations on a single genetic background [R14–R16] (e.g. the HIV-1 strain BF520.W14M.C2 in [R14]), whereas clinical data contain diverse populations of viruses between and within individuals. It is more likely for diverse viral populations to contain variants in which positive epistasis between escape mutations and the background genome is present. Therefore, it is reasonable to expect that genetic data originating in clinical trials show more pathways of escape, resulting in a faster viral rebound following bNAb infusion. Nevertheless, DMS experiments are less costly for identifying escape variants compared to trials, and they provide a baseline to assess the efficacy of different bNAbs for therapy and further in-vivo investigations. More experiments would be necessary for a more systematic understanding of the limitations of each approach.”</p><disp-quote content-type="editor-comment"><p>4) More discussion should be focused around specific use cases of the work. Particularly, since the framework is most predictive for early rebound times, it should be emphasized that the results from this work would best translate to, e.g., the design of short term suppressive treatments, rather than therapy efficacy over longer timescales, which would require a more complete characterization.</p></disp-quote><p>We agree with the reviewers that we should emphasize the utility of our approach in designing short-term treatments, which we have included in the Discussion section. We have also added a discussion about combining ART and bNAb therapy for longer term treatments.</p><p>From the Discussion section (lines 433-455):</p><p>“The statistical agreement between our coarse-grained model and the observed distribution of the rebound times (Figure 3-B) implies that many of the mechanistic details are of secondary importance in predicting viral escape. Nonetheless, our approach falls short of reproducing the detailed characteristics of viremia traces in patients, especially at very short or very long times, during which the dynamics of T-cell response or the decay of bNAbs could play a role [R17–R19]. The relationship between the short-term suppression of the virus, which is the focus of this analysis, and the long-term treatment success is complicated by reestablishment of HIV from the latent reservoirs and different modes of intra-host HIV evolution [R20,R21].</p><p>One strategy to achieve a longer term treatment success is by combining bNAb therapy with ART. One main advantage of bNAb therapy is the fact that it can be administered once every few months, in contrast to ART, which should be taken daily and missing a dose could lead to viral rebound. Although multivalent bNAb therapy reduces the chances of short-term viral escape, viral escape remains a real obstacle for longer term success of a treatment with bNAbs. Alternatively, (fewer) bNAbs can be administered in combination with ART [R22,R23], whereby ART could lower the replication rate of the HIV population, reducing the viral diversity and the chances of viral escape. Specifically, we can expect that emergence and establishment of rare (i.e., strongly deleterious) escape variants against bNAbs to be less likely in ART+ patients, which suggests that fitness-limited bNAbs should be more effective in conjunction with ART. Still, more data would be necessary to understand the longterm efficacy of such augmented therapy, and specifically the role of viral reservoirs in this context. A modeling approach could then shed light on how ART administration and bNAb therapy could be combined to efficiently achieve viral suppression.”</p><p>Moreover, we also discuss aspects of therapy optimization (e.g. safety) that must be considered when identifying the most promising therapy.</p><p>From the Discussion section (lines 491-498):</p><p>“It should be noted that our analysis in [figure 4c (antibody ranking)] only focuses on one aspect of therapy optimization, i.e., the suppression of escape. Other factors, including potency (neutralization efficacy) and half-life of the bNAb, or the patient’s tolerance of bNAbs at different dosage should also be taken into account for therapy design. For example, the bNAb 10E8, which we identified as of the most promising mono-therapy candidates in Figure 4, is shown to be poorly tolerated by patients with short half-life [R24], making it undesirable for therapy purposes. Thus, the bNAb candidates shown in Figure 4C should be taken as a guideline to be complemented with further assessment of efficacy and safety for therapy design.”</p><disp-quote content-type="editor-comment"><p>5) More discussion of how the predicted fitness costs compare to the older fitness landscape work would be useful context in the discussion.</p></disp-quote><p>We thank the reviewers for pointing this out to us. We have included a comparison of our approach to other fitness inference work in the Methods section, Inference of selection for escape mutations against each bNAb (lines 902-919):</p><p>“Prior work has also inferred the fitness effect of mutations in HIV, but our approach differs in important aspects. For instance, maximum entropy models have been used to infer the preference of different amino acids in the Gag and the env proteins of HIV-1 from their prevalences across sequences sampled from different patients [R25,R26]. The inferred preference values can explain the in-vitro growth rate (fitness) of the associated viral strains, especially for sites that are relatively conserved and are not the drivers of antigenic evolution in HIV-1. However, further modeling would be needed to quantitively map these inferred amino acid preferences onto population genetics measures that can be used to characterize the evolutionary dynamics of an HIV population. Other work has used longitudinal HIV-1 sequence data to infer selection and to characterize the role of selective sweeps due to immune pressure, genetic hitchhiking and recombination in the turnover of HIV-1 populations within patients [R27–R30]. In contrast, our work focuses on the expected composition of the population in a viremic patient prior to the start of treatment as opposed to the history of a viral population. Our approach uses a self-consistent formalism for inference of the population genetics parameters (e.g. population diversity and selection strength) and for the evolutionary simulations used to predict outcomes. Therefore, we can directly interpret the fitted parameters in terms of both the viral dynamics and the pre-treatment state of HIV-1 populations within patients.”</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>General comments/questions:</p><p>In the Abstract (and Discussion), it is stated that bnAbs may serve as an alternative strategy to antiretroviral therapy against HIV, yet in the Introduction it is stated that augmenting antiretroviral therapy with bnAbs may be a fruitful strategy against HIV. Perhaps highlight the more promising approach of the two for consistency?</p></disp-quote><p>We thank the reviewer for pointing out this inconsistency to us. We have now included a paragraph in the Discussion section about augmenting ART with bNAb Therapy (lines 442-455):</p><p>“One strategy to achieve a longer term treatment success is by combining bNAb therapy with ART. One main advantage of bNAb therapy is the fact that it can be administered once every few months, in contrast to ART, which should be taken daily and missing a dose could lead to viral rebound. Although multivalent bNAb therapy reduces the chances of short-term viral escape, viral escape remains a real obstacle for longer term success of a treatment with bNAbs. Alternatively, (fewer) bNAbs can be administered in combination with ART [R22,R23], whereby ART could lower the replication rate of the HIV population, reducing the viral diversity and the chances of viral escape. Specifically, we can expect that emergence and establishment of rare (i.e., strongly deleterious) escape variants against bNAbs to be less likely in ART+ patients, which suggests that fitness-limited bNAbs should be more effective in conjunction with ART. Still, more data would be necessary to understand the longterm efficacy of such augmented therapy, and specifically the role of viral reservoirs in this context. A modeling approach could then shed light on how ART administration and bNAb therapy could be combined to efficiently achieve viral suppression.”</p><disp-quote content-type="editor-comment"><p>Line 52 states that prior work on designing bnAb therapies did not consider viral dynamics, yet the following sentence appears to give theoretical examples of just this (&quot;dynamics of viremia&quot;). Was the first sentence referring to prior experimental work?</p></disp-quote><p>We have fully restructured and extended the introduction in response to the Q #1, from essential revisions. We have also extended the paragraph that the reviewer is referring to: we have now separate discussions on the experimental work to measure the breadth of bNAbs for optimal therapy design without modeling the dynamics of viremia, and the mechanistic modeling and theoretical work to describe the details of the viremia dynamics in trial data. We believe these modifications have clarified the points conveyed in the introduction; see the response to Q#1 from essential revisions and the marked changes in the introduction.</p><disp-quote content-type="editor-comment"><p>In general, I find the paragraph in the Introduction between lines 52-72 to be a bit unfocused; what are the authors wishing to communicate here? Specifically, regarding lines 58-72, it seems like one could skip straight from line 57 to 73 and it would flow just as well.</p></disp-quote><p>We thank the reviewer for pointing this out and apologize for the confusing text. As noted in response Q #1 from essential revisions, we have restructured the Introduction to address this point.</p><disp-quote content-type="editor-comment"><p>Line 93: are the authors referring to cancer cells, or cancer-causing pathogens? Do such extensive longitudinal sequence datasets also exist for resistant bacteria and cancer-causing pathogens as for HIV, that would enable translation of this approach to those settings?</p></disp-quote><p>We clarified the language and explicitly mention “cancer tumor cells” in the manuscript.</p><p>Still, the reviewer’s question about cancer-causing pathogens is very interesting. There are various longitudinal studies for hepatitis C virus (HCV). The evolutionary rate of HCV is also comparable to that of HIV [R31]. Moreover, there is growing evidence that (naturally emerging) broadly neutralizing antibodies play an important role in immune-mediated control of hepatitis C virus (HCV) infection [R32]. Therefore it is likely that our modeling approach would be of relevance for therapy design against HCV. We have now added the example of HCV in the introduction.</p><p>Longitudinal data for HBV and HPV (two other cancer-causing pathogens) are more limited, but it would be interesting to collect and study such data.</p><disp-quote content-type="editor-comment"><p>Line 106-107, Equation 1 appears to model the virus population size as a function of time (N(t)), rather than the rebound time explicitly (perhaps reword slightly?).</p><p>Line 119: in defining the actual rebound time, T=-γ^-1*logx, it would seem that this is a constant, since γ is a constant, and x is also an inferred constant. If this is correct, why is equation 1 needed? Likely, I am just missing something here!</p></disp-quote><p>The reviewer is correct that equation 1 is the viral population size over time N(t). Specifically, this equation refers to the total viral population without reference to type, in the continuous deterministic limit (i.e. ignoring the noise terms in equation 2.) of the stochastic individual-based model. We simulate treatment outcomes using the full stochastic birth-death model, but we use this deterministic limit to analyze observed trajectories of patient viremia. Fitting N(t) is the basis for measuring the characteristic rebound time T and then for connecting the rebound time to the initial frequency of resistant variants x. This quantity is patient-specific—it is a single number characterizing the patient’s viremic response to treatment, but it varies from patient to patient. We have added clarifying wording and added patient-indicating subscripts to the parameters to make this clear (lines145-147):</p><p>“The maximum-likelihood fits of N(t) to the viremia measurements in Figure 3—figure supplement 1-3 specifies the initial resistant fraction xp and thus the rebound time Tp in each patient p, which in this simple model, is given by Tp = −γ−1 logxp.”</p><disp-quote content-type="editor-comment"><p>Line 135: it might be helpful to talk more physically about what is meant by the 'birth' and 'death' of a variant (variant completely dies out? Or the variant population declines as a result of bnAb infusion?). Does a single amino acid mutation move a variant a to another type b?</p></disp-quote><p>As an individual-based model, it is not birth and death of a variant, but rather birth and death of an individual member of a variant class (or generally an individual within a population). We have modified the language in the section Model: Stochastic evolutionary dynamics of HIV subject to bNAb therapy to clarify when we are describing the dynamics for individual virions (lines 164-169):</p><p>“At each generation, a virus with phenotype a can undergo one of three processes: birth, death and mutation to another type b, with rates βa, δa, and µa→b, respectively (Figure 1-B). The net growth rate of the viral subpopulation with phenotype a is the birth rate minus the death rate, γa = βa − δa (Figure 1-C). The total rate of events (birth and death) per virion λ = βi +δi modulates the amount of stochasticity in this birth-death process, which we assume to be constant across phenotypic variants.”</p><p>Regarding “Does a single amino acid mutation move a variant a to another type b?”: The amino acids at each site are grouped into two categories: susceptible and resistant. Replacing a susceptible amino acid with a resistant amino acid changes the type and fitness of the virus, but if the substitution replace an amino acid with another from the same category, the type of the virus is unchanged. Note that furthermore, a change of type does not necessarily move a virus between the susceptible and resistant classes. A virus is resistant to a given therapy if it has at least one escape mutation against each antibody, for all antibodies in a given therapy; see figure 1E for the details regarding the mutational model.</p><disp-quote content-type="editor-comment"><p>Line 155: Is not the mutation rate of HIV well known already? Is the rate inferred by the authors in line with past estimates?</p></disp-quote><p>The reviewer is correct that the mutation rates are known, both in-vitro and in-vivo. We were interested in the transition/transversion ratio as it manifests in formulation of the frequency spectrum (equation 12 in Methods, page 17). This ratio, rather than mutation rate itself, is necessary to model the frequency distribution of resistant viruses. We compare the result of our analysis to the estimate from [R33] in Methods (Page 21, as well as Figure 2-Supplement 1B-E) and find it in agreement. Nonetheless, for consistency, we used our likelihood estimates for the transition/transversion ratio in our further analysis, since we measured this ratio using the standing variation in untreated patients, and that our model is concerned with how mutational processes maintain resistant variants in steady state (standing variation) of a population. In [R33] and elsewhere, mutation rates are often measured using the divergence along a lineage over time.</p><disp-quote content-type="editor-comment"><p>Line 156-157: The authors state that the 'fastest process in the dynamics…is the growth rate of susceptible viruses&quot;. Should this not say 'resistant viruses&quot;, since γ = 1/3 days<sup>-1</sup> vs. 3 days<sup>-1</sup> for susceptible viruses, or &quot;slowest process&quot;?</p></disp-quote><p>The reviewer is correct, and we have fixed the typo.</p><disp-quote content-type="editor-comment"><p>Line 174: &quot;mutational target size&quot; is not very intuitive for me. I know it is defined later on lines 211-213, but perhaps this can be summarized or stated more intuitively here, as well as in the Discussion?</p></disp-quote><p>We have added a brief intuitive description at this line (now lines 204-205):</p><p>“The mutational target size for escape from the bNAb (i.e., the number of paths leading to escape, weighted by their respective probabilities) …”</p><disp-quote content-type="editor-comment"><p>Lines 178-182: the authors propose to infer mutation and fitness characteristics of escape-mediating HIV variants via sequence data. Work out of Arup Chakraborty's lab at MIT comes to mind on developing HIV fitness landscapes. Would this not offer the same information for parameterizing the birth-death model? Perhaps the potential relevance/connection between those past works and the current work could be briefly discussed.</p></disp-quote><p>We thank the reviewer for pointing this out to us. Please see our response to Q#5 from the essential revisions.</p><disp-quote content-type="editor-comment"><p>In the section on 'Diversity of the viral population', it seems counterintuitive to me that characterizing only synonymous mutations as a measure of neutral genetic diversity would allow one to determine the 'chance to observe a rare (e.g., resistant) mutation' (line 185), since this implies a change in the amino acid sequence of the protein. I must not be thinking about this correctly; can the authors please clarify this for me?</p></disp-quote><p>The reviewer is right in that neutral diversity alone is not enough to determine the “chance to observe a rare (e.g. resistant) mutation.” The neutral diversity is only part of our larger model that also includes the mutational targets size and the fitness effects. We have made the wording of this section more precise (lines 216-218):</p><p>“The neutral genetic diversity θ = 2Nkµ/λ (i.e., the number of segregating alleles) is an observable that relates to key population genetics parameters, i.e., the per-nucleotide mutation rate µ, the population carrying capacity Nk, and the total number of events per virus in the birth-death process λ, which determines the noise amplitude in the evolutionary dynamics (Methods). Nk and λ together determine the effective population size Ne = Nk/λ.”</p><p>To further clarify why neutral diversity is important for the inference of the non-synonomous substitution frequency: Note that the transition-mediated diversity θts = 2Neµts, is proportional to the effective population size Ne = Nk/λ with a fixed, known timescale µts. Because the value of Ne is shared across synonymous and non-synonymous sites, we can achieve higher statistical precision by determining Ne through θts using the synonymous sites, and then independently fitting the fitness differences from the frequency of non-synonymous substitutions.</p><disp-quote content-type="editor-comment"><p>Lines 222-223: The footprint of a bnAb is often larger than the actual epitope, which may contain both variable and conserved sites (e.g., the CD4 binding site). Thus, bnAbs must bind to both residue types. Given this, why do the authors expect HIV escape mutations to be intrinsically deleterious for the virus (implying they occur mostly at conserved sites), vs. occurring at the nearby variable sites that bnAbs also contact? For example, the following paper, https://www.pnas.org/content/115/4/E564, states that &quot;Even for the relatively &quot;conserved&quot; CD4 binding-site region, only mutations at some residues are predicted to incur large fitness costs upon mutations.&quot;</p></disp-quote><p>Yes, the variable regions mediate escape. However even the variable regions are not completely free from stabilizing fitness. We see that the distribution of amino acids at the escape sites we identify have much reduced entropy compared to the most diverse regions of env, the so-called hyper-variable regions (see the spreadsheet at https://www.hiv.lanl.gov/components/sequence/HIV/featuredb/search/env_ab_search_pub.comp for entropy estimates along gp160). There must therefore be stabilizing selection at these escape sites, reducing the amino-acid distribution entropy. At the same time, we agree that the strength of this selection need not be large. Note the selection we infer is only strong compared to mutation, and the relative fitness costs on absolute growth rate are generally not observable in the lab (perhaps 1% of the wild-type growth rates.)</p><p>The intrinsic fitness cost is not assumed, it is determined from the frequency data. It is possible for the inference process to return zero or even negative fitness costs and to include such costs in the simulation. However, it is certainly true that for a bNAb to be broad, escape must be rare. It is this feature which means that our fitness inference (which depends on observed frequencies) is generally expected to return a positive fitness cost of escape (or else infer an extremely small mutational target size). Otherwise escape alleles would be too common in sera and neutralization panels to be identified as broad in the first place. Therefore, our inferred valued cost values are consistent with this picture.</p><disp-quote content-type="editor-comment"><p>Line 314: what do the authors classify as 'early rebound'? Below 56 days?</p></disp-quote><p>Yes, we have clarified this term in the manuscript now. Early rebound refers to any rebound time occurring within 56 days of the start of therapy.</p><disp-quote content-type="editor-comment"><p>Line 330-332: the first part of this statement makes sense to me (that fitness-limiting bnAbs like PGT151 are best against high-diversity viral populations), but I am not certain about the second part. Wouldn't fitness-limiting and mutation-limiting bnAbs be equally good against low-diversity viral populations?</p></disp-quote><p>In the limit of very low diversity, the effect of selection is very weak since selection can act only on the circulating alleles. Therefore, the frequencies of resistant variants are determined by the mutational target size of each variant, irrespective of the fitness cost. It is therefore more advantageous to use a mutation-limiting antibody against a low-diversity viral population, rather than a selection-limiting antibody.</p><disp-quote content-type="editor-comment"><p>Lines 378-379: Might it be possible for the authors to speculate on how the exclusion of the dynamics of Ab concentration and IC50 neutralization during treatments could affect their results/conclusions?</p></disp-quote><p>We thank the reviewer for bringing up this interesting point. We have now added a new appendix (Appendix 3) discussing the impact of incomplete neutralization on viral rebound. We have also added language in the Discussion section, Limitations (page 12; lines 464-471):</p><p>In our model of viral escape, we neglect the possibility of incomplete escape of the virus due to the reduced neutralization efficacy of bNAbs as their concentrations decay during trials. In Appendix 3, we show that this simplifying assumption is valid as long as the IC50 is not the same order of magnitude as the initial dosage concentration of the infused bNAb. Notably, the data from therapy trials used in this study fall into the regime for which we can neglect the impact of incomplete neutralization (Appendix 3-Figure 2). However, taking into account the dependence of viral fitness on bNAb concentration and its neutralization efficacy, as in the model proposed by [R34], could improve the long-term predictive power of our approach.</p><p>Moreover, in Appendix 3 we explore the effects of incomplete neutralization on rebound trajectories. As we show in Appendix 3-Figure 1, if an antibody has an IC50 against the viral variant which is an order of magnitude above the initial antibody concentration, the viral dynamics very closely follows the idealized “escaped” trajectory (i.e., with complete neutralization). On the other hand, for an IC50 an order of magnitude below the initial concentration, the viral dynamics behave similarly to a completely neutralized virus, with a late rebound (later than 8 weeks). We found that the most important effect of incomplete neutralization on the dynamics of viremia occurs when the antibody has an IC50 against a resistant variant that is roughly of similar magnitude to the initial bNAb concentration in a patient’s serum; see Appendix 3-Figure 1. In Appendix 3-Figure 2 we show the distribution of IC50 and the initial bNAb concentration from the 10-1074 trial [R35] to see how often we would expect IC50 and initial concentration to be of the same order of magnitude. We find that the IC50 values in this trial are much lower (higher) for susceptible (resistant) variants compared to the initial bNAb concentration in all patients. Therefore, our simplified model assuming that a viral variant is either fully resistant or susceptible to a bNAb (i.e., no incomplete escape) is a reasonable approach for capturing the statistics of treatment failure at the concentrations tested in these trials. Nonetheless, developing a genotype-to-neutralization model such as the ones in [R1,R2] may allow for a more nuanced approach to characterize neutralization in future work.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>In Appendix 1, the authors might consider coloring the resistant and susceptible amino acid identities based on the data source (DMS, patient-derived, crystallography).</p></disp-quote><p>We hope the added section on DMS comparison (the new Appendix 4) clarifies this since it covers the cases where sites are called by more than one method.</p><p>References:</p><p>[R1] Wagh K, Bhattacharya T, Williamson C, Robles A, Bayne M, et al. (2016) Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. PLOS Pathogens 12: e1005520.</p><p>[R2] Yu WH, Su D, Torabi J, Fennessey CM, Shiakolas A, et al. (2019) Predicting the broadly neutralizing antibody susceptibility of the HIV reservoir. JCI Insight 4: e130153.</p><p>[R3] Mayer BT, deCamp AC, Huang Y, Schiffer JT, Gottardo R, et al. (2022) Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention. PLOS Computational Biology 18: e1010003.</p><p>[R4] Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD (1996) HIV-1 Dynamics in vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time. Science 271: 1582–1586.</p><p>[R5] Rong L, Feng Z, Perelson AS (2007) Emergence of HIV-1 Drug Resistance During Antiretroviral Treatment. Bulletin of Mathematical Biology 69: 2027–2060.</p><p>[R6] Rong L, Dahari H, Ribeiro RM, Perelson AS (2010) Rapid emergence of protease inhibitor resistance in hepatitis C virus. Science translational medicine 2: 30ra32.</p><p>[R7] Tomaras GD, Yates NL, Liu P, Qin L, Genevieve G Fouda, et al. (2008) Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia. Journal of Virology 82: 12449–12463.</p><p>[R8] Cardozo-Ojeda EF, Perelson AS (2021) Modeling HIV-1 Within-Host Dynamics After Passive Infusion of the Broadly Neutralizing Antibody VRC01. Frontiers in Immunology 12: 710012.</p><p>[R9] Stephenson KE, Julg B, C Sabrina Tan, Zash R, Walsh SR, et al. (2021) Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: A randomized, placebocontrolled, phase 1 clinical trial. Nature Medicine 27: 1718–1724.</p><p>[R10] Feder AF, Rhee SY, Holmes SP, Shafer RW, Petrov DA, et al. (2016) More effective drugs lead to harder selective sweeps in the evolution of drug resistance in HIV-1. <italic>eLife</italic> 5: e10670.</p><p>[R11] Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, et al. (2012) HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492: 118–122.</p><p>[R12] Mendoza P, Gruell H, Nogueira L, Pai JA, Butler AL, et al. (2018) Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature 561: 479–484.</p><p>[R13] Kong R, Mark K Louder, Wagh K, Bailer RT, deCamp A, et al. (2014) Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes. Journal of Virology 89: 2659–2671.</p><p>[R14] Dingens AS, Haddox HK, Overbaugh J, Bloom JD (2017) Comprehensive Mapping of HIV-1 Escape from a Broadly Neutralizing Antibody. Cell Host Microbe 21: 777–787.e4.</p><p>[R15] Dingens AS, Arenz D, Weight H, Overbaugh J, Bloom JD (2019) An Antigenic Atlas of HIV-1 Escape from Broadly Neutralizing Antibodies Distinguishes Functional and Structural Epitopes. Immunity 50: 520–532.e3.</p><p>[R16] Schommers P, Gruell H, Abernathy ME, Tran MK, Dingens AS, et al. (2020) Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody. Cell 180: 471–489.e22.</p><p>[R17] Lu CL, Murakowski DK, Bournazos S, Schoofs T, Sarkar D, et al. (2016) Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science 352: 1001–1004.</p><p>[R18] Reeves DB, Huang Y, Duke ER, Mayer BT, Cardozo-Ojeda EF, et al. (2020) Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials. PLoS Comput Biol 16: e1007626.</p><p>[R19] Saha A, Dixit NM (2020) Pre-existing resistance in the latent reservoir can compromise VRC01 therapy during chronic HIV-1 infection. PLoS Comput Biol 16: e1008434.</p><p>[R20] Liu B, Zhang W, Zhang H (2019) Development of CAR-T cells for long-term eradication and surveillance of HIV-1 reservoir. Current Opinion in Virology 38: 21–30.</p><p>[R21] Margolis DM, Koup RA, Ferrari G (2017) HIV antibodies for treatment of HIV infection. Immunological reviews 275: 313–323.</p><p>[R22] Horwitz JA, Halper-Stromberg A, Mouquet H, Gitlin AD, Tretiakova A, et al. (2013) HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc Natl Acad Sci USA 110: 16538–16543.</p><p>[R23] Gruell H, Klein F (2018) Antibody-mediated prevention and treatment of HIV-1 infection. Retrovirology 15: 73.</p><p>[R24] Kwon YD, Georgiev IS, Ofek G, Zhang B, Asokan M, et al. (2016) Optimization of the Solubility of HIV-1Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design. Journal of Virology 90: 5899–5914.</p><p>[R25] Louie RHY, Kaczorowski KJ, Barton JP, Chakraborty AK, Matthew R McKay (2018) Fitness landscape of the human immunodeficiency virus envelope protein that is targeted by antibodies. Proceedings of the National Academy of Sciences 115.</p><p>[R26] Ferguson AL, Mann JK, Omarjee S, Ndung’u T, Walker BD, et al. (2013) Translating HIV sequences into quantitative fitness landscapes predicts viral vulnerabilities for rational immunogen design. Immunity 38: 606–617.</p><p>[R27] Zanini F, Puller V, Brodin J, Albert J, Neher RA (2017) in vivo mutation rates and the landscape of fitness costs of HIV-1. Virus Evol 3: vex003.</p><p>[R28] Neher RA, Leitner T (2010) Recombination rate and selection strength in HIV intra-patient evolution. PLoS Comput Biol 6: e1000660.</p><p>[R29] Illingworth CJR, Raghwani J, Serwadda D, Sewankambo NK, Robb ML, et al. (2020) A de novo approach to inferring within-host fitness effects during untreated HIV-1 infection. PLOS Pathogens 16: e1008171.</p><p>[R30] Haddox HK, Dingens AS, Hilton SK, Overbaugh J, Bloom JD (2018) Mapping mutational effects along the evolutionary landscape of HIV envelope. <italic>eLife</italic> 7: e34420.</p><p>[R31] Tisthammer KH, Dong W, Joy JB, Pennings PS (2021) Comparative Analysis of Within-Host Mutation Patterns and Diversity of Hepatitis C Virus Subtypes 1a, 1b, and 3a. Viruses 13.</p><p>[R32] Keck ZY, Pierce BG, Lau P, Lu J, Wang Y, et al. (2019) Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design. PLoS Pathog 15: e1007772.</p><p>[R33] Zanini F, Puller V, Brodin J, Albert J, Neher RA (2017) in vivo mutation rates and the landscape of fitness costs of HIV-1. Virus evolution 3.</p><p>[R34] Meijers M, Vanshylla K, Gruell H, Klein F, L¨assig M (2021) Predicting in vivo escape dynamics of HIV-1 from a broadly neutralizing antibody. Proceedings of the National Academy of Sciences 118: e2104651118.</p><p>[R35] Caskey M, Schoofs T, Gruell H, Karagounis T, Kreider EF, et al. (2017) Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nature medicine 23: 185–191.</p><p>[R36] Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP, et al. (2015) Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522: 487–491.</p><p>[R37] Schoofs T, Klein F, Braunschweig M, Kreider EF, Feldmann A, et al. (2016) HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science 352: 997–1001.</p><p>[R38] Caskey M, Schoofs T, Gruell H, Settler A, Karagounis T, et al. (2017) Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat Med 23: 185–191.</p><p>[R39] Bar-On Y, Gruell H, Schoofs T, Pai JA, Nogueira L, et al. (2018) Safety and anti-viral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nature medicine 24: 1701–1707.</p></body></sub-article></article>